Pocket Prescriber



Edited by Timothy RJ Nicholson and Donald RJ Singer



Pocket Prescriber

Edited by

Timothy RJ Nicholson MBBS BSC **MS**C **MRCP MRCP**SYCH Academic Clinical Lecturer, Section of Cognitive Neuropsychiatry, Institute of Psychiatry, London, UK

Donald RJ Singer BMEDBIOL MD FRCP

Professor of Clinical Pharmacology and Therapeutics, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick and University Hospitals Coventry and Warwickshire, Coventry, UK



First published in Great Britain in 2004 Second edition 2006 Third edition 2009 This fourth edition published in 2011 by Hodder Arnold, an imprint of Hodder Education, an Hachette UK Company, 338 Euston Road, London NW1 3BH

http://www.hoddereducation.com

© 2011 Timothy RJ Nicholson and Donald RJ Singer

All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency. In the United Kingdom such licences are issued by the Copyright Licensing Agency: Saffron House, 6-10 Kirby Street, London ECIN & BTS

Hachette UK's policy is to use papers that are natural, renewable and recyclable products and made from wood grown in sustainable forests. The logging and manufacturing processes are expected to conform to the environmental regulations of the country of origin.

Whilst the advice and information in this book are believed to be true and accurate at the date of going to press, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. In particular (but without limiting the generality of the preceding disclaimer) every effort has been made to check drug dosages; however it is still possible that errors have been missed. Furthermore, dosage schedules are constantly being revised and new side-effects recognized. For these reasons the reader is strongly urged to consult the drug companies' printed instructions before administering any of the drugs recommended in this book.

British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress

ISBN-13 978 1 444 12187 2

1 2 3 4 5 6 7 8 9 10

Commissioning Editor: Caroline Makepeace Project Editor: Joanna Silman Production Controller: Kate Harris Cover Designer: Helen Townson

Typeset in 8/10 pt Sabon by Macmillan Publishing Solutions, Chennai, India Printed and bound in Spain

What do you think about this book? Or any other Hodder Arnold title? Please visit our website: www.hoddereducation.com

CONTENTS

Contributors	v
Foreword	vii
Acknowledgements	viii
How to use this book	ix
List of abbreviations	xi
How to prescribe safely	XX
Common/useful drugs	1
Drug selection	167
Antibiotics	168
Hypertension management	178
Asthma	181
Analgesia	183
Palliative care and subcutaneous pumps	184
Antiemetics	187
Alcohol withdrawal	190
Antidepresssants	192
How to prescribe	195
Insulin	196
Anticoagulants	200
Thrombolysis	208
Controlled drugs	212
Miscellaneous	215
Intravenous fluids	216
Steroids	219
Sedation/sleeping tablets	221
Benzodiazepines	223
Side effect profiles	224
Cytochrome P450	228

C0	N٦	E	NT	S
----	----	---	----	---

Medical emergencies	229
Acute coronary syndromes (ACS)	230
Acute LVF	233
Accelerated hypertension	234
Atrial fibrillation	235
Acute asthma	237
COPD exacerbation	238
Pulmonary embolism	238
Acute upper GI haemorrhage	239
Sepsis (severe or septic shock)	241
Epilepsy	241
DKA	243
HONK	245
↓Glucose	245
Thyrotoxic crisis	246
Myxoedema coma	247
Addisonian crisis	247
Electrolyte disturbances	248
Overdoses	249
Reference information	257
Coma	258
Cognitive impairment	259
Useful formulae	260
Common laboratory reference values	261
Index	265

CONTRIBUTORS

Adam MC Archibald BSc(Hons) MBChB

FY2 Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh

Peter J Barnes DM DSc FRCP FMedSci FRS

Professor and Consultant in Respiratory Medicine, National Heart & Lung Institute, Imperial College London

Alison Bedlow BSc MBBS FRCP Consultant Dermatologist, South Warwickshire NHS Foundation Trust

Aodhan Breathnach

Consultant Medical Microbiologist, Department of Medical Microbiology St George's Hospital, London

Emma C Derrett-Smith BSc MBBS MRCP

Clinical Research Fellow, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London

Timothy WR Doulton BSc MBBS MRCP MD

Consultant Nephrologist, Kent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust

Thomas M Galliford MBBS BSc(Hons) MRCP

SpR Department of Diabetes and Endocrinology, Imperial College NHS Healthcare Trust, London

Beth D Harrison MA BM BCh DM FRCP FRCPath

Consultant Haematologist, University Hospital Coventry and Warwickshire NHS Trust

Steven Harsum MBBS BSc PhD FRCOphth

Consultant Ophthalmologist, Sutton Eye Unit, Epsom & St Helier NHS Trust

Robin DC Kumar MBBS BSc FRCA

Clinical Fellow in Neuroanaesthesia, National Hospital for Neurology and Neurosurgery, Queen Square, London

CONTRIBUTORS

Simon J Little BA(Cantab) MBBS MRCP

SpR St Georges Hospital, London; and Wellcome Trust Research Fellow, Functional Neurosurgery and Experimental Neurology, Oxford University

Pete Maskell MBBS FRCP MSc

Consultant Stroke Physician and Elderly Care Lead, Maidstone and Tunbridge Wells NHS Trust

Allison C Morton BMedSci MBChB MRCP PhD

Consultant Cardiologist, Sheffield Teaching Hospitals NHS Foundation Trust; and Clinical Research Manager, NIHR Cardiovascular Biomedical Research Unit, Northern General Hospital, Sheffield

Victor Pace FRCP

Consultant in Palliative Medicine, St Christopher's Hospice, Sydenham, London

Stephen D Quinn MB BS BSc MRCOG

Clinical Research Fellow, Imperial College London; and Honorary Specialist Registrar, Imperial College Healthcare NHS Trust, London

Ricardo Sainz-Fuertes LMS MSc MRCPsych

MRC Clinical Research Training Fellow, Institute of Psychiatry, King's College London and Honorary Specialist Registrar in Psychiatry, South London and Maudsley NHS Foundation Trust

Biba Stanton BMedSci MBBS MRCP PhD

Specialist Registrar, National Hospital for Neurology and Neurosurgery, Queen Square, London

Rudolf Uher MD PhD MRCPsych

Clinical Lecturer, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London

Esther Unitt BMedSci MBBS MRCP DM

Consultant Gastroenterologist and Hepatologist at the University Hospital, Coventry and Warwickshire Hospitals NHS Trust

W Stephen Waring PhD FRCP(Edin)

Consultant in Acute Medicine & Toxicology, Acute Medical Unit, York Teaching Hospital NHS Foundation Trust

vi

FOREWORD

Contemporary medical practice necessitates a broad knowledge of drug treatments, which are constantly being updated and modified. I am delighted to write the foreword for this volume which, in the principle of the very best travel guides, is small but packed with essential and easily accessible information. Of all the subjects that are in the medical curriculum, pharmacology can sometimes seem especially abstract and theoretical. A quick flick through the pages of this book that are relevant to one's own speciality is an immediate reminder of the importance of understanding the ways in which the drugs that we routinely prescribe are handled. The clear identification of hazardous side effects and potential interactions is especially welcome. Finally, the section providing current information and management guidelines for commonly encountered medical emergencies is both clear and comprehensive.

Safe use of the modern therapeutic armamentarium is a daunting task for junior doctors and medical students. Although there has been a large growth in electronic resources and some excellent online textbooks have been produced, there remains a critical need for small reference texts that can be carried at all times and used to check drug doses or potential interactions at the point of prescription. The simple precaution of checking facts in any unfamiliar prescribing situation is likely to prevent mistakes, and exemplifies current emphasis on safe-practice and clinical risk management.

I believe that even the most senior specialist could learn something from this book's pages and that a comprehensive up-to-date volume such as this is an essential part of any junior doctor's tool kit, and will prove useful far beyond its target audience.

> Professor Dame Carol M. Black DBE Former president of the Royal College of Physicians

ACKNOWLEDGEMENTS

This book is dedicated to my family and friends as well as all the inspirational teachers I have been lucky enough to learn from over the years, in particular John Youle, Katie Blackman, Jerry Kirk, Carol Black, Huw Beynon, Martin Rossor, Michael Trimble, Maria Ron, Matthew Hotopf and Tony David.

Particular thanks for their help and time to Anand and Subbu, Houman Ashrafian, Selma Avbek, Prithwish Banneriee, Amlan Basu, Nick Bateman, Simone Brackenborough, Harris Birthright, Gurpreet Chana, Roger Cross, Jonny Crowston, Chris Denton, Samantha Dickinson, Paul Dilworth, Michael Duick, Phil Dyer, Nick Eynon-Lewis, Fahad Farooqi, Catherine Farrow, Roger Fernandes, Arosha Fernando, Denise Forth, Jack Galliford, Hamid Ghodse, Natasha Gilani, Caroline Goh, Ashan Gunarathne, Nadya Hamedi, Jane Henderson, Peter Hargreaves, Nicholas Hirsch, Rick Holliman, Emily Horwill, Saadhiya Hussain, Nick Jackson, Sudhesh Kumar, Ruey-Leng Loo, Graham MacGregor, Mel Mahadevan, Omar Malik, Janada Mamza, Chung Man Wan, Joela Matthews, Narbeh Melikian, Hina Mistry, Neil Muchatuta, Dev Mukerjee, Tejal Patel, Rahul Patel, Rakita Patel, Gideon Paul, Annabel Price, Deirdre Prinsloo, Gemma Robinson, Sailesh Sankar, Muriel Shannon, Amar Sharif, Jennifer Sharp, Bran Sivakumar, Sian Stanley, Richard Stratton, Henry Squire, Sheena Thomas, Mike Travis, Aaron Vallance, Payal Vasani, Jim Wade, Mandy Wan and Javne Yeung.

Special thanks to Helen Galley.

The information in this book has been collated from many sources, including manufacturer's information sheets ('SPCs' – Summary of Product Characteristics sheets), the *British National Formulary* (BNF), national and international guidelines, as well as numerous pharmacology and general medical books, journals and papers. Where information is not consistent between these sources that from the SPCs has generally been taken as definitive.

HOW TO USE THIS BOOK

STANDARD LAYOUT OF DRUGS

DRUG/TRADE NAME

Class/action: More information is given for generic forms, especially for the original and most commonly used drug(s) of each class. **Use:** use^x (correlating to dose as below).

Cl: contraindications; **L** (liver failure), **R** (renal failure), **H** (heart failure), **P** (pregnancy), **B** (breastfeeding). *Allergy to active drug, or any excipients (other substances in the preparation) assumed too obvious to mention.*

Caution: L (liver failure), **R** (renal failure), **H** (heart failure), **P** (pregnancy), **B** (breastfeeding), **E** (elderly patients). *If a* contraindication is given for a drug it is assumed too obvious to mention that a caution is also inherently implied.

SE: side effects; listed in order of frequency encountered. Common/important side effects set in **bold**.

Warn: information to give to patients before starting drug. Monitor: parameters that need to be monitored during treatment. Interactions: included only if very common or potentially serious; ↑/↓P450 (induces/inhibits cytochrome P450 metabolism), W+ (increases effect of warfarin), W- (decreases effect of warfarin). Dose: dose^x (for Use^x as above). NB Doses are for adults only.

Important points highlighted at end of drug entry.

Use/dose^{NICE}: National Institute of Health and Clinical Excellence guidelines exist for the drug (basics often in BNF – see www.nice.org.uk for full details).

Dose^{BNF/SPC}: dose regimen complicated; please refer to BNF and/or SPC (Summary of Product Characteristics sheet; the manufacturer's information sheet enclosed with drug packaging – can also be viewed at or downloaded from www.emc.medicines.org.uk). **Asterisks** (*) and **daggers** (†) denote links between information within local text. Only relevant sections are included for each drug. Trade names (in OUTLINE font) are given only if found regularly on drug charts or if non-proprietary (generic, non-trade-name) drug does not exist yet.

KEY

- See Potential dangers highlighted with skull and cross-bones
- New drug or new indication under intense surveillance by Committee on Safety of Medicines (CSM): *important to report all suspected drug reactions via Yellow Card scheme* (accurate as going to press: from December 2010 CSM list)
- Good for: reasons to give a certain drug when choice exists
- Bad for: reasons to not give a certain drug when choice exists
- \Rightarrow Causes/goes to
- .:. Therefore
- Δ Change/disturbance
- Ψ Psychiatric
- ↑ Increase/high
- ↓ Decrease/low

 \uparrow/\downarrow electrolytes refers to serum levels, unless stated otherwise.

DOSES

od	once daily	nocte	at night
bd	twice daily	mane	in the morning
tds	three times daily	prn	as required
qds	four times daily	stat	at once

ROUTES

im intramu	scular	ро	oral
inh inhaled		pr	rectal
iv intraven	ous	sc	subcutaneous
ivi intraven	ous infusion	top	topical
neb via nebu	ıliser	sl	sublingual



Routes are presumed po, unless stated otherwise.

5-ASA 5HT A&E	5-aminosalicylic acid 5-hydroxytryptamine (= serotonin) accident and emergency
AAC	antibiotic-associated colitis
Ab	antibody
ACC	American College of Cardiology
ACCP	American College of Chest Physicians
ACE-i	ACE inhibitor
ACh	acetylcholine
ACS	acute coronary syndrome
ADP	adenosine phosphate
AF	atrial fibrillation
Ag	antigen
AHA	American Heart Association
ALL	acute lymphoblastic leukaemia
ALP	alkaline phosphatase
ALS	adult life support (algorithms of European
	Resuscitation Council)
ALT	alanine(-amino) transferase
AMI	acute myocardial infarction
AMTS	abbreviated mental test score (same as MTS)
ANA	anti-nuclear antigens
APTT	activate partial thromboplastin time
ARB(s)	angiotensin receptor blocker(s)
ARDS	adult respiratory distress syndrome
ARF	acute renal failure
AS	aortic stenosis
ASAP	as soon as possible
assoc	associated
AST	aspartate transaminase
AV	arteriovenous
AVM	arteriovenous malformation
AVN	atrioventricular node
AZT	zidovudine
BBB	bundle branch block

BCSH BCT BF BG BHS BIH BIPAP BM	British Committee for Standards in Haematology broad complex tachycardia blood flow serum blood glucose in mmol/l; <i>see also CBG</i> British Hypertension Society benign intracranial hypertension bilevel/biphasic positive airway pressure bone marrow (NB: BM is often used, confusingly, to signify finger-prick glucose; CBG (capillary blood glucose) is used for this purpose in this book)
BMI	body mass index = weight $(kg)/height (m)^2$
BP	blood pressure
BPH	benign prostatic hypertrophy
BTS	British Thoracic Society
Bx	biopsy
С	constipation () IP $1 = 1 = 1 = 1 = 0$
Са	cancer (NB: calcium is abbreviated to Ca^{2+})
CAH	congenital adrenal hyperplasia cerebral blood flow
CBF CBG	
CBG	capillary blood glucose in mmol/l (finger-prick testing) (NB: BM is often used to denote this, but this is confusing and less accurate and thus not used in this book)
CCF	congestive cardiac failure
cf	compared with
CI	contraindicated
CK	creatine kinase
CLL	chronic lymphocytic leukaemia
CML	chronic myelogenous leukaemia
CMV	cytomegalovirus
CNS	central nervous system
CO	cardiac output
COPD	chronic obstructive pulmonary disease
COX	cyclo-oxygenase
CPR	cardiopulmonary resuscitation
CRF	chronic renal failure
CRP	C reactive protein

xii

CVAcerebrovascular accidentCVPcentral venous pressureCXRchest X-rayDdiarrhoeaD&Vdiarrhoea and vomitingD_12/3dopamine receptor subtype 1/2/3DAdopamineDCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrocardiogramECTelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbatesFBCfull blood count	CSF CSM CT	cerebrospinal fluid Committee on Safety of Medicines computerised tomography
CXRchest X-rayDdiarrhoeaD&Vdiarrhoea and vomitingD_12/3dopamine receptor subtype 1/2/3DAdopamineDCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes mellitusDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	CVA	
CXRchest X-rayDdiarrhoeaD&Vdiarrhoea and vomitingD_12/3dopamine receptor subtype 1/2/3DAdopamineDCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes mellitusDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	CVP	central venous pressure
D&Vdiarrhoea and vomitingD&Vdiarrhoea and vomitingD_1/2/3dopamine receptor subtype 1/2/3DAdopamineDCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	CXR	
D1/2/3dopamine receptor subtype 1/2/3DAdopamineDCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes mellitusDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Resuscitation rateexaceexacerbates	D	
D1/2/3dopamine receptor subtype 1/2/3DAdopamineDCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes mellitusDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Resuscitation rateexaceexacerbates	D&V	diarrhoea and vomiting
DCTdistal convoluted tubuledfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetic ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	D _{1/2/3}	
dfxdefectsDIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetic ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	DA	dopamine
DIdiabetes insipidusDICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetes ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	DCT	distal convoluted tubule
DICdisseminated intravascular coagulationDIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetic ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	dfx	defects
DIGAMIglucose, insulin and potassium intravenous infusion used in acute myocardial infarctionDKAdiabetic ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	DI	diabetes insipidus
used in acute myocardial infarctionDKAdiabetic ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drugdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	DIC	disseminated intravascular coagulation
DKAdiabetic ketoacidosisDMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drugdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	DIGAMI	glucose, insulin and potassium intravenous infusion
DMdiabetes mellitusDMARDdisease-modifying anti-rheumatoid arthritis drugdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates		used in acute myocardial infarction
DMARDdisease-modifying anti-rheumatoid arthritis drug dtdtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	DKA	diabetic ketoacidosis
dtdue toDWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexaceexacerbates	DM	diabetes mellitus
DWIdiffusion weighted (imaging); specialist MRI mostly used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	DMARD	disease-modifying anti-rheumatoid arthritis drug
used for stroke/TIADxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates		due to
DxdiagnosisEØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	DWI	diffusion weighted (imaging); specialist MRI mostly
EØeosinophilse'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates		used for stroke/TIA
e'lyteelectrolyteEBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	Dx	diagnosis
EBVEpstein-Barr virusECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates		eosinophils
ECGelectrocardiogramECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	e'lyte	electrolyte
ECTelectroconvulsive therapyEFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	EBV	Epstein-Barr virus
EFejection fractionENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	ECG	electrocardiogram
ENTear, nose and throatEPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	ECT	electroconvulsive therapy
EPSEextrapyramidal side effectsERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	EF	ejection fraction
ERCEuropean Resuscitation CouncilESCEuropean Society of CardiologyESRerythrocyte sedimentation rateexacexacerbates	ENT	ear, nose and throat
ESC European Society of Cardiology ESR erythrocyte sedimentation rate exac exacerbates	EPSE	extrapyramidal side effects
ESR erythrocyte sedimentation rate exac exacerbates	ERC	
exac exacerbates	ESC	
	ESR	
FBC full blood count	exac	
	FBC	full blood count

Fe	iron
FFP	fresh frozen plasma
FHx	family history
FiO ₂	inspired O ₂ concentration
FMF	familial Mediterranean fever
fx	effects
G6PD	glucose-6-phosphate dehydrogenase
GABA	gamma aminobutyric acid
GBS	Guillain–Barré syndrome
GCS	Glasgow Coma Scale
GFR	glomerular filtration rate
GI	gastrointestinal
GIK	glucose, insulin and K ⁺ infusion
GMC	General Medical Council (of UK)
GTN	glyceryl trinitrate
GU	genitourinary
h	hour(s)
H(O)CM	hypertrophic (obstructive) cardiomyopathy
Hb	haemoglobin
HB	heart block
Hct	haematocrit
HDL	high density lipoprotein
HF	heart failure
HIV	human immunodeficiency virus
HLA	human leucocyte antigen
HMG-CoA	3-hydroxy-3-methyl-glutaryl coenzyme A
HONK	hyperosmolar non-ketotic state
hrly	hourly
HSV	herpes simplex virus
HTN	hypertension
HUS	haemolytic uraemic syndrome
Hx	history
IBD	inflammatory bowel disease
IBS	irritable bowel syndrome
ICP	intracranial pressure
ICU	intensive care unit

xiv

IHD	ischaemic heart disease
IL-2	interleukin 2
im	intramuscular
inc	including
inh	inhaled
INR	international normalised ratio (prothrombin ratio)
IOP	intraocular pressure
ITP	immune/idiopathic thrombocytopenic purpura
ITU	intensive therapy unit
iv	intravenous
IVDU	intravenous drug user
ivi	intravenous infusion
Ix	investigation
K^+	potassium (serum levels unless stated otherwise)
LØ	lymphocytes
LA	long-acting
LBBB	left bundle branch block
LDL	low density lipoprotein
LF	liver failure
LFTs	liver function tests
LMWH	low-molecular-weight heparin
LP	lumbar puncture
LVF	left ventricular failure
MØ	macrophages
mane	in morning
MAOI	monoamine oxidase inhibitor
MAP	mean arterial pressure
MCA	middle cerebral artery
MCV	mean corpuscular volume
metab	metabolised
MG	myasthenia gravis
MHRA	Medicines and Healthcare Products Regulatory
	Authority (UK)
MI	myocardial infarction
MMF	mycophenolate mofetil
MMSE	Mini-Mental State Examination (scored out of 30 [*])

MD	1:0:1 1 (1
MR	modified-release (drug preparation) [†]
MRI	magnetic resonance imaging
MRSA	methicillin-resistant Staphylococcus aureus
MS	multiple sclerosis
MTS	(abbreviated) Mental Test Score (scored out of 10*)
MUST	malnutrition universal screening tool
Mx	management
Ν	nausea
N&V	nausea and vomiting
NØ	neutrophils
NA	noradrenaline (norepinephrine)
Na^1	sodium (serum levels unless stated otherwise)
NBM	nil by mouth
NCT	narrow complex tachycardia
NDRI	noradrenaline and dopamine reuptake inhibitor
neb	via nebuliser
NGT	nasogastric tube
NH	non-Hodgkin's (lymphoma)
NIHSS	National (US) Institute of Health Stroke Scale
NIV	non-invasive ventilation
NMJ	neuromuscular junction
NMS	neuroleptic malignant syndrome
NPIS	National Poisons Information Service
NSAID	nonsteroidal anti-inflammatory drug
NSTEMI	non-ST elevation myocardial infarction
NYHA	New York Heart Association
OCD	obsessive compulsive disorder
OCP	oral contraceptive pill
OD	overdose (<i>NB</i> : <i>od</i> = <i>once daily</i> !)
OGD	oesophagogastroduodenoscopy
p'way(s)	pathway(s)
PAN	polyarteritis nodosa
PBC	primary biliary cirrhosis
PCI	percutaneous coronary intervention (now preferred
	term for percutaneous transluminal coronary
	angioplasty (PTCA), which is a subtype of PCI)

xvi

PCOS	polycystic ovary syndrome
PCP	Pneumocystis carinii pneumonia
PCV	packed cell volume
PDA	patent ductus arteriosus
PE	pulmonary embolism
PEA	pulseless electrical activity
PEG	percutaneous endoscopic gastrostomy
PG(x)	prostaglandin (receptor subtype x)
phaeo	phaeochromocytoma
PHx	past history (of)
PID	pelvic inflammatory disease
PML	progressive multifocal leukoencephalopathy
PMR	polymyalgia rheumatica
ро	by mouth
PO ₄	phosphate (serum levels, unless stated otherwise)
PPI	proton pump inhibitor
pr	rectal
prep(s)	preparation(s)
prn	as required
PSA	prostate specific antigen
Pt	platelet(s)
PT	prothrombin time
PTH	parathyroid hormone
PTSD	post-traumatic stress disorder
PU	peptic ulcer
PUO	pyrexia of unknown origin
PVD	peripheral vascular disease
Px	prophylaxis
QT(c)	QT interval (corrected for rate)
RA	rheumatoid arthritis
RAS	renal artery stenosis
RBF	renal blood flow
RF	renal failure
RLS	restless legs syndrome
ROSIER	recognition of stroke in emergency room scale for
	diagnosis of stroke/TIA

xviii LIST OF AE	xviii LIST OF ABBREVIATIONS		
RR	respiratory rate		
RRT	renal replacement therapy		
RSV	respiratory syncytial virus		
RTI	respiratory tract infection		
RV	right ventricle		
RVF	right ventricular failure		
Rx	treatment		
SAH	subarachnoid haemorrhage		
SAN	sinoatrial node		
SBE	subacute bacterial endocarditis		
SC	subcutaneous		
SE(s)	side effect(s)		
sec	second(s)		
SIGN	Scottish Intercollegiate Guidelines Network		
SIADH	syndrome of inappropriate antidiuretic hormone		
SJS	Stevens–Johnson syndrome		
sl	sublingual		
SLE	systemic lupus erythematosus		
SOA	swelling of ankles		
SOB (OE)	shortness of breath (on exertion)		
SPC	summary of product characteristic sheet (see page vii)		
spp	species		
SR	slow/sustained release (drug preparation)		
SSRI	selective serotonin reuptake inhibitor		
SSS	sick sinus syndrome		
STEMI	ST elevation myocardial infarction		
supp	suppository		
SVT	supraventricular tachycardia		
t _{1/2}	half-life		
T ₃	triiodothyronine/liothyronine		
T ₄	thyroxine $(\uparrow/\downarrow T_4 = hyper/hypothyroid)$		
TCA	tricyclic antidepressant		
TE	thromboembolism		
TEDS	thromboembolism deterrent stockings		
TEN	toxic epidermal necrolysis		
TFTs	thyroid function tests		

TG	triglyceride
TIBC	total iron binding capacity
TIMI score	risk score for UA/NSTEMI named after TIMI
	(thrombolysis in MI) trial
TNF	tumour necrosis factor
top	topical
TPMT	thiopurine methyltransferase
TPR	total peripheral resistance
TTA(s)	(drugs) to take away, i.e. prescriptions for inpatients
	on discharge/leave (aka TTO)
TTO(s)	see TTA
TTP	thrombotic thrombocytopenic purpura
U&Es	urea and electrolytes
UA(P)	unstable angina (pectoris)
UC	ulcerative colitis
URTI	upper respiratory tract infection
UTI	urinary tract infection
UV	ultraviolet
V	vomiting
VE(s)	ventricular ectopic(s)
VF	ventricular fibrillation
vit	vitamin
VLDL	very low density lipoprotein
VT	ventricular tachycardia
VTE	venous thromboembolism
VZV	varicella zoster virus (chickenpox/shingles)
W	with
w/in	within
w/o	without
WCC	white cell count
WE	Wernicke's encephalopathy
wk	week
WPW	Wolf-Parkinson-White syndrome

Wt weight

xs excess

Zollinger-Ellison syndrome ZE

xix

HOW TO PRESCRIBE SAFELY

Take time/care to \downarrow risk to patients (and protect yourself). Always check the following are correct for all prescriptions: patient, indication and drug, legible format (generic name, clarity, handwriting, identifiable signature), dosage, frequency, time(s) of day, date, duration of treatment, route of administration.

DO

- Make a clear, accurate record in the notes of all medicines prescribed, written at the time of prescription
- · Complete allergy box and alert labels, where relevant
- Include on all drug charts and TTAs the patient's surname and given name, date of birth, date of admission and consultant (if possible use a printed label for patient details)
- **PRINT** (i.e. use upper case) all drugs as approved (generic) names, e.g. 'IBUPROFEN' *not* 'muroflem'
- State dose, route and frequency, giving strength of solutions/creams
- Write the word microgram in full; avoid abbreviations such as mcg or μ
- Abbreviate the word gram to 'g' (rather than 'gm' which is easily confused with mg)
- Write the word 'units' in full, preceded by a space; abbreviating to 'U' can be misread as zero (a 10-fold error)
- Document weight where dosing is weight-dependent
- Write quantities <1 g in mg (e.g. 400 mg not 0.4 g)
- Write quantities <1 mg in micrograms (e.g. 200 micrograms not 0.2 μg). (This is of particular importance for handwritten prescriptions. In this book, due to space constraints we use μg.)
- Not use trailing zeroes (10 mg *not* 10.0 mg)
- Precede decimal points with another figure (e.g 0.8 ml *not* .8 ml) and only use decimals where unavoidable
- Check and recheck calculations
- Provide clear additional instructions, e.g. for monitoring, review of antibiotic route and duration, maximum daily/24 h dose for PRN drugs

- Specify solution to be used and duration of any iv infusions/ injections
- · Avoid using abbreviated/non-standard drug names
- Avoid writing 'T' (tablet sign) for non-tablet formulations, e.g. sprays
- Amend a prescribed drug by drawing a line through it, date and initial this, then rewrite as new prescription
- Check and count number of drugs when rewriting a drug chart
- Check when prescribing unfamiliar drug(s)/doses or drugs you were familiar with but haven't prescribed recently.

IMPORTANT FURTHER ADVICE

1 Make sure choice of drug and dose is right for the patient, their condition and significant comorbidity, with particular attention to age^{*}, gender, ethnicity, renal or liver dysfunction, risk of drug–drug and drug–disease interactions, and risks in pregnancy (and those of child-bearing age who may become pregnant) and during breastfeeding. Anticipate possible effects of over-the-counter and herbal medicines and lifestyle (e.g. dietary salt and alcohol intake).

*Although arbitrary age of >65 denotes 'elderly', fx of age can occur earlier/later and are continuous.

- 2 Common settings where drug problems occur are often predictable if you understand relevant pathology, routes of drug metabolism (liver, P450, renal, etc) and drug mechanisms of action. Take particular care with:
- Renal or liver disease
- Pregnancy/breastfeeding: use safest options (in the UK consider consulting the National Teratology Information Service; tel: 0191 232 1525)
- NSAIDs/bisphosphonates and peptic ulcer disease
- Asthma and β-blockers
- Conditions worsened by antimuscarinic drugs (see p. 225): urinary retention/BPH, glaucoma, paralytic ileus
- Rare conditions where drugs commonly pose risk, e.g. porphyria, myasthenia, G6PD deficiency, phaeo.

HOW TO PRESCRIBE SAFELY

- 3 Always ensure informed consent; agree proposed prescriptions with the patient (or carer if patient has authorised their involvement in their care or has lost capacity), explaining proposed benefits, nature and duration of treatment, clarifying concerns, warning of possible, especially severe, adverse effects, highlighting recommended monitoring and review arrangements and stating what the patient should do in the event of a suspected adverse reaction. Only in extreme emergencies can it be justified to have not done this. For drugs with common potentially fatal/severe side effects document that these risks have been explained to, and accepted by, the patient.
- **4** See legal advice on eligibility to prescribe and use of unlicensed medicines on the GMC website (www.gmc-uk.org).
- **5** Make sure that you are being objective. Prescribing should be for the benefit of the patient not the prescriber.
- **6** Keep up to date about medicines you are prescribing and the related conditions you are treating.
- 7 Follow CSM guidance on reporting suspected adverse reactions to medicines (see top right link at www.mhra.gov.uk for details of the Yellow Card reporting scheme and downloads of reported adverse drug reactions for specific medicines).
- 8 Ensure continuity of care by keeping the patient's GP (or other preferred medical adviser) informed about prescribing, monitoring and follow-up arrangements and responsibilities.
- **9** Check that appropriate previous medicines are continued and over-the-counter and herbal medicine use is recorded.
- **10** Patient Group Directions: the GMC advises these should be limited to situations where there is a 'distinct advantage for patient care ... consistent with appropriate professional relationships and accountability'.

xxii

Common/useful drugs

ABCIXIMAB/REOPRO

Antiplatelet agent – monoclonal Ab against platelet glycoprotein IIb/IIIa receptor (involved in Pt aggregation).

Use: Px of ischaemic complications of PCI and Px of MI in unstable angina unresponsive to conventional Rx awaiting PCI^{NICE} (see p. 230).

Cl: active internal bleeding, CVA w/in 2 years, intracranial neoplasm, aneurysm or AVM. Major surgery, intracranial/intraspinal surgery or trauma w/in 2 months. Hypertensive retinopathy, vasculitis, \downarrow Pt, haemorrhagic diathesis, severe \uparrow BP. **L** (if severe)/**R** (if requiring haemodialysis)/**B**.

Caution: drugs that *t*bleeding risk, L/R/LP/E.

SE: bleeding* / \downarrow Pt*, **N&V**, \downarrow **BP**, \downarrow HR, pain (chest, back or pleuritic), headache, fever. Rarely, hypersensitivity, tamponade, ARDS.

Monitor: FBC* (baseline plus 2–4 h, 12 h and 24 h after giving) and clotting (baseline at least).

Dose: 250 µg/kg iv over 1 min, then 0.125 µg/kg/min (max 10 µg/min) ivi; see BNF/product literature for dose timing. *NB: use iv non-pyrogenic, low protein binding filter. Needs concurrent heparin.* Specialist use only: get senior advice or contact on-call cardiology.

ACAMPROSATE/CAMPRAL EC

Modifies GABA transmission $\Rightarrow \downarrow$ pleasurable fx of alcohol $\therefore \downarrow$ s craving and relapse rate.

Use: maintaining alcohol abstinence.

CI: L (only if severe), R/P/B.

SE: GI upset, pruritus, rash, Δ libido.

Dose: 666 mg tds po if age 18–65 years (avoid outside this age range) and >60 kg (if <60 kg give 666 mg mane then 333 mg noon and nocte). *Start ASAP after alcohol stopped. Usually give for 1 year.*

ACARBOSE

Oral hypoglycaemic: α -glucosidase inhibitor. Delays digestion and \downarrow s absorption of starch and sucrose (also $\Rightarrow \downarrow$ postprandial hyperglycaemia in type 1 DM). **Use:** DM not controlled by conventional oral hypoglycaemics. **Cl:** IBD, hernia, Hx of abdominal surgery or obstruction **R** (if severe) **L/P/B**.

SE: flatulence, GI upset, rarely hepatitis.

Monitor: LFTs.

Interactions: may *hypoglycaemic* fx of sulphonylureas and insulin.

Dose: initially 50 mg od po, \uparrow up to 200 mg tds po.

AGIDEX Alginate raft-forming oral suspension for acid reflux. **Dose:** 10–20 ml after meals and at bedtime (NB: 3 mmol Na⁺/5 ml)

ACETAZOLAMIDE/DIAMOX

Carbonic anhydrase inhibitor (sulphonamide).

Use: glaucoma (acute-angle closure, primary open-angle unresponsive to maximal topical Rx, or secondary), \uparrow ICP. Rarely for epilepsy or diuresis.

Cl: \downarrow K⁺, \downarrow Na⁺, \uparrow Cl⁻ acidosis, sulphonamide allergy. **L** (if severe)/**R**. **Caution:** acidosis, pulmonary obstruction **R**/**P**/**E**.

SE: nausea/GI upset, paraesthesia, drowsiness, mood Δ , headache, Δ LFTs. If prolonged use acidosis (metabolic) and e'lyte Δ s. Rarely blood disorders and skin reactions (inc SJS/TENS).

Monitor: FBC, U&E if prolonged use.

Interactions: \uparrow s levels of carbamazepine. Can \uparrow cardiac toxicity (via $\downarrow K^+$) of disopyramide, flecainide, lidocaine and cardiac glycosides. \downarrow s fx of methenamine and \uparrow fx of quinidine.

Dose: 0.25–1 g/day po or iv^{SPC}. Available in 250 mg MR tablets (as Dlamox SR; max 2 tablets/day).

 \Re Extravasation at injection site can \Rightarrow necrosis \Re .

ACETYLCYSTEINE/PARVOLEX

Precursor of glutathione, which detoxifies metabolites of paracetamol.

Use: paracetamol OD.

Caution: asthma*.

SE: allergy: rash, bronchospasm*, anaphylactoid reactions (esp if ivi too quick**).

Dose: initially 150 mg/kg in 200 ml 5% glucose as ivi over 15 min, then 50 mg/kg in 500 ml over 4 h, then 100 mg/kg in 1 litre over 16 h. NB: use max weight of 110 kg for dose calculation, even if patient weighs more. Ensure not given too quickly**.

See pp. 251 for Mx of paracetamol OD and treatment line graph.

ACICLOVIR (previously ACYCLOVIR)

Antiviral. Inhibits DNA polymerase *only in infected cells*: needs activation by viral thymidine kinase (produced by herpes spp). **Use:** *iv:* severe HSV or VZV infections, e.g. meningitis, encephalitis and in immunocompromised patients (esp HIV – also used for Px); *po/top:* mucous membrane, genital, eye infections.

Caution: dehydration*, R/P/B.

SE: at \uparrow doses: **ARF**, **encephalopathy** (esp if dehydrated*). Also **hypersensitivity**, seizures, GI upset, blood disorders, skin reactions (including photosensitivity), headache, many non-specific neurological symptoms, \downarrow Pt, \downarrow WBC. Rarely Ψ reactions and hepatotoxicity.

Interactions: levels \uparrow d by probenecid.

Dose: 5 mg/kg tds ivi over 1 h (10 mg/kg if HSV encephalitis or VZV in immunocompromised patients); po/top^{SPC/BNF}.

 \Re ivi leaks \Rightarrow severe local inflammation/ulceration \Re .

ACTIVATED CHARCOAL see Charcoal.

AGTRAPID Short-acting soluble insulin; see p. 196 for use.

ADENOSINE

Purine nucleoside. Slows AVN conduction time, dilates coronary arteries; acts on its own specific receptors.

Use: Rx of paroxysmal SVT (esp if accessory p'ways e.g. WPW) and Dx of SVT (NCT or BCT; ↓s rate to reveal underlying rhythm). **Cl:** A sthma* (consider verapamil instead). 2nd-/3rd-degree AV

block or sick sinus syndrome (if either w/o pacemaker).

4

Caution: heart transplant (↓dose), AF/atrial flutter (↑s accessory pathway conduction), ↑QTc, COPD*.

SE: bronchospasm*, \downarrow BP. Rarely \downarrow HR/asystole and arrhythmias (mostly transient).

Warn: can \Rightarrow transient unpleasant feelings: facial flushing, dyspnoea, choking feeling, nausea, chest pain and light-headedness.

Interactions: fx \uparrow by **dipyridamole**: \downarrow initial adenosine dose to 0.5–1 mg and watch for \uparrow bleeding (*anti-Pt fx of dipyridamole also* \uparrow *d by adenosine*). fx \downarrow d by **theophyllines** and caffeine. Use with digoxin may \uparrow risk of VF.

Dose: 3–6 mg iv over 2 sec; double dose and repeat every 1–2 min until response or significant AV block (max 12 mg/dose). *NB: attach cardiac monitor and give via central (or large peripheral) vein, then flush.*

 $t_{1/2} < 10$ sec: often needs readministration (esp if given for Rx cf Dx).

ADRENALINE (im/iv)

Sympathomimetic: powerful stimulation of α (vasoconstriction), β_1 ([†]HR, [†]contractility) and β_2 (vasodilation, bronchodilation, uterine relaxation). Also \downarrow s immediate mast cell cytokine release. **Use:** CPR and anaphylaxis (see algorithms on inside and outside front cover, respectively). Rarely for other causes of bronchospasm

or shock (e.g. 2° to spinal/epidural anaesthesia).

Caution: cerebrovascular* and heart disease (esp arrhythmias and HTN), DM, $\uparrow T_4$, glaucoma (angle closure), labour (esp 2nd stage), phaeo. H/E.

SE: ↑HR, **↑BP**, anxiety, sweats, tremor, headache, peripheral vasoconstriction, arrhythmias, pulmonary oedema (at [↑]doses), N&V, weakness, dizziness, Ψ disturbance, hyperglycaemia, urinary retention (esp if [↑]prostate), local reactions. Rarely CVA* (2° to HTN: monitor BP).

Interactions: fx \uparrow d by dopexamine, TCAs, ergotamine and oxytocin. Risk of: 1. $\uparrow\uparrow$ BP and \downarrow HR with non-cardioselective β -blockers (can also $\Rightarrow \downarrow$ HR), TCAs, MAOIs and moclobemide. 2. arrhythmias with digoxin, quinidine and volatile liquid

anaesthetics (e.g. halothane) and TCAs. Avoid use with tolazine or rasagiline.

Dose: CPR: 1 mg iv = 10 ml of 1 in 10 000 (100 µg/ml) then flush with ≥ 20 ml saline. If no or delayed iv access, try intraosseous route and, if this is not possible, give 2–3 mg via endotracheal tube diluted to 10 ml with sterile water. Repeat as per ALS algorithm (see front cover). Anaphylaxis: 0.5 mg im (or sc) = 0.5 ml of 1 in 1000 (1 mg/ml); repeat after 5 min if no response. (If cardiac arrest seems imminent or concerns over im absorption, give 0.5 mg iv slowly = 5 ml of 1 in 10 000 (100 µg/ml) at 1 ml/min until response – get senior help first if possible as iv route $\Rightarrow \uparrow$ risk of arrhythmias.)

 \searrow Don't confuse 1 in 1000 (im) with 1:10 000 (iv) solutions \bigotimes .

ADVIL see Ibuprofen.

AGGRASTAT see Tirofiban; IIb/IIIa inhibitor (anti-Pt drug) for IHD.

▼AGOMELATINE/VALDOXAN

Antidepressant: melatonin receptor agonist (also $5HT_{2C}$ antagonist); resynchronises circadian rhythms and \uparrow s NA/DA in frontal cortex. **Use:** depression; esp if risk of inconsistent use (low risk of withdrawal syndrome on discontinuation) or if prominent insomnia/sleep reversal.

CI: dementia L/B.

Caution: elderly, history of mania (bipolar). R/P/E.

SE: nausea, diarrhoea, abdo pain, Δ LFTs (\uparrow transaminases in 5%; usually transient), drowsiness, headache, sweating, anxiety. **Monitor:** LFTs before and 6, 12 and 24 wks after starting. **Interactions:** levels $\uparrow\uparrow$ by strong CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin – avoid) and \uparrow by moderate inhibitors

(e.g. propranolol, enoxacin). ↑ risk of convulsions with atomoxetine. Avoid with artemether/lumefantrine.

Dose: 25 mg nocte (can \uparrow to 50 mg nocte after 2 wks).

ALENDRONATE (ALENDRONIC ACID)/FOSAMAX

Bisphosphonate: \downarrow s osteoclastic bone resorption. **Use:** osteoporosis Rx and Px (esp if on corticosteroids). **CI:** delayed GI emptying (esp achalasia and oesophageal stricture/other abnormalities), \downarrow Ca²⁺, unable to sit/stand upright \geq 30 min, **R**(if severe)/**P**/**B**.

Caution: upper GI disorders (inc gastritis/PU) R.

SE: oesophageal reactions^{*}, GI upset/distension, \downarrow Ca²⁺, \downarrow PO₄²⁻ (transient), PU, hypersensitivity (esp skin reactions), myalgia. Rarely osteonecrosis and femoral stress fractures (discontinue drug and should receive no further bisphosphonates).

Warn: take with full glass of water on an empty stomach ≥ 30 min before, and stay upright until breakfast*. Stop tablets and seek medical attention if symptoms of oesophageal irritation develop. **Dose:** 10 mg mane^{SPC/BNF} (10 mg od dosing can be given as once-wkly 70-mg tablet *if for post-menopausal osteoporosis*).

ALFACALCIDOL

1- α -hydroxycholecalciferol: partially activated vitamin D (1 α hydroxy group normally added by kidney), but still requires hepatic (25)-hydroxylation for full activation. **Use:** severe vitamin D deficiency (esp 2° to CRF.)

CI/SE: \uparrow Ca²⁺

Caution: nephrolithiasis, E.

Monitor: Ca²⁺: monitor levels, watch for symptoms (esp N&V), rash, nephrocalcinosis.

Interactions: fx may be \downarrow d by barbiturates and anticonvulsants. **Dose:** initially 1 µg od po; maintenance 0.25–1 µg od po. NB: \downarrow dose in elderly.

VALISKIREN

Direct renin inhibitor (\downarrow s angiotensinogen \Rightarrow angiotensin I). **Use:** essential HTN (*for advice on stepped HTN Mx see p. 178*). **Cl:** potent P-glycoprotein inhibitors (*ciclosporin, verapamil, quinidine) **P/B**. **Caution:** dehydration (risk of \downarrow BP), RAS, diuretics, \downarrow Na⁺ diet, **↑K⁺, moderate potent P-glycoprotein inhibitors (*keto-/itraconazole, clari-/teli-/ery-thromycin, amiodarone), DM***, **R**(if GFR <30 ml/min)/H/P/B/E.

SE: diarrhoea, dizziness, ↓BP, ↑K⁺, ↓GFR. Rarely rash, nasopharyngitis, angioedema, ↓Hb.

Monitor: U&Es esp ** \uparrow K⁺ if taking ACE-i, ARBs, K⁺ sparing diuretics, K⁺ salts (inc dietary salt substitutes) or heparin. Check BG/HbA_{1C} regularly***.

Interactions: metab by/ \downarrow/\uparrow **P450** \therefore many; \downarrow s furosemide levels. Levels \downarrow by irbesartan; levels \uparrow by keto-/itra-conazole. fx \downarrow by \downarrow Na⁺ diet and NSAIDs. fx \uparrow by P-glycoprotein inhibitors (see *CI/Caution). **Dose:** initially 150 mg od, \uparrow ing to 300 mg od if required.

ALLOPURINOL

Xanthine oxidase inhibitor: \downarrow s uric acid synthesis.

Use: Px of **gout**, renal stones (urate or Ca^{2+} oxalate) and other \uparrow urate states (esp 2° to chemotherapy).

Cl: acute gout: can worsen – don't start drug during attack (but don't stop drug if acute attack occurs during Rx).

Caution: R (\downarrow dose), L (\downarrow dose and monitor LFTs), P/B.

SE: GI upset, Severe skin reactions (stop drug if rash develops and allopurinol is implicated – can reintroduce cautiously if mild reaction and no recurrence). Rarely, neuropathy (and many non-specific neurological symptoms), blood disorders, RF, hepatotoxicity, gynaecomastia, vasculitis.

Warn: report rashes, maintain good hydration.

Interactions: \$ fx/toxicity of **azathioprine** (and possibly other cytotoxics, esp ciclosporin), chlorpropamide and theophyllines. Level \downarrow d by salicylates and probenecid. \uparrow rash with ampicillin and amoxicillin. **W+**.

Dose: initially 100 mg od po (\uparrow if required to max of 900 mg/day in divided doses of up to 300 mg) after food. Usual dose 300 mg/day. **NB:** \downarrow **dose in LF or RF**.

Initial Rx can \uparrow gout: give colchicine or NSAID (e.g. indometacin or diclofenac – *not aspirin*) Px until ≥ 1 month after urate normalised.

ALPHAGAN see Brimonidine; α -agonist eye drops for glaucoma.

ALTEPLASE ((recombinant) tissue-type plasminogen activator, rt-PA, TPA). Recombinant fibrinolytic.

Use: acute **MI**, acute massive **PE** (with haemodynamic instability). Acute ischaemic CVA w/in 3 h of onset (specialist use only).

CI/Caution/SE: See p. 208 for use in MI (for use in PE/CVA, see SPC). L (avoid if severe).

Dose: MI: total dose of 100 mg – regimen depends on time since onset of pain: 0-6h: 15 mg iv bolus, then 50 mg ivi over 30 min, then 35 mg ivi over 60 min; 6-12h: 10 mg iv bolus, then 50 mg ivi over 60 min, then four further 10 mg ivis, each over 30 min. **PE:** 10 mg iv over 1–2 min then 90 mg ivi over 2 h.

▲ ↓doses if patient <65 kg; see SPC ▲. If MI concurrent unfractionated iv heparin needed for ≥24 h; see p. 208. Heparin also needed if giving for PE; see SPC.

ALUMINIUM HYDROXIDE

Antacid, PO_4 -binding agent (\downarrow s GI absorption).

Use: dyspepsia, $\uparrow PO_4$ (which can $\uparrow risk$ of bone disease; esp good if secondary to RF, when $\uparrow Ca^{2+}$ can occur dt $\uparrow PTH$, as other PO₄ binders often contain Ca^{2+}).

CI: \downarrow PO₄, porphyria.

SE: constipation^{*}. Aluminium can accumulate in RF (esp on dialysis) \Rightarrow \uparrow risk of encephalopathy, dementia, osteomalacia.

Interactions: can \downarrow absorption of oral antibiotics (e.g. tetracyclines). **Dose:** 1–2 (500-mg) tablets or 5–10 ml of 4% suspension prn (qds often sufficient). \uparrow doses to individual requirements, esp if for \uparrow PO₄. Also available as 475 mg capsules as Alueaps (contains \downarrow Na⁺). Most effective taken with meals and at bedtime. Consider

laxative Px*.

AMANTADINE

Weak DA agonist; \uparrow s release and \downarrow s reuptake of DA. Also antiviral properties; \downarrow s release of viral nucleic acid.

10 COMMON/USEFUL DRUGS

Use: Parkinson's *disease* (not other *Parkinsonism*) and dyskinesias. Also used for Px of influenza A (if immunocompromised, vaccine CI or in exposed health workers).

Cl: gastric ulcer (inc Hx of), epilepsy, **R** (if creatinine clearance <15 ml/min), **P/B**.

Caution: confused or hallucinatory states L/H/E.

SE: confusion, hallucinations, leg oedema.

Warn: Can \downarrow skilled task performance (esp driving). Stop drug slowly*. **Interactions:** memantine \uparrow risk of CNS toxicity, anticholinergics. **Dose:** 100–400 mg daily^{SPC/BNF}. **NB:** \downarrow **dose in RF**.

NB: stop slowly*: risk of withdrawal syndrome.

AMFEBUTAMONE see Bupropion; aid to smoking cessation.

AMILORIDE

 $K^+\mbox{-sparing diuretic (weak): inhibits DCT <math display="inline">Na^+$ reabsorption and K^+ excretion.

Use: oedema (2° to HF, cirrhosis or \uparrow aldosterone), HTN (esp in conjunction with \uparrow K⁺-wasting diuretics as combination preparations; see Co-amilofruse and Co-amilozide). For advice on stepped HTN *Mx see p. 178.*

CI: $\uparrow K^+$, R.

Caution: DM (as risk of RF; monitor U&E), \uparrow risk of acidosis, $\downarrow Na^+$, **P/B/E**.

SE: $\uparrow K^+$, **GI upset**, headache, dry mouth, $\downarrow BP$ (esp postural), $\downarrow Na^+$, rash, confusion. Rarely encephalopathy, hepatic/renal dysfunction. **Interactions:** $\uparrow s$ lithium levels. Can \uparrow nephrotoxicity of NSAIDs. **Dose:** 2.5–20 mg od (or divide into bd doses).

Solution \mathbb{A}^+ Beware if on other drugs that \mathbb{A}^+ , e.g. spironolactone, triamterene, ACE-i, ARBs and ciclosporin. Don't give oral K⁺ supplements inc dietary salt-substitute tablets \mathbb{A}^+ .

AMINOPHYLLINE

Methylxanthine bronchodilator: as the ophylline but $\uparrow H_2O$ solubility (is mixed w ethylenediamine) and \downarrow hypersensitivity. **Use/CI/Caution/SE/Interactions:** see Theophylline; also available iv for use in acute severe bronchospasm; see p. 237. & NB: has many important interactions (dose adjustment may be needed) and can \Rightarrow arrhythmias (use cardiac monitor if giving iv) &.

Monitor: serum levels at 6, 18 and 24 h after starting ivi. Also do levels initially if taking po.

Dose: po: MR preparation (*Phyllocontin continus*) $\Rightarrow \downarrow$ SEs, has different doses at 225–450 mg bd (or 350–700 mg bd if Fortie tablets – for smokers and others with short $t_{1/2}$). *If on a particular brand, ensure this is prescribed as they have different pharmacokinetics. iv:* load* with 5 mg/kg (usually = 250–500 mg) over ≥ 20 min, then 0.5 mg/kg/h ivi, then adjusted to keep plasma levels at 10–20 mg/l (= 55–110 µmol/l). If possible, contact pharmacy for dosing advice to consider interactions, obesity and liver/heart function.

AMIODARONE

Class III antiarrhythmic: ↑s refractory period of conducting system; useful as has ↓negative inotropic fx than other drugs and can give when others ineffective/CI.

Use: tachyarrhythmias: esp paroxysmal SVT, AF, atrial flutter, nodal tachycardias, VT and VF. Also in CPR/periarrest arrhythmias. **CI:** ↓HR (sinus), sinoatrial HB, SAN disease or severe conduction disturbance w/o pacemaker, Hx of thyroid disease/iodine sensitivity, **P/B**.

Caution: porphyria, $\downarrow K^+$ (\uparrow risk of torsades), L/R/H/E.

SE: Acute: N&V (dose-dependent), \downarrow **HR/BP**. Chronic: rarely but seriously \uparrow **o** \downarrow **T**₄, **interstitial lung disease** (e.g. fibrosis, but reversible if caught early), **hepatotoxicity**, **conduction disturbances** (esp \downarrow HR). Common: **malaise**, **fatigue**, photosensitive skin (rarely 'grey-slate'), corneal deposits \pm 'night glare' (reversible), tremor, sleep disorders. Less commonly: optic neuritis (rare but can \downarrow vision), peripheral neuropathy, blood disorders, hypersensitivity. **Monitor:** TFTs and LFTs (baseline then 6-monthly). Also baseline K^+ and CXR (watch for \uparrow SOB/alveolitis).

Warn: avoid sunlight/use sunscreen (inc several months after stopping). **Interactions:** \uparrow s fx of phenytoin and digoxin. Other class III and many class Ia antiarrhythmics, antipsychotics, TCAs, lithium, erythromycin, co-trimoxazole, antimalarials, nelfinavir, ritonavir \Rightarrow \uparrow risk of ventricular arrhythmias. Verapamil, diltiazem and β -blockers \Rightarrow \uparrow risk of \downarrow HR and HB **W**+.

Dose: *po:* load with 200 mg tds in 1st wk, 200 mg bd in 2nd wk, then (usually od) maintenance dose according to response (long $t_{1/2}$: months before steady plasma concentration) *NB: initiate in hospital or specialist outpatient service; iv:* (extreme emergencies only) 150–300 mg in 10–20 ml 5% glucose over ≥ 3 min (don't repeat for at least 15 min); *ivi:* 5 mg/kg over 20–120 min (max 1.2 g/day). For use in cardiac arrest/periarrest arrhythmias see ALS and tachycardia algorithms in the front and back cover flaps of this book respectively. wive via central line (if no time for insertion, give via largest Venflon possible) with ECG monitoring. Avoid giving if severe respiratory failure or \downarrow BP (unless caused by arrhythmia) as can worsen. Avoid iv boluses if CCF/cardiomyopathy we

AMITRIPTYLINE

Tricyclic antidepressant (TCA): blocks reuptake of NA (and 5-HT). **Use:** depression¹ (esp if insomnia, ↓appetite, psychomotor slowing or agitation prominent. NB: ↑danger in OD cf other antidepressants; see p. 194), neuropathic pain².

Cl: recent MI (w/in 3 months), arrhythmias (esp HB), mania, **L** (if severe).

Caution: cardiac/thyroid disease, epilepsy*, glaucoma (angle closure), ↑prostate, phaeo, porphyria, anaesthesia. Also Hx of mania, psychosis or urinary retention, L/H/P/B/E.

SE: antimuscarinic fx (see p. 225), cardiac fx (arrhythmias, HB, HR, postural \downarrow BP, dizziness, syncope: dangerous in OD), \uparrow Wt, sedation^{**} (often \Rightarrow 'hangover'), seizures^{*}. Rarely mania, fever, blood disorders, hypersensitivity, Δ LFTs, \downarrow Na⁺ (esp in elderly), neuroleptic malignant syndrome.

Warn: may impair driving**.

Interactions: AAOIs \Rightarrow HTN and CNS excitation. Never give with, or <2 wks after, MAOI . Levels \uparrow d by SSRIs, phenothiazines and cimetidine. \uparrow Risk of arrhythmias with **amiodarone, pimozide** (is CI), thioridazine and some class I antiarrhythmics. \uparrow risk of paralytic ileus with antimuscarinics. \uparrow s sedative fx of alcohol. \uparrow CNS toxicity with **sibutramine** (is CI). **Dose:** initially 75 mg (30–50 mg in elderly) nocte or in divided doses (\uparrow if required to max 200 mg/day); initially 25 mg (10 mg in elderly) \uparrow ing if required².

AMLODIPINE/ISTIN

Ca²⁺ channel blocker (dihydropyridine): as nifedipine, but \Rightarrow no \downarrow contractility or \uparrow HF.

Use: HTN (*for advice on stepped HTN Mx see p. 178*), angina (esp 'Prinzmetal's' = coronary vasospasm).

Cl: ACS, cardiogenic shock, significant aortic stenosis, P/B.

Caution: BPH (poly-/nocturia), acute porphyria, L.

SE: as nifedipine but \uparrow ankle swelling and possibly \downarrow vasodilator fx (headache, flushing and dizziness).

Interactions: less than other Ca^{2+} channel blockers but may fx of theophyllines and care needed with inducers of cytochrome 3A4.

Dose: initially 5 mg od po (\uparrow if required to 10 mg). NB: consider \downarrow dose in LF.

AMOXICILLIN

Broad-spectrum penicillin; good GI absorption (can give po and iv).

Use: mild pneumonias¹ (esp community-acquired), UTI, *Listeria* meningitis, endocarditis Px and many ENT/dental/other infections. Often used with clavulanic acid as co-amoxiclav.

CI/Caution/SE/Interactions: see Ampicillin.

Dose: 500–1000 mg tds po/iv¹; for other severe infections see SPC/BNF (mild/moderate infections usually 250–500 mg tds po). **NB:** \downarrow dose in RF.

AMPICILLIN

Broad-spectrum penicillin for iv use: has \downarrow GI absorption cf amoxicillin, which is preferred po.

Use: Meningitis (esp *Listeria*; see p. 175)¹, Px pre-operative or for endocarditis during invasive procedures if valve lesions/prostheses, respiratory tract/ENT infections (esp community-acquired pneumonia dt *Haemophilus influenzae* or *Streptococcus pneumoniae*), UTIs (not for blind Rx, as *Escherichia coli* often resistant).

Cl: penicillin hypersensitivity (NB: cross-reactivity with cephalosporins possible).

Caution: EBV/CMV infections, ALL, CLL (all *risk* of rash), **R**. **SE:** rash (erythematous, maculopapular: often does not reflect true allergy) commoner in RF or crystal nephropathy **N&V&D** (rarely AAC), hypersensitivity, CNS/blood disorders.

Interactions: levels \uparrow by probenecid. \uparrow risk of rash with allopurinol. Can \downarrow fx of OCP (warn patient) and \uparrow levels of methotrexate. **Dose:** 2 g 4-hrly ivi¹; most other indications 0.25–1 g qds po/im/iv^{SPC/BNF}. **NB:** \downarrow **dose in RF**.

ANTABUSE see Disulfiram; adjunct to alcohol withdrawal.

ANTACIDS see Alginates (e.g. Acidex, Gastrocote, Gaviscon or Peptae) or Co-magaldrox.

AQUEOUS CREAM Emulsifying ointment (phenoxyethanol in purified water). Topical cream used as emollient in dry skin conditions and as a soap-substitute.

▼ARIPIPRAZOLE/ABILIFY

Atypical (third generation) antipsychotic; *partial* D_2 (and $5HT_{1A}$) agonist $\Rightarrow \downarrow$ dopaminergic neuronal activity. Also potent $5HT_{2A}$ antagonist. **Use:** schizophrenia, mania (Px and acute Rx).

CI: B.

Caution: cerebrovascular disease, Hx or \uparrow risk of seizures, family Hx of \uparrow QT L/P/E.

SE: EPSE (esp akathisia/restlessness, although generally $\Rightarrow \downarrow$ EPSE than other antipsychotics), dizziness, sedation (or insomnia), blurred vision,

fatigue, headache, gastrointestinal upset, anxiety and \$salivation. Rarely \uparrow HR, depression, orthostatic \downarrow BP. Very rarely skin/blood disorders, \uparrow QTc, DM, NMS, tardive dyskinesia, seizures and CVA. **Interactions: metab by P450** \therefore many; most importantly levels \uparrow by quinidine, fluoxetine, paroxetine, keto/itra-conazole, HIV protease inhibitors and levels \downarrow by carbamazepine, rifampicin, rifabutin, phenytoin, primodone, efavirenz, nevirapine and St John's wort. **Dose:** 10–15 mg po od (max 30 mg/od); 5.25–15 (usually 9.75) mg im as single dose repeated after \ge 2 h if required (max 3 injections/ day or combined im/po dose of 30 mg/day). NB: \downarrow dose in elderly.

ARTHROTEC

Combination tablets of diclofenac with misoprostol (200 μ g/tablet) to \downarrow GI SEs (esp PU/bleeds).

Cl/Caution/SE/Interactions: see Diclofenac and Misoprostol. **Dose:** 50 mg bd/tds po or 75 mg bd (prescribed as dose of diclofenac).

ASACOL see Mesalazine: 'new' aminosalicylate for UC with \downarrow SEs. Available po (3–6 tablets of 400 mg per day in divided doses), as suppositories (0.75–1.5 g daily in divided doses) or as foam enemas (1–2 g daily).

ASPIRIN

NSAID. Inhibits COX-1 and COX-2 $\Rightarrow \downarrow$ PG synthesis (\therefore antiinflammatory and antipyrexial) and \downarrow thromboxane A₂ (\therefore anti-Pt aggregation).

Use: mild to moderate pain/pyrexia¹, IHD and thromboembolic CVA Px^2 and acute Rx^3 .

Cl: <16 years old, unless specifically indicated (can \Rightarrow Reye's syndrome), PU (active or PHx of), haemophilia, gout, hypersensitivity to any NSAID, R(GFR<10 ml/min)/L(if severe)/B. Caution: asthma, uncontrolled HTN, any allergic disease*, G6PD deficiency, dehydration, L/R(avoid if either severe)/P/E. SE: GI irritation, \uparrow bleeding time, bleeding (esp GI: $\uparrow\uparrow$ risk if also anticoagulated)**. Rarely hypersensitivity* (anaphylaxis, bronchospasm, skin reactions), ARF, hepatotoxicity, ototoxic in OD. 16

Interactions: \GI bleeding with anticoagulants^{**}, other NSAIDs (avoid), SSRIs & venlafaxine. W + Can \Rightarrow $\$ levels of methotrexate, $\$ fx anticonvulsants & \downarrow fx spironolactone.

Dose: 300–900 mg 4–6-hrly (max 4 g/day)¹, 75 mg od², 300 mg stat³. Stop 7 days before surgery if significant bleeding is expected. If cardiac surgery or patient has ACS, consider continuing.

ATENOLOL

 β -blocker: (mildly) cardioselective* ($\beta_1 > \beta_2$), $\uparrow H_2O$ solubility $\therefore \downarrow$ central fx** and \uparrow renal excretion***.

Use: HTN^1 (for advice on stepped HTN Mx see p. 178), angina², MI (w/in 12 h as early intervention)³, arrhythmias⁴.

Cl/Caution/SE/Interactions: see Propranolol $\Rightarrow \downarrow$ bronchospasm* (but avoid in all asthma/only use in COPD if no other choice) and \downarrow sleep disturbance/nightmares**.

Dose: 25–50 mg od po¹; 100 mg od po²; 5 mg iv over 5 min then 50 mg po 15 min later then start 50 mg bd 12 h later³; 50–100 mg od po⁴ (for iv doses see SPC/BNF). **NB: consider \downarrowdose in RF*****.

ATORVASTATIN/LIPITOR

HMG-CoA reductase inhibitor.

Use/Cl/Caution/SE: see Simvastatin.

Interactions: Trisk of myopathy with Set **fibrates**, daptomycin, ciclosporin, nicotinic acid, itra-/posa-conazole. Levels Tby clari-/ teli-thromycin.

Dose: initially 10 mg nocte (\uparrow if necessary, at intervals \geq 4 wks, to max 80 mg).

iv ATROPINE (SULPHATE)

Muscarinic antagonist: blocks vagal SAN and AVN stimulation, bronchodilates and \downarrow s oropharyngeal secretions.

Use: severe \downarrow HR (see algorithm on inside front cover) or HB¹, CPR² (see ALS universal algorithm on inside back cover),

organophosphate/ anticholinesterase* OD/poisoning³ and specialist anaesthetic uses.

Cl: (*don't apply if life-threatening condition/CPR!*): glaucoma (angle closure), MG (*unless anticholinesterase overdosage*, when atropine is indicated*), paralytic ileus, pyloric stenosis, bladder neck obstruction (e.g. ↑prostate).

Caution: Down's syndrome, gastro-oesophageal reflux, diarrhoea, UC, acute MI, HTN, \uparrow HR (esp 2° to \uparrow T₄, cardiac insufficiency or surgery), pyrexia, P/B/E.

SE: transient ↓**HR** (followed by ↑**HR**, palpitations, arrhythmias), antimuscarinic fx (see p. 225), N&V, confusion (esp in elderly), dizziness.

Dose: 0.3–1.0 mg iv¹; 3 mg iv² (*if no iv/intraosseous access, give 6 mg with 10 ml saline via endotracheal tube*); 1–2 mg im/iv every 10–30 min³ (every 5 min in severe cases) up to max 100 mg in 1st 24 h, until symptomatic response (skin flushes and dries, pupils dilate, $HR\uparrow s$).

ATROVENT see Ipratropium; bronchodilator for COPD/asthma.

AUGMENTIN see Co-amoxiclav (amoxicillin + clavulanic acid) 375 or 625 mg tds po (1.2 g tds iv).

AZATHIOPRINE

Antiproliferative immunosuppressant: inhibits purine-salvage p'ways; prodrug for 6-mercaptopurine.

Use: prevention of transplant rejection, autoimmune disease (esp as steroid-sparing agent, but also maintenance Rx for SLE/vasculitis). **Cl:** hypersensitivity (to azathioprine *or mercaptopurine*), **P/B. Caution:** L/R/E.

SE: myelosuppression (dose-dependent, \Rightarrow înfections, esp HZV), hepatotoxicity, hypersensitivity reactions (inc interstitial nephritis: *stop drug!*), N&V&D (esp initially), pancreatitis. Rarely cholestasis, alopecia, pneumonitis, risk of neoplasia, hepatic veno-occlusion. Warn: immediately report infections or unexpected bruising/bleeding.

Monitor: FBC (initially \geq wkly \downarrow ing to \geq 3-monthly), LFTs, U&Es. **Interactions:** fx \uparrow by **allopurinol**, ACE-i, ARBs, trimethoprim (and septrin). fx \downarrow by rifampicin. **W**-. **Dose:** Initially 1-5 mg/kg daily $\leq 8 \text{ wks}$, then 1-4 mg/kg daily^{SPC/BNF} (preferably po as iv very irritant). **NB:** \downarrow **dose in RF**.

Sefore starting Rx, screen for common gene defect that \downarrow s TPMT enzyme (which metabolises azathioprine) activity: if homozygote for defect avoid azathioprine; if heterozygote, \downarrow dose (esp if taking aminosalicylate derivatives, e.g. olsalazine, mesalazine or sulfasalazine) \bigotimes .

AZITHROMYCIN

Macrolide antibiotic: see Erythromycin. **Use:** see Erythromycin (but with \uparrow activity against Gram –ve and \downarrow activity against Gram +ve organisms). **Cl:** as erythromycin, plus **L** (if severe). **Caution/SE/Interactions:** as erythromycin (NB: \uparrow **P450** \therefore many interactions) but $\Rightarrow \downarrow$ GI SEs.

Dose: 500 mg od po *for 3 days only* (continue for 7 days for typhoid); for GU infections 1 g od po *as single dose*.

AZOPT see Brinzolamide; eye drops for glaucoma.

AZT see Zidovudine; antiretroviral for HIV.

BACLOFEN

Skeletal muscle relaxant: \downarrow s spinal reflexes, general CNS inhibition at \uparrow doses.

Use: spasticity, if chronic/severe, (esp 2° to MS or cord pathology). **Cl:** PU.

Caution: Ψ disorders, epilepsy, Hx of PU, Parkinson's, porphyria, DM, hypertonic bladder sphincter, respiratory/cerebrovascular disease, L/R/P/E.

SE: sedation, \downarrow muscle tone, nausea, urinary dysfunction, GI upset, \downarrow BP. Others rare: \uparrow spasticity (*stop drug!*), multiple neurological/ Ψ symptoms, cardiac/hepatic/respiratory dysfunction. **Warn:** may \downarrow skilled tasks (esp driving), \uparrow s fx of alcohol. **Interactions:** fx \uparrow by TCAs. May \uparrow fx of antihypertensives. **Dose:** 5 mg tds po (after food) \uparrow ing, if required, to max of 100 mg/day. **NB** \downarrow **dose in RF**. In severe cases, can give by intrathecal pump (see SPC/BNF).

Stop gradually over $\geq 1-2$ wks to avoid withdrawal symptoms: confusion, \uparrow spasticity, Ψ reactions, fits, \uparrow HR.

BACTROBAN see Mupirocin; topical antibiotic (esp for nasal MRSA). See local policy for infection control.

BECLOMETASONE

Inh corticosteroid: \downarrow s airway oedema and mucous secretions. **Use:** chronic asthma not controlled by short-acting β_2 agonists alone (start at step 2 of BTS guidelines; see p. 181).

Caution: TB (inc quiescent).

SE: oral candidiasis (2° to immunosuppression: \downarrow d by rinsing mouth with H₂O after use), hoarse voice. Rarely glaucoma, hypersensitivity. \uparrow Doses may \Rightarrow adrenal suppression, Cushing's, \downarrow bone density, \downarrow growth (controversial).

Dose: 200–2000 μ g daily inh (normally start at 200 μ g bd). Use high-dose inhaler if daily requirements are >800 μ g^{SPC/BNF}. Specify named product for CFC metered disc inhalers as dose ranges from 50 to 400 μ g/delivery. CFC-free pressurized metered dose inhalers are not interchangeable.

Rarely \Rightarrow paradoxical bronchospasm: can be prevented by switching from aerosol to dry powder forms or by using inh β_2 agonists.

BECOTIDE see Beclometasone.

BENDROFLUMETHIAZIDE

Thiazide diuretic: \downarrow s Na⁺ (and Cl) reabsorption from DCT \Rightarrow Na⁺ and H₂O loss and stimulates K⁺ excretion.

Use: oedema¹ (2° to HF or low–protein states), HTN² (in short term by \downarrow ing fluid volume and CO; in long term by \downarrow ing TPR; *for advice on stepped HTN Mx see p. 178*), Px against renal stones in hypercalciuria³.

CI: \downarrow K⁺ (refractory to Rx), \downarrow Na⁺, \uparrow Ca²⁺, Addison's disease, \uparrow urate (if symptoms), **L/R** (if either severe, otherwise caution). **Caution:** porphyria, and can worsen gout, DM or SLE, **P/B/E. SE:** dehydration (esp in elderly), \downarrow **BP** (esp postural), \downarrow K⁺, GI upset, impotence, \downarrow Na⁺, alkalosis (with \downarrow Cl), \downarrow Mg²⁺, \uparrow Ca²⁺, \uparrow urate/gout, \uparrow glucose, lipid metabolism (esp \uparrow cholesterol), rash, photosensitivity, blood disorders (inc \downarrow Pt, \downarrow NØ), pancreatitis, intrahepatic cholestasis, hypersensitivity reactions (inc severe respiratory and skin reactions), arrhythmias. **Interactions:** \uparrow s **lithium** levels. fx \downarrow by **NSAIDs** and oestrogens. If \downarrow K⁺ can \uparrow toxic fx of many drugs (esp digoxin, NSAIDs, corticosteroids and many antiarrhythmics). \uparrow risk of \downarrow Na⁺ with carbamazepine \uparrow risk of \downarrow K⁺ with amphotericin. **Dose:** initially 5–10 mg mane po¹, then \downarrow dose *frequency* (i.e. omit days) if possible; 2.5 mg od po^{2,3} (little benefit from \uparrow doses).

BENZYLPENICILLIN (= PENICILLIN G)

Penicillin with poor po absorption .: only given im/*iv*: used mostly against streptococcal (esp *S. pneumoniae*) and neisserial (esp *N. gonorrhoeae*, *N. meningitidis*) infections.

Use: severe skin infections (esp cellulitis, wound infections, gas gangrene) in conjunction with other agents (see p. 176), meningitis, endocarditis, ENT infections, anthrax.

Cl: penicillin hypersensitivity (NB: cross-reactivity with cephalosporins common).

Caution: Hx of allergy, false +ve glycosuria, R*.

SE: hypersensitivity (inc fever, arthralgia, rashes, urticaria, angioedema, anaphylaxis, serum sickness-like reactions, haemolytic \downarrow Hb, interstitial nephritis), **diarrhoea** (rarely AAC). Rarely blood disorders (\downarrow Pt, \downarrow NØ, coagulation disorders), CNS toxicity (inc convulsions, esp at \uparrow doses or if RF*). \uparrow doses can $\Rightarrow \downarrow K^+$ (and $\downarrow Na^+$). **Interactions:** levels \uparrow d by probenecid. \uparrow risk of rash with allopurinol. Can \downarrow fx of OCP.

Dose: 0.6-1.2 g qds iv (or im/ivi). If very severe, give 2.4 g every 4 h (only as iv/ivi). **NB:** \downarrow **dose in RF**.

BETAHISTINE/SERC

Histamine analogue (H₁ antagonism and H₃ antagonism): \uparrow s middle-ear microcirculation $\Rightarrow \downarrow$ endolymphatic pressure. **Use:** Ménière's disease (if tinnitus, vertigo or hearing loss). **Cl:** phaeo. **Caution:** asthma, Hx of PU, **P/B**. **SE:** GI upset. Rarely headache, rash, pruritus. **Dose:** 16 mg tds po (maintenance usually 24–48 mg/day).

BETAMETHASONE CREAM (0.1%)/OINTMENT

'Potent' strength topical corticosteroid (rarely used as weaker 0.05% or 0.025% preparations).

Use: inflammatory skin conditions, in particular eczema.

Cl: untreated infection, rosacea, acne.

SE: skin atrophy, worsening of infections, acne.

Dose: apply thinly 1–2 times per day. Use 'ointment' in dry skin conditions.

BETNOVATE see Betamethasone cream 0.1% (potent strength). Available as Betnovate RD (moderate strength) 0.025%.

BEZAFIBRATE

Fibrate (lipid-lowering): $\Rightarrow \downarrow TG$, $\downarrow LDL$, $\uparrow HDL$ by stimulating lipoprotein lipase ($\Rightarrow \downarrow$ conversion of VLDL/TG to LDL and $\Rightarrow \uparrow LDL$ clearance from circulation). Also \Rightarrow (mild) \downarrow cholesterol. Use: hyperlipidaemias (esp if $\uparrow TG :$ types IIa/b, III, IV, V). CI: gallbladder disease, PBC, \downarrow albumin (esp nephrotic syndrome), R*/L (if either severe; otherwise caution), P/B.

Caution: \downarrow T₄ (needs to be corrected).

SE: GI upset, \downarrow appetite, \uparrow gallstones, myositis (rarer but important: \uparrow risk if RF*). Also impotence, rash (inc pruritus, urticaria), headache. Rarer: dizziness, vertigo, fatigue, hair loss, blood disorders (\downarrow Hb, \downarrow WCC, \downarrow Pt).

Interactions: \mathcal{D} 'statins' \Rightarrow **\text{Trisk of myositis** \mathcal{D} . \uparrow s fx of antidiabetics. \uparrow risk of hepatotoxicity with MAOIs. Can \uparrow renal toxicity of ciclosporin. **W**+.

COMMON/USEFUL DRUGS

Dose: 200 mg tds po (after food). MR 400 mg od preps available^{BNF}. **NB:** \downarrow **dose in RF**.

BICARBONATE see Sodium bicarbonate.

BIMATOPROST EYE DROPS/LUMIGAN

Topical PG analogue for glaucoma; see Latanoprost. Use/Cl/Caution/SE: see Latanoprost. Dose: 1 drop od.

BISOPROLOL

β-blocker, cardioselective ($\beta_1 > \beta_2$). Use: HTN¹ (for advice on stepped HTN Mx see p. 178), angina², HF³.

Cl/Caution/SE/Interactions: as propranolol, but also CI in HF needing inotropes or if SAN block; caution if psoriasis.

Dose: 10 mg od po^{1,2} (maintenance 5–20 mg od); initially 1.25 mg od po³(\uparrow ing slowly to max 10 mg od)^{SPC/BNF}. **NB:** \downarrow **dose in LF or RF**.

BOSENTAN/TRACLEER

Endothelin receptor antagonist: relaxes vascular smooth muscle. **Use:** pulmonary arterial HTN¹, Px of digital ulcers in systemic sclerosis.²

Cl: acute porphyria, P/B.

Caution: ↓BP (systolic BP <85 mmHg), **L** (avoid if severe). **SE:** Δ **LFTs**, ↓BP, palpitations, oedema, headache, flushing, bleeding/↓Hb, hypersensitivity reactions, dyspepsia.

Warn: avoid sudden withdrawal and report symptoms of LF. **Monitor:** LFTs monthly (and 2 wks after dose \uparrow) and Hb monthly for 1st 4 wks then 3-monthly.

Interactions: metab by and **↑P450**. Levels \uparrow by ciclosporin, keto-/flu-/itra-conazole. Levels \downarrow by rifampicin. \downarrow s fx of OCP and simvastatin. \uparrow risk of hepatoxicity with glibenclamide. **Dose:** initially 62.5 mg po bd for 4 wks then \uparrow to 125 mg bd^{1,2} (can \uparrow to 250 mg bd¹)^{SPC/BNF}.

BOWEL PREPARATIONS

Bowel-cleansing solutions for preparation for GI surgery/Ix. **CI:** GI obstruction/ulceration/perforation, ileus, gastric retention, toxic megacolon/colitis, **H**.

Caution: UC, DM, heart disease, reflux oesophagitis, ↑risk of regurgitation/aspiration (e.g. ↓swallow/gag reflex/GCS), R/P.

SE: nausea, bloating, abdominal pains, vomiting. Dose: see Citramag, Fleet (Phospho-soda), Klean-prep, Picolax.

BRIGANYL see Terbutaline (inh β_2 agonist for asthma). Various delivery devices available^{SPC/BNF}.

BRIMONIDINE EYE DROPS/ALPHAGAN

Topical α_2 agonist: \downarrow s aqueous humour production $\therefore \downarrow$ s IOP. **Use:** open-angle glaucoma, ocular HTN (esp if β -blocker or PG analogue CI or fails to \downarrow IOP).

Caution: postural JBP/HR, Raynaud's, cardiovascular disease (esp IHD), cerebral insufficiency, depression*, P/B/R/L.

SE: sedation, headache, dry mouth, HTN, blurred vision, local reactions (esp discomfort, pruritus, hyperaemia, follicular conjunctivitis). Rarely, palpitations, depression*, hypersensitivity. **Interactions:** AGA MAOIs, TCAs, mianserin (or other antidepressants affecting NA transmission) are CI.

Dose: 1 drop bd of 0.2% solution. Also available as od combination drop with timolol 0.5% (Combigan).

BRINZOLAMIDE/AZOPT

Topical carbonic anhydrase inhibitor for glaucoma. Similar to dorzolamide (\downarrow s aqueous humour production). **Cl: R** (if GFR <30 ml/min)

Dose: 1 drop bd/tds. Also available as od combination drop with timolol 0.5% (Azarga).

BROMOCRIPTINE

DA agonist; \downarrow s pituitary release of prolactin/growth hormone. **Use:** Parkinsonism if L-dopa insufficient/not tolerated, NMS, endocrine disorders¹ (if prolactin or growth hormone related).

COMMON/USEFUL DRUGS

Cl: toxaemia of pregnancy, hypersensitivity to ergot alkaloids, uncontrolled HTN. Also HTN/IHD postpartum or in puerperium. **Caution:** cardiovascular disease, porphyria, Raynaud's disease, serious Ψ disorders (esp psychosis), P/B.

SE: GI upset, postural \downarrow BP (esp initially and if \uparrow alcohol intake), behavioural Δ s (confusional states, Ψ disorders), \uparrow sleep (sudden onset/daytime). Rarely but seriously **fibrosis***: pulmonary**, cardiac, retroperitoneal*** (can \Rightarrow ARF).

Warn: of ↑sleep. Report persistent cough** or chest/abdo pain. Monitor: ESR*, U&Es***, CXR**; pituitary size and visual fields (pregnancy and¹)**.

Interactions: levels \uparrow by ery-/clari-thromycin and octreotide. **Dose:** 1–30 mg/day^{SPC/BNF}. **NB: consider** \downarrow **dose in LF**.

 $\label{eq:BUCCASTEM Prochlorperazine (antiemetic) buccal tablets: absorbed rapidly from under top lip <math>\therefore$ don't need to be swallowed and retained in stomach for absorption if N&V.

Caution: L.

Dose: 3-6 mg bd.

▼BUDESONIDE

Inh corticosteroid for asthma¹; similar to beclometasone but stronger (approximately double the strength per microgram). Also available po or as enemas for IBD^2 (see BNF).

Caution: L.

Dose: 200–800 µg bd inh (aerosol or powder) or 1–2 mg bd neb¹.

BUMETANIDE

Loop diuretic: inhibits Na^+/K^+ pump in ascending loop of Henle. **Use/Cl/Caution/SE/Monitor/Interactions:** as furosemide; also headaches, gynaecomastia and at \uparrow doses can \Rightarrow myalgia.

Dose: 1 mg mane po $(500 \,\mu\text{g}$ may suffice in elderly), \uparrow ing if required (5 mg/24 h usually sufficient; \uparrow by adding a lunchtime dose, then \uparrow ing each dose). 1–2 mg im/iv (repeat after 20 min if required). 2–5 mg ivi over 30–60 min.

NB: give iv in severe oedema; bowel oedema $\Rightarrow \downarrow po$ absorption.

24

BUPROPION (= AMFEBUTAMONE)/ZYBAN

NA and to lesser extent DA reuptake inhibitor (NDRI) developed as antidepressant, but also \uparrow s success of giving up smoking. **Use:** (adjunct to) smoking cessation^{NICE}.

Cl: CNS tumour, acute alcohol/benzodiazepine withdrawal, Hx of seizures*, eating disorders, bipolar disorder, **L** (if severe cirrhosis)/**P/B**. **Caution:** if \uparrow risk of seizures*: alcohol abuse, Hx of head trauma and DM, **R/E**.

SE: seizures^{*}, insomnia (and other CNS reactions, e.g. anxiety, agitation, depression, fever, headaches, tremor, dizziness). Also \uparrow HR, AV block, \uparrow or \downarrow BP^{**}, chest pain, hypersensitivity (inc severe skin reactions), GI upset, \uparrow Wt, mild antimuscarinic fx (esp **dry mouth**; see p. 225 for others).

Monitor: BP**.

Interactions: \downarrow **P450** \therefore many interactions, but importantly **CNS** drugs, esp if \downarrow seizure threshold*, e.g. antidepressants (\bigotimes MAOIs; avoid together, including <2 wks after MAOI \bigotimes), antimalarials, antipsychotics (esp risperidone), quinolones, sedating antihistamines, systemic corticosteroids, theophyllines, tramadol. Ritonavir $\Rightarrow \downarrow$ plasma level of bupropion.

Dose: 150 mg od for 6 days then 150 mg bd for max 9 wks (\downarrow dose if elderly or \uparrow seizure risk^{SPC/BNF}). Start 1–2 wks before target date of stopping smoking. **NB: max 150 mg/day in LF or RF**.

BURINEX Bumetanide 1-mg tablets.

BUSCOPAN see Hyoscine butylbromide; GI antispasmodic.

GAGIT see Calcium carbonate.

CACIT D3 Calcium carbonate + low dose vitamin D_3 .

Use: Px of vitamin D deficiency.

Caution: L.

Dose: 1 tablet od (= $12.6 \text{ mmol Ca}^{2+} + 11 \mu \text{g}$ cholecalciferol).

GALCICHEW see Calcium carbonate.

Dose: 1 tablet od. Each tablet = $12.6 \text{ mmol Ca}^{2+} + 5 \mu \text{g vit D}_3$ (colecalciferol) or $10 \mu \text{g vit D}_3$ in 'forte' preparations.

CALCIPOTRIOL OINTMENT AND CREAM

Vitamin D analogue for plaque psoriasis. **SE:** local skin reactions (itching, redness). **Caution:** use <100 g/wk, **E**. **CI:** patients with disorders of Ca²⁺ metabolism. **Use:** apply twice daily.

CALCITONIN

Synthetic hormone (normally produced by C cells of thyroid): binds to specific osteoclast receptors $\Rightarrow \downarrow$ resorption of bone and $\downarrow Ca^{2+}$. Its fx are specific to abnormal (high-turnover) bone.

Use: $\uparrow Ca^{2+}$ (esp dt malignancy; also \downarrow s bone metastases pain), Paget's disease (\downarrow s pain and neurological symptoms, e.g. deafness). Rarely for Px/Rx of postmenopausal osteoporosis. **Cl:** $\downarrow Ca^{2+}$.

Caution: Hx of *any* allergy, R/H/P/B.

SE: GI upset (esp N&V), flushing, \uparrow urinary frequency, taste, vision/sensory Δ , hypersensitivity (inc anaphylaxis), myalgia, local inflammation.

Dose: see BNF/SPC.

CALCIUM CARBONATE

Use: osteoporosis, $\downarrow Ca^{2+}$, $\uparrow PO_4$ (esp 2° to RF; binds PO₄ in gut $\Rightarrow \downarrow$ absorption).

Cl: conditions assoc with \uparrow Ca²⁺ (in serum or urine).

Caution: sarcoid, Hx of kidney stones, phenylketonuria, **R**. **SE:** GI upset, $\uparrow Ca^{2+}$ (serum or urine), $\downarrow BP$, $\downarrow HR$, arrhythmias. **Interactions:** fx \uparrow by thiazides, fx \downarrow by corticosteroids, \downarrow s absorption of tetracyclines (give ≥ 2 h before or 6 h after) and bisphosphonates. **Dose:** as required up to 40 mmol/day in osteoporosis if ↓dietary intake, e.g. Calcichew (standard 12.6-mmol or 'forte' 25-mmol tablets), Calcium 500 (12.5-mmol tablets) or Adcal (15-mmol tablets).

CALCIUM CHLORIDE

Ca²⁺ for emergency iv use: mostly CPR as ⇒ ↑venous irritation cf calcium gluconate. Can also use for severe ↓Ca²⁺ or ↑K⁺. CI: VF, conditions assoc with ↑Ca²⁺ (in serum or urine). SE: GI upset, ↑Ca²⁺, ↓HR, ↓BP, arrhythmias. Dose: available as syringes of 10 ml of 10% solution (= total of 6.8 mmol Ca²⁺). Give iv no quicker than 1 ml/min (otherwise can ⇒ arrhythmias) as per indication and clinical/e'lyte response. E.g. Mim-I-J@: often in crash trolleys if iv Ca²⁺ needed urgently.

 $\begin{array}{l} \textbf{CALCIUM + ERGOCALCIFEROL} \ tablets \ of \ 2.4 \ mmol \ Ca^{2+} + \\ low-dose \ (10 \ \mu g) \ ergocalciferol \ (= \ calciferol \ = \ vitamin \ D_2). \\ \textbf{Use:} \ Px \ of \ vitamin \ D \ deficiency. \\ \textbf{Cl/Caution/SE:} \ see \ Ergocalciferol. \\ \textbf{Dose:} \ 1 \ tablet \ od^{SPC/BNF}. \end{array}$

CALCIUM GLUCONATE

iv preparation of Ca^{2+} (also available po, but used rarely). **Use:** $\downarrow Ca^{2+}$ (if severe)¹, $\uparrow K^+$ (\downarrow s arrhythmias: 'cardioprotective', see p. 248)², $\uparrow Mg^{2+}$.

CI/SE: as calcium chloride.

Dose: 10 ml of 10% iv over 3 min (= total of 2.2 mmol Ca^{2+})^{1,2}, repeating if necessary according to clinical and electrolyte response; consider following with ivi¹.

CALCIUM RESONIUM

Polystyrene sulphonate ion-exchange resin. **Use:** mild/moderate $\uparrow K^+$ (not for *initial** Mx of severe $\uparrow K^+$). **Cl:** obstructive bowel disease, diseases likely to $\uparrow Ca^{2+}$ ($\uparrow PTH$, multiple myeloma, sarcoid, metastatic cancer), K⁺<5mmol/l. **Caution:** P/B. **SE:** GI upset (esp constipation; often need Px of 10–20 ml lactulose), $\downarrow K^+$, $\downarrow Mg^{2+}$, $\uparrow Ca^{2+}$.

Interactions: ↑risk GI obstruction with aluminium hydroxide, ↑risk of alkalosis with aluminium carbonate and magnesium hydroxide. May ↓lithium and levothyroxine levels.

Dose: 15 g tds/qds po. NB: takes 24–48 h to work*. Also available as 30-g enemas (rarely \Rightarrow rectal ulceration and colonic necrosis: needs cleansing enema first and washout afterwards; see SPC).

GALGIUM SANDOZ Ca^{2+} supplement syrup; 108.3 mg (2.7 mmol) $Ca^{2+}/5$ ml.

CALPOL Paracetamol (paediatric) suspension.

Dose: according to age; all doses can be given up to max frequency qds (min dose spacing = 4 h): 3 months–1 year 60–120 mg, 1–5 years 120–250 mg, 6–12 years 250–500 mg, >12 years 500–1000 mg (= adult dose).

NB: Two strengths available: 'standard' Paedlatric (120 mg/5 ml) and stronger 6 Plus (250 mg/5 ml).

CANDESARTAN/AMIAS

Angiotensin II antagonist. **Use:** HTN¹ (for advice on stepped HTN Mx see p. 178) or HF^2 (when ACE-i not tolerated).

Cl: cholestasis, L (if severe)/P/B.

Caution/SE/Interactions: see Losartan.

Dose: initially 8 mg od¹ (2 mg if LF, 4 mg if RF/intravascular volume depletion) \uparrow ing at 4-wk intervals if necessary to max of 32 mg od; initially 4 mg od² \uparrow ing at intervals \geq 2 wks to 'target dose' of 32 mg od (or max tolerated). **NB:** \downarrow **dose in LF**.

CANESTEN

Clotrimazole 1% cream: antifungal, esp for vaginal candida infections (thrush). Also available as powder, solution and spray for hairy areas. **Dose:** apply bd/tds.

CAPTOPRIL

ACE-i: short-acting: largely replaced by longer-acting drugs. **Use:** HTN (for advice on stepped HTN Mx see p. 178), HF, post-MI, and diabetic nephropathy (i.e. consistent proteinuria). **Cl:** renovascular disease* (known or suspected bilateral RAS), angioedema/other hypersensitivity 2° to ACE-i, porphyria, P. **Caution:** symptomatic aortic stenosis, Hx of idiopathic or hereditary angioedema, if taking drugs that $\uparrow K^{+**}$, L/R/B/E. **SE:** \downarrow **BP** (esp with 1st dose, if HF, dehvdrated or on diuretics, dialysis or \downarrow Na⁺ diet \therefore take at night), **RF**^{*}, dry cough, \uparrow K⁺, acidosis, hypersensitivity (esp rashes and angioedema), photosensitivity, Δ taste, upper respiratory tract symptoms (inc sore throat/ sinusitis/rhinitis), GI upset, Δ LFTs (rarely cholestatic jaundice/ hepatitis), pancreatitis, blood disorders, many non-specific neuro symptoms. **Monitor:** U&Es, esp baseline and 2 *wks after starting**. **Interactions:** fx \downarrow d by NSAIDs (also \Rightarrow \uparrow risk RF*). **Diuretics**, TCAs and antipsychotics \Rightarrow risk of $\downarrow \downarrow$ BP. \uparrow s fx of lithium (and antidiabetics).

Dose: 6.25–75 mg bd po^{SPC/BNF}. **NB:** ↓**dose in RF**. ****Beware if on other drugs that** ↑K⁺, e.g. amiloride, spironolactone, triamterene, ARBs and ciclosporin. Don't give with oral K⁺ supplements – inc dietary salt substitutes .

CARBAMAZEPINE/TEGRETOL

Antiepileptic, mood stabiliser, analgesic; \downarrow s synaptic transmission. **Use:** epilepsy¹ (generalised tonic-clonic and partial seizures, but may exacerbate absence/myoclonic seizures), Px bipolar disorder² (if unresponsive to lithium), neuralgia³ (esp post-herpetic, trigeminal and DM-related).

Cl: unpaced AV conduction dfx, Hx of BM suppression, acute porphyria.

Caution: cardiac disease, Hx skin disorders (HLA-B*1502 in Han Chinese or Thai origin have \uparrow risk of SE – esp SJS), Hx haematological drug reactions, glaucoma, L/R, P (\Rightarrow neural tube dfx* $\therefore \Rightarrow$ folate Px and screen for dfx), B.

Dose-related SEs: N&V, headache, drowsiness, dizziness,

vertigo, ataxia, visual Δ (esp double vision): control by \downarrow ing dose, Δ dose times/spacing or use of MR preparations^{**}.

Other SEs: skin reactions (transient erythema common), blood disorders (esp \downarrow WCC*** – often transient, \downarrow Pt, aplastic anaemia), \uparrow gamma-GT (usually not clinically relevant), oedema, \downarrow Na⁺ (inc SIADH), HF, arrhythmias. Many rarer SEs^{SPC/BNF}, including suicidal thoughts/behaviour.

Monitor: serum levels (optimum therapeutic range = 4–12 mg/l), U&Es, LFTs, FBC***.

Warn: driving may be impaired, and watch for signs of liver/skin/ haematological disease. Inform patient (and carers) of risk of suicidal thoughts/behaviour and to seek medical advice if develops.

Interactions: $\uparrow P450$... many (see $^{SPC/BNF}$) – may cause failure of OCP; fx are $\uparrow d$ by ery-/clari-thromycin, isoniazid, verapamil and diltiazem; and fx are $\downarrow d$ by phenytoin, phenobarbitone. $\bigotimes CI$ with MAOIs $\bigotimes ... W-$.

Dose: initially 100-200 mg od/bd (\uparrow slowly to max of $1.6 \text{ g/day}^{2.3}$ or 2 g/day^{1}). (MR forms^{**} available^{SPC/BNF})

CARBIMAZOLE

Thionamide antithyroid: peroxidase inhibitor; stops $I^- \Rightarrow I_2$ and $\therefore \downarrow s$ T_3/T_4 production. Possibly also immunosuppressive fx. Use: $\uparrow T_4$.

Caution: L, P/B (can cause fetal/neonatal goitre/ \downarrow T₄ \therefore use min dose to control symptoms and monitor neonatal development closely – 'block-and-replace' regimen \therefore not suitable).

SE: hypersensitivity: rash and pruritus (if symptoms not tolerated or not eased by antihistamines, switch to propylthiouracil), fever, arthralgia. Also GI disturbance (esp nausea), headache, rash and pruritis. Rarely hepatic dysfunction, alopecia, blood disorders – esp **agranulocytosis*** (0.5%) and ↓WCC (often transient and benign).

Warn/monitor: see box below.

Dose: 15–60 mg/day in 2–3 divided doses (\downarrow dose once euthyroid; maintenance dose usually 5–15 mg od, unless on 'block-and-replace'

regimen, where $\uparrow d$ doses are maintained). Normally give for only 12–18 months. Remission often occurs; if not, other Rx (e.g. surgery/radioiodine) may be needed.

CARVEDILOL

 $\beta\text{-blocker: non-selective but also blocks } \alpha_1 \therefore \Rightarrow arterial vasodilation.}$

Use: HF¹ (added to stable treatment). Less commonly for angina² and HTN³(*for advice on stepped HTN Mx see p. 178*).

Cl/Caution: as propranolol, plus **L**. Also **H** if severe *and chronic* HF (caution in severe *and non-chronic* HF, and avoid if acute or decompensated HF needing iv inotropes).

SE: as propranolol, but worse postural \downarrow BP.

Interactions: as propranolol, but can \uparrow levels of ciclosporin. **Dose:** initially 3.125 mg bd¹ (\uparrow at intervals \geq 2 wks to max of 25–50 mg bd); initially 12.5 mg bd²/od³ (can \uparrow to 50 mg/day). Before \uparrow ing dose, check HF and renal function not worsening.

CEFACLOR

Oral 2nd-generation cephalosporin.

Use: mild respiratory infections, UTIs, external infections (skin/soft tissue infections, sinusitis, otitis media), esp in pregnancy* (is one of the safest antibiotics) or dt *H. influenzae*.

Cl: cephalosporin hypersensitivity.

Caution: if at ↑risk of AAC (e.g. recent other antibiotic use, ↑age, severe underlying disease, ↑hospital/nursing home stay, GI surgery, conditions/drugs that ↓gastric acidity (esp PPIs)), penicillin hypersensitivity (10% also allergic to cephalosporins), **R** (↓doses may be required; threshold depends on individual cephalosporin^{SPC/BNF}), **P/B** (but appropriate to use*).

COMMON/USEFUL DRUGS

SE: GI upset (esp N&D, but also AAC), allergy (anaphylaxis, fever, arthralgia, skin reactions (inc severe)), ARF, interstitial nephritis (reversible), hepatic dysfunction, blood disorders, CNS disturbance (inc headache).

Interactions: levels *ty* probenecid, mild **W**+.

Dose: 250 mg tds po (500 mg tds in severe infections; max 4 g/day). **NB:** ↓ **dose in RF**.

Cephalosporins can \Rightarrow false-positive Coombs' and urine glucose tests.

CEFALEXIN

Oral 1st-generation cephalosporin.

Use/Cl/Caution/SE/Interactions: see Cefaclor and **AAC warning. Dose:** 250 mg qds or 500 mg bd/tds po (\uparrow in severe infections to max 1.5 g qds). For Px of UTI, give 125 mg po nocte. **NB:** \downarrow **dose in RF**.

CEFOTAXIME

Parenteral 3rd-generation cephalosporin.

Use: severe infections, esp meningitis and sepsis 2° to hospitalacquired pneumonia, UTI, pyelonephritis, soft-tissue infections, gonorrhoea.

Cl/Caution/SE/Interactions: see Cefaclor and **AAC warning**, but can also rarely \Rightarrow arrhythmias if given as rapid iv injection. **Dose:** 1 g bd im/iv/ivi (\uparrow ing to max of 3 g qds if needed). **NB:** \downarrow **dose in RF**.

CEFRADINE

Oral or parenteral 1st-generation cephalosporin. **Use:** as cefaclor, plus pre-operative Px¹.

Cl/Caution/SE/Interactions: see Cefaclor and **AAC** warning. **Dose:** po: 250–500 mg qds *or* 0.5–1 g bd (max 1 g qds). **im/iv/ivi:** 0.5–1 g qds (max 2 g qds). 1–2 g im/iv at induction¹. **NB:** ↓**dose in RF.**

CEFTAZIDIME

Parenteral 3rd-generation cephalosporin: good against *Pseudomonas*.

32

Use: see Cefotaxime (often reserved for ITU setting).

Cl/Caution/SE/Interactions: see Cefaclor and AAC warning.

Dose: 1 g tds im/iv/ivi, \uparrow ing (with care in elderly) to 2 g tds or 3 g bd iv (not im, where max single dose is 1 g) if life-threatening, e.g. meningitis, immunocompromised. **NB:** \downarrow **dose in RF**.

CEFTRIAXONE

Parenteral 3rd-generation cephalosporin.

Use: as cefotaxime, plus pre-operative Px^1 .

Cl/Caution/SE/Interactions: as Cefaclor and **AAC warning**, plus **L** (if coexistent RF), **R** (if severe), caution if dehydrated, young or immobile (can precipitate in urine or gallbladder). Rarely \Rightarrow pancreatitis and \uparrow PT.

Dose: 1 g od im/iv/ivi (max 4 g/day); 1−2 g im/iv/ivi at induction¹. NB: ↓dose in RF.

Max im dose = 1 g per site; if total >1 g, give at divided sites.

CEFUROXIME

Parenteral and oral 2nd-generation cephalosporin: good for some Gram-negative infections (*H. influenzae*, *N. gonorrhoeae*) and better than 3rd-generation cephalosporins for Gram-positive infections (esp *S. aureus*).

Use: *po:* respiratory infections¹, UTIs², pyelonephritis³; *iv:* severe infections⁴, pre-operative Px⁵.

Cl/Caution/SE/Interactions: see Cefaclor and **AAC warning**. **Dose:** 250–500 mg bd po¹; 125 mg bd po²; 250 mg bd po³; 750 mg tds/qds iv/im⁴ (1.5 g tds/qds iv in very severe infections and 3 g tds if meningitis); 1.5 g iv at induction (+750 mg iv/im tds for 24 h if high-risk procedure)⁵. **NB:** \downarrow **dose in RF**.

▼CELECOXIB/CELEBREX

NSAID which selectively inhibits COX-2 $\therefore \downarrow$ GI SEs (COX-1 mediated). *Provides no Px against IHD/CVA* (unlike aspirin). **Use:** osteo/rheumatoid arthritis^{NICE}, ankylosing spondylitis. Beneficial GI fx (\downarrow bleeding) lost if on aspirin \therefore don't use together.

Cl: IHD, **cerebrovascular disease**, *active* bleeding/PU, PVD, hypersensitivity to aspirin or any other NSAID (inc asthma, angioedema, urticaria, rhinitis), *sulphonamide* hypersensitivity, IBD, **L**(if severe)/**R**(GFR<30) **H**(moderate-severe)/**P**/**B**.

Caution: Hx of PU/GI bleeding, H(mild), left ventricular dysfunction, HTN, ¹Cardiovascular risk (e.g. DM, ¹lipids, smokers), oedema R*/L(if either mild-moderate)/E.

SE/Interactions: as ibuprofen, but $\Rightarrow \downarrow PU/GI$ bleeding (but only if not in combination with aspirin) & $\Rightarrow \uparrow risk$ of MI/CVA. Very rarely \Rightarrow seizures. Also, fluconazole $\Rightarrow \uparrow serum$ levels. Mild W+.

Dose: 100–200 mg bd po. **Jdose in RF***. *Consider gastroprotective Rx*.

COX-2 inhibitors and *risk* of cardiovascular

complications: CSM advises assessment of cardiovascular risk and use in preference to other NSAIDs only if at $\uparrow\uparrow$ risk of GI ulcer, perforation or bleeding. Use lowest effective dose and duration.

CEPH- see CEF-

CETIRIZINE/ZIRTEK

Non-sedating antihistamine: selective peripheral H₁ antagonist; antimuscarinic.

Use: symptomatic relief from allergy (esp hay fever, urticaria). **Cl:** acute porphyria, **P/B**.

Caution: epilepsy, ↑prostate/urinary retention, glaucoma, pyloroduodenal obstruction, R/L.

SE: mild antimuscarinic fx (see p. 225), very mild sedation, headache.

Warn: may impair driving.

Dose: 10 mg od (or 5 mg bd) po. ↓**dose in severe RF** *Consider gastroprotective Rx*.*

CHARCOAL

Binds and \downarrow s absorption of tablets/poisons.

Use: ODs (up to 1 h post-ingestion; longer if MR/SR preparations or antimuscarinic drugs. See p. 249).

Caution: corrosive poisons, \downarrow GI motility (can \Rightarrow obstruction), \downarrow GCS (risk of aspiration, unless endotracheal tube in situ).

Dose: 50 g po. Give once for paracetamol and most drugs apart from alcohols or metal ions. Repeated doses (every 4 h) often needed for barbiturates, carbamazepine, phenytoin, digoxin, dapsone, paraquat, quinine, salicylates, theophylline and MR/SR preparations.

CHLORAMPHENICOL iv (and po)

Broad-spectrum antibiotic: inhibits bacterial protein synthesis (... 'static'); very potent action, but SEs limit use.

Use: severe infections (esp *H. influenzae*) and rickettsiae (e.g. typhoid).

CI: porphyria, **L** (avoid if possible)/**P**/**B**.

Caution: avoid repeated courses R/E.

SE: blood disorders (inc aplastic ↓Hb), neuritis (peripheral, optic), GI upset, hepatotoxicity, hypersensitivity, stomatitis, glossitis.

Monitor: FBC, serum drug levels* pre-dose (trough) and 1-h post-dose (peak).

Interactions: \uparrow s fx of sulphonylureas, phenytoin, ciclosporin and tacrolimus. \uparrow risk of agranulocytosis with clozapine. Phenobarbital and primidone \downarrow its fx. **W**+.

Dose: 50 mg/kg/day in 4 divided doses iv (or rarely po), \uparrow ing to 100 mg/kg/day if life-threatening infection. **NB:** \downarrow **dose/check levels*** in **RF and elderly.**

CHLORAMPHENICOL EYE DROPS

Topical antibiotic, with no significant systemic fx, for superficial bacterial eye infections (e.g. conjunctivitis), or as prophylaxis, e.g. postoperatively or for corneal abrasions. Can rarely \Rightarrow aplastic anaemia.

Dose: 1 drop of 0.5% qds. Can give as 1% ointment qds (or nocte only if taking drops in daytime as well).

CHLORDIAZEPOXIDE

Benzodiazepine, long-acting. **Use:** anxiety (esp in alcohol withdrawal). **Cl/Caution/SE/Interactions:** see Diazepam.

Dose: 10 mg tds po, \uparrow ing if required to max of 100 mg/day. **NB:** \downarrow **dose in RF, LF and elderly**. \uparrow dose if benzodiazepine-resistant or in initial Rx of alcohol withdrawal (see p. 190 for reducing

regimen).

CHLORHEXIDINE

Disinfectant mouthwash or solution for skin cleansing before invasive procedures and bladder washout.

Cl: avoid contact with eye, middle ear, brain, meninges, body cavities.

CHLOROQUINE

Antimalarial: inhibits protein synthesis and DNA/RNA polymerases.

Use: malaria Px¹ (only as Rx² if 'benign' spp (i.e. *P. ovale/vivax/ malariae*); *P. falciparum* often resistant. Rarely for RA, SLE.

Caution: G6PD deficiency, severe GI disorders, can worsen psoriasis and MG, neurological disorders (esp epilepsy*), L (avoid other hepatotoxic drugs), R/P.

SE: GI upset, headache (mild, transient), **visual** Δ (rarely retinopathy^{**}), **seizures**^{*}, hypersensitivity/skin reactions (inc pigment Δ s), hair loss. Rarely **BM suppression**, cardiomyopathy. Arrhythmias common in OD.

Monitor: FBC, vision^{**} (ophthalmology review if long-term Rx). **Interactions:** absorption \downarrow by antacids. \uparrow risk of arrhythmias with amiodarone and moxifloxacin. \uparrow risk of convulsions with mefloquine. \uparrow s levels of digoxin and ciclosporin. \downarrow s levels of praziquantel.

Dose: Px^1 : 300 mg once wkly *as base (specify on prescription: don't confuse with salt doses)*. Used mostly in conjunction with other drugs, depending on local resistance patterns^{SPC/BNF}. Rx^2 : see p. 174. NB: \downarrow dose in RF.

CHLORPHEN(IR)AMINE/PIRITON

Antihistamine: H_1 antagonist (peripheral *and central* : sedating). **Use:** allergies¹ (esp drug reactions, hay fever, urticaria),

anaphylaxis² (inc blood transfusion reaction³).

Cl: hypersensitivity to any antihistamine.

Caution: pyloroduodenal obstruction, urinary retention/↑prostate, thyrotoxicosis, asthma, bronch-itis/-iectasis, severe HTN/ cardiovascular disease, glaucoma, epilepsy, R/L/P/B.

SE: drowsiness (rarely paradoxical stimulation), antimuscarinic fx (esp dry mouth; see p. 225), GI upset, arrhythmias, ↓BP, skin and hypersensitivity reactions (inc bronchospasm, photosensitivity). If given iv can cause transient CNS stimulation.

Warn: driving may be impaired.

Interactions: can \uparrow phenytoin levels. \bigotimes **MAOIs** can \Rightarrow $\uparrow\uparrow$ antimuscarinic fx (SPC says chlorphenamine CI if MAOI given w/in 2 wks but evidence unclear) \bigotimes .

Dose: $4 \text{ mg } 4\text{--}6\text{-}hrly \text{ po}^1(\max 24 \text{ mg}/24 \text{ h}); 10 \text{ mg iv over} 1 \min^2 (\operatorname{can} \uparrow \operatorname{to} 20 \text{ mg}, \max 40 \text{ mg}/24 \text{ h}); 10\text{--}20 \text{ mg sc}^3 (\max 40 \text{ mg}/24 \text{ h}).$

CHLORPROMAZINE

Phenothiazine ('typical') antipsychotic: dopamine antagonist (D_1 and 3 $> D_2$ and 4). Also blocks serotonin (5HT_{2A}), histamine (H₁), adrenergic ($\alpha_{1>2}$) and muscarinic receptors, causing many SEs. **Use:** schizophrenia¹, acute sedation² (inc mania, severe anxiety, violent behaviour), intractable hiccups³. **Cl:** CNS depression (inc coma), elderly patients with dementia, Hx of blood dyscrasias, severe cardiovascular disease. **Caution:** Parkinson's, drugs that \uparrow QTc, epilepsy, MG, phaeo, glaucoma (angle-closure), \uparrow prostate, severe respiratory disease, jaundice, blood disorders, predisposition to postural \downarrow BP, \uparrow or \downarrow temperature. Avoid direct sunlight (\Rightarrow photosensitivity), *L/R/H/P/B/E*. **Class SE:** sedation, extrapyramidal fx (see p. 227), antimuscarinic fx (see p. 225), seizures, \uparrow Wt, \downarrow BP (esp postural), ECG Δ s (\uparrow QTc), arrhythmias, endocrine fx (menstrual Δ s, galactorrhoea, gynaecomastia, seval dysfunction). ALFTs/jaundice, blood disorders (inc agranulocytosis, \downarrow WCC), \downarrow or \uparrow temperature (esp in elderly), rash/ \uparrow pigmentation, **neuroleptic malignant** syndrome. Don't crush tablets (contact hypersensitivity; also possible from iv solution).

Warn: avoid alcohol/direct sunlight, \downarrow s skilled tasks (e.g. driving). **Monitor:** FBC, BP.

Interactions: fx \uparrow d by TCAs (esp antimuscarinic fx), lithium (esp extrapyramidal fx \pm neurotoxicity), ritonavir, cimetidine and β -blockers (esp arrhythmias with sotalol; propranolol fx also \uparrow d by chlorpromazine). \uparrow risk of CNS toxicity with sibutramine. Avoid artemether/lumefantrine and drugs that \uparrow QTc or risk of ventricular arrhythmias (e.g. disopyramide, moxifloxacin).

Dose: 25-300 mg tds po^{SPC/BNF}; 25-50 mg tds/qds im (painful, and may $\Rightarrow \downarrow$ BP/ \uparrow HR). **NB:** \downarrow dose in elderly (approx 1/3–1/2 adult dose but 10 mg od po may suffice) or if severe RF.

CICLESONIDE/ALVESCO

Inh corticosteroid for asthma, similar to beclomethasone but od. **Caution: L**.

Dose: 80-160 µg od inh (aerosol).

CICLOSPORIN

Calcineurin inhibitor: $\Rightarrow \downarrow$ IL-2-mediated LØ proliferation. **Use:** immunosuppression (esp nephrotic syndrome and post-transplant), atopic dermatitis, psoriasis, RA. **CI:** only apply if given for nephrotic syndrome: uncontrolled infection or HTN, malignancy. Avoid co-treatment with sirolimus. **Caution:** HTN, \uparrow urate, porphyria, drugs that $\uparrow K^+$, L/R/P/B/E. **SE:** nephrotoxicity and tremor (both dose-related), $\uparrow BP$, hepatotoxicity, GI upset, biochemical Δs ($\uparrow K^+$, \uparrow urate/gout, $\downarrow Mg^{2+}$, \uparrow cholesterol, \uparrow glucose), pancreatitis. Rarely neuromuscular symptoms, HUS, neoplasms (esp lymphoma), BIH, encephalopathy, demyelination (esp if liver transplant).

Warn: hypertrichosis, gingival hypertrophy, avoid XS sun exposure (photosensitivity); burning sensation in hands and feet. **Monitor:** levels, LFTs, U&Es, Mg²⁺, lipids, BP.

Interactions: metab by **P450**, \therefore many, particularly antibacterials and antifungals^{SPC/BNF} (cephalosporins and penicillins OK). Levels esp \downarrow by phenytoin, carbamazepine, phenobarbital, St John's wort, rifampicin, orlistat, ticlopidine and octreotide. Levels esp \uparrow by ery-/clari-thromycin, keto-/flu-/itra-conazole, protease inhibitors, diltiazem, nicardipine, verapamil, metoclopramide, amiodarone, allopurinol, danazol, ursodeoxycholic acid, corticosteroids and OCP. Can \uparrow levels of digoxin and diclofenac. Nephrotoxic and myotoxic drugs can become more so.

Dose: specialist use^{SPC/BNF}. Must prescribe by brand name (Neoral, Sandimmun or SangGya) as have different bioavailabilities and changing brands can \therefore ↓immunosuppression or ↑toxicity. **NB: dose adjustment needed if LF or RF**.

Solution \mathbb{R}^{2} Check all new drugs for interactions before prescribing if on ciclosporin: $\uparrow d$ levels \Rightarrow toxicity; $\downarrow d$ levels may \Rightarrow rejection $\mathcal{Q}_{\mathcal{A}}$.

CIMETIDINE

As ranitidine, but $\uparrow\uparrow$ interactions (\downarrow **P450** and W+) and \uparrow gynaecomastia \therefore prescribed rarely. Dose: 400 mg bd (can \uparrow to 4-hrly^{SPC/BNF}). NB: \downarrow dose if LF or RF.

CIPROFLOXACIN

(Fluoro)quinolone antibiotic: inhibits DNA gyrase; 'cidal' with broad spectrum, but particularly good for Gram-negative infections. **Use: GI infections**¹ (esp salmonella, shigella, campylobacter), **respiratory infections** (non-pneumococcal pneumonias², esp *Pseudomonas*). Also GU infections (esp UTIs³, acute uncomplicated cystitis in women⁴, gonorrhoea⁵), 1st-line initial Rx of anthrax. **Cl:** hypersensitivity to any quinolone, **P/B**.

Caution: seizures (inc Hx of, or predisposition to), MG (can worsen), G6PD deficiency, children/adolescents (theoretical risk of arthropathy), avoid \uparrow urine pH or dehydration*, **R**.

SE: GI upset (esp N&D, rarely AAC), pancreatitis, **neuro-\Psi fx** (esp confusion, **seizures**; also headache, dizziness, hallucinations, sleep and mood Δ s), **tendinitis ± rupture** (esp if elderly or taking steroids), chest pain, oedema, **hypersensitivity** (rash, pruritis, fever).

Rarely hepatotoxicity, RF/interstitial nephritis, crystalluria*, blood disorders, \uparrow glucose, skin reactions (inc photosensitivity**, SJS, TEN). **Warn:** avoid UV light**, avoid ingesting Fe- and Zn-containing products (e.g. antacids***). May impair skilled tasks/driving. **Interactions:** \uparrow s levels of theophyllines; NSAIDs $\Rightarrow \uparrow$ risk of seizures; \uparrow s nephrotoxicity of ciclosporin; FeSO₄ and antacids*** $\Rightarrow \downarrow$ ciprofloxacin absorption (give 2 h before or 6 h after ciprofloxacin), **W+**.

Dose: 250–750 mg bd po, 100–400 mg bd ivi (each dose over 1 h) according to indication^{SPC/BNF} (100 mg bd po for 3 days for cystitis); 500 mg po single dose⁴; 100 mg iv single dose⁵. **NB: \dose if severe RF**.

 \searrow Stop if tendinitis, severe neuro- Ψ fx or hypersensitivity \bigotimes .

CITALOPRAM/CIPRAMIL

SSRI antidepressant.

Use: depression¹ (and panic disorder). Useful if polypharmacy, as \downarrow interactions and \downarrow cardio-/hepato-toxicity cf other SSRIs (see p. 192). **CI/Caution/SE/Warn:** as fluoxetine, but \uparrow risk of withdrawal syndrome if stopped abruptly.

Interaction: \bigotimes Never give with, or <2 wks after, MAOIs \bigotimes . **Dose:** 20 mg od¹ (†ing if necessary to max 60 mg). NB: \downarrow dose if LF.

CITRAMAG see Bowel preparations

Cl: R (if severe).
 Caution: risk of ↑Mg²⁺ in RF.
 Dose: 1 sachet at 8 am and 3 pm the day before GI surgery or Ix.

CLARITHROMYCIN

Macrolide antibiotic: binds 50S ribosome; 'static' at low doses, 'cidal' at high doses.

Use: atypical pneumonias (as alternative to erythromycin; see p. 168), part of triple therapy for *H. pylori* (see p. 173). **Cl/Caution/SE/Interactions:** as erythromycin, but $\Rightarrow \downarrow$ GI SEs. **Dose:** 250–500 mg bd po or 500 mg bd iv. **NB:** \downarrow **dose if RF**.

40

CLEXANE see Enoxaparin; low-molecular-weight heparin.

CLINDAMYCIN

Antibiotic; same action (but different structure and \therefore class) as clarithromycin; good against staphylococci (esp if resistant to penicillin) and anaerobes (esp bacteroides); penetrates bone well. **Use:** osteomyelitis, intra-abdominal sepsis, endocarditis Px, falciparum malaria. *Use limited due to SEs (esp AAC)*. **Cl:** diarrhoea. **Caution:** GI disease, porphyria, atopy, **L/R/P/B**. **SE:** GI upset (often \Rightarrow **AAC**), hepatotoxicity, blood disorders, local reactions at injection site, arthralgia, myalgia, hypersensitivity. **Monitor:** U&Es, LFTs. **Interactions:** \uparrow s fx of neuromuscular blocking agents. **Dose:** 150–450 mg qds po; 0.6–4.8 g daily in divided doses im/ivi (doses >600 mg must be as ivi), max single dose iv is 1.2 g. Stop drug if diarrhoea develops: AAC common and potentially

fatal.

CLOBETASOL PROPIONATE 0.05% CREAM OR OINTMENT/DERMOVATE

Very-potent-strength topical corticosteroid.

Use: short-term Rx of severe inflammatory skin conditions (esp discoid lupus, lichen simplex and palmar plantar psoriasis).

Cl: untreated infection, rosacea, acne.

SE: skin atrophy, worsening of infections, acne (↑SEs cf less potent topical steroids).

Dose: apply thinly od/bd, usually under specialist supervision.

CLOBETASONE BUTYRATE 0.05% CREAM OR

OINTMENT/EUMOVATE

Moderately-potent-strength topical corticosteroid.

Use: inflammatory skin conditions, esp eczema.

Cl: untreated infection, rosacea, acne.

SE: skin atrophy, worsening of infections, acne.

Dose: apply thinly od/bd.

CLONAZEPAM

42

Benzodiazepine; long-acting (see p. 223)

Use: epilepsy (all forms¹ inc status epilepticus²). Not licensed, but often used, for Ψ disorders³ (esp psychosis and mania).

CI/Caution/SE/Warn/Interactions: see Diazepam.

Dose: $0.5-1 \text{ mg} \uparrow \text{ing}$ according to response to max $20 \text{ mg/day}^{1/3}$ in divided doses; 1 mg iv (over $\geq 2 \text{ min}$) or as ivi².

CLOPIDOGREL/PLAVIX

Antiplatelet agent: ADP receptor antagonist. \uparrow antiplatelet fx cf aspirin (but also \uparrow SEs).

Use: Px of atherothrombotic events if STEMI or NSTEMI (for 12 months in combination with aspirin, aspirin continued indefinitely), MI (within 'a few' to 35 days), ischaemic CVA (within 7 days to 6 months) or peripheral arterial disease. For use in ACS (see p. 230).

Cl: active bleeding, L (if severe – otherwise caution), B.

Caution: Tbleeding risk; trauma, surgery, drugs that Tbleeding risk (*not recommended with warfarin*), R/P.

SE: haemorrhage (esp GI or intracranial), **GI upset**, PU, pancreatitis, headache, fatigue, dizziness, paraesthesia, rash/pruritus, hepatobiliary/ respiratory/blood disorders (↓NØ, ↑EØ, very rarely, TTP).

Monitor: FBC and for signs of occult bleeding (esp after invasive procedures).

Dose: 75 mg od. If not already on clopidogrel, usually load with 300 mg for ACS then 75 mg od starting next day. If pre-PCI, load with 300–600 mg usually on morning of procedure.

Stop 7 days before operations if antiplatelet fx not wanted (e.g. major surgery); discuss with surgeons doing operation.

CLOTRIMAZOLE/CANESTEN

Imidazole antifungal (topical).

Use: external candida infections (esp vaginal thrush).

Caution: can damage condoms and diaphragms.

Dose: 2–3 applications/day of 1% cream, continuing for 14 days after lesion healed. Also available as powder/solution/spray for hairy areas, as pessary, and in 2% strength.

CLOZAPINE

Atypical antipsychotic: blocks dopamine $(D_4 > D_1 > D_{2 \text{ and } 3})$ and $5\text{HT}_{2\text{A}}$ receptors. Also mild blockade of muscarinic and adrenergic receptors.

Use: schizophrenia, but only if resistant or intolerant (e.g. severe extrapyramidal fx) to other antipsychotics^{NICE}.

Cl: severe cardiac disorders (inc Hx of circulatory collapse, myocarditis, cardiomyopathy), coma/severe CNS depression, alcoholic/toxic psychosis, drug intoxication, Hx of agranulocytosis or $\downarrow N\emptyset$, bone marrow disorders, paralytic ileus, uncontrolled epilepsy, **R/H** (if severe, otherwise caution), **L** (inc active liver disease), **B**.

Caution: Hx of epilepsy, cardiovascular disease, ↑prostate, glaucoma (angle-closure), P/E.

SE: as olanzapine, but also can $\Rightarrow \downarrow N\emptyset^*$ (3% of patients) and **agranulocytosis** (1%). Also commonly \Rightarrow **salivation** (Rx with hyoscine hydrobromide), $\downarrow BP$ (esp during initial titration), **constipation** (can \Rightarrow ileus/obstruction: have low threshold for giving laxatives), $\uparrow Wt$, sedation. Less commonly seizures, urinary incontinence, priapism, **myocarditis/cardiomyopathy** (*stop immediately!*), $\uparrow HR$, arrhythmias, hyperglycaemia, N&V, $\uparrow BP$, delirium, RF, $\downarrow Pt$. Rarely hepatic dysfunction (*stop immediately!*), $\uparrow TG$, neuroleptic malignant syndrome.

Monitor: FBC*, BP (esp during start of Rx), serum levels (pre-dose) and cardiac function (get baseline ECG/watch for persistent \uparrow HR).

Interactions: as chlorpromazine, plus care with all drugs that constipate, [↑]QT threshold or ↓leucopoiesis (e.g. cytotoxics, sulphonamides/co-trimoxazole, chloramphenicol, penicillamine, carbamazepine, phenothiazines, esp depots). Caffeine, risperidone, SSRIs, cimetidine and erythromycin [↑]clozapine levels. Smoking, carbamazepine and phenytoin ↓clozapine levels.

Dose: initially 12.5 mg nocte, ↑ing to 200–450 mg/day^{SPC/BNF} usually given bd (max 900 mg/day). ↓doses if elderly.

If >2 days' doses missed, restart at 12.5 mg od and \uparrow gradually.

Monitoring: primarily to avoid fatal agranulocytosis, is done by the manufacturers: in the UK Clozaril Patient Monitoring Service (tel: 0845 7698269), Denzapine Monitoring Service (tel: 0845 0090110) or Zaponex Treatment Access System (tel: 0207 3655842). Register and then authorise/monitor baseline and subsequent FBCs* and serum levels*. These are very useful resources for all clozapine questions.

CO-AMILOFRUSE

Diuretic combination preparation for oedema that keeps K⁺ stable: amiloride (K⁺-sparing) + furosemide (K⁺-wasting) in 3 strengths of tablet as 2.5/20, 5/40 and 10/80 (reflecting amiloride mg/furosemide mg). **Monitor:** BP, U&Es. **Dose:** 1 tablet mane (NB: *specify strength!*).

CO-AMILOZIDE

Diuretic combination preparation for HTN (*for advice on stepped* HTN Mx see p. 178), CCF and oedema. Keeps K^+ stable: amiloride (K⁺-sparing) + hydrochlorothiazide (K⁺-wasting) in 2 strengths of tablet as 2.5/25 and 5/50 (reflecting amiloride mg/hydrochlorothiazide mg).

Caution: crystalluria esp if ↑dose or RF. **Monitor:** BP, U&Es.

Dose: 1/2–4 tablets daily, according to tablet strength and indication ^{SPC/BNF}.

CO-AMOXICLAV/AUGMENTIN

Combination of a moxicillin + clavulanic acid (β -lact amase inhibitor) to overcome resistance.

Use: UTIs, respiratory/skin/soft-tissue (plus many other) infections. Reserve for when β -lactamase-producing strains known/strongly suspected or other Rx has failed.

44

CI/Caution/SE/Interactions: as ampicillin, plus caution if anticoagulated, **L** (*Trisk of cholestasis*), **P**.

Dose: as amoxicillin dose: 250 mg tds po (500 mg tds po if severe); 1 g tds/qds iv/ivi. Non-proprietary and as Augmentin. **NB:** Jose if LF.

CO-BENELDOPA/MADOPAR

L-dopa + benserazide (peripheral dopa-decarboxylase inhibitor). **Use:** Parkinsonism.

CI/Caution/SE/Warn/Interactions: see Levodopa.

Dose: (*expressed as levodopa only*) initially 50 mg tds/qds, ↑ing total dose and number of doses, according to response, to usual maintenance of 400–800 mg/day (Jin elderly). Available in dispersible form.

CO-CARELDOPA/SINEMET

L-dopa + carbidopa (peripheral dopa-decarboxylase inhibitor). **Use:** Parkinsonism.

Cl/Caution/SE/Warn/Interactions: see Levodopa.

Dose: (*expressed as levodopa only*) initially 50–100 mg tds, ↑ing total dose and number of doses, according to response, to usual maintenance of 400–800 mg/day (↓in elderly). Available in dispersible form.

CO-CODAMOL (8/500) = codeine 8 mg + paracetamol 500 mg per tablet.

Use/Cl/Caution/SE/Interactions: see Paracetamol and Codeine. **Warning:** prescribe by dose as also available as 15/500 and 30/500. **Dose:** 2 tablets qds prn. **NB:** ↓**dose if LF, RF or elderly**.

©O-DANTHRAMER see Dantron; stimulant laxative. **Dose:** 1–2 capsules or 5–10 ml suspension nocte (available in regular and strong formulations).

CO-DANTHRUSATE see Dantron; stimulant laxative. **Dose:** 1–3 capsules or *5*–15 ml suspension nocte.

CODEINE (PHOSPHATE)

Weak opiate analgesic. Mainly metabolised to morphine. Use: mild/moderate pain, diarrhoea, anti-tussive. Cl: acute respiratory depression, risk of ileus, [↑]ICP/head

injury/coma, P.

Caution: all other conditions where morphine is either contraindicated or cautioned.

SE: as morphine, but milder. **Constipation** is the major problem: dose and length of Rx-dependent; anticipate this and give laxative Px as appropriate, esp in elderly. Also sedation, esp if LF.

Interactions: \bigotimes MAOIs: don't give within 2 weeks of \bigotimes . As morphine, but does not interact with baclofen, gabapentin and ritonavir.

Dose: 30–60 mg up to 4-hrly po/im (max 240 mg/24 h). Genetic ultrarapid metabolisers (3% of Europeans, 8% of Americans, 40% of North Africans) risk serious toxicity & poor metabolisers obtain little analgesia. Watch closely when initiating & adjust dose/change drug accordingly. NB: ↓dose if LF, RF or elderly.

©O=DYDRAMOL Dihydrocodeine 10 mg + paracetamol 500 mg per tablet.

Dose: 1–2 tablets 4–6 hourly, max qds po. Usually prescribed 2 tablets qds (prn). **NB:** ↓**dose if LF, RF or elderly**.

COLCHICINE

Anti-gout: binds to tubulin of leucocytes and stops their migration to uric acid deposits $\therefore \Rightarrow \downarrow$ inflammation. NB: slow action (needs >6 h to work).

Use: gout: Rx of acute attacks or Px when starting allopurinol* (which can initially \uparrow symptoms) or awaiting other drugs to work. **CI:** blood dyscrasias, **P**

Caution: GI diseases, L/H/R/B/E.

SE: GI upset (N&V&D and abdominal pain – all common and dose-related). Rarely GI haemorrhage, hypersensitivity, renal/hepatic impairment, peripheral neuritis, myopathy, alopecia,

↓spermatogenesis (reversible), blood disorders (if prolonged Rx).

Interactions: \uparrow s nephro-/myo-toxicity of ciclosporin, fx \downarrow by thiazide diuretics, toxicity \uparrow by erythromycin and tolbutamide. **Dose:** 0.5 mg bd/qds for 7 days (start ASAP after symptom onset). More aggressive loading regimens exist^{SPC/BNF} but $\Rightarrow \uparrow$ GI upset w/o significant \uparrow in response. Continue 0.5 mg bd when starting allopurinol*. **NB:** \downarrow **dose if RF**.

COLESTYRAMINE

Anion exchange resin. Binds bile acids in gut preventing reabsorption; \Rightarrow \uparrow hepatic cholesterol \Rightarrow bile acids; \Rightarrow \uparrow hepatic LDL receptors \Rightarrow \uparrow LDL cholesterol plasma clearance. **Use:** pruritus (2° to PBC or partial biliary obstruction)¹, diarrhoeal disorders². If diet and other measures insufficient: hyperlipidaemia³ (esp type IIa), Px of IHD⁴, 1° hypercholesterolaemia⁵. **Cl:** ineffective in complete biliary obstruction. **Caution:** Risk of *vitamins*. Sachets contain sucrose or aspartame. DM. P/B. **SE:** \downarrow Vits A/D/K, \uparrow bleeding risk, taste Δ , GI upset/obstruction, \uparrow Cl⁻ acidosis. **Warn:** take other drugs >1 h before or > 4-6 h after colestyramine*. Monitor: for vitamin deficiency (and INR if on warfarin). **Interactions:** delay or \downarrow drug absorption* inc digoxin, tetracycline, chlorothiazide, thyroxine. W + or W -.

Dose: initially 4 g od, \uparrow ing if required by 4 g/wk to 8 g/day¹ (max 36 g/day^{2,3,4,5})

NB: take with ≥ 150 ml suitable liquid/4 g sachet.

CO-MAGALDROX antacid (AIOH + MgOH).

Dose: 10–20 ml 20–60 min after meals, and at bedtime or prn.

COMBIVENT Compound bronchodilator (salbutamol + ipratropium bromide).

Dose: 2.5 ml (one vial: ipratropium 500 μ g + salbutamol 2.5 mg) tds/qds neb^{SPC/BNF}.

CORSODYL Chlorhexidine mouthwash for Rx/Px of mouth infections (inc MRSA eradication); see local infection protocol.

CO-TRIAMTERZIDE

Diuretic for HTN¹(for advice on stepped HTN Mx see p. 178), or oedema²: triamterene (\uparrow s K⁺) combined with hydrochlorothiazide (\downarrow s K⁺) to keep K⁺ stable.

Monitor: BP, U&Es.

Dose: initially 1 tablet¹ (or 2 tablets²) mane of 50/25 strength (= 50 mg triamterene + 25 mg hydrochlorothiazide), \uparrow ing if necessary to max of 4 tablets/day.

CO-TRIMOXAZOLE/SEPTRIN

Antibiotic combination preparation: 5 to 1 mixture of sulfamethoxazole (a sulphonamide) + trimethoprim \Rightarrow synergistic action (individually are 'static' but collectively are 'cidal'). **Use:** PCP; other uses limited due to SEs (also rarely used for toxoplasmosis and nocardiosis).

Cl: porphyria, **L/R** (if either severe, otherwise caution).

Caution: blood disorders, asthma, G6PD deficiency, risk factors for \downarrow folate P/B/E.

SE: skin reactions (inc SJS, TEN), blood disorders ($\downarrow N\emptyset$, $\downarrow Pt$, \downarrow Glucose, BM suppression, agranulocytosis) relatively common, esp in elderly. Also N&V&D (inc AAC), nephrotoxicity, hepatotoxicity, hypersensitivity, anorexia, abdo pain, glossitis, stomatitis, pancreatitis, arthralgia, myalgia, SLE, pulmonary infiltrates, seizures, ataxia, myocarditis.

Interactions: \uparrow s phenytoin levels. \uparrow s risk of arrhythmias with amiodarone, crystalluria with methenamine, antifolate fx with pyrimethamine, agranulocytosis with clozapine and toxicity with ciclosporin, azathioprine, mercaptopurine and methotrexate. **W+**. **Dose:** PCP Rx: 120 mg/kg/day po/ivi in 2–4 divided doses (PCP Px 480–960 mg od po). **NB:** \downarrow **dose if RF**.

Stop immediately if rash or blood disorder occurs &.

CYCLIZINE

Antihistamine antiemetic.

Use: N&V Rx/Px (esp 2° to iv/im opioids, but not 1st choice in angina/MI/LVF*), vertigo, motion sickness, labyrinthine disorders. **Cl/Caution/SE/Warn:** as chlorphenamine, but also avoid in severe HF* (may undo haemodynamic benefits of opioids). Antimuscarinic fx (see p. 225) are most prominent SEs.

Dose: 50 mg po/im/iv tds.

CYCLOPENTOLATE 0.5%/1% EYE DROPS/MYDRILATE

For pupil dilation (for pain relief and prevention of complications in uveitis). Also cycloplegic (paralyses accommodation); useful for refracting children.

SE: blurred vision.

Dose: 1 drop (tds for prolonged use). 30 min to work, lasts several hours.

CYCLOPHOSPHAMIDE

Cytotoxic¹ and immunosuppressant²: alkylating agent (cross-links DNA bases, \downarrow ing replication).

Use: cancer¹, autoimmune diseases²: esp vasculitis (inc rheumatoid arthritis, polymyositis and SLE (esp if renal/cerebral involvement)), systemic sclerosis, Wegener's, nephrotic syndrome in children. **Cl:** haemorrhagic cystitis, **P/B**.

Caution: BM suppression, severe infections, L/R.

SE: GI upset, alopecia (reversible). Others rare but important: hepatotoxicity, blood disorders, malignancy (esp acute myeloid leukaemia), ↓fertility (can be permanent), cardiac toxicity, pulmonary fibrosis (at high doses), haemorrhagic cystitis (only if given *iv:* ensure good hydration, give 'mesna' as Px; can occur months after Rx).

Warn: ↓fertility may be permanent (bank sperm if possible) – need to counsel and obtain consent regarding this before giving. Monitor: FBC.

Interactions: can [†]fx of oral hypoglycaemics. [†]risk of agranulocytosis with clozapine and toxicity with pentostatin.

CYCLOSPORIN see Ciclosporin

CYPROTERONE ACETATE

Anti-androgen; blocks androgen receptors. Also ↑s progestogens. **Use:** Ca prostate¹ (as adjunct), acne² (esp 2° to PCOS, where used with ethinylestradiol as co-cyprindiol), rarely for hypersexuality/ sexual deviation³ (*males only!*).

Cl: (*none apply if for Ca prostate*) advanced DM (if vascular disease), sickle cell, malignancy/wasting diseases, Hx of TE, age <18 years (can $\Rightarrow \downarrow$ bone/testicular development), severe depression, L/P/B. **SE: fatigue, gynaecomastia**, $\uparrow or \downarrow Wt$, hepatotoxicity, blood disorders, hypersensitivity, osteoporosis, \downarrow spermatogenesis (reversible), TE, depression, carbohydrate metabolism and hair Δ s. **Monitor:** FBC, LFTs, adrenocortical function. **Warn:** driving and other skilled tasks may be impaired. **Dose:** 200–300 mg po daily in divided doses¹, 50 mg bd po³.

▼DABIGATRAN (ETEXILATE)/PRADAXA

Oral anticoagulant; direct thrombin inhibitor. Rapid onset and doesn't require therapeutic monitoring (unlike warfarin). **Use:** Px of VTE after total knee or hip replacement. **CI:** active bleeding, impaired haemostasis, **L** (if severe) **P/B**. **Caution:** bleeding disorders, active GI ulceration, recent surgery, bacterial endocarditis, anaesthesia with postoperative indwelling epidural catheter (risk of paralysis; give initial dose ≥ 2 h after catheter removal and monitor for neurological signs), weight <50 kg, **R** (avoid if creatinine clearance <30 ml/min) H/E. **SE:** haemorrhage. hepatobiliary disorders.

Monitor: for \downarrow Hb or signs of bleeding (stop drug if severe). **Interactions:** NSAIDs \uparrow risk of bleeding. Levels \uparrow by amiodarone*. **Dose:** 110 mg (75 mg if >75 years old) 1–4 h after surgery then 220 mg od (150 mg if >75 years old) for 9 days after knee replacement or 27–34 days after hip replacement). NB: \downarrow dose in RF, elderly or if taking amiodarone*.

50

▼DALTEPARIN/FRAGMIN

Low-molecular-weight heparin (LMWH). **Use:** DVT/PE Rx¹ and Px² (inc pre-operative), ACS (with aspirin)³. **Cl/Caution/SE/Monitor/Interactions:** see Heparin. **Dose:** all sc: 200 units/kg (max 18 000 units) od¹; 2500–5000 units od² (according to risk^{SPC/BNF}) for \geq 5 days; 120 units/kg bd³ for \geq 5 days (max 10 000 units bd) reviewing dose if >8 days needed^{SPC/BNF}. Consider monitoring anti Xa (3–4 h post dose) $\pm \downarrow$ dose if RF (i.e. creatinine >150), pregnancy, Wt >100 kg or <45 kg; see p. 205.

DANTRON

Stimulant laxative; theoretical risk of **carcinogenicity***. **Use:** constipation (often limited to the terminally ill*). **Caution/SE:** see Senna; possible carcinogenic risk. (CI if GI obstruction, **P/B**) **Dose:** see ©o-danthramer and ©o-danthrusate.

DARBEPOETIN see Erythropoietin (recombinant form for \downarrow Hb).

DERMOVATE see Clobetasol propionate (steroid) cream 0.05%.

DESFERRIOXAMINE

Chelating agent; binds Fe (and Al) in gut \downarrow ing absorption/ \uparrow ing clearance.

Use: \uparrow Fe: acute (OD/poisoning¹), chronic (e.g. xs transfusions for blood disorders, haemochromatosis when venesection CI). Also for \uparrow Al (e.g. 2° to dialysis).

Caution: Al-induced encephalopathy (may worsen), *Trisk of Yersinia*/mucormycosis infection **R/P/B**.

SE: \downarrow **BP** (related to rate of ivi), lens opacities, retinopathy, GI upset, blood disorders, hypersensitivity. Also neurological/respiratory/renal dysfunction. \uparrow doses can $\Rightarrow \downarrow$ growth and bone Δ s.

Monitor: vision and hearing during chronic Rx.

Dose: acutely up to 15 mg/kg/h ivi (max 80 mg/kg/day)¹. Otherwise according to degree of Fe or Al overload^{SPC/BNF}.

DEXAMETHASONE 0.1% EYE DROPS/MAXIDEX

Topical corticosteroid.

Use: uveitis, Px of post-eye surgery anterior segment inflammation. **Cl:** ocular infection.

SE: ocular infection (aggravation of existing or ^susceptibility) or ocular HTN. If prolonged use, glaucoma and cataract possible. **Dose:** 1 drop qds (max 1 hrly); specialist use only.

DEXAMETHASONE PHOSPHATE

Glucocorticoid; minimal mineralocorticoid activity, long duration of action (see p. 219).

Use: cerebral oedema (from malignancy), spinal cord compression, Dx of Cushing's, N&V (2° to chemotherapy or surgery),

allergy/inflammation (esp if unresponsive shock), congenital adrenal hyperplasia, rheumatic disease.

Cl/Caution/SE/Warn/Interactions: see Prednisolone and steroids section (p. 219).

Dose: cerebral oedema: acutely 10 mg iv, then 4 mg im qds 2–4 days (if not life-threatening, some go straight to 4 mg qds iv then switch to po a few days later, stopped gradually over 5–7 days). For other indications, see SPC/BNF.

 \searrow Doses given here are for dexamethasone phosphate and must be prescribed as such: other forms have different doses \bigotimes !

DF118 (suffix FORTE often omitted) Dihydrocodeine preparation. **Dose:** 40–80 mg tds po (max 240 mg/day).

NB: tablets are different dose to non-proprietary dihydrocodeine.

DIAMORPHINE (HEROIN HYDROCHLORIDE)

Strong opiate (1.5 × strength of morphine if both given iv). **Use:** severe pain (acute and chronic)¹, AMI², acute LVF³.

CI/Caution/SE/Interactions: as morphine, but less nausea/ \downarrow BP. **& Respiratory depression** (esp elderly) **&**

Dose: 5–10 mg sc/im (or 1/4-1/2 this dose iv) up to 4-hrly¹; 5 mg iv (at 1–2 mg/min) followed by further 2.5–5 mg if necessary², 2.5–5 mg (at 1 mg/min) iv³. Can give via sc pump in chronic pain/ palliative care: see p. 184. **NB:** \downarrow **dose if elderly, LF or RF**.

DIAZEMULS iv diazepam *emulsion*: $\Rightarrow \downarrow$ venous irritation.

DIAZEPAM

Benzodiazepine, long-acting.

Use: seizures (esp status epilepticus¹, febrile convulsions), *shortterm* Rx of acute alcohol withdrawal², anxiety³, insomnia⁴ (if also anxiety; if not, then shorter-acting forms preferred as $\Rightarrow \downarrow$ hangover sedation). Also used for muscle spasm⁵.

Cl: respiratory depression, marked neuromuscular respiratory weakness inc unstable myasthenia gravis, sleep apnoea, acute pulmonary insufficiency, chronic psychosis, depression (don't give diazepam alone), **L** (if severe).

Caution: respiratory disease, muscle weakness (inc MG), Hx of drug/alcohol abuse, personality disorder, porphyria, R/P/B/E.

SE: respiratory depression (rarely apnoea), drowsiness,

dependence. Also ataxia, amnesia, headache, vertigo, GI upset, jaundice, \downarrow BP, \downarrow HR, visual/libido/urinary disturbances, blood disorders. **Warn:** sedation \uparrow by alcohol and $\Rightarrow \downarrow$ driving/skilled task ability. **Interactions:** metab by **P450** \therefore many: ery-/clari-/-teli-thromycin, quinu-/dalfo-pristin and flu-/itra-/keto-/posa-conazole can \uparrow levels. Sedative fx \uparrow by antipsychotics, antidepressants, antiepileptics and antiretrovirals. Can \uparrow fx of zidovudine and sodium oxybate. \uparrow risk of \downarrow HR/BP and respiratory depression with im olanzapine.

Dose: for status epilepticus¹ and alcohol withdrawal², see p. 235 and p. 186, respectively; 2 mg tds po (\uparrow up to 30 mg/day)^{3,5}; 5–15 mg nocte po⁴. **NB: Jdose if elderly, LF or RF.** If chronic exposure to benzodiazepines, \uparrow doses may be needed; don't stop suddenly, as can \Rightarrow withdrawal; see p. 217 for details.

Respiratory depression: if \uparrow doses used (esp iv/im), monitor O₂ sats and have O₂ (± intubation equipment) at hand, caution with flumazenil – see p. 255 for Mx &.

DICLOFENAC

Medium-strength NSAID; non-selective COX inhibitor. **Use:** pain/inflammation, esp musculoskeletal; RA, osteoarthritis, acute gout, postoperative, dental. **Cl/Caution/SE/Interactions:** as ibuprofen, but somewhat \uparrow risk PU/GI bleeds & thrombotic events (\downarrow risk PU/GI bleeds if given with misoprostol as Arthr@@@). **Doses ≥150 mg daily associated with significant thrombotic risk.** Avoid in acute porphyria. Ciclosporin \Rightarrow ↑serum levels. Mild **W+**.

Dose: 25–50 mg tds po or 75 mg bd po (or im, but for max of 2 days); 75–150 mg/day pr (**divided doses**). Max 150 mg/day. Rarely used $iv^{BNF/SPC}$. **NB: Avoid in RF.**

DIFFLAM Benzydamine: topical NSAID for painful inflammatory conditions of oropharynx (e.g. mouth ulcers, radio-/chemo-therapy-induced mucositis). Available as spray (4–8 sprays 1.5–3-hrly) or oral rinse (15 ml 1.5–3-hrly, diluting in water if stinging). Rarely \Rightarrow hypersensitivity reactions.

DIGIBIND Anti-digoxin Ab for digoxin toxicity/OD unresponsive to supportive Rx. See SPC for dose.

DIGOXIN

Cardiac glycoside: \downarrow s HR by slowing AVN conduction and \uparrow ing vagal tone. Also weak inotrope.

Use: AF (and other SVTs), HF.

Cl: HB (intermittent complete), 2nd-degree AV block, VF, VT, HOCM (can use with care if also AF and HF), SVTs 2° to WPW.

Caution: recent MI, $\downarrow K^{+*}/\downarrow T_4$ (both $\Rightarrow \uparrow$ digoxin sensitivity*), SSS, rhythms resembling AF (e.g. atrial tachycardia with variable AV block), R/E (\downarrow dose), P.

SE: generally mild unless rapid ivi, xs Rx or OD: **GI upset** (esp nausea), **arrhythmias/HB**, **neuro-\Psi disturbances** (inc visual Δ s, esp blurred vision and yellow/green halos), fatigue, weakness, confusion, hallucinations, mood Δ s. Also gynaecomastia (if chronic Rx), rarely \downarrow Pt, rash, \uparrow EØ.

Monitor: U&Es, digoxin levels (ideally take 6 h post-dose: therapeutic range = $1-2 \mu g/l$).

Interactions: digoxin fx/toxicity \uparrow d by Ca²⁺ antagonists (esp verapamil), amiodarone, propafenone, quinidine, antimalarials, itraconazole, amphotericin, ciclosporin, St John's wort and diuretics (mostly via \downarrow K^{+*}), but also ACE-i/ARBs and spironolactone (despite potential \uparrow K⁺). Cholestyramine and antacids can \downarrow digoxin absorption.

Dose: *non-acute AF/SVTs:* load with 125–250 µg bd po (maintenance dose $62.5-250 \mu$ g od). For HF: $62.5-125 \mu$ g od. **NB:** \downarrow **dose if RF, elderly or digoxin given** <**2** wks ago. Digoxin loading for acute AF/SVTs: *either* 0.75–1 mg as ivi over 2 h *or* 500 µg po repeated 12 h later. Then follow non-acute schedule.

DIHYDROCODEINE see Codeine; similar-strength opioid. **Dose:** 30-60 mg 4-6 hourly po (or up to 50 mg 4-6 hourly im/sc) with or after food. \uparrow doses can be given under close supervision. \downarrow dose if RF.

DILATING EYE DROPS (for funduscopy). Generally safe but rarely \Rightarrow angle closure glaucoma (suspect if develops red painful eye with \downarrow vision and nausea; *ophthalmic emergency*). Dilation blurs vision. Driving unsafe for at least 4 hours when both eyes dilated. Apply 1 drop and allow 15 mins for effect.

- 1 Tropicamide 1% Most common; CI in children <1 yr old (use 0.5%).
- 2 Phenylephrine 2.5% or 10% Frequently used in combination with tropicamide. 2.5% most common. 10% ↑s systemic SEs. CI if cardiac disease, HTN, ↑HR, aneurysms, ↑T₄.

Consider cycloplegic forms (e.g. cyclopentolate 1%) for refraction in children or if analgesia required, e.g. corneal abrasions & uveitis (\downarrow s ciliary spasm).

DILTIAZEM

Rate-limiting benzothiazepine Ca^{2+} channel blocker: \downarrow s HR and contractility* (but < verapamil) and \downarrow s BP. Also dilates peripheral/ coronary arteries.

56

Use: Rx/Px of angina¹ (esp if β -blockers CI) and HTN² (for advice on stepped HTN Mx see p. 178).

Cl: LVF* with pulmonary congestion, ↓↓HR, 2nd/3rd-degree AV block (without pacemaker), SSS, acute porphyria **P/B**.

Caution: 1st-degree AV block, \downarrow HR, \uparrow PR interval, L/R/H.

SE: headache, flushing, GI upset (esp N&C), oedema (esp ankle), ↓HR, ↓BP, gum hyperplasia. Rarely SAN/AVN block, arrhythmias, rash, hepatotoxicity, gynaecomastia.

Interactions: β -blockers and verapamil (can \Rightarrow asystole, AV block, $\downarrow \downarrow$ HR, HF). \uparrow s fx of digoxin, ciclosporin, theophyllines, carbamazepine and phenytoin. \Re \uparrow risk of VF with iv dandrolene \Re . **Dose:** 60 mg tds (\uparrow ing to max of 360 mg/day)¹; 180–480 mg/day in 1 or 2 doses² (*suitable for HTN only as MR preparation: no non-proprietary forms exist and brands vary in clinical fx* \therefore specify which is required^{SPC/BNF}). NB: Consider \downarrow ing doses if LF or RF.

DIPROBASE Paraffin-based emollient cream/ointment for dry skin conditions (e.g. eczema, psoriasis).

DIPYRIDAMOLE/PERSANTIN

Antiplatelet agent: inhibits Pt aggregation, adhesion and survival (also \Rightarrow arterial dilation: inc coronaries).

Use: 2° prevention of ischaemic TIA/CVA¹, Px of TE from prosthetic valves (as adjunct to warfarin)².

Caution: recent MI, angina (if unstable), aortic stenosis, coagulation disorders, \downarrow BP, MG*, migraine (may worsen), H/B. **SE:** GI upset, dizziness, myalgia, headache, \downarrow BP, \uparrow HR, hot flushes, rarely worsening of IHD, hypersensitivity (rash, urticaria, bronchospasm, angioedema), \uparrow postoperative bleeding, \downarrow Pt. **Interactions:** \downarrow s fx (but \uparrow s hypotensive fx) of cholinesterase inhibitors*, \uparrow s fx of adenosine. **W+**.

Dose: 200 mg bd po as MR preparation (Persantlin retard)^{1,2}; 100-200 mg tds po². All doses to be taken with food.

DISODIUM ETIDRONATE see Pamidronate.

DISODIUM PAMIDRONATE see Pamidronate.

DISULFIRAM/ANTABUSE

Alcohol dehydrogenase inhibitor: \Rightarrow ^systemic acetaldehyde \Rightarrow unpleasant SE when alcohol ingested (inc small amounts \therefore care with alcohol-containing medications, foods, toiletries). Use: alcohol withdrawal (maintenance of). CI: Hx of IHD or CVA, HTN, psychosis, ^suicide risk, severe personality disorder, H/P/B. Caution: DM, epilepsy, respiratory disease, L/R. SE: only if alcohol ingested – N&V, flushing, headache, ^HR, \downarrow BP (\pm collapse if xs alcohol intake). Interactions: ^s fx of phenytoin, ^toxicity with paraldehyde W+. Dose: initially 800 mg od, \downarrow ing to 100–200 mg od over 5 days. Review if >6 months. NB: Must have consumed no alcohol within at least 24 h of 1st dose. Prescribe under specialist supervision.

DOBUTAMINE

Inotropic sympathomimetic: mostly β_1 fx $\Rightarrow \uparrow$ contractility. \downarrow fx on HR compared with dopamine. **Use:** shock (cardiogenic, septic). **Caution:** severe \downarrow BP.

SE: \uparrow HR, \uparrow BP (if xs Rx), phlebitis, \downarrow Pt. **Interactions:** risk of \uparrow BP crisis with β -blockers (esp if fram calactive?)

'non-selective').

Dose: $2.5-10 \mu g/kg/min$ ivi, titrating to response (via central line, preferably with invasive cardiac monitoring). Often given with dopamine; seek expert help.

DOCUSATE SODIUM

Stimulant laxative: $\Rightarrow \uparrow GI$ motility (also a softening agent). Use/Caution/SE: see Senna (CI if GI obstruction).

Dose: 50–100 mg up to tds po (max 500 mg/day). Also available as enemas^{SPC/BNF}.

DOMPERIDONE

Antiemetic: D_2 antagonist – inhibits central nausea chemoreceptor trigger zone. Poor BBB penetration \therefore ↓central SEs (extrapyramidal fx, sedation) cf other dopamine antagonists.

Use: N&V, esp 2° to chemotherapy or 'morning-after pill', and in Parkinson's disease or migraine. Rarely for gastro-oesophageal reflux and dyspepsia.

CI: prolactinoma, when GI obstruction harmful, L.

Caution: GI obstruction R/P/B.

SE: rash, allergy, \uparrow prolactin (can \Rightarrow gynaecomastia, galactorrhoea and hyperprolactinoma). Rarely \downarrow libido, dystonia and extrapyramidal fx.

Dose: 10 mg tds po (can ↑to max 20 mg qds); 60 mg bd pr. Not available im/iv. **NB:** ↓**dose if RF**.

DONEPEZIL/ARICEPT

Acetylcholinesterase inhibitor (reversible); see Rivastigmine. Use: Alzheimer's disease: moderate^{NICE} or mild. CI: P/B.

Caution: supraventricular conduction dfx (esp SSS), ↑risk of PU (e.g. Hx of PU or NSAID), COPD/asthma, extrapyramidal symptoms can worsen, L.

SE: cholinergic fx (see p. 225), **GI upset** (esp initially), insomnia (if occurs, change dose to mane), headache, fatigue, dizziness, syncope, rash, Ψ disturbances. Rarely \downarrow or \uparrow BP, seizures, PU/GI bleeds, SAN/AVN block, hepatotoxicity.

Interactions: metab by **P450** \therefore inhibitors and inducers on p. 228 could \uparrow or \downarrow levels, respectively; check BNF/SPC.

Dose: 5 mg nocte (\uparrow to 10 mg after 1 month if necessary); specialist use only – need review for clinical response and tolerance. Continue only if MMSE remains 10–20^{NICE}.

DOPAMINE

Inotropic sympathomimetic: dose-dependent fx on receptors: low doses $(2-3 \ \mu g/kg/min)$ stimulate peripheral DA receptors but little else $\therefore \Rightarrow \uparrow$ renal perfusion*; higher doses (>5 $\mu g/kg/min)$ also

have β_1 fx (\Rightarrow \uparrow contractility); even higher doses have α fx (\Rightarrow vasoconstriction, but can worsen HF).

Use: shock, esp if ARF* or cardiogenic (e.g. post-MI or cardiac surgery).

Cl: tachyarrhythmias, phaeo, $\uparrow T_4$.

Caution: correct hypovolaemia before giving.

SE: N&V, \downarrow or \uparrow BP, \uparrow HR, peripheral vasoconstriction.

Interactions: fx \uparrow by cyclopropane and halogen hydrocarbon anaesthetics (are CI) or MAOIs (can $\Rightarrow \uparrow\uparrow$ BP; consider $\downarrow\downarrow$ dose of dopamine).

Dose: initially $2-5 \mu g/kg/min$ ivi (via central line, preferably with invasive cardiac monitoring), then adjust to response; seek specialist help.

DORZOLAMIDE/TRUSOPT

Topical carbonic anhydrase inhibitor: as acetazolamide (oral preparation, which is more potent but has SEs^*).

Use: glaucoma (esp if β -blocker or PG analogue CI or fails to \downarrow IOP). **CI:** \uparrow CI⁻ acidosis, **R** (severe only), **P/B**.

Caution: Hx of renal stones[†], L.

SE: local irritation & allergic reactions, blurred vision, bitter taste, rash. Rarely* systemic SEs (esp urolithiasis[†]) and interactions; see Acetazolamide.

Dose: apply 2% drop bd/tds. Available as combination drop with timolol 0.5% (Gesept).

DOXAPRAM

Respiratory stimulant: \uparrow s activity of respiratory and vasomotor centres in medulla $\Rightarrow \uparrow$ depth (and, to lesser extent, rate) of breathing. Also indirect fx by stimulation of chemoreceptors in aorta and carotid artery.

Use: hypoventilation, life-threatening respiratory failure – usually only if dt transient/reversible cause, e.g. post-operative/-general anaesthetic or acute deterioration with known precipitant. Mostly used in preventing respiratory depression 2° to \uparrow FiO₂ used in severe respiratory acidosis (can be harmful if CO₂ \downarrow or normal).

60 COMMON/USEFUL DRUGS

Cl: severe asthma or HTN, IHD, $\uparrow T_4$, epilepsy, physical obstruction of respiratory tract.

Caution: if taking MAOIs, L/H/P.

SE: headache, flushing, chest pains, arrhythmias, vasoconstriction, ↑BP, ↑HR, laryngo-/broncho-spasm, cough, salivation, GI upset, dizziness, seizures.

Dose: specialist use only (mostly in ITU).

DOXAZOSIN/CARDURA

 α_1 -Blocker \Rightarrow systemic vasodilation and relaxation of internal urethral sphincter $\therefore \Rightarrow \downarrow$ TPR¹ and \uparrow bladder outflow². **Use:** HTN¹ (*for advice on stepped HTN Mx see p. 178*), BPH². **Cl: B**.

Caution: postural \downarrow BP, micturition syncope, L/H/P/E.

SE: postural \downarrow **BP** (esp after 1st dose*), dizziness, headache, urinary incontinence (esp women), GI upset (esp N&V), drowsiness/fatigue, syncope, mood Δ s, dry mouth, oedema, somnolence, blurred vision, rhinitis. Rarely erectile dysfunction, \uparrow HR, arrhythmias, hypersensitivity/rash. Chronic Rx \Rightarrow beneficial lipid Δ s (\uparrow HDL, \downarrow LDL, \downarrow VLDL, \downarrow TG, \downarrow Pt, \downarrow NØ). **Interactions:** \uparrow s hypotensive fx of diuretics, β-blockers, Ca²⁺

antagonists, silden-/tadal-/varden-afil, general anaesthetics, moxisylyte and antidepressants.

Dose: initially 1 mg od (give 1st dose before bed*), then slowly \uparrow according to response (max 16 mg/day¹ or 8 mg/day²). 4 mg or 8 mg od if MR preparation, as Cardura XL.

DOXYCYCLINE

Tetracycline antibiotic: inhibits ribosomal (30S) subunit. Has longest $t_{1/2}$ of all tetracyclines \therefore od dosing.

Use: genital infections, esp syphilis, chlamydia, PID, salpingitis, urethritis (non-gonococcal). Also **tropical diseases**, e.g. *Rickettsia* (inc Q fever), *Brucella*, Lyme disease (*Borrelia burgdorferi*), malaria (Px/Rx, not 1st-line), mycoplasma (genital/respiratory), COPD infective exac (*H. influenzae*), anthrax (Rx/Px).

Cl/Caution/SE/Interactions: as tetracycline, but can give with caution if RF, although is also CI in SLE and achlorhydria. Can \Rightarrow anorexia, flushing, tinnitus and can \uparrow ciclosporin levels. **Warn:** avoid UV light and Zn-/Fe-containing products (e.g. antacids). **Dose:** 100–200 mg od/bd^{SPC/BNF}. **NB:** \downarrow **dose in RF**.

▼DULOXETINE/CYMBALTA^{1,2,3} OR YENTREVE⁴

5HT and noradrenaline reuptake inhibitor.

Use: depression¹ (see p. 192), generalised anxiety disorder², diabetic neuropathy³ (review need ≤ 3 monthly and stop if inadequate response after 2 months), stress urinary incontinence⁴ (assess benefit/tolerability after 2–4 wks).

Cl: R (avoid if creatinine clearance <30 ml/min) **L/P/B**. **Caution:** cardiac disease, Hx of mania or seizures, ****IOP, susceptibility to angle closure glaucoma, bleeding disorders/on drugs ****ing bleeding risk, **H/P/B/E**.

SE: N&V&C, abdominal pain, dyspepsia, Wt∆, ↓appetite, palpitations, hot flushes, insomnia, sexual dysfunction,

Interactions: metabolism \downarrow by ciprofloxacin, fluvoxamine. \uparrow 5HT fx with St John's wort and antidepressants (esp moclobemide and MAOIs; avoid concomitant use and don't start for 1 wk after stopping duloxetine). Avoid with artemether/lumefantrine. \uparrow risk CNS toxicity with sibutramine.

Warn: patient not to stop suddenly*

Dose: 60 mg od¹; initially 30 mg od (\uparrow to max 120 mg/day if required)²; 60 mg od (\uparrow to bd if required)³; 40 mg bd⁴. NB: stop gradually over 1–2 wks to \downarrow risk of withdrawal fx* (see p. 220).

EDROPHONIUM

Short-acting cholinesterase antagonist, given iv/im during Tensilon test for Dx of MG: look for \downarrow signs (e.g. \uparrow power, \downarrow ptosis).

ENALAPRIL/INNOVACE

ACE-i.

Use: HTN^1 (for advice on stepped HTN Mx see p. 178), LVF^2 . **Cl/Caution/SE/Interactions:** as Captopril, plus L. 62

Dose: initially $5 \text{ mg od}^1 (2.5 \text{ mg od}^2)$ (the function of the response max 40 mg/day. **NB:** Use elderly, taking diuretics or **RF**.

ENOXAPARIN/CLEXANE

Low-molecular-weight heparin (LMWH). **Use:** DVT/PE Rx¹ and Px² (inc pre-operative), ACS (with aspirin)³. **Cl/Caution/SE/Monitor/Interactions:** as Heparin, plus **B**. **Dose:** (all sc; 1 mg = 100 units) 1.5 mg/kg od¹, 40 mg od (20 mg od if not high risk)², 1 mg/kg bd³.

Consider monitoring anti-Xa (3–4 h post dose) and \downarrow dose if RF (i.e. creatinine >150), pregnancy, Wt >100 kg or <45 kg; see p. 201.

ENSURE Protein and calorie supplement drinks.

EPADERM Paraffin-based emollient ointment for very dry skin (and as soap substitute).

EPILIM see Valproate.

EPINEPHRINE see Adrenaline.

EPOETIN see Erythropoietin (recombinant form for \downarrow Hb).

EPROSARTAN/TEVETEN

Angiotensin II antagonist; see Losartan. Use: HTN (for advice on stepped HTN Mx see p. 178) CI: L (if severe), P/B. Caution/SE/Interactions: see Losartan. Dose: 600 mg od (max 800 mg od). Start at 300 mg and then ↑as required if elderly, RF or LF.

EPTIFIBATIDE/INTEGRILIN

Antiplatelet agent: glycoprotein IIb/IIIa receptor inhibitor – stops binding of fibrinogen and inhibits platelet aggregation.

Use: Px of MI in unstable angina or NSTEMI (if last episode of chest pain w/in 24 h), esp if high risk and awaiting PCI^{NICE} (see p. 230). **CI:** haemorrhagic diathesis, severe trauma or major surgery w/in 6 wks, abnormal bleeding or CVA w/in 30 days, Hx of haemorrhagic CVA or

intracranial disease (AVM, aneurysm or neoplasm), \downarrow Pt, \uparrow INR, severe HTN, L (if significant), R (if severe), B.

Caution: drugs that ↑bleeding risk (esp thrombolysis), **P. SE:** bleeding.

Monitor: FBC (baseline, w/in 6 h of giving, then at least daily) plus clotting and creatinine (baseline at least).

Dose: initially $180 \ \mu$ g/kg iv bolus followed by ivi of $2 \ \mu$ g/kg/min for up to 72 h (or 96 h if PCI during treatment). **NB: needs concurrent heparin and** \downarrow **dose if RF**^{SPC/BNF}.

Specialist use only: get senior advice or contact on-call cardiology.

ERGOCALCIFEROL (= CALCIFEROL)

Vit D₂: needs renal (1) and hepatic (25) hydroxylation for activation. **Use:** vitamin D deficiency.

Cl: \uparrow Ca²⁺, metastatic calcification.

Caution: R (if high 'pharmacological'* doses used), B.

SE: \uparrow Ca²⁺. If over-Rx: **GI upset**, weakness, headache,

polydipsia/polyuria, anorexia, RF, arrhythmias.

Monitor: Ca^{2+} (esp if N&V develops or \uparrow doses in RF*).

Interactions: fx \downarrow by anticonvulsants and \uparrow by thiazides.

Dose: $10-20 \ \mu g \ (400-800 \ units) \ od \ as part of multivitamin preparations or combined with calcium lactate or phosphate as 'calcium + ergocalciferol': non-proprietary preparations available but is often prescribed by trade name (e.g. Cach D3, or Calcilenew D3). Tdoses of 0.25-1.0 mg od (of 'pharmacological strength' preparations*) used for GI malabsorption and chronic liver disease (up to 5 mg daily for <math>\downarrow$ PTH or renal osteodystrophy).

*Specify strength of tablet required to avoid confusion^{SPC/BNF}.

ERYTHROMYCIN

Macrolide antibiotic: binds 50S ribosome; 'static' at low doses, 'cidal' at high doses.

Use: atypical pneumonias (with other agents; see p. 168), rarely *Chlamydia*/other GU infections, *Campylobacter* enteritis. Often used if allergy to penicillin.

COMMON/USEFUL DRUGS

Cl: macrolide hypersensitivity or if taking terfenadine, pimozide, ergotamine or dihydroergotamine.

Caution: ¹QTc (inc drugs that predispose to), porphyria, L/R/P/B. **SE: GI upset** (rarely AAC), **dry itchy skin**, hypersensitivity (inc SJS, TEN), arrhythmias (esp VT), chest pain, reversible hearing loss (dose-related, esp if RF), cholestatic jaundice.

Interactions: \downarrow **P450** \therefore many; most importantly \uparrow s levels of ciclosporin, digoxin, theophyllines and carbamazepine, **W**+. **Dose:** 500 mg qds po (250 mg qds if mild infection, 1 g qds if severe); 50 mg/kg daily iv in 4 divided doses. NB: venous irritant \therefore give po if possible.

ERYTHROPOIETIN

Recombinant erythropoietin.

Use: \downarrow Hb 2° to CRF or chemotherapy (AZT or platinumcontaining). Also unlicensed use for myeloma, lymphoma and certain myelodysplasias. 3 types: α (Eprex), β (NeoRecormon) and longer-acting darbepoetin (Aranesp).

SE: \uparrow BP, \uparrow K⁺, headache, arthralgia, oedema, TE. Rarely \Rightarrow red cell aplasia (esp subcutaneous Eprex if RF, which is now CI) \bigotimes . **Cl/Caution/Dose:** specialist use only^{SPC/BNF}; given subcutaneously (self-administered) or iv (as inpatient). \downarrow Fe/folate (monitor), \uparrow Al, infections and inflammatory disease can \downarrow response. NB: *transfusion is 1st-line Rx for* \downarrow Hb 2° to cancer chemotherapy.

ESCITALOPRAM/CIPRALEX

SSRI (active enantiomer of citalopram). Use: Depression (see p. 192), OCD, anxiety disorders. Cl/Caution/SE/Warn/Interactions: as citalopram. Dose: initially 10 mg od, ↑ing if necessary to 20 mg od. NB: halve doses if elderly, LF and for most anxiety disorders.

ESMOLOL

 β -blocker: cardioselective ($\beta_1 > \beta_2$) and short-acting*. **Use:** SVTs (inc AF, atrial flutter, sinus \uparrow HR), HTN (esp perioperatively), acute MI (*safer than long-acting preparations).

CI/Caution/SE/Interactions: see Propranolol.

Dose: usually 50–200 µg/kg/min ivi, preceded by loading dose if perioperative^{SPC}.

ESOMEPRAZOLE/NEXIUM

PPI; as Omeprazole, plus R (if severe).

Dose: 20 mg od po (40 mg od for 1st 4 wks, if for gastro-oesophageal reflux); 20–40 mg/day iv^{SPC/BNF}($\mathbf{\nabla}$). **NB:** Max 20 mg/day if severe LF.

▼ETANERCEPT/ENBREL

Monoclonal Ab against TNF- α (an inflammatory cytokine). **Use:** severe arthritis (rheumatoid^{NICE}, juvenile idiopathic^{NICE} and psoriatic), severe plaque psoriasis^{NICE} and ankylosing spondylitis^{NICE}.

Cl/Caution/Interactions: See SPC.

SE: blood disorders, severe infections, CNS demyelination, GI upset, exac of HF, headache. *Specialist use only*. Don't give live vaccines during Rx. Risk of infections (e.g. TB, inc extrapulmonary) and theoretical malignancy risk .

ETHAMBUTOL

Anti-TB antibiotic: inhibits cell-wall synthesis ('static'). **Use:** TB initial Rx phase (1st 2 months) *if isoniazid resistance known or suspected* (see pp. 167–8).

Cl: optic neuritis, \downarrow vision.

Caution: R (monitor levels^{*} and \downarrow dose if creatinine clearance <30 ml/min), P/E.

SE: neuritis; peripheral and optic (can $\Rightarrow \downarrow$ visual acuity**, colour-blindness, \downarrow visual fields $\therefore \Rightarrow$ baseline and regular ophthalmology review). Rarely GI upset, skin reactions, \downarrow Pt. Warn: patient to report immediately any visual symptoms – use alternative drug if unable to do this (e.g. very young, \downarrow IQ). Monitor: visual acuity** (inc baseline before Rx), plasma levels*. Dose: 15 mg/kg od (30 mg/kg 3 times a week if 'supervised' Rx)^{SPC/BNF}. NB: \downarrow dose if RF.

▼ETORICOXIB/ARGOXIA

NSAID, selective COX-2 inhibitor.

Use: osteo¹/rheumatoid² arthritis^{NICE}, ankylosing spondylitis², acute gout³.

Cl/Caution/SE/Interactions: as celecoxib (except fluconazole interaction), plus CI in uncontrolled HTN (persistently >140/90 mmHg) – monitor BP w/in 2 wks of starting & regularly thereafter. Also \uparrow s ethinylestradiol levels & rifampicin $\Rightarrow \downarrow$ serum levels. *Not* CI in sulphonamide hypersensitivity. Mild [**W**+]. **Dose:** 30–60 mg od¹; 90 mg od²; 120 mg od³ for max 8 days. **NB**:

↓dose if LF.

EUMOVATE see Clobetasone butyrate 0.05%; steroid cream.

FANSIDAR

Antimalarial: combination tablet of pyrimethamine (25 mg) + sulfadoxine (500 mg).

Use: Rx of falciparum malaria (with or following quinine).

Cl: sulphonamide or pyrimethamine allergy, porphyria.

Caution: blood disorders, asthma, G6PD deficiency, L/R/P/B/E. **SE:** blood disorders, skin reactions*, pulmonary infiltrates, insomnia, GI upset, nephrotoxicity, hepatotoxicity, hypersensitivity. **Monitor:** FBC (if chronic Rx) and for rash* or cough/SOB (stop drug). **Dose:** see BNF/SPC.

FELODIPINE/PLENDIL

Ca²⁺ channel blocker (dihydropyridine): as amlodipine but $\Rightarrow \downarrow$ HF/-ve inotropic fx.

Use: HTN¹ (for advice on stepped Mx see p. 178), angina Px^2 . **Cl:** IHD (if unstable angina or w/in 1 month of MI), significant aortic stenosis, acute porphyria, **H** (if uncontrolled)/**P**.

Caution: stop drug if angina/HF worsen, L/B.

SE: as nifedipine but ↑ankle swelling and possibly ↓vasodilator fx (headache, flushing and dizziness).

Interactions: metab by **P450** \therefore levels \uparrow by cimetidine, erythromycin, ketoconazole and **grapefruit juice**. Hypotensive fx \uparrow by α -blockers. Levels \downarrow by primidone. \uparrow s fx of tacrolimus. **Dose:** initially 5 mg od, \uparrow if required to 10 mg (max 20 mg¹). NB: \downarrow dose if LF or elderly.

FENTANYL

Strong opioid; used in severe chronic/palliative pain (top/sl/buccal/ nasal spray) and in anaesthesia (iv).

Cl: acute respiratory depression, risk of ileus, \uparrow ICP/head injury/coma. **Caution:** all other conditions where morphine is CI or cautioned,

but better tolerated in RF. Also DM, cerebral tumour.

SE: as morphine but generally $\downarrow N\&V/constipation$.

Interactions: as morphine but levels \uparrow (not \downarrow) by ritonavir, levels \uparrow by itra-/flu-conazole & no known interaction with gabapentin. **Warn:** patients/carers of signs/symptoms of opiate toxicity.

Dose: *Patches:* last 72 h and come in 5 strengths: 12, 25, 50, 75 and 100, which denote release of μ g/h (to calculate initial dose, these are approx equivalent to daily oral morphine requirement of 45, 90, 180, 270 and 360 mg, respectively).

Lozenges (buccal) for 'breakthrough' pain as Acting: initially 200 μg over 15 min, repeating after 15 min if needed and adjusting dose to give max 4 dose units (available as 200, 400, 600, 800, 1200 or 1600 μg) daily.

Tablets: for 'breakthrough' pain as \checkmark Effortora (buccal) or \checkmark Abstral(sl) 100, 200 or 300 µg^{SPC/BNF}. \checkmark Abstral also available in 400, 600 or 800 µg doses^{SPC/BNF}. Only use if taking regular opioids (fatalities reported otherwise). If >4 doses/day needed, adjust background analgesia.

Nasal spray: for 'breakthrough' pain as ♥Instanyl; 50, 100 or 200 µg doses^{SPC/BNF}.

NB: \downarrow dose if LF or elderly. No initial \downarrow dose needed in RF, but may accumulate over time. Unless given iv has prolonged onset/offset; use only when opioid requirements stable & cover 1st 12 hrs after initial Rx with prn short acting opioid.

NB: fever/external heat can \Rightarrow \uparrow absorption (\therefore \uparrow fx) from patches. Only for use if have previously tolerated opioids. If serious adverse reactions remove patch immediately and monitor for up to 24 h. Unless given iv has prolonged onset / offset; use only when opioid requirements stable & cover 1st 12 hrs after initial Rx with prn short acting opioid.

FERROUS FUMARATE

As ferrous sulphate, but \$\JGI upset; available in UK as Fersaday (322-mg tablet od as Px or bd as Rx), Fersamal (1-2 tablets of 210 mg tds) or Galfer (305 mg capsule od/bd).

FERROUS GLUCONATE

As ferrous sulphate, but \downarrow GI upset. Px: 600 mg od; Rx: 1.2–1.8 g/day in 2–3 divided doses.

FERROUS SULPHATE

Oral Fe preparation. **Use:** Fe-deficient ↓Hb Rx/Px.

Caution: P.

SE: dark stools (can confuse with melaena, which smells worse!), **GI upset** (esp **nausea**; consider switching to ferrous gluconate/ fumarate or take with food, but latter can $\Rightarrow \downarrow$ absorption), Δ bowel habit (dose-dependent).

Dose: Rx: 200 mg bd/tds. Px: 200 mg od.

FINASTERIDE

Antiandrogen: 5- α -reductase inhibitor; \downarrow s testosterone conversion to more potent dihydrotestosterone.

Use: BPH¹ (\downarrow s prostate size and symptoms), male-pattern baldness². **Caution:** Ca prostate (can $\Rightarrow \downarrow$ PSA and \therefore mask), obstructive uropathy, **P** (teratogenic; although not taken by women, partners of those on the drug can absorb it from handling crushed tablets and from semen, in which it is excreted \therefore *females must avoid handling tablets, and sexual partners of those on the drug must use condoms if, or likely to become, pregnant*).

SE: sexual dysfunction, testicular pain, gynaecomastia, hypersensitivity (inc swelling of lips/face).

Dose: 5 mg od¹ (Proscar), 1 mg od²(Propecia).

FLAGYL see Metronidazole; antibiotic for anaerobes

FLECAINIDE

Class Ic antiarrhythmic; local anaesthetic; ↓s conduction.

Use: VT¹ (if serious and symptomatic), SVT² (esp junctional re-entry tachycardias and paroxysmal AF).

Cl: SAN dysfunction, atrial conduction dfx, HB (not 1st-degree), BBB, AF post-cardiac surgery, chronic AF (with no attempts at cardioversion), Hx of MI plus asymptomatic VEs or non-sustained VT, valvular heart disease (if haemodynamically compromised), **H**.

Caution: pacemakers, ensure e'lytes normalised before use, L/R/P/B/E.

SE: GI upset, syncope, dyspnoea, vision/mood disturbances. Rarely arrhythmias.

Monitor: pre-dose plasma levels in LF or RF (keep at 0.2–1 mg/l), ECG if giving iv.

Interactions: levels $\uparrow d$ by amiodarone, ritonavir, fluoxetine and quinine. $\uparrow s$ digoxin levels. Myocardial depression may occur with β -blockers/verapamil. $\uparrow risk$ of arrhythmias with antipsychotics, TCAs, artemether/lumefantrine and dolasetron.

Dose: initially 100 mg bd po, \downarrow ing after 3–5 days if possible (max 400 mg/day)¹; 50 mg bd po, \uparrow ing if necessary to 300 mg/day². Acutely, 2 mg/kg iv over 10–30 min (max 150 mg), then (if required) 1.5 mg/kg/h ivi for 1 h, then \downarrow ing to 100–250 µg/kg/h for up to 24 h, then give po (max cumulative dose in 1st 24 h = 600 mg). NB: \downarrow dose if LF/RF.

FLEET (PHOSPHO-SODA) see Bowel preparations.

Dose: 45 ml (mixed with 120 ml water, then followed by 240 ml water) taken twice: for morning procedures, at 7 am and 7 pm the day before; for afternoon procedures, at 7 pm the day before and at 7 am on the day of procedure.

FLIX@TIDE see Fluticasone (inh steroid). 50, 100, 250 or 500 µg/puff as powder. 50, 125 or 250 µg/puff as aerosol. **Dose:** 100–2000 µg/day^{SPC/BNF} (aerosol doses spowder doses).

FLOMAXTRA XL see Tamsulosin; α_1 -blocker for \uparrow prostate.

FLUCLOXACILLIN

Penicillin (penicillinase-resistant).

COMMON/USEFUL DRUGS

Use: penicillin-resistant (β -lactamase-producing) staphylococcal infections, esp skin¹ (surgical wounds, iv sites, cellulitis, impetigo, otitis externa), rarely as adjunct in pneumonia¹. Also osteomyelitis², endocarditis³.

Cl/Caution/SE/Interactions: as benzylpenicillin, plus CI if Hx of flucloxacillin-associated jaundice/hepatic dysfunction and caution if LF, as rarely \Rightarrow hepatitis or **cholestatic jaundice** (may develop up to 2 months after Rx stopped).

Dose: 250–500 mg qds po/im (or up to 2 g qds iv)¹; up to 2 g qds iv²; 2 g qds (4-hrly if Wt > 85 kg) iv³. **NB:** \downarrow **dose in severe RF.**

FLUCONAZOLE

Triazole antifungal: good po absorption and CSF penetration. **Use:** fungal meningitis (esp cryptococcal), candidiasis (mucosal, vaginal, systemic), other fungal infections (esp tinea, pityriasis). **Caution:** susceptibility to QTc, L/R/P/B.

SE: GI upset, hypersensitivity (can \Rightarrow angioedema, TEN, SJS, anaphylaxis: if develops rash, stop drug or monitor closely), hepatotoxicity, headache. Rarely blood/metabolic (\uparrow lipids, $\downarrow K^+$) disorders, dizziness, seizures, alopecia.

Monitor: LFTs; stop drug if features of liver disease develop. **Interactions:** \downarrow **P450** \therefore many; most importantly, \uparrow s fx of theophyllines, ciclosporin, phenytoin and tacrolimus. Also \downarrow clopidogrel fx. **W+**. **Dose:** 50–400 mg/day po or iv according to indication^{SPC/BNF}. **NB:** \downarrow **dose in RF**.

FLUDROCORTISONE

Mineralocorticoid (also has glucocorticoid actions). **Use:** adrenocortical deficiency, esp Addison's disease¹. **Cl/Caution/Interactions:** See Prednisolone. **SE:** H₂**O/Na⁺ retention**, \downarrow K⁺ (monitor U&Es). Also can \Rightarrow immunosuppression (and other SEs of corticosteroids; see p. 221). **Dose:** 50–300 µg/day po¹.

FLUMAZENIL

Benzodiazepine antagonist (competitive).

70

Use: benzodiazepine OD/toxicity (only if respiratory depression and ventilatory support not immediately available).

Cl: life-threatening conditions controlled by benzodiazepines (e.g. \uparrow ICP, status epilepticus).

Caution: mixed ODs (esp TCAs), benzodiazepine dependence (may \Rightarrow withdrawal fx; see p. 223), Hx of panic disorder (can \Rightarrow relapse), head injury, epileptics on long-term benzodiazepine Rx (may \Rightarrow fits), L/P/B/E.

SE: N&V, dizziness, flushing, rebound anxiety/agitation, transient ↑BP/HR. Very rarely anaphylaxis.

Dose: initially 200 μ g iv over 15 sec, then, if required, further doses of 100 μ g at 1 min intervals. *Max total dose 1 mg (2 mg in ITU)*. Can also give as ivi at 100–400 μ g/h adjusting to response. NB: see p. 255 for Rx of acute OD.

NB: short $t_{1/2}$ (40–80 min); observe closely after Rx and consider further doses or ivi (at 0.1–0.4 mg/h adjusted to response).

Flumazenil is not recommended as a diagnostic test and should not be given routinely in overdoses as risk of inducing:

- fits (esp if epileptic)
- withdrawal syndrome (if habituated to benzodiazepines)
- arrhythmias (esp if co-ingested TCA or amphetamine-like drug).

If in any doubt get senior opinion and exclude habituation to benzodiazepines and get ECG before giving unless life-threatening respiratory depression and benzodiazepine known to be cause <u>w</u>.

FLUOXETINE/PROZAC

SSRI antidepressant: long $t_{1/2}$ compared with others*. Use: depression¹, other Ψ disorders (inc bulimia², OCD³). Cl: active mania.

Caution: epilepsy, receiving ECT, Hx of mania or bleeding disorder (esp GI), heart disease, DM^{\dagger} , glaucoma (angle closure), \uparrow risk of bleeding, age < 18 yrs L/R/H/P/B/E.

Class SEs: GI upset, \downarrow Wt, insomnia**, agitation**, headache, hypersensitivity. Can \Rightarrow withdrawal fx when stopped (see p. 226)

:. stop slowly; more important for SSRIs with $\downarrow t_{1/2}^*$. Rarely extrapyramidal (see p. 227) and antimuscarinic fx (see p. 225), sexual dysfunction, convulsions, $\downarrow Na^+$ (inc SIADH), blood disorders, GI bleed, serotonin syndrome (see p. 227) and suicide.

Specific SEs: rarely hypoglycaemia[†], **vasculitis** (**rash** may be 1st sign). **Warn:** can \downarrow performance at skilled tasks (inc driving). Don't stop suddenly (not as important as for other SSRIs).

Interactions: \downarrow **P450** \therefore many, but most importantly \uparrow s levels of TCAs, benzodiazepines, clozapine and haloperidol. \uparrow s lithium toxicity and \Rightarrow HTN and \uparrow CNS fx with sele-/rasa-giline (and other dopaminergics). \uparrow risk of CNS toxicity with drugs that \uparrow 5HT (e.g. tramadol, sibutramine, sumatriptan, St John's wort). \uparrow risk of bleeding with aspirin and NSAIDs. Levels \uparrow by ritonavir. Antagonises antiepileptics (but \uparrow s levels of carbamazepine and phenytoin). Avoid with artemether/lumefantrine and tamoxifen. \bigotimes Never give with, or <2 wks after, MAOIs \bigotimes . (Mild W+.)

Dose: initially $20 \text{ mg}^{1,3}$ (\uparrow to max 60 mg) od; $60 \text{ mg} \text{ od}^2$ – give mane as can \downarrow sleep**. **NB:** \downarrow **dose in LF**.

FLUTICASONE/FLIXOTIDE (various delivery devices available^{BNF}) Inhaled corticosteroid for asthma: see Beclometasone.

Dose: 100–2000 µg/day inh (or 0.5–2 mg bd as nebs).

1 µg equivalent to 2 µg of beclometasone or budesonide.

FOLIC ACID (= FOLATE)

Vitamin: building block of nucleic acids. Essential co-factor for DNA synthesis \Rightarrow normal erythropoiesis.

Use: megaloblastic ↓Hb Rx/Px if haemolysis/dialysis¹ (or GI malabsorption where ↑doses may be needed), Px against neural-tube dfx in pregnancy² (esp if on antiepileptics), Px of mucositis and GI upset if on methotrexate³.

Cl: malignancy (unless megaloblastic \downarrow Hb due to \downarrow folate is an important complication).

Caution: undiagnosed megaloblastic \downarrow Hb (i.e. \downarrow B₁₂, as found in pernicious anaemia) – folate given without B₁₂ in B₁₂ deficiency can precipitate subacute combined degeneration of spinal cord.

SE: malaise, bronchospasm, allergy.

Dose: 5 mg od^1 (in maintenance, \downarrow frequency of dose, often to wkly); 400 µg od² (unless mother has neural-tube defect herself or has previously had a child with a neural-tube defect, when 5 mg od needed); 5 mg once wkly³.

FOMEPIZOLE Antidote for toxic alcohols.

FONDAPARINUX/ARIXTRA

Anticoagulant; activated factor X inhibitor. Use: ACS (UA, NSTEMI or STEMI), Px of VTE, Rx of DVT/PE. Cl: active bleeding, bacterial endocarditis.

Caution: bleeding disorders, active PU, other drugs that \hat{r} isk of bleeding, recent intracranial haemorrhage, recent brain/ophthalmic/ spinal surgery, spinal/epidural anaesthesia (avoid Rx doses), Wt <50 kg. R (avoid or \downarrow dose according to indication and creatinine

clearance^{SPC/BNF}), L/P/B/E.

SE: bleeding, \downarrow Hb, \downarrow (or \uparrow)Pt, coagulopathy, purpura, oedema, LFT Δ s, GI upset. Rarely \downarrow K⁺, \downarrow BP, hypersensitivity.

Dose: UA/NSTEMI/Px of VTE 2.5 mg sc od (start 6-h post-op); STEMI 2.5 mg iv/ivi od for 1st day then sc; Rx of PE/DVT by Wt (<50 kg = 5 mg sc od, 50–100 kg = 7.5 mg sc od, >100 kg = 10 mg sc od). NB: Length of Rx depends on indication^{SPC/BNF}, timing of doses post-op critical if Wt <50 kg or elderly. **Consider** \downarrow dose in RF. Specialist use only: get senior advice or contact on-call cardiology/ haematology.

FORMOTEROL (= EFORMOTEROL)/FORADIL, OXIS

Long-acting β_2 agonist 'LABA'; as Salmeterol plus L. **Dose:** 6–48 µg daily (mostly bd regime)^{SPC/BNF} inh (min/max doses vary with preparations^{SPC/BNF}).

FOSPHENYTOIN

Antiepileptic: prodrug of phenytoin; allows safer rapid loading. **Use:** epilepsy (esp 'status' & seizures assoc with neurosurgery/head injury).

Cl/Caution/SE/Monitor/Warn/Interactions: as phenytoin, but \downarrow SEs (esp \downarrow arrhythmias and 'purple glove syndrome'). **Dose:** as phenytoin, but prescribe as 'phenytoin sodium equivalent' and note \clubsuit fosphenytoin 1.5 mg = phenytoin 1 mg \clubsuit . **NB: consider** \downarrow dose in LF or RF.

FOSTAIR

Combination asthma inhaler: each puff contains 100 μg beclomethasone (steroid) + 6 μg formoterol (long-acting β_2 -agonist) in a metered dose inhaler.

Dose: 1-2 puffs bd inh.

FRAGMIN see Dalteparin; low-molecular-weight heparin.

FRUMIL see Co-amilofruse; tablets are 5/40 (5 mg amiloride + 40 mg furosemide) unless stated as LS (2.5/20) or FORTE (10/80).

FRUSEMIDE now called Furosemide.

FUROSEMIDE (previously Frusemide).

Loop diuretic: inhibits Na⁺/K⁺ pump in ascending loop of Henle \Rightarrow \downarrow resorption and \therefore \uparrow loss of Na⁺/K⁺/Cl/H₂O.

Use: LVF (esp in acute pulmonary oedema, but also in chronic LVF/CCF or as Px during blood transfusion), resistant HTN (*for advice on stepped HTN Mx see p. 178*), oliguria secondary to ARF (after correcting hypovolaemia first).

Cl: $\downarrow \downarrow K^+$, $\downarrow Na^+$, cirrhosis (if precomatose), **R** (if anuria). **Caution**: \downarrow BP, \uparrow prostate, porphyria, diabetes, L/P/B.

SE: \downarrow **BP** (inc postural), \downarrow **K**⁺, \downarrow **Na**⁺, \downarrow Ca²⁺, \downarrow Mg²⁺, \downarrow Cl alkalosis. Also \uparrow **urate/gout**, GI upset, \uparrow glucose/impaired glucose tolerance, \uparrow cholesterol/TGs (temporary). Rarely **BM suppression** (stop drug), RF, skin reactions, pancreatitis, tinnitus/deafness (if \uparrow doses or RF: reversible).

Interactions: ↑s toxicity of digoxin, flecanide, solatol, NSAIDs, vancomycin, gentamicin and lithium. ↓s fx of antidiabetics. NSAIDs may ↓diuretic response.

Monitor: U&Es; if $\downarrow K^+$, add po K⁺ supplements/K⁺-sparing diuretic or change to combination tablet (e.g. co-amilofruse).

Dose: usually 20–80 mg po/im/iv daily in divided doses. 1 doses used in acute LVF (see p. 233) and oliguria. If HF or RF, ivi (max 4 mg/min) can \Rightarrow smoother control of fluid balance^{SPC/BNF}. For blood transfusions, a rough guide is to give 20 mg with every unit if *existing LVF*, and with every 2nd unit if *at risk of LVF*. NB: may need 1 dose in RF. Give iv if severe ordema: as bowel ordema $\Rightarrow \downarrow po$ absorption.

FUSIDIC ACID/FUGIDIN

Antibiotic: good bone penetration and activity against S. aureus. Use: osteomyelitis, endocarditis (2° to penicillin-resistant staphylococci) - needs 2nd antibiotic to prevent resistance. **Caution:** biliary disease or obstruction ($\Rightarrow \downarrow$ elimination), L/P/B. SE: GI upset, hepatitis*, Rarely: skin/blood disorders, ARF. **Monitor:** LFTs* (esp if chronic Rx, [↑]doses or LF). **Dose:** 500 mg tds po (equivalent to 750 mg tds if using suspension) – in severe infection to [↑]1g tds po; 500 mg tds iv (6–7 mg/kg tds if Wt <50 kg). NB: \downarrow dose in LF.

FUSIDIC ACID 1% EYE DROPS/FUGITHALMIG

Topical antibiotic (esp vs. Staphylococcus); commonly used for blepharitis.

Dose: 1 drop bd.

FYBOGEL

Laxative: bulking agent (ispaghula husk) for constipation (inc IBS). **Cl:** ↓swallow, GI obstruction, faecal impaction, colonic atony. **Dose:** 1 sachet or 10 ml bd after meals with water.

GABAPENTIN

Antiepileptic: similar structure to GABA but mechanism of action is different from drugs affecting GABA receptors.

Use: neuropathic pain, epilepsy (adjunctive Rx of partial seizures \pm 2° generalisation).

Caution: Hx of psychosis or DM, R/P/B/E.

SE: fatigue/somnolence, dizziness, cerebellar fx (esp ataxia; see p. 227), dipl-/ambly-opia, headache, rhinitis. Rarely **WCC**, GI upset, arthra-/mv-algia, skin reactions, suicidal ideation.

Interactions: fx \downarrow by antidepressants and antimalarials (esp mefloquine).

Dose: initially 300 mg od, \uparrow ing by 300 mg/day to max 3.6 g daily in 3 divided doses (*NB: stop drug over* $\geq 1 \ wk$). **NB:** \downarrow **dose in RF.** Can give false-positive urinary dipstick results for proteinuria.

GASTROGOTE Compound alginate for acid reflux.

Dose: 5-15 ml or $1-2 \text{ tablets after meals and at bedtime (NB: 2.13 mmol Na⁺/5 ml and 1 mmol Na⁺/tablet).$

GAVISCON (ADVANCE) Alginate raft-forming oral suspension for acid reflux.

Dose: 5-10 ml or 1-2 tablets after meals and at bedtime (NB: 2.3 mmol Na⁺ and 1 mmol K⁺/5 ml and 2.25 mmol Na⁺ and 1 mmol K⁺/tablet). Ensure good hydration, esp if elderly, GI narrowing or \downarrow GI motility.

GELOFUSINE

Colloid plasma substitute (gelatin-based) for iv fluid resuscitation (see p. 216). 1 l contains 154 mmol Na^+ (but no K^+).

GENTAMICIN

Aminoglycoside: broad-spectrum 'cidal' antibiotic; inhibs ribosomal 30S subunit. Good Gram-negative aerobe/staphylococci cover; other organisms often need concurrent penicillin \pm metronidazole. **Use:** severe infections, esp sepsis, meningitis, endocarditis. Also pyelonephritis/prostatitis, biliary tract infections, pneumonia. **CI:** MG*.

Caution: obesity, R/P/B/E.

SE: ototoxic, nephrotoxic (dose- and Rx length-dependent), hypersensitivity, rash. Rarely AAC, N&V, seizures, encephalopathy, blood disorders, myasthenia-like syndrome* (at \uparrow doses; reversible), \downarrow Mg²⁺ (if prolonged Rx).

Monitor: serum levels** after 3 or 4 doses (earlier if RF).

Interactions: fx (esp toxicity) [↑]by loop diuretics (esp **furosemide**), cephalosporins, vancomycin, amphotericin, ciclosporin, tacrolimus and cytotoxics; if these drugs must be given, space doses as far from

time of gentamicin dose as possible. \uparrow s fx of muscle relaxants and anticholinesterases. W+.

Dose: once daily regimen: initially 5–7 mg/kg ivi adjusting to levels (NB: consult local protocol and od regimen not suitable if endocarditis, >20% total body surface burns or creatinine clearance <20 ml/min). **Multiple daily regimen:** 3–5 mg/kg/day in 3 divided doses im/iv/ivi (if endocarditis give 1 mg/kg tds iv).

NB: ↓doses if RF (and consider if elderly or ↑↑BMI), otherwise adjust according to serum levels*: call microbiology department if unsure.

**Gentamicin levels: Measure peak at 1 h post-dose (ideally = 5–10 mg/l) and trough immediately predose (ideally ≤ 2 mg/l). Halve ideal peak levels if for endocarditis. If levels high, can \uparrow spacing of doses (as well as \downarrow ing amount of dose); as \Rightarrow \uparrow risk of ototoxicity, monitor auditory/vestibular function.

NB: od regimens usually only require **pre-dose** level.

GLIBENCLAMIDE

Oral antidiabetic (long-acting sulphonylurea): \uparrow s pancreatic insulin release – stimulates β islet cell receptors (and inhibits gluconeogenesis).

Use: type 2 DM; requires endogenous insulin to work. Not recommended for obese* (use metformin) or elderly** (use short-acting preparations, e.g. gliclazide).

Cl: ketoacidosis, acute porphyria, **L/R** (if either severe, otherwise caution), **P/B**.

Caution: may need to replace with insulin during intercurrent illness/surgery, porphyria, **E**.

SE: hypoglycaemia (esp in elderly^{**}), **GI upset**, **\uparrowWt^{*}**, headache. Rarely hypersensitivity (inc skin) reactions, blood disorders, hepatotoxicity and transient visual Δ s (esp initially).

Interactions: fx \uparrow d by chloramphenicol, sulphonamides (inc co-trimoxazole), sulfinpyrazone, antifungals (esp flu-/mic-onazole), warfarin, fibrates and NSAIDs. Levels \downarrow by rifampicin/rifabutin. \uparrow Risk of hepatotoxicity with bosentan.

Dose: initially 5 mg mane (with food), \uparrow ing as necessary (max 15 mg/day). **NB:** \downarrow **dose in severe LF**.

GLICLAZIDE

Oral antidiabetic (short-acting sulphonylurea).

Use/CI/Caution/SE/Interactions: as glibenclamide, but shorter action* and hepatic metabolism** mean \downarrow d risk of hypoglycaemia (esp in elderly* and RF**).

Dose: initially 40–80 mg mane (with food), 1 mg as necessary (max 320 mg/day). MR tablets available (Diamileron MR) of which 30 mg has equivalent effect to 80 mg of normal release (dose initially is 30 mg od, 1 mg if necessary to max 120 mg od). NB: ↓dose in RF or severe LF.

GLIMEPIRIDE

Oral antidiabetic (short-acting sulphonylurea).

Use/CI/Caution/SE/Interactions: as gliclazide, plus manufacturer recommends monitoring of FBC and LFTs. CI in severe LF. May need to substitute with insulin; seek specialist advice.

Dose: initially 1 mg mane (with food), ↑ing as necessary (max 6 mg/day).

GLIPIZIDE

Oral antidiabetic (short-acting sulphonylurea).

Use/CI/Caution/SE/Interactions: as gliclazide.

Dose: initially 2.5–5.0 mg mane (with food), 1 ing as necessary (max single dose 15 mg; max daily dose 20 mg). **NB:** 4 dose in severe LF and RF.

GLUCAGON

Polypeptide hormone: $\hat{}$ s hepatic glycogen conversion to glucose. **Use:** hypoglycaemia: if acute and severe, esp if no iv access or if 2° to xs insulin (see p. 245).

CI: phaeo.

Caution: glucagonomas/insulinomas. Will not work if hypoglycaemia is chronic (inc starvation) or 2° to adrenal insufficiency.

SE: N&V&D, \downarrow BP, \downarrow K⁺, hypersensitivity, **W**+. **Dose:** 1 mg (= 1 unit) **im** (or sc/iv)^{SPC/BNF}. Often stocked in cardiac arrest ('crash') trolleys.

GLYCEROL (= GLYCERIN) SUPPOSITORIES

Rectal irritant bowel stimulant. **Use:** constipation: 1st-line suppository if oral methods such as lactulose and senna fail. **Dose:** 1–2 pr prn.

GLYCERYL TRINITRATE see GTN.

GRANISETRON

Antiemetic: 5HT_3 antagonist. **Use:** N&V; see Ondansetron. **Caution:** GI obstruction (inc subacute), $\uparrow QTc$, **P/B**. **SE:** constipation (or diarrhoea), headache, sedation, fatigue, dizziness. Rarely seizures, chest pain, $\downarrow BP$, Δ LFTs, rash, hypersensitivity. **Dose:** 1 mg bd or 2 mg od po/iv/ivi for non-specialist use. 2–3 mg loading doses often given before chemotherapy^{SPC/BNF} (max 9 mg/24 h).

GTN (= GLYCERYL TRINITRATE)

Nitrate: \Rightarrow coronary artery + systemic vein dilation $\Rightarrow \uparrow O_2$ supply to myocardium and \downarrow preload, $\therefore \downarrow O_2$ demand of myocardium. **Use:** Angina, LVF.

Cl: \downarrow BP, $\downarrow \downarrow$ Hb, aortic/mitral stenosis, constrictive pericarditis, tamponade, HOCM, glaucoma (closed-angle), hypovolaemia, \uparrow ICP. **Caution:** recent MI, \downarrow T₄, hypothermia, head trauma, cerebral haemorrhage, malnutrition, \sqcup R (if either severe).

SE: \downarrow **BP** (inc postural), **headache**, dizziness, flushing, \uparrow HR. **Interactions:** $\underset{\longrightarrow}{\otimes}$ sildenafil, tadalafil and vardenafil (are CI as $\Rightarrow \downarrow \downarrow$ BP) $\underset{\longrightarrow}{\otimes}$. \downarrow s fx of heparins (if given iv).

Warn: may develop tolerance with ↓therapeutic effect (esp if long-term transdermal patch use) and don't stop abruptly.

Dose: 2 sprays or tablets sl prn (also available as transdermal SR patches^{SPC/BNF}). For acute MI/LVF: $10-200 \mu$ g/min ivi, titrating to clinical response and BP (see p. 230).

HALOPERIDOL

Butyrophenone ('typical') antipsychotic: dopamine antagonist $(D_{2 \text{ and } 3} > D_{1 \text{ and } 4})$. Also blocks serotonin $(5HT_{2A})$, histamine (H_1) , adrenergic $(\alpha_{1 > 2})$ and muscarinic receptors, causing many SEs. **Use:** acute sedation¹ (e.g. agitation, behavioural disturbance – esp in elderly and Ψ disorders), schizophrenia², N&V³.

Cl/Caution/SE: as chlorpromazine, but $\Rightarrow \uparrow$ incidence of **extrapyramidal fx** (see p. 227), although $\Rightarrow \downarrow$ sedation, \downarrow skin reactions, \downarrow antimuscarinic fx, \downarrow BP fx, but can \Rightarrow hypoglycaemia and SIADH. Also risk of CNS toxicity with lithium.

Interactions: metab by **P450** \therefore many, but most importantly: levels \uparrow by fluoxetine, venlafaxine, quinidine, buspirone and ritonavir. Levels \downarrow by carbamazepine, phenytoin, rifampicin. \uparrow risk of arrhythmias with amiodarone and \downarrow s fx of anticonvulsants.

Dose: $1.5-5.0 \text{ mg bd/tds po} (\max 30 \text{ mg/day})^{1,2}$; 2-10 mg im/iv4-8-hrly (max 18 mg/day)^{1,2}; $0.5-2.0 \text{ mg tds im/sc/iv}^3$. Also used im as a 4-wkly 'depot'² if concerns over compliance. **NB:** \downarrow **dose in severe RF or elderly**.

Start at bottom of dose range if naive to antipsychotics, esp if elderly. See p. 221 for advice on acute sedation.

HARTMANN'S SOLUTION

Compound sodium lactate iv fluid; used mostly in surgery and trauma. 1 l contains **5 mmol K**⁺, 2 mmol Ca²⁺, 29 mmol HCO₃, 131 mmol Na⁺, 111 mmol Cl⁻.

HEPARIN, standard/unfractionated (NB: \neq LMWHs).

iv (and rarely sc) anticoagulant: potentiates protease inhibitor antithrombin III, which inactivates thrombin. Also inhibits factors IXa/Xa/XIa/XIIa.

Use: anticoagulation if needs to be immediate or quickly reversible (only as inpatient); DVT/PE Rx/Px (inc preoperative), MI/unstable angina Rx/Px, extracorporeal circuits (esp haemodialysis, cardiopulmonary bypass).

Cl: haemorrhagic disorders (inc haemophilia), \downarrow Pt (inc Hx of HIT*), severe HTN, PU, acute bacterial endocarditis, recent cerebral

haemorrhage or major surgery/trauma to eye/brain/spinal cord, epidural/spinal anaesthesia (but can give Px doses), **L** (if severe, esp if oesophageal varices).

Caution: $\uparrow K^{+**}$, R/P/E.

SE: haemorrhage, \downarrow Pt* (HIT*), hypersensitivity (inc anaphylaxis, urticaria, angioedema), \uparrow K⁺** (inhibits aldosterone: \uparrow risk if DM, CRF, acidosis or on K⁺-sparing drugs), osteoporosis (if prolonged Rx). **Monitor:** FBC* if >5 days Rx, U&E** if > 7 days Rx. **Interactions:** fx may \downarrow by GTN ivi. NSAIDs \Rightarrow \uparrow bleeding risk. **Dose:** see p. 204 (inc dose-adjustment advice). \clubsuit HIT* Heparin Induced Thrombocytopenia: immune mediated \therefore delayed onset – \uparrow risk if Rx for >5 days (see p. 204) \clubsuit .

HUMALOG see Insulin lispro; short-acting recombinant insulin. Also available as biphasic preparations (MIX 25, MIX 50), are combined with longer-acting isophane suspension.

HUMULIN Recombinant insulin available in various forms:

- 1 HUMULIN S soluble, short-acting for iv/acute use.
- 2 HUMULIN I isophane (combined with protamine), long-acting.
- HUMULIN M 'biphasic' preparations, combination of short-acting (S) and long-acting (I) forms to give smoother control throughout the day. Numbers denote 1/10% of soluble insulin (i.e. MS = 30% soluble insulin).

HYDRALAZINE

Antihypertensive: vasodilates smooth muscle (arteries > veins). **Use:** HTN^1 (inc severe², esp if RF or pregnancy), HF^3 . For advice on *HTN Mx see p. 178*.

Cl: severe \uparrow HR, myocardial insufficiency (2° to mechanical obstruction, e.g. aortic/mitral stenosis or constrictive pericarditis), cor pulmonale, dissecting aortic aneurysm, SLE*, porphyria, **H** (if 'high output', e.g. \uparrow T₄).

Caution: IHD, cerebrovascular disease, L/R/P/B. **SE:** (*all SEs* \downarrow *if dose 100 mg/day*) **↑HR, GI upset, headache**, **lupus-like syndrome**^{*} (watch for unexplained \downarrow Wt, arthritis, ill health – measure ANA* and dipstick urine for protein if on high doses/clinical suspicion). Also fluid retention (\downarrow d if used with diuretics), palpitations, dizziness, flushing, \downarrow BP (even at low doses), blood disorders, arthr-/my-algia, rash and can worsen IHD. **Dose:** 25–50 mg bd po¹; 5–10 mg iv² (can be repeated after 20–30 min) or 50–300 µg/min ivi²; 25–75 mg tds/qds po³. **NB:** \downarrow **dose if LF or RF.**

HYDROCORTISONE BUTYRATE CREAM (0.1%)

Potent-strength topical corticosteroid. NB: much stronger than 'standard' (i.e. non-butyrate) hydrocortisone cream; see below!

HYDROCORTISONE CREAM/OINTMENT (1%)

Mild-strength topical corticosteroid (rarely used as weaker 0.5%, 0.25% and 0.1% preparations).

Use: inflammatory skin conditions, in particular eczema.

Cl: untreated infection, rosacea, acne.

SE: rare compared to more potent steroids: skin atrophy, worsening of infections, acne.

Dose: apply thinly 1 or 2 times per day.

HYDROCORTISONE iv/po

Glucocorticoid (with significant mineralocorticoid activity). **Use:** acute hypersensitivity (esp anaphylaxis, angioedema), Addisonian crisis, asthma, COPD, $\downarrow T_4$ (and $\uparrow T_4$), IBD. Also used po in chronic adrenocortical deficiency.

Cl/Caution/SE/Interactions: see p. 219.

Dose: *acutely:* 100–500 mg im or slowly iv up to qds if required. Exact dose recommendations vary: consult local protocol if unsure (see Medical emergencies section of this book for rational starting dose for some specific indications). *Chronic replacement:* usually 20–30 mg po daily in divided doses (usually 2/3 in morning and 1/3 nocte), often together with fludrocortisone.

HYDROXOCOBALAMIN

Vitamin B12 replacement.

82

Use: pernicious anaemia (also macrocytic anaemias with neurological involvement, tobacco amblyopia, Leber's optic atrophy).

SE: skin reactions, nausea, 'flu-like symptoms, $\downarrow K^+$ (initially), rarely anaphylaxis.

Interactions: fx \downarrow by OCP and chloramphenicol. **Dose:** 1 mg im injection: frequently at first for Rx (3–7/wk: exact number depends on indication^{SPC/BNF}) until no further improvement, then \downarrow frequency (to once every 1–3 months) for maintenance.

HYDROXYCARBAMIDE (= HYDROXYUREA)

Antineoplastic agent for primary polycythaemia and essential thrombocythaemia (1st line Rx) and CML (initial Rx only). Also (unlicensed) use for severe psoriasis.

Cl/Caution: see SPC.

SE: Nausea, blood disorders (esp **myelosuppression**), skin reactions. **Dose:** 20–30 mg/kg daily titrated against full blood count. Specialist use only.

HYDROXYCHLOROQUINE/PLAQUENIL

DMARD (\downarrow s activation of dendritic cells/inflammatory response) and antimalarial (action as chloroquine).

Use: RA, SLE, dermatological disorders aggravated/caused by sunlight. **Cl/Caution/SE/Interactions/Monitor:** see Chloroquine.

Dose: 200-400 mg/day.

Seek expert advice before commencing treatment.

HYOSCINE BUTYLBROMIDE/BUSCOPAN

Antimuscarinic: ↓s GI motility. Does not cross BBB (unlike hyoscine *hydrobromide*) ∴ less sedative.

Use: GI (or GU) smooth-muscle spasm; esp biliary colic,

diverticulitis and IBS. Rarely used for dysmenorrhoea.

Cl: glaucoma (closed-angle), MG, megacolon ↑prostrate.

Caution: GI obstruction, \uparrow prostate/urinary retention, \uparrow HR (inc \uparrow T₄) H/P/B/E.

SE: antimuscarinic fx (see p. 225), drowsiness, confusion.

84

Interactions: ↓s fx of metoclopramide (and vice versa) and sublingual nitrates. ↑s tachycardic fx of β-agonists. **Dose:** 20 mg qds po (for IBS, start at 10 mg tds) or 20 mg im/iv (repeating once after 30 min, if necessary; max 100 mg/day).

Don't confuse with hyoscine *hydrobromide*: different fx and doses!

HYOSCINE HYDROBROMIDE (= SCOPOLAMINE)

Antimuscarinic: predominant fx on CNS (\downarrow s vestibular activity¹). Also \downarrow s respiratory/oral secretions^{2,3}.

Use: motion sickness¹, terminal care/chronic ↓swallow² (e.g. CVA), hypersalivation 2° to antipsychotics³ (unlicensed use).

Cl: glaucoma (closed-angle).

Caution: GI obstruction, ↑prostate/urinary retention,

cardiovascular disease, porphyria, Down's, MG, L/R/P/B/E.

SE: antimuscarinic fx (see p. 225), generally sedative (although

rarely \Rightarrow paradoxical agitation when given as sc infusion).

Warn: driving may be impaired, \uparrow s fx of alcohol.

Interactions: \downarrow s fx of sublingual nitrates (e.g. GTN).

Dose: 300 μ g 6-hrly po (max 3 doses/24 h)¹ (or as transdermal patches; release 1 mg over 72 h); 0.6–2.4 mg/24 h as sc infusion² (see p. 184 for use in palliative care); 300 μ g bd po³ (can \uparrow to tds).

Don't confuse with hyoscine *butylbromide*: different fx and doses!

HYPROMELLOSE 0.3% EYE DROPS/TEARS

NATURALE

Artificial tears for treatment of dry eyes. **Dose:** 1 drop prn, max 4–6 times/day unless preservative free drops.

IBUGEL/IBULEVE Ibuprofen topical gel (latter also as spray and mousse), for musculoskeletal pain.

IBUPROFEN

Mild-moderate strength NSAID. Non-selective COX inhibitor; analgesic, anti-inflammatory and antipyrexial[†] properties.

Use: mild/moderate pain¹ (inc musculoskeletal, headache, migraine, dysmennorrhoea, dental, post-op; not 1st choice for gout/rheumatoid arthritis), mild local inflammation².

Cl: Hx of hypersensitivity to aspirin or any other NSAID (inc asthma/angioedema/urticaria/rhinitis). **Active/Hx of PU/GI** bleeding/perforation, L/R/H(if any of these 3 are severe)/P(3rd trimester). **Caution:** Asthma, allergic disorders, uncontrolled HTN, PVD,

cerebrovascular disease, cardiovascular risk factors (if considering long-term Rx), connective tissue disorders, coagulopathy, IBD. *Can mask signs of infection*[†]. L/R/P(1st/2nd trimester)/B/E.

SE: GI upset/bleeding/PU (*less than other NSAIDs*). Fluid retention/oedema, ARF, hypersensitivity reactions (esp bronchospasm and skin reactions, inc, very rarely, SJS/TEN), headache. >1.2g/day \Rightarrow small \uparrow risk thrombotic events. Reversible \downarrow female fertility if long-term use. Very rarely, blood disorders, \uparrow BP, \uparrow K+.

Interactions: \downarrow s fx of antihypertensives and diuretics, \uparrow risk GI bleeding with aspirin, anticoagulants, corticosteroids, SSRIs, venlafaxine, erlotinib. \uparrow s (toxic) fx of methotrexate, AZT, tacrolimus, digoxin, quinolones, lithium, sulphonylureas and phenytoin. \uparrow risk of RF with ACE-i, ARB, diuretics and ciclosporin, mild W+.

Dose: 200–400 mg tds po¹ (max dose for RA: 2.4 g/day); topically as gel². **NB:** Avoid in **RF & consider gastroprotective Rx**.

INDAPAMIDE

Thiazide derivative diuretic; see Bendroflumethiazide.

Use: HTN (for advice on stepped HTN Mx see p. 178).

Cl: Hx of sulphonamide derivative allergy, $\downarrow K^+$, $\downarrow Na^+$, $\uparrow Ca^{2+}$, **L/R** (if either severe).

Caution: \uparrow PTH (stop if \uparrow Ca²⁺), \uparrow aldosterone, gout, porphyria, R/P/B/E.

SE: as bendroflumethiazide, but reportedly fewer metabolic disturbances (esp less hyperglycaemia).

Monitor: U&Es, urate.

Interactions: \uparrow s lithium levels and toxicity of digoxin (if $\Rightarrow \downarrow K^+$). **Dose:** 2.5 mg od mane (or 1.5 mg od of SR preparation).

INDOMETACIN

High-strength NSAID; non-selective COX inhibitor.

Use: musculoskeletal pain¹, esp RA, ankylosing spondylitis, OA, acute gout²; dysmenorrhoea³. Use limited by SEs*. Specialist uses: PDA closure, premature labour^{SPC/BNF}.

Cl/Caution/SE/Interactions: as ibuprofen, but \uparrow incidence of SEs*, inc PU/GI bleeds, thrombotic events, but also GI upset and headache. Light-headedness (impairing driving) is common. Rarely: Ψ disturbances, convulsions, syncope, blood disorders, \uparrow CBG, peripheral neuropathy, optic neuritis, intestinal strictures; pr doses may \Rightarrow rectal irritation/bleeding. Caution in epilepsy, Parkinsonism & Ψ disturbance. Probenecid $\Rightarrow \uparrow$ serum levels. \uparrow risk of ARF with triamterene: avoid. Mild **W**+.

Dose: 25–50 mg max qds po or 100 mg max bd pr¹. 150–200 mg/day in divided doses, \downarrow ing dose once pain under control². 75 mg/day in divided doses³. MR preparations available^{SPC/BNF}. **NB:** \downarrow **dose in RF & consider gastroprotective Rx.**

▼INFLIXIMAB/REMICADE

Monoclonal Ab against TNF- α (inflammatory cytokine). **Use:** Crohn's/UC^{NICE}, RA, psoriasis (for skin or arthritis)^{NICE} or ankylosing spondylitis resistant to steroids/immunosuppression^{NICE}. **CI:** TB or other severe infections, **H** (unless mild when only caution), **P/B**.

Caution: infections, demyelinating CNS disorders, L/R.

SE: severe infections, **TB** (inc extrapulmonary), **CCF** (exac of), **CNS demyelination**. Also GI upset, 'flu-like symptoms, cough, fatigue, headache. Tincidence of hypersensitivity (esp transfusion) reactions.

Dose: specialist use only. Often prescribed concurrently with methotrexate.

INSULATARD Long-acting (isophane) insulin, either recombinant human or porcine.

INSULIN see pp. 196-200 for different types and prescribing advice.

INTEGRILIN see Eptifibatide; anti-Pt agent for IHD.

IODINE AND IODIDE see Lugol's solution; used for $\uparrow\uparrow T_4$.

 \mathbb{POGOL} see Mesalazine; 'new' aminosalicylate for UC, with \downarrow SEs.

IPRATROPIUM

Inh muscarinic antagonist; bronchodilator and \downarrow s bronchial secretions.

Use: $chronic^1$ and $acute^2$ bronchospasm (COPD > asthma). Rarely used topically for rhinitis.

SE: antimuscarinic fx (see p. 225), usually minimal.

Caution: glaucoma (angle closure only; protect patient's eyes from drug, esp if giving nebs: use tight-fitting mask), bladder outflow obstruction (e.g. \uparrow prostate), P/B.

Dose: 20–40 μ g tds/qds inh¹ (max 80 μ g qds); 250–500 μ g qds neb² (\uparrow ing up to 4-hrly if severe).

IRBESARTAN/APROVEL

Angiotensin II antagonist.

Use: HTN (for advice on stepped HTN Mx see p. 178), type 2 DM nephropathy.

CI: P/B.

Caution/SE/Interactions: see Losartan.

Dose: initially 150 mg od, \uparrow ing to 300 mg od if required (halve initial dose if age >75 years or on haemodialysis).

IRON TABLETS see Ferrous sulphate/fumarate/gluconate.

ISMN see Isosorbide mononitrate.

ISMO see Isosorbide mononitrate.

ISONIAZID

Antituberculous antibiotic; 'static'. **Use:** TB (see p. 171). **Cl:** drug-induced liver disease.

Caution: Hx of psychosis/epilepsy/porphyria or if \uparrow d risk of neuropathy[†] (e.g. DM, alcohol abuse, CRF, malnutrition, HIV: give pyridoxine 10–20 mg od as Px), porphyria, L/R/P/B.

SE: optic neuritis, peripheral neuropathy[†], hepatitis^{*}, rash, gynaecomastia, GI upset. Rarely lupus, blood disorders (inc rarely agranulocytosis^{**}), hypersensitivity, convulsions, psychosis.

Warn: patient of symptoms of liver disease and to seek medical help if they occur.

Monitor: LFTs*, FBC**.

Interactions: \downarrow **P450** \therefore many, but most importantly \uparrow s levels of carbamazepine, phenytoin, ethosuximide and benzodiazepines **W**+. **Dose:** by weight^{SPC/BNF} or as combination preparation (see p. 171). Take on empty stomach (\geq 30 min before or \geq 2 h after meal). Acetylator-dependent metabolism: if slow acetylator \Rightarrow \uparrow risk of SEs.

ISOSORBIDE MONONITRATE (ISMN)

Nitrate; as GTN, but po rather than sl delivery.

Use/CI/Caution/SE/Interactions: as GTN, but $\Rightarrow \downarrow$ headache. **Dose:** 10–40 mg bd/tds po (od MR preparations available^{SPC/BNF}).

ISTIN see Amlodipine; Ca²⁺ channel blocker for HTN/IHD.

ITRACONAZOLE/SPORANOX

Triazole antifungal: needs acidic pH for good po absorption*. **Use:** fungal infections (candida, tinea, cryptococcus, aspergillosis, histoplasmosis, onychomycosis, pityriasis versicolor).

Caution: risk of HF: Hx of cardiac disease or if on negative inotropic drugs (risk \uparrow s with dose, length of Rx and age), L/R/P/B. **SE:** HF, hepatotoxicity**, GI upset, headache, dizziness, peripheral neuropathy (if occurs, stop drug), cholestasis, menstrual Δ s, skin reactions (inc angioedema, SJS). With prolonged Rx can $\Rightarrow \downarrow K^+$, oedema, hair loss.

Monitor: LFTs** if Rx > 1 month or Hx of (or develop clinical features of) liver disease: stop drug if become abnormal. **Interactions:** \downarrow **P450** \therefore many; most importantly \uparrow s risk of **myopathy with statins** (avoid together) and \uparrow s risk of **HF with negative inotropes** (esp Ca²⁺ blockers). \uparrow s fx of \clubsuit midazolam,

88

quinidine, **pimozide** \bigotimes , ciclosporin, digoxin, indinavir and siro-/tacro-limus. fx \downarrow d by rifampicin, phenytoin and **antacids***, **W+**. **Dose:** dependent on indication^{SPC/BNF}. *Take capsules with food* (or liquid on empty stomach). NB: consider \downarrow dose in LF.

VIVABRADINE/PROCORALAN

↓s HR by selective cardiac pacemaker I_f channel current blockade ⇒ ↓SAN myocyte Na⁺ and K⁺ entry.

Use: angina (if sinus rhythm and β -blockers CI/not tolerated). **CI:** severe \downarrow HR (<60 bpm) or \downarrow BP, cardiogenic shock, ACS (inc acute MI), acute CVA, 2nd or 3rd degree HB, SSS, pacemaker dependent, SAN block congenital \uparrow QT syndrome, strong **P450 3A4** inhibitors**, **L**(if severe)/**H**(if moderate/severe)/**P/B**.

Caution: retinitis pigmentosa, galactose intolerance*/Lapp lactase deficiency*/glucose-galactose malabsorption*, **R/E**.

SE: visual Δs (esp luminous phenomena^{*}), \downarrow HR, HB, ectopics, VF, headaches, dizziness. Less commonly GI upset, cramps, dyspnoea, $\uparrow E\emptyset$, \uparrow uric acid, \downarrow GFR.

Warn: tablets contain lactose^{*}, may \downarrow vision if night driving/using machinery with rapid light intensity Δ s.

Monitor: HR(maintain resting ventricular rate > 50 bpm) and rhythm, BP.

Interactions: ⊗metab by P450 3A4; inhibitors [↑]levels and strong inhibitors^{**} (clari-/ery-/josa-/teli-thromycin, itra-/keto-conazole, nelfi-/rito-navir, nefazodone) are CI but ↓doses can be given with fluconazole. Inducers ↓levels (inc rifampicin, barbiturates, phenytoin, St John's wort). Levels also [↑]by diltiazem and verapamil. [↑]risk of VF with drugs that [↑]QTc (inc amiodarone, disopyramide, mefloquine, pentamidine, pimozide, sertindole, sotalol) **⊗**.

Dose: initially 5 mg bd po; \uparrow ing if required after 3–4 wks to max 7.5 mg bd po. NB: consider \downarrow dose if not tolerated, elderly or severe RF^{SPC/BNF}.

KAY-CEE-L

KCl syrup (1 mmol/ml) for $\downarrow K^+$; see Sando-K.

Dose: according to serum K^+ : average 25–50 ml/day if diet normal. Caution if taking other drugs that $\uparrow K^+$. **NB:** \downarrow **dose if RF**.

KETOCONAZOLE/NIZORAL

Imidazole antifungal: good po absorption.

Use: fungal infection Rx (if systemic, severe or resistant to topical Rx) and Px if immunosuppression; use limited (due to hepatotoxicity) to dermatophytosis, Malassezia folliculitis and cutaneous or oropharyngeal candidosis and only when topical and oral agents can't be used. CI: L/P/B.

Caution: porphyria.

SE: hepatitis*, GI upset, skin reactions (rash, urticaria, pruritus, photosensitivity, rarely angioedema), gynaecomastia, blood disorders, paraesthesia, dizziness, photophobia.

Monitor: LFTs*, esp if Rx > 14 days.

Warn: seek urgent medical attention if signs of LF (explain symptoms to patient).

Interactions: \P450 : many; most importantly, **\\$** risk of **myopathy** with statins (avoid together). \uparrow s fx of \Re midazolam, quinidine, pimozide &, vardenafil, eplerenone, cilostazol, reboxetine, aripiprazole, sertindole, felodipine, ergot alkaloids, antidiabetics, buprenorphine, artemether/lumefantrine, indi-/rito-navir and ciclosporin (and possibly theophyllines). Is fx of rifampicin (rifampicin can also \downarrow fx of ketoconazole, as can phenytoin and clopidogrel), **W**+. **Dose:** 200 mg od po *with food* (400 mg od in severe/resistant cases).

KLEAN-PREP see Bowel preparations.

Dose: up to 2 powder sachets the evening before and repeated on the morning of GI surgery or Ix.

LABETALOL

β-blocker with arteriolar vasodilatory properties : also $\Rightarrow \downarrow$ TPR. Use: uncontrolled/severe HTN (inc during pregnancy¹ or post-MI² or with angina). For advice on HTN Mx see p. 178. **Cl/Caution/SE/Interactions:** as propranolol, plus can \Rightarrow \Re severe/postural \downarrow BP \Re and hepatotoxicity* (L).

Monitor: LFTs* (if deteriorate stop drug).

Dose: initially 100 mg bd po (halve dose in elderly), 1 ing every fortnight if necessary to max of 600 mg qds po; if essential to \downarrow BP rapidly give 50 mg iv over \geq 1 min repeating after 5 min if necessary (or can give 2 mg/min ivi), up to max total dose 200 mg; 20 mg/h ivi¹, doubling every 30 min to max of 160 mg/h; 15 mg/h ivi², \uparrow ing slowly to max of 120 mg/h. **NB: consider ↓dose in RF**.

LACRI-LUBE

Artificial tears (liquid paraffin) for dry eyes. **SE:** blurred vision ∴ usually used at bedtime (or if vision secondary

consideration, e.g. Bell's palsy or blind eye).

Dose: 1 drop prn.

LACTULOSE

Osmotic laxative¹: bulking agent. Also $\downarrow s$ growth of NH₄-producing bacteria².

Use: constipation¹, hepatic encephalopathy².

Cl: GI obstruction, galactosaemia.

Caution: lactose intolerance.

SE: flatulence, distension, abdominal pains.

Dose: 15 ml od/bd¹ (\uparrow dose according to response; NB: *can take* 2 *days to work*); 30–50 ml tds². *Take with plenty of water.*

LAMISIL see Terbinafine.

▼LAMOTRIGINE/LAMICTAL

Antiepileptic: \downarrow s release of excitatory amino acids (esp glutamate) via action on voltage-sensitive Na⁺ channels.

Use: epilepsy (esp partial and 1° or 2° generalised tonic–clonic), Px depressive episode in bipolar disorder.

Caution: avoid abrupt withdrawal[†] (rebound seizure risk; taper off over ≥ 2 wks unless stopping due to serious skin reaction*), L/R/P/B/E. **SE: cerebellar symptoms** (see p. 227), **skin reactions*** (often severe, e.g. SJS, TEN, lupus, esp in children, if on valproate, or high initial doses), **blood disorders**** (\downarrow Hb, \downarrow WCC, \downarrow Pt), N&V. Rarely, \downarrow memory, sedation, Ψ disorders, sleep Δ , acne, pretibial ulcers, alopecia, worsening of seizures, poly-/an-uria, **hepatotoxicity**. **Monitor:** U&Es, FBC, LFTs, clotting.

92 COMMON/USEFUL DRUGS

Warn: report rash* plus any 'flu-like symptoms, signs of infection/ \downarrow Hb or bruising**. Don't stop tablets suddenly[†]. Risk of suicidal ideation.

Interactions: fx are ↓d by OCP, phenytoin, carbamazepine, mefloquine, TCAs and SSRIs. fx ↑d by valproate. **Dose:** 25–700 mg daily^{SPC/BNF}; ↑dose slowly to ↓risk of skin reactions* (also need to restart at low dose). **NB:** ↓**dose in LF**.

LANSOPRAZOLE/ZOTON

PPI. As omeprazole, but \downarrow interactions. **Dose:** 15–30 mg od po (\downarrow to 15 mg od for maintenance).

LARIAM see Mefloquine; antimalarial (Px and Rx).

LASIX see Furosemide; loop diuretic.

LATANOPROST 0.01%/XALATAN

Topical PG analogue: ↑s uveoscleral outflow. **Use:** ↑IOP in glaucoma and *ocular* HTN (1st line agent). **Caution:** asthma (if severe), aphakia, pseudophakia, uveitis, macular oedema P/B.

SE: iris colour Δ^* (can \Rightarrow permanent \uparrow brown pigmentation, esp if uniocular use), blurred vision, local reactions (e.g. conjunctival hyperaemia in up to 30% initially). Also darkening of periocular skin and \uparrow eyelash length (both reversible). Rarely cystoid macular oedema (if aphakia), uveitis, angina.

Warn: can Δ iris colour*.

Dose: 1 drop od.

LEFLUNOMIDE/ARAVA

DMARD; inhibits pyrimidine synthesis (also anti-inflammatory fx). **Use:** active rheumatoid or psoriatic arthritis if standard DMARDs (e.g. methotrexate or sulfasalazine) CI or not tolerated.

Cl: severe immunodeficiency, BM suppression, severe

hypoproteinaemia, serious infection, L/R/P/B.

Caution: blood disorders, recent hepato-/myelo-toxic drugs, TB (inc Hx of).

SE: BM toxicity, **†**risk of **infection/malignancy**, hepatotoxicity (potentially life-threatening in 1st 6 months), SJS, HTN.

Warn: teratogenic: must exclude pregnancy before starting Rx and use contraception during Rx (and until drug no longer active*). **Monitor:** LFTs, FBC, BP.

Dose: specialist use only.

Long $t_{1/2}^*$: if serious SE discontinue treatment and needs prolonged washout period or active measures (e.g. cholestyramine 8 g tds or activated charcoal 50 g qds) to \uparrow elimination if wishing to conceive.

LEVOBUNOLOL

β-blocker eye drops: similar to timolol $\Rightarrow \downarrow$ aqueous humour production. *Significant systemic absorption can occur*. **Use:** chronic simple (wide-/open-angle) glaucoma.

Cl/Caution/Interactions: as propranolol; interactions less likely. **SE:** local reactions. Rarely anterior uveitis and anaphylaxis. Can \Rightarrow systemic fx, esp bronchoconstriction/cardiac fx; see Propranolol. **Dose:** 1 drop of 0.5% solution od/bd.

LEVODOPA (= L-DOPA)

Precursor of dopamine: needs concomitant peripheral dopa decarboxylase inhibitor such as benserazide (see Co-beneldopa) or carbidopa (see Co-careldopa) to limit SEs.

Use: Parkinsonism.

Cl: glaucoma (closed-angle), taking MAOIs*, melanoma[†], **P/B**. **Caution:** pulmonary/cardiovascular/ Ψ disease, endocrine disorder, glaucoma (open angle), osteomalacia, Hx of PU or convulsions, ventricular arrhythmias, **L/R**.

SE: dyskinesias, abdominal upset, postural \downarrow BP/arrythmias, drowsiness, aggression, Ψ disorders (confusion, depression, suicide, hallucinations, psychosis, hypomania), seizures, dizziness, headache, flushing, sweating, peripheral neuropathy, taste Δ s, rash/pruritus, can reactivate melanoma[†], Δ LFTs, GI bleeding, blood disorders, dark body fluids (inc sweat).

Warn: can \Rightarrow daytime sleepiness (inc sudden-onset sleep) and \downarrow ability to drive/operate machinery.

94

Interactions: fx \downarrow d by neuroleptics, SEs \uparrow d by bupropion, **risk of** \uparrow **BP crisis with MAOIs**^{*}, risk of arrhythmias with halothane. **Dose:** 125–500 mg daily, *after food*, \uparrow ing according to response. Abrupt withdrawal can \Rightarrow neuroleptic malignant-like syndrome.

LEVOMEPROMAZINE (= METHOTRIMEPRAZINE)

Phenothiazine antipsychotic; as chlorpromazine, but used in palliative care (see p. 184) as has good antiemetic¹ and sedative² fx, but little respiratory depression.

Use: refractory N&V¹ or restlessness/distress² in the terminally ill. **Cl/Caution/SE/Interactions:** as chlorpromazine, but \uparrow risk of postural \downarrow **BP** (esp in elderly: don't give if age >50 years and ambulant) and \uparrow risk of seizures (caution if epilepsy/brain tumour). **Dose:** 6.25–25 mg po/sc/im/iv od/bd (can \uparrow to tds/qds), or 25–200 mg/24 h sc infusion. **Parenteral dose is half equivalent oral dose.** NB: for N&V low doses may be effective and $\Rightarrow \downarrow$ sedation. Doses >25 mg sc/24 hrs rarely needed except as major sedation. NB: \downarrow dose in RF and elderly.

LEVOTHYROXINE see Thyroxine.

LIBRIUM see Chlordiazepoxide; long-acting benzodiazepine.

LIDOCAINE (previously Lignocaine)

Class Ib antiarrhythmic (↓s conduction in Purkinje and ventricular muscle fibres), local anaesthetic (blocks axonal Na⁺ channels). **Use:** ventricular arrhythmias (esp post-MI), local anaesthesia. **Cl:** myocardial depression (if severe), SAN disorders, atrioventricular block (all grades), porphyria. **Caution:** epilepsy, severe hypoxia/hypovolaemia/↓HR, L/H/P/B/E.

SE: dizziness, drowsiness, confusion, tinnitus, blurred vision, paraesthesia, GI upset, arrhythmias, \downarrow BP, \downarrow HR. Rarely respiratory depression, seizures, anaphylasis.

Monitor: ECG during iv administration.

Interactions: \uparrow risk of arrhythmias with antipsychotics, dolasetron and quinu-/dalfo-pristin. \uparrow myocardial depression with other antiarrhythmics and β -blockers. Levels \uparrow by

propranolol, ataza-/lopi-navir and cimetidine. Prolongs action of suxamethonium.

Dose (for ventricular arrhythmias): 50–100 mg iv at rate of 25–30 mg/min followed immediately by ivi at 4 mg/min for 30 min then 2 mg/min for 2 h and 1 mg/min thereafter (\downarrow dose further if drug needed for >24 h). NB: short $t_{1/2}$... if 15 min delay in setting up ivi, can give max 2 further doses of 50–100 mg iv ≥10 min apart. In emergencies, can often be found stocked in crash trolleys as Minifet syringes of 1% (10 mg/ml) or 2% (20 mg/ml) solutions.

 \bigotimes Local anaesthetic preparations must never be injected into veins or inflamed tissue, as can \Rightarrow systemic fx (esp arrhythmias) \bigotimes .

LIGNOCAINE see Lidocaine.

LIOTHYRONINE (= L-TRI-IODOTHYRONINE) SODIUM

Synthetic T₃: quicker and more potent action than thyroxine (T₄). **Use:** severe hypothyroidism (e.g. myxoedema coma*: see p. 247). **Cl/Caution/SE/Interactions:** see Thyroxine.

Dose: 5–20 µg iv slowly. Repeat every 4–12 h as necessary; seek expert help. Also available po, but thyroxine (T_4) often preferred. NB: 20 µg liothyronine = 100 µg (levo)thyroxine.

Concurrent hydrocortisone iv is often also needed*; see p. 247.

LISINOPRIL

ACE-i; see Captopril. **Use:** HTN¹ (for advice on stepped HTN Mx see p. 178), HF², Px of IHD post-MI³, DM nephropathy⁴.

CI/Caution/SE/Interactions: as Captopril.

Dose: initially 10 mg od¹ (2.5–5.0 mg if RF or used with diuretic) \uparrow ing if necessary to max 80 mg/day; initially 2.5–5 mg od^{2,4} adjusted to response to usual maintenance of 5–20 mg/day. Doses post-MI³ depend on BP^{SPC/BNF}. NB: \downarrow dose in LF or RF.

LITHIUM

Mood stabiliser: modulates intracellular signalling; blocks neuronal Ca²⁺ channels and changes GABA pathways.

Use: mania Rx/Px, bipolar disorder Px. Rarely for recurrent depression Px and aggressive/self-mutilating behaviour Rx. **CI:** \downarrow T₄ (if untreated), Addison's, SSS, cardiovascular disease, **P** (\Rightarrow Ebstein's anomaly: esp in 1st trimester), **R/H/B**. (NB: manufacturers don't agree on definitive list and all CI are **relative** – decisions should be made in clinical context and expert help sought if unsure.) **Caution:** thyroid disease, MG, **E**.

SE: thirst, polyuria, GI upset (\uparrow Wt, N&V&D), *fine* tremor* (NB: in toxicity \Rightarrow *coarse* tremor), tardive dyskinesia, muscular weakness, acne, psoriasis exacerbation, \uparrow WCC, \uparrow Pt. Rarer but serious: \downarrow (or \uparrow) T₄ \pm goitre (esp in females), renal impairment (diabetes insipidus, interstitial nephritis), arrhythmias. Very rarely can \Rightarrow neuroleptic malignant syndrome.

Monitor: serum levels 12 *h* post-dose: keep at 0.6–1 mmol/l (>1.5 mmol/l may \Rightarrow toxicity, esp if elderly), U&Es, TFTs. **Warn:** report symptoms of $\downarrow T_4$, avoid dehydration.

Interactions: toxicity (± levels) ↑d by **NSAIDs**, **diuretics**** (esp thiazides), SSRIs, ACE-i, ARBs, amiodarone, methyldopa, carbamazepine and haloperidol. Theophyllines, caffeine and antacids may ↓lithium levels.

Dose: see SPC/BNF: 2 *types* (salts) available with different doses ('carbonate' 200 mg = 'citrate' 509 mg) and bioavailabilities of particular *brands* vary ∴ *must specify salt and brand required*. For 'carbonate' starting dose usually 200 mg nocte, adjusting to plasma levels (maintenance usually 600 mg – 1 g nocte). NB: ↓dose in LF. Consider stopping 24 h before major surgery or ECT; restart once e'lytes return to normal. Discuss with anaesthetist ± psychiatrist.

Lithium toxicity

Features: D&V, coarse tremor*, cerebellar signs (see p. 227), renal impairment/oliguria, \downarrow BP, \uparrow reflexes, convulsions, drowsiness \Rightarrow coma. *Rx*: stop drug, control seizures, correct electrolytes (normally need saline ivi; high risk if \downarrow Na⁺: avoid low-salt diets and diuretics**). Consider haemodialysis if RF.

LOCOID see Hydrocortisone butyrate 0.1% (potent steroid) cream.

LOFEPRAMINE

2nd generation TCA. **Use:** depression (see p. 192)

Cl/Caution/SE/Warn/Monitor/Interactions: as amitriptyline but also **R** (if severe). Also $\Rightarrow \downarrow$ sedation (sometimes alerting – don't give nocte if occurs) and \downarrow anticholinergic and cardiac SEs $\therefore \downarrow$ danger in OD.

Dose: 140–210 mg daily in divided (bd/tds) doses.

LOPERAMIDE/IMODIUM

Antimotility agent: synthetic opioid analogue; binds to receptors in GI muscle $\Rightarrow \downarrow$ peristalsis, \uparrow transit time, \uparrow H₂O/electrolyte resorption, \downarrow gut secretions, \uparrow sphincter tone. Extensive 1st-pass metabolism \Rightarrow minimal systemic opioid fx.

Use: diarrhoea.

Cl: constipation, ileus, megacolon, bacterial enterocolitis 2° to invasive organisms (e.g. salmonella, *Shigella*, *Campylobacter*), abdominal distension, active UC/AAC, pseudomembranous colitis.

Caution: in young (can \Rightarrow fluid + electrolyte depletion), L/P.

SE: constipation, abdominal cramps, bloating, dizziness, drowsiness, fatigue. Rarely hypersensitivity (esp skin reactions), paralytic ileus.

Dose: initially 4 mg, then 2 mg after each loose stool (max 16 mg/day for 5 days). *NB: can mask serious GI conditions.*

LORATADINE

Non-sedating antihistamine: see Cetirizine. **Dose:** 10 mg od. Non-proprietary or as Clarthym.

LORAZEPAM

Benzodiazepine, short-acting (see p. 223). **Use:** sedation¹ (esp acute behavioural disturbance/ Ψ disorders, e.g. acute psychosis), status epilepticus². **Cl/Caution/SE/Interactions:** see Diazepam.

Dose: 0.5–2 mg po/im/iv prn (bottom of this range if elderly/ respiratory disease/naive to benzodiazepines; top of range

if young/recent exposure to benzodiazepines; max 4 mg/day)¹;

0.1 mg/kg ivi at 2 mg/min (max 4 mg repeated once after 10 mins if necessary)². **NB:** \downarrow dose in **RF**.

Solution Beware respiratory depression: have O_2 (\pm resuscitation trolley) at hand, esp if respiratory disease or giving high doses im/iv **Solution**.

▼LOSARTAN/COZAAR

Angiotensin II receptor antagonist: specifically blocks renin–angiotensin system \therefore does not inhibit bradykinin and \Rightarrow dry cough.

Use: HTN (*for advice on stepped HTN Mx see p. 178*), Px of type 2 DM nephropathy (if ACE-i not tolerated*).

CI: P/B.

Caution: RAS, HOCM, mitral/aortic stenosis, if taking drugs that $\uparrow K^{+**}$, L/R/E.

SE/Interactions: as captopril, but \downarrow dry cough (major reason for ACE-i intolerance*). As with ACE-i, can $\Rightarrow \uparrow K^+$ (esp if taking $\uparrow K^+$ sparing diuretics/salt substitutes or if RF).

Dose: initially 25-50 mg od (\uparrow ing to max 100 mg od). **NB:** \downarrow **dose in LF or RF**.

 \mathscr{A}^{**} Beware if on other drugs that $\uparrow K^+$, e.g. amiloride, spironolactone, triamterene, ACE-i and ciclosporin. Don't give with oral K^+ supplements (inc dietary salt substitutes) \mathscr{A} .

LOSEC see Omeprazole; PPI (ulcer-healing drug).

LUGOL'S SOLUTION

Oral I₂ solution.

Use: $\uparrow T_4$ if severe ('thyroid storm' see p. 246) or pre-operatively. **CI: B**.

Caution: not for long-term Rx, P.

SE: hypersensitivity.

Dose: 0.1–0.3 ml tds (of solution containing 130 mg iodine/ml).

LYMECYCLINE

Tetracycline, broad-spectrum antibiotic (see Tetracycline). **Use:** acne vulgaris.

Cl/Caution/SE/Interactions: as tetracycline.

Dose: 408 mg od for \geq 8 wks (can \uparrow to bd for other indications).

MADOPAR see Co-beneldopa; L-dopa for Parkinson's.

MAGNESIUM SULPHATE (iv)

Mg²⁺ replacement.

Use: life-threatening asthma¹ (unlicensed indication), serious arrhythmias² (esp if torsades or if $\downarrow K^+$; often caused by $\downarrow Mg^{2+}$), MI³ (equivocal evidence of \downarrow mortality), eclampsia/pre-eclampsia⁴ (\downarrow s seizures), symptomatic $\downarrow Mg^{2+5}$ (mostly 2° to GI loss). **Caution:** monitor BP, respiratory rate and urine output, L/R. **SE:** flushing, \downarrow BP, GI upset, thirst, \downarrow reflexes, weakness, confusion/drowsiness. Rarely arrhythmias, respiratory depression, coma. Interactions: \uparrow risk of \downarrow BP with Ca²⁺ channel blockers.

Dose: 4–8 mmol ivi over 20 min¹; 8 mmol iv over 10–15 min² (repeating once if required); 8 mmol ivi over 20 min then ivi of 65–72 mmol over 24 h³; 4 mg ivi over 5–10 min then ivi at 1 mg/h until 24 hr after the last seizure; up to 160 mmol ivi/im according to need⁵ (over up to 5 days). For iv injection, use concentrations of \leq 20%; if using 50% solution dilute 1 part with \geq 1.5 parts water for injection.

MANNITOL

Osmotic diuretic. **Use:** cerebral oedema¹ (and glaucoma). **CI:** pulmonary oedema, **H**. **SE:** GI upset, fever/chills, oedema. Rarely seizures, HF. **Dose:** 0.25–2 g/kg as rapid ivi over 30–60 min¹.

MAXOLON see Metoclopramide; antiemetic (DA antagonist).

MEBEVERINE

Antispasmodic: direct action on GI muscle. **Use:** GI smooth-muscle cramps (esp IBS, diverticulitis). **CI:** ileus (paralytic).

Caution: porphyria, P.

SE: hypersensitivity/skin reactions. **Dose:** 135–150 mg tds (20 min before food) or 200 mg bd of SR

```
preparation (Colofac MR).
```

MEFENAMIC ACID/PONSTAN

Mild NSAID; non-selective COX inhibitor.

Use: musculoskeletal pain, dysmenorrhoea, menorrhagia. **Cl/Caution/SE/Interactions:** as ibuprofen, but also CI if IBD, caution if epilepsy or porphyria. Can \Rightarrow severe diarrhoea, skin reactions, stomatitis, paraesthesia, fatigue, haemolytic/aplastic \downarrow Hb, \downarrow Pt. Mild **W**+.

Dose: 500 mg tds po.

MEFLOQUINE/LARIAM

Antimalarial; kills asexual forms of *Plasmodium*. **Use:** malaria Px^1 (in areas of chloroquine-resistant falciparum spp) and rarely as Rx *if not taking the drug as* Px. **Cl:** hypersensitivity *to mefloquine or quinine*, Hx of neuro- Ψ

disorders (inc depression, convulsions).

Caution: epilepsy, cardiac conduction disorders, L/P/B.

SE: GI upset, neuro- Ψ reactions (dizziness, \downarrow balance, headache, convulsions, sleep disorders, neuropathies, tremor, anxiety, depression, psychosis, hallucinations, panic attacks, agitation). Also cardiac fx (AV block, other conduction disorders, \uparrow or \downarrow HR, \uparrow or \downarrow BP), hypersensitivity reactions.

Warn: can \downarrow driving/other skilled tasks and \Rightarrow neuro- Ψ reactions. **Interactions:** \uparrow risk of seizures with quinine, chloroquine and hydroxychloroquine. \downarrow s fx of anticonvulsants (esp valproate and carbamazepine). \uparrow risk of arrhythmias with amiodarone, quinidine, moxifloxacin and pimozide. Avoid artemether/ lumefantrine.

Dose: 250 mg once-wkly¹ (\downarrow dose if Wt <45 kg)^{SPC/BNF}.

Need to start Px 2 1/2 wks before entering endemic area (to identify neuro- Ψ reactions; 75% of reactions occur by 3rd dose) and continue for 4 wks after leaving endemic area.

MEROPENEM

Carbapenem broad-spectrum antibiotic (β -lactam, but non-penicillin/ non-cephalosporin).

Use: Gram +ve and -ve aerobic and anaerobic infections.

Caution: β -lactam sensitivity (avoid if immediate hypersensitivity reaction) L/R/P/B.

SE: GI upset (N&V&D – inc AAC), Δ LFTs, headache, blood/skin disorders. Rarely seizures, SJS/TENS.

Monitor: LFTs.

Dose: 500 mg tds iv/ivi (\uparrow to 1 g tds if severe infection or 2 g tds if meningitis or exacerbation of lower RTI in CF). **NB:** \uparrow **interval ±** \downarrow **dose if RF**^{SPC/BNF}.

MESALAZINE

'New' aminosalicylate: as sulfasalazine, but with ↓sulphonamide SEs. **Use:** UC (Rx/maintenance of remission).

Cl: *bypersensitivity to any salicylates*, coagulopathies, **R** (caution only if mild), **L** (caution only if not severe).

Caution: P/B/E.

SE: GI upset, blood disorders, hypersensitivity (inc lupus), RF. **Warn:** report unexplained bleeding, bruising, fever, sore throat or malaise.

Monitor: U&E, FBC (stop drug if blood disorder suspected). **Interactions:** fx ↓by lactulose. NSAIDs and azathioprine may ↑nephrotoxicity.

Dose: as Asacol (or Ipocol, Pentasa or Salofalk).

MESNA

Binds to metabolite (acrolein) of thiol-containing chemotherapy agents (cyclophosphamide, ifosfamide), which are toxic to urothelium and can \Rightarrow severe haemorrhagic cystitis. Give as Px before chemotherapy; see SPC for details.

METFORMIN

Oral antidiabetic (biguanide): ⇒ ↑insulin sensitivity w/o affecting levels (⇒ ↓gluconeogenesis and ↓GI absorption of glucose and

↑peripheral use of glucose). Only active in presence of endogenous insulin (i.e. functional islet cells).

Use: type 2 DM: usually 1st-line if diet control unsuccessful (esp if obese, as \Rightarrow less \uparrow Wt than sulphonylureas).

Cl: DKA, \uparrow risk of lactic acidosis (e.g. severe dehydration/ infection/peripheral vascular disease, shock, major trauma, respiratory failure, alcohol dependence, **recent MI***, **general anaesthetic** or iodine-containing radiology contrast media***), **L/R/P/B**.

SE: GI upset (esp initially or if \uparrow doses), taste disturbed, headache. Rarely \downarrow vit B₁₂ absorption, lactic acidosis[†] (stop drug).

Dose: initially 500 mg mane, 1 ing as required to max 3 g/day usually in 2 or 3 divided doses. *Take with meals*. **NB:** 4 dose in mild **RF**, avoid in severe **KF**.

See *Both often coexist in coronary angiography: stop drug on day of procedure (giving insulin if necessary; see p. 196) and restart 48 h later, having checked that renal function has not deteriorated. Stop on day of surgery ahead of general anaesthetic** and restart when renal function normal set.

METHADONE

Opioid agonist: \downarrow euphoria and long $t_{1/2} \ (\Rightarrow \downarrow withdrawal symptoms)$ compared with other opioids.

Use: opioid dependence as aid to withdrawal.

Cl/Caution/SE/Interactions: as morphine but levels not \uparrow by ritonavir, but are by voriconazole and cimetidine and \uparrow risk of ventricular arrhythmias with atomoxetine and amisulpride. Can \uparrow QTc (caution if family history of sudden death).

Dose: *individual requirements vary widely according to level of previous abuse:* sensible starting dose is 10–20 mg/day po, 1 ing by 10–20 mg every day until no signs or symptoms of withdrawal – which usually stop at 60–120 mg/day. Then aim to wean off gradually. Available as non-proprietary solutions (1 mg/ml) or as M@thad@s@ (10 mg/ml or 20 mg/ml). Can give sc/im^{SPC/BNF}.

NB: \downarrow dose if LF, RF or elderly.

See Don't confuse solutions of different strengths see .

102

METHIONINE

Sulphur-containing amino acid: binds toxic metabolites of paracetamol.

Use: paracetamol OD <12 h *post-ingestion* (ineffective after this), mostly when acetylcysteine ivi cannot be given (e.g. outside hospital).

CI: metabolic acidosis.

Caution: schizophrenia (can worsen), L.

SE: N&V, irritability, drowsiness.

Interactions: can \downarrow fx of L-dopa.

Dose: 2.5 g po 4-hrly (for 4 *doses only: total dose* = 10 g).

METHOTREXATE

Immunosuppressant, antimetabolite: dihydrofolate reductase inhibitor (\downarrow s nucleic acid synthesis).

Use: rheumatoid arthritis¹ (1st-line DMARD), psoriasis (if severe/resistant), **Ca** (ALL, non-Hodgkin's lymphoma, choriocarcinoma, various solid tumours), rarely in Crohn's disease.

Cl: severe blood disorders, active infections, immunodeficiency, **R/L** (if either significant, otherwise caution), **P** (females and *males* must avoid conception for ≥ 3 months after stopping treatment), **B**.

Caution: effusions (esp ascites and pleural effusions: drain before starting treatment as risk of \uparrow toxicity), blood disorders, UC, PU, \downarrow immunity, porphyria, E.

SE: mucositis/GI upset, myelosuppression, skin reactions. Rarely pulmonary fibrosis/pneumonitis (esp RA), liver toxicity fibrosis (esp in psoriatics), neurotoxicity (inc necrotising demyelinating leukoencephalopathy), seizures, RF (esp tubular necrosis).

Monitor: U&Es, FBC, LFTs \pm procollagen 3 protein (to monitor for hepatic fibrosis).

Interactions: NSAIDs(eg in RA), trimethoprim, co-trimoxazole, corticosteroids, probenecid, nitrous oxide, pyrimethamine, clozapine, cisplatin, acitretin, ciclosporin all \Rightarrow \uparrow toxicity \pm levels. **Warn:** avoid over-the-counter NSAIDs*, report any clinical features of infection (esp sore throat).

104

Dose: 2.5–7.5 mg once a week¹ (can split dose into 3×2.5 mg at 12-h intervals), max 25 mg/wk. For other uses see BNF/SPC. **NB:** \downarrow dose in **RF**. Usually needs concomitant folic acid (range 5 mg once/wk–5 days/wk (omitted day of and day after, methotrexate)).

 \Re NB: dose is only once a week: potentially fatal if given daily \Re .

METHOTRIMEPRAZINE see Levomepromazine; DA

antagonist.

METHYLDOPA

Centrally acting α_2 agonist.

Use: HTN; esp pregnancy-induced and 1° HTN during pregnancy. *For advice on HTN Mx see p. 178.*

Cl: depression, phaeo, porphyria, **L** (if active liver disease).

Caution: Hx of depression/L, R.

SE: (minimal if dose <1 g/day) dry mouth, sedation, dizziness, weakness, headache, GI upset, postural \downarrow BP, \downarrow HR. Rarely **blood disorders**, **hepatotoxicity**, pancreatitis, Ψ disorders, Parkinsonism, lupus-like syndrome, false +ve direct Coomb's test.

Monitor: FBC, LFTs.

Interactions: \uparrow s neurotoxicity of lithium. Hypotensive fx \uparrow d by antidepressants, anaesthetics and salbutamol ivi. **Avoid with, or within 2 wks of, MAOIs** \bigotimes .

Dose: initially 250 mg bd/tds (125 mg bd in elderly), ↑ing gradually at intervals ≥2 days (max 2 g/day in elderly) to max of 3 g/day. **NB:** ↓**dose in RF**.

METHYLPREDNISOLONE

Glucocorticoid (mild mineralocorticoid activity). **Use:** acute flares of inflammatory diseases¹ (esp rheumatoid arthritis, MS), cerebral oedema, Rx of graft rejection. **Cl/Caution/SE/Interactions:** see Steroids section (p. 213). **Dose:** acutely, 250 mg-1 g ivi od¹ (normally for 3 days). Also available po and as im depot.

METOCLOPRAMIDE/MAXOLON

Antiemetic: D_2 antagonist: acts on central chemoreceptor trigger zone and directly stimulates GI tract ($\Rightarrow \uparrow$ motility).

Use: N&V, esp GI (gastroduodenal, biliary, hepatic) or opiate-/ chemotherapy-induced.

Cl: GI obstruction/perforation/haemorrhage (inc 3-4 days post-GI surgery), phaeo, **B**.

Caution: epilepsy, porphyria, L/R/P/E.

SE: extrapyramidal fx (see p. 227 – esp in elderly and young females: reversible if drug stopped w/in 24 h or with procyclidine), drowsiness, restlessness, GI upset, behavioural/mood Δ s, \uparrow prolactin. Rarely skin reactions, neuroleptic malignant syndrome.

Interactions: 1s fx of NSAIDs and ciclosporin levels. 1s risk of extrapyramidal fx of antipsychotics, SSRIs and TCAs.

Dose: 10 mg tds po/sc/im/iv. **NB:** ↓ **dose in RF, LF**.

METOLAZONE

Potent thiazide-like diuretic: as bendroflumethiazide, plus has additive diuretic fx with loop diuretics. **Use:** oedema¹, HTN² (for HTN Mx advice see p. 178). **Cl/Caution/SE/Interactions:** see Bendroflumethiazide. **Monitor:** e'lytes (esp Na⁺/K⁺) closely.

Dose: 5-10 mg od po (mane), \uparrow ing if needed to max of 80 mg/day^1 ; initially 5 mg od, then on alternate days for maintenance².

METOPROLOL

β-Blocker, cardioselective ($β_1 > β_2$), short-acting. **Use:** HTN¹ (for advice on stepped HTN Mx see p. 178), angina², arrhythmias³, migraine Px⁴, \uparrow T₄ (adjunct)⁵.

CI/Caution/SE/Interactions: see Propranolol.

Dose: 50-100 mg bd po^{1,4}; 50-100 mg bd/tds po^{2,3}; 50 mg qds po⁵. Can give 2–5 mg iv^{SPC/BNF} repeating to max 10–15 mg. See p. 230 for use in AMI/ACS. **NB:** Jdose in LF.

METRONIDAZOLE/FLAGYL

Antibiotic, 'cidal': binds DNA of anaerobic (and microaerophilic) bacteria/protozoa.

106 COMMON/USEFUL DRUGS

Use: anaerobic and protozoal infections, abdominal sepsis (esp *Bacteroides*), aspiration pneumonia, C. *difficile* (AAC), *H. pylori* eradication (see p. 173), *GiardialEntamoeba* infections, Px during GI surgery. Also dental/gynaecological infections, bacterial vaginosis (*Gardnerella*), PID.

Caution: avoid with alcohol: drug metabolised to acetaldehyde and other toxins \Rightarrow flushing, abdominal pain, \downarrow BP ('disulfiram-like' reaction), acute porphyria, L/P/B.

SE: GI upset (esp N&V), taste disturbed, skin reactions. Rarely, drowsiness, headache, dizziness, dark urine, hepatotoxicity, blood disorders, myalgia, arthralgia, seizures (transient), ataxia,

peripheral neuropathy (if prolonged Rx).

Interactions: can \uparrow busulfan, lithium and phenytoin levels, **W**+. **Dose:** 500 mg tds ivi/400 mg tds po/ for severe infections. Lower doses can be given po or higher doses pr (1 g bd/tds) according to indication^{SPC/BNF}. **NB:** \downarrow **dose in LF**.

MICONAZOLE

Imidazole antifungal (topical) but *systemic absorption can occur*. **Use:** oral fungal infections (give po), cutaneous fungal infections (give topically).

CI: L.

Caution: acute porphyria, P/B.

SE: GI upset. Rarely hypersensitivity, hepatotoxicity. Interactions: as ketoconazole, but less commonly significant. W+. Dose: po: oral gel (Daktarim) 5–10 ml qds (after food) or buccal tablets (VLoramy© 50 mg od mane. top: apply 1–2 times/day.

MIDAZOLAM

Benzodiazepine, very short-acting (see p. 223).

Use: sedation for stressful/painful procedures¹ (esp if amnesia desirable) and for agitation/distress in palliative care².

Cl/Caution/SE/Warn/Interactions: see Diazepam.

Dose: 1.0–7.5 mg iv¹; initially 2 mg (0.5–1 mg if elderly) over 60 sec, then titrate up slowly until desired sedation achieved using 0.5–1.0-mg boluses over 30 sec (can also give $im^{SPC/BNF}$); 2.5–5 mg sc prn² (or via

sc pump; see p. 184). Also available as buccal liquid (10 mg/ml, special preparation) – unlicensed use. **NB: ↓dose in RF or elderly**. Beware respiratory depression: have flumazenil and O₂ (± resuscitation trolley) at hand, esp if respiratory disease

or giving high doses im/iv &.

MINOCYCLINE

Tetracycline antibiotic: inhibits ribosomal (30S subunit) protein synthesis; broadest spectrum of tetracyclines. **Use:** acne¹.

CI/Caution/SE/Interactions: as tetracycline, but ↓bacterial resistance, although ↑risk of SLE and irreversible skin/body fluid discoloration. Can also use (with caution) in RF.

Dose: 100 mg od po¹ (can \uparrow to bd for other indications). Use for \geq 3 months in acne.

MINOXIDIL

Peripheral vasodilator (arterioles \gg veins): also \Rightarrow \uparrow CO, \uparrow HR, fluid retention \therefore *always needs concurrent* β *-blocker and diuretic.* **Use:** HTN (if severe/Rx-resistant); *for HTN Mx advice see p. 178.* **Cl:** phaeo.

Caution: IHD, acute porphyria, R/P/B.

SE: hypertrichosis, coarsening of facial features (reversible, but makes it less suitable for women), ↑Wt, peripheral oedema, pericardial effusions, angina (dt ↑HR). Rarely, GI upset, gynaecomastia/breast tenderness, renal impairment, skin reactions. **Dose:** initially 2.5–5 mg/day in 1 or 2 divided doses, ↑ing if needed up to usual max of 50 mg/day. NB: ↓dose in elderly and dialysis patients. Also used topically for male-pattern baldness.

MIRTAZAPINE/ZISPIN

Antidepressant: Noradrenaline And Specific Serotonin Agonist (NASSA); specifically stimulates $5HT_1$ receptors (antagonises $5HT_2/5HT_3$), antagonises central presynaptic α_2 receptors. Use: depression, esp in elderly* or if insomnia[†] see p. 192. Cl/Caution/SE: as fluoxetine, but $\Rightarrow \downarrow$ sexual dysfunction/ GI upset, \uparrow sedation[†] (esp during titration) and \uparrow appetite/Wt

COMMON/USEFUL DRUGS

(can be beneficial in elderly^{*}). Rarely, blood disorders (inc agranulocytosis^{**}), Δ LFTs, convulsions, myoclonus, oedema. **Warn:** of initial sedation, to not stop suddenly (risk of withdrawal;

see p. 220) and to report signs of infection** (esp sore throat, fever): stop drug and check FBC if concerned.

Interactions: avoid with other sedatives (inc alcohol), sibutramine and artemether/lumefantrine. & Never give with, or <2 wks after, MAOIs &.

Dose: initially 15 mg nocte 1 ing to 30 mg after 1-2 wks (max 45 mg/day). Note lower doses more sedating than higher doses.

MISOPROSTOL

Synthetic PGE₁ analogue: \downarrow s gastric acid secretion.

Use: Px/Rx of PU (esp NSAID-induced). Unlicensed uses: po or topically to cervix for induction of labour, to induce medical abortion and to ripen cervix for surgical abortion; also in postpartum haemorrhage.

Cl: Sepregnancy (actual or planned; only give to women of childbearing age if high risk of PU and contraceptives prescribed), **P/B**.

Caution: cardiovascular/cerebrovascular disease (can $\Rightarrow \downarrow$ BP).

SE: diarrhoea. Rarely, other GI upset, rash, light-headedness, menstrual Δs , vaginal bleeding, premature birth.

Warn: women of child-bearing age of risks to pregnancy and need for adequate contraception when taking.

Dose: most often used with diclofenac as Arthrotec. Also available with naproxen as Mapratec. Both these preparations contain 200 mcg misoprostol per tablet, i.e. total daily dose < the ideal 800 mcg.

MIXTARD 'Biphasic' insulin preparations, available as 20, 30, 40 or 50, which refer to the percentage of soluble (short-acting) insulin; the rest is isophane (long-lasting) insulin.

MMF see Mycophenolate mofetil; immunosuppressant.

MOMETASONE (FUROATE) CREAM

OR OINTMENT/ELOGON

Potent topical corticosteroid.

108

Use: inflammatory skin conditions, esp eczema.

Cl: untreated infection, rosacea, acne.

SE: skin atrophy, worsening of infections, acne.

Dose: apply thinly od top (use 'ointment' in dry skin conditions).

MONTELUKAST/SINGULAIR

Leukotriene receptor antagonist: \downarrow s Ag-induced bronchoconstriction.

Use: *non-acute* asthma (see BTS guidelines, p. 181), esp if large exercise-induced component or associated seasonal allergic rhinitis.

Caution: acute asthma, Churg–Strauss syndrome P/B.

SE: headache, GI upset, myalgia, dry mouth/thirst. Rarely **Churg–Strauss syndrome:** asthma (\pm rhin-/sinus-itis) with systemic vasculitis and $\uparrow E \varnothing^*$.

Monitor: FBC* and for development of vasculitic (purpuric/ non-blanching) rash, peripheral neuropathy, \uparrow respiratory/cardiac symptoms: all signs of possible Churg–Strauss syndrome. **Dose:** 10 mg nocte (\downarrow doses if <15 years old^{SPC/BNF}).

MORPHGESIC SR Morphine (sulphate) tablets (10, 30, 60 or 100 mg). Doses given bd; see p. 184. NB: ↓dose if LF, RF or elderly.

MORPHINE (SULPHATE)

Opiate analgesic.

Use: severe pain (inc post-op), AMI and acute LVF.

Cl: acute respiratory depression, obstructive airways disease, \uparrow risk of paralytic ileus, acute abdomen, delayed gastric emptying, biliary colic, acute alcoholism, \uparrow ICP/head injury (respiratory depression \Rightarrow CO₂ retention and cerebral vasodilation $\Rightarrow \uparrow$ ICP), phaeo. **H** (if 2° to chronic lung disease).

Caution: \downarrow respiratory reserve, \downarrow BP/shock, biliary tract disorders (NB: biliary colic is CI), pancreatitis, \downarrow T₄, adrenocorticoid insufficiency, \uparrow prostate/urethral stricture, arrhythmias, IBD, bowel obstruction, MG, L (can \Rightarrow coma), R/P/B/E.

SE: N&V (and other GI disturbance) constipation^{*} (can \Rightarrow ileus), **respiratory depression**, seizures (at \uparrow doses), \downarrow BP (inc orthostatic. NB: rarely $\Rightarrow \uparrow$ BP), sedation, dry mouth, urinary retention, RF. bronchospasm, pulmonary oedema, Jcough reflex, biliary tract spasm, Δ LFTs, \uparrow pancreatitis, \downarrow/\uparrow HR, hypothermia, muscle rigidity/fasciculation/myoclonus, oedema, ¹ICP, vertigo, syncope, headache, miosis, sensory disturbance, pruritis, anorexia, allodynia, mood $\Delta(\uparrow \text{ or } \downarrow)$, delirium, hallucinations, restlessness, amenorrhoea, Ulibido, rhabdomyolysis, **dependence**. Rarely, skin reactions. Interactions: A MAOIs (don't give within 2 wks of) . Levels by ritonavir. \downarrow s levels of ciprofloxacin. \uparrow sedative fx with antihistamines, baclofen, alcohol (also $\Rightarrow \downarrow BP$), TCAs, antipsychotics (also $\downarrow BP$), anxiolytics/hypnotics, barbiturates and moclobemide (also $\Rightarrow \uparrow CNS$ and \uparrow/\downarrow BP). \uparrow s fx of sodium oxybate, gabapentin. **Dose:** Acute pain: 5–20 mg sc/im 4-hrly; 2.5–15 mg iv up to 4-hrly (at 2 mg/min). NB: iv doses are generally 1/4-1/2 im doses. AMI: 5-10 mg iv, repeated if necessary. Acute LVF: 5-10 mg iv. Chronic pain: use po as Oramorph solution or as MST Continus, Morphogesic, MXL, Sevredol or Zomorph tablets - see p. 184; note dose adjustment may be required when switching brands. Also

note dose adjustment may be required when switching brands. Also available pr as suppositories of 10, 15, 20 and 30 mg giving 15-30 mg up to 4-hrly. Unless short-term Rx, always consider laxative Px*. Can îdoses and frequency with expert supervision and always adjust dose to response. NB: ↓dose if LF, RF or elderly. If ↓BMI or elderly, titrate dose up slowly, monitor O₂ sats and have naloxone ± resuscitation trolley at hand .

MST CONTINUS Oral morphine (sulphate), equivalent in efficacy to Oramorph but SR: dose every 12 hrs. Need to specify if *tablets* (5, 10, 15, 30, 60, 100 or 200 mg) or *suspension* (sachets of 20, 30, 60, 100 or 200 mg to be mixed with water). See also Palliative Care (p. 184). NB: ↓dose if LF, RF or elderly.

MUPIROCIN/BACTROBAN

Topical antibiotic for bacterial infections (esp nasal MRSA); available as ointment and cream (*specify which*) bd/tds. Local MRSA eradication protocols often exist; if not, then a sensible regimen is to give for 5–10 days and then swab 2 days later, repeating regimen if culture still positive.

MXL GAPSULES Morphine (sulphate) capsules (30, 60, 90, 120, 150 or 200 mg), equivalent in efficacy to Oramorph but SR: dose od. See also Palliative Care (p. 184). NB: Jdose if LF, RF or elderly.

MYCOPHENOLATE MOFETIL (MMF)

Immunosuppressant: \downarrow s B-/T-cell lymphocytes (and \downarrow s Ab production by B-cells).

Use: transplant rejection Px, autoimmune diseases, vasculitis. **CI: P/B**

Caution: active serious GI diseases[†], **E**.

Monitor: FBC and LFTs (2-wkly for 2 months, then monthly for 1st year).

Warn: patient to report unexplained bruises/bleeding/signs of infection. Avoid strong sunlight*.

SE: GI upset, blood disorders (esp $\downarrow N\emptyset$, $\downarrow Pt$), weakness, tremor, headache, \uparrow cholesterol, $\uparrow or \downarrow K^+$. Rarely GI

ulceration/bleeding/perforation[†], hepatotoxicity, skin neoplasms*. **Interactions:** ↑risk of agranulocytosis with clozapine. Levels ↓by rifampicin.

Dose: Specialist use only^{SPC/BNF}.

N-ACETYLCYSTEINE see Acetylcysteine; paracetamol antidote.

NALOXONE

Opioid receptor antagonist for opiate reversal if OD or over-Rx. **Caution:** cardiovascular disease, if taking cardiotoxic drugs, physical dependence on opioids, H.

Dose: 0.4-2.0 mg iv (or sc/im), much larger doses may be needed for certain opioids (e.g. tramadol), repeating after 2 min if no response (or \uparrow ing if severe poisoning). *NB: Short-acting:* may need repeating every 2–3 min (to total 10 mg) then review and consider ivi (10 mg made up to 50 ml with 5% dextrose; useful start rate is 60% of initial dose over 1 h, then adjusted to response).

NALTREXONE

112

Opioid antagonist: \downarrow s euphoria of opioids if dependence and \downarrow s craving and relapse rate in alcoholic withdrawal (opioids thought to mediate alcohol addiction; not licensed for this in UK yet).

Use: Opioid and alcohol withdrawal; start >1 wk after stopping*.

Cl: if still taking opioids (can precipitate withdrawal*), **L** (inc acute hepatitis).

Caution: R/P/B.

SE: GI upset, hepatoxicity, sleep and Ψ disorders. Monitor: LFTs.

Warn: patient that trying to overcome opiate blockade OD can \Rightarrow acute intoxication.

Dose: initial dose 25 mg od po, thereafter 50 mg od (or 350 mg per week split into 2×100 mg and 1×150 mg doses); specialist use only. *NB: also* \sqrt{s} fx of opioid analgesics.

NAPROXEN

Moderate-strength NSAID; non-selective COX inhibitor. **Use:** rheumatic disease¹, other acute musculoskeletal pain², dysmenorrhoea² inc postoperative, acute gout³.

CI/Caution/SE/Interactions: as ibuprofen, but \uparrow SEs, notably, \uparrow risk PU/GI bleeds. Probenecid \Rightarrow \uparrow serum levels. Mild **W+**. Lowest thrombotic risk of any NSAID.

Dose: 250–500 mg bd¹; 500 mg initially then 250 mg 6–8-hrly²; 750 mg initially then 250 mg 8-hrly³. Also available with misoprostol as Px against PU (as Naprates). NB: ↓dose in RF & consider gastroprotective Rx.

NARATRIPTAN/NARAMIG

 $5HT_{1B/1D}$ agonist for acute migraine. **Cl/Caution/SE/Interactions:** see Sumatriptan. **Dose:** 2.5 mg po (can repeat after ≥ 4 h if responded then recurs). Max 5 mg/24 h (2.5 mg if LF or RF).

NARCAN see Naloxone; opiate antidote.

NICORANDIL

 K^+ -channel activator (\Rightarrow arterial dilation $\Rightarrow \downarrow$ afterload) with nitrate component (\Rightarrow venous dilation $\Rightarrow \downarrow$ preload).

Use: angina Px/Rx (unresponsive to other Rx).

Cl: \downarrow BP (esp cardiogenic shock), LVF with \downarrow filling pressures, **B**. **Caution:** hypovolaemia, acute pulmonary oedema, ACS with LVF and \downarrow filling pressures, **P**.

SE: headache (often only initially*), flushing, dizziness, weakness, N&V, ↓BP, ↑HR (dose-dependent). Rarely GI/perianal ulcers (consider stopping drug), myalgia, angioedema, hepatotoxicity.
Interactions: Se risk of ↓↓BP with silden-/tadal-/varden-afil Se.
Dose: 5–30 mg bd (start low, esp if susceptible to headaches*).

NICOTINIC ACID/NIASPAN

Water-soluble B-complex vitamin; \downarrow s synthesis of cholesterol/TGs and \uparrow s HDL-cholesterol. Flushing prostaglandin mediated. **Use:** dyslipidaemia (\uparrow cholesterol, \uparrow TG, \downarrow HDL-cholesterol) *added to statin or if statin not tolerated.*

Cl: active bleeding, active PU disease. L(if severe)/B.

Caution: ACS, gout, history of PU, \uparrow alcohol intake, DM. R/P. **SE:** GI upset, dyspepsia, flushing, itch, rash, headache \uparrow HR, \downarrow BP, syncope, SOB, oedema, \uparrow uric acid, \uparrow INR, \downarrow Pt, \downarrow phosphate, DM, muscle disorders. Rarely rhabdomyolysis, anorexia.

Warn: avoid alcohol or hot drink around time of tablet (*flushing* and itch); false +ve urine G result.

Monitor: BG, CK (if *risk* myopathy) and LFTs (if mild-moderate LF). **Interactions:** *risk* of myopathy with statins.

Dose: 375 mg (MR tablets) od nocte after low fat snack; \uparrow dose weekly for 4 wks then monthly if needed. Maintenance dose 1–2 g od nocte.

NIFEDIPINE

Ca²⁺ channel blocker (dihydropyridine): dilates smooth muscle, esp arteries (inc coronaries). Reflex sympathetic drive \Rightarrow \uparrow HR and \uparrow contractility $\therefore \Rightarrow \downarrow$ HF cf other Ca²⁺ channel blockers (e.g. verapamil, and to a lesser degree diltiazem), which $\Rightarrow \downarrow$ HR + \downarrow contractility. Also diuretic fx. **Use:** angina Px¹, HTN² (for advice on stepped HTN Mx see *p*. 178), Raynaud's³.

Cl: cardiogenic shock, clinically significant aortic stenosis, ACS (inc w/in 1 month of MI).

Caution: angina or LVF can worsen (consider stopping drug), \downarrow BP, DM, BPH, acute porphyria L/R/H/P/B.

SE: flushing, headache, ankle oedema, dizziness, \downarrow BP, palpitations, poly-/nocturia, rash/pruritus, GI upset, weakness, myalgia, arthralgia, gum hyperplasia, rhinitis. Rarely, PU, hepatotoxicity.

Interactions: metab by **P450**. \uparrow s fx of digoxin, theophylline and tacrolimus. \downarrow s fx of quinidine. Quinu-/dalfo-pristin, ritonavir and grapefruit juice \uparrow fx of nifedipine. Rifampicin, phenytoin and carbamazepine \downarrow fx of nifedipine. Risk of $\downarrow \downarrow$ BP with α -blockers, β -blockers or Mg²⁺ iv/im.

Dose: 5–20 mg tds po³; use long-acting preparations for HTN/angina, as normal-release preparations \Rightarrow erratic BP control and reflex \uparrow HR, which can worsen IHD (e.g. Adalat LA or Retard and many others with differing fx and doses^{SPC/BNF}). **NB:** \downarrow dose if severe LF.

NITROFURANTOIN

Antibiotic: 'static' at \downarrow doses, 'cidal' at \uparrow doses. Only active in urine (no systemic antibacterial fx).

Use: UTIs.

Cl: G6PD deficiency, acute porphyria, **R** (also $\Rightarrow \downarrow$ activity of drug: it needs to be concentrated in urine), **P/B**.

Caution: DM, lung disease, ↓Hb, ↓vitamin B, ↓folate, electrolyte imbalance, susceptibility to peripheral neuropathy, L/E.

SE: GI upset, pulmonary reactions (inc effusions, fibrosis), peripheral neuropathy, hypersensitivity. Rarely, hepatotoxicity, cholestasis, pancreatitis, arthralgia, alopecia (transient), skin reactions (esp exfoliative dermatitis), blood disorders, BIH.

Dose: 50 mg qds po (\uparrow to 100 mg if severe chronic recurrent infection); od nocte if for Px. *Take with food*. Not available iv or im. NB: can \Rightarrow false-positive urine dipstick for glucose and discolour urine.

NORADRENALINE (= NOREPINEPHRINE)

Vasoconstrictor sympathomimetic: stimulates α -receptors \Rightarrow vasoconstriction.

Use: \downarrow BP (unresponsive to other Rx)¹, cardiac arrest². **Cl:** \uparrow BP, **P**.

Caution: thrombosis (coronary/mesenteric/peripheral), Prinzmetal's angina, post-MI, $\uparrow T_4$, DM, $\downarrow O_2$, $\uparrow CO_2$, hypovolaemia (uncorrected), E.

SE: can \downarrow BF to vital organs (esp kidney). Also headache, \downarrow HR, arrhythmias, peripheral ischaemia. \uparrow BP if over-Rx.

Interactions: Solve is a rrhythmias with halothane and cyclopropane Risk of βP with clonidine, MAOIs and TCAs. **Dose:** 80 µg/ml ivi at 0.16–0.33 ml/min¹ (adjust according to response); 0.5–0.75 ml of 200 µg/ml solution iv stat². (Solve NB: doses given here are for noradrenaline acid tartrate, not base).

NORETHISTERONE

Progestogen (testosterone analogue).

Use: endometriosis¹, dysfunctional uterine bleeding and menorrhagia², dysmenorrhoea³, postponement of menstruation⁴. **Cl:** liver/genital/breast cancers (unless progestogens being used for these conditions), atherosclerosis, undiagnosed vaginal bleeding, acute porphyria, Hx of idiopathic jaundice, severe pruritis, pemphigoid during pregnancy.

Caution: risk of fluid retention, TE disease, diabetes, depression. L/H/R.

SE: \uparrow weight, nausea, headache, dizziness, insomnia, drowsiness, breast tenderness, acne, depression, Δ libido, skin reactions, hirsuitism & alopecia.

Dose: 5 mg bd-tds daily po for $\ge 4-6$ months, commencing on day 5 of cycle (can \uparrow to 10 mg bd-tds if spotting occurs, \downarrow ing when stops)¹; 5 mg tds po for 10 days for Rx (for Px give 5 mg bd po from day 19–26 of cycle)²; 5 mg tds po from day 5–24 for 3–4 cycles³; 5 mg tds po starting 3 days prior to expected menstruation onset (bleeding will commence 2–3 days after stopping)⁴.

NUROFEN see Ibuprofen; NB: 'over-the-counter' use can \Rightarrow poor response to HTN and HF Rx.

NYSTATIN

Polyene antifungal.

Use: *Candida* infections: topically for skin/mucous membranes (esp mouth/vagina); po for GI infections (not absorbed).

SE: GI upset (at ↑doses), skin reactions.

Dose: po suspension: 0.5–1 million units qds, usually for 1 wk, for Rx (or 1 million units od for Px) *after food*.

OFLOXACIN 0.3% EYE DROPS/EXOCIN

Topical antibiotic; mostly used for corneal ulcers¹ (only start if corneal Gram stain/cultures taken and specialist not available).

Caution: P/B.

SE: local irritation. Rarely dizziness, headache, numbness, nausea. **Dose:** 1 drop 2–4 hourly for 1st 2 days then qds (max 10 days)¹. See SPC for other uses.

OLANZAPINE/ZYPREXA

'Atypical' antipsychotic: D_2 and $5HT_2$ (+ mild muscarinic) antagonist. **Use:** schizophrenia^{NICE}, mania, bipolar Px, acute sedation. **Cl:** glaucoma (angle closure), **B**. *If giving im also acute MI/ACS*, $\downarrow BP/HR$, *SSS or recent beart surgery.*

Caution: drugs that \uparrow QTc, dementia, cardiovascular disease (esp if Hx of or \uparrow risk of CVA/TIA), DM*, \uparrow prostate, Parkinson's, Hx of epilepsy, blood disorders, paralytic ileus. \uparrow s fx of alcohol, L/R/H/P/E. **SE: sedation**, \uparrow Wt, ankle oedema, Δ LFTs, postural \downarrow BP (esp initially \therefore titrate up dose slowly). \uparrow glucose* (rarely \circledast DM/DKA \circledast). Also extrapyramidal/anticholinergic fx (see p. 224; often transient) and rarely neuroleptic malignant syndrome and hepatotoxicity.

Monitor: BG* (\pm HbA_{1C}), LFTs, U&Es, FBC, prolactin, Wt, lipids (and CK if neuroleptic malignant syndrome suspected). If giving im closely monitor cardiorespiratory function for \geq 4 h post-dose, esp if given other antipsychotic or benzodiazepine.

Interactions: metab by **P450** \therefore many, but most importantly, levels \downarrow by carbamazepine and smoking. \uparrow risk of \downarrow NØ with valproate. Levels may be \uparrow by ciprofloxacin. \uparrow risk of CNS toxicity with sibutramine. \uparrow risk of arrhythmias with drugs that \uparrow QTc and atomoxetine. \uparrow risk of \downarrow BP with general anaesthetics. \downarrow s fx of anticonvulsants.

Dose: 5–20 mg po daily (preferably nocte to avoid daytime sedation). Available in 'melt' form if \downarrow compliance/swallowing (as Veloctab). Available in quick-acting im form (\mathbf{V}) for acute sedation; give 5–10 mg (2.5–5 mg in elderly) repeating 2 h later if necessary to max total daily dose, inc po doses, of 20 mg (max 3 injections/day for 3 days).

NB: im doses not recommended with im/iv benzodiazepines (\uparrow risk of respiratory depression) which should be given ≥ 1 h later; if benzodiazepines already given, use with caution and closely monitor cardiorespiratory function.

OLMESARTAN/OLMETEC

Angiotensin II antagonist: see Losartan. **Use:** HTN; *for advice on stepped HTN Mx see p.* 178. **CI:** biliary obstruction, **P/B**.

Caution/SE/Interactions: see Losartan.

Dose: initially 10 mg od, \uparrow ing to max 40 mg (20 mg in LF, RF or elderly).

OMEGA-3-ACID ETHYL ESTERS 90/OMACOR

Essential fatty acid combination: 1 g capsule = eicosapentaenoic acid 460 mg and decosahexaenoic acid 380 mg. Use: Adjunct to diet in type IIb and III $\uparrow TG^1$ (with statin) or type IV. Added for 2° prevention w/in 3 months of acute MI². CI: B. Caution: bleeding disorders, anticoagulants, DM L/P. SE: GI; rarer: taste disorder, dry nose, dizziness, hypersensitivity, hepatotoxicity, headache, rash, \downarrow BP, DM, \uparrow WBC.

Monitor: LFTs, INR.

Dose: Capsules: 2–4 g od¹; 1 g od². Take with food.

OMEPRAZOLE/LOSEC

PPI: inhibits H⁺/K⁺ ATPase of parietal cells $\Rightarrow \downarrow$ acid secretion. **Use:** PU Rx/Px (esp if on NSAIDs), gastro-oesophageal reflux disease (if symptoms severe or complicated by haemorrhage/ulcers/stricture)^{NICE}. Also used for *H. pylori* eradication and ZE syndrome.

Caution: can mask symptoms of gastric Ca, L/P/B.

SE: GI upset, headache, dizziness, arthralgia, weakness, skin reactions. Rarely, hepatotoxicity, blood disorders, hypersensitivity. Interactions: \downarrow (and \uparrow) P450 \therefore many, most importantly \uparrow s phenytoin, cilostazol, diazepam, raltegravir and digoxin levels. \downarrow s fx of ataza-/nelfi-/tipra-navir, mild W+.

Dose: 20 mg od po, \uparrow ing to 40 mg in severe/resistant cases and \downarrow ing to 10 mg od for maintenance if symptoms stable; 20 mg bd for *H. pylori* eradication regimens (see p. 173). If unable to take po (e.g. perioperatively, \downarrow GCS, on ITU), give 40 mg iv od either over 5 min or as ivi over 20–30 min. **NB: max dose 20 mg if LF**. **NB:** also specialist use iv for acute bleeds. Usually as 8 mg/h ivi for 721 h is order series and for the series of **D**.

72 h if endoscopic evidence of PU (prescribed as divided infusions, as drug is unstable). Contact pharmacy \pm GI team for advice on indications and exact dosing regimens.

ONDANSETRON

Antiemetic: $5HT_3$ antagonist: acts on central and GI receptors. **Use:** N&V, esp if resistant to other Rx or severe postoperative/ chemotherapy-induced.

Caution: GI obstruction (inc subacute), $\uparrow QTc^*$, L (unless mild), P/B. **SE: constipation** (or diarrhoea), **headache**, sedation, fatigue, dizziness. Rarely seizures, chest pain, $\downarrow BP$, Δ LFTs, rash, hypersensitivity. **Interactions:** metab by **P450**. Levels \downarrow by rifampicin, carbamazepine and phenytoin. \downarrow s fx of tramadol. Avoid with drugs that $\uparrow QTc^*$. **Dose:** 8 mg bd po; 16 mg od pr; 8 mg 2–8-hrly iv/im. Max 24 mg/day usually (8 mg/day if LF). Can also give as ivi at 1 mg/h for max of 24 h. Exact dose and route depends on indication^{SPC/BNF}.

ORAMORPH Oral morphine solution for severe pain, esp useful for prn or breakthrough pain (see p. 184 for use in palliative care).

Dose: see morphine. Multiply sc/im morphine dose by 2 to obtain approx equivalent^{Oramorph} dose. **NB:** \downarrow **dose if LF or RF**. Solution mostly commonly used is 10 mg/5 ml, but can be 100 mg/5 ml \therefore specify strength if prescribing in ml (rather than mg).

OTOSPORIN Ear drops for otitis externa (esp if bacterial infection suspected): contains antibacterials (neomycin, polymyxin B) and hydrocortisone 1%.

Dose: 3 drops tds/qds.

OXYBUTYNIN

Anticholinergic (selective M_3 antagonist); antispasmodic (\downarrow s bladder muscle contractions).

Use: detrusor instability (also neurogenic bladder instability, nocturnal enuresis).

Cl: bladder outflow or GI obstruction, urinary retention, severe UC/toxic megacolon, glaucoma (narrow angle), MG, **B**.

Caution: \uparrow prostate, autonomic neuropathy, hiatus hernia (if reflux), \uparrow T₄, IHD, arrhythmias, porphyria, L/R/H/P/E.

SE: antimuscarinic fx (see p. 225), GI upset, palpitations/ \uparrow HR, skin reactions – mostly dose-related and reportedly less severe in MR preparations*.

Dose: initially 5 mg bd/tds po (2.5 mg bd if elderly) ↑ing if required to max of 5 mg qds (bd if elderly). Also available as MR tablet (Lyntmel XL* 5–20 mg od) and transdermal patch (Kentera 36 mg; releases 3.9 mg/day and lasts 3–4 days).

OXYCODONE (HYDROCHLORIDE)/OXYNORM

Opioid for moderate/severe pain (esp in palliative care.) **Cl:** as fentanyl, plus acute abdomen, delayed gastric emptying, chronic constipation, cor pulmonale, acute porphyria.

L(if moderate/severe)/R (if severe), P/B.

Caution: all other conditions where morphine is CI/cautioned.

SE/Interactions: as morphine, but does not interact with baclofen, gabapentin and ritonavir.

Dose: 4–6-hrly po/sc/iv or as sc infusion. NB: 2.5 mg sc/iv = 5 mg po = approx 10 mg morphine po. Available in MR form as OxyContlin (12-hrly). NB: \downarrow dose if LF, RF or elderly.

OXYTETRACYCLINE

Tetracycline antibiotic: inhibits ribosomal protein synthesis. **Use:** acne vulgaris (and rosacea).

Cl/Caution/SE/Interactions: as tetracycline, plus caution in porphyria.

Dose: 500 mg bd po 1h before food or on empty stomach.

PABRINEX

Parenteral (iv or im) vitamins that come as a pair of vials. Vial 1 contains B_1 (thiamine*), B_2 (riboflavin) and B_6 (pyridoxine). Vial 2 contains C (ascorbic acid), nicotinamide and glucose.

Use: Acute vitamin deficiencies (esp thiamine*).

Caution: Rarely \Rightarrow anaphylaxis (esp if given iv too quickly). Ensure access to resuscitation facilities.

*See p. 190 for Wernicke's encephalopathy Px/Rx in alcohol withdrawal.

(DISODIUM) PAMIDRONATE

Bisphosphonate: \downarrow s osteoclastic bone resorption. Use: $\uparrow Ca^{2+}$ (esp metastatic: also \downarrow s pain)¹, Paget's disease², myeloma. CI: P/B.

Caution: Hx of thyroid surgery, cardiac disease, L/R/H.

SE: 'flu-like symptoms (inc fever, transient pyrexia), **GI upset** (inc haemorrhage), **dizziness/somnolence** (common post-dose*), \uparrow (or \downarrow) **BP**, seizures, musculoskeletal pain, osteonecrosis (esp in cancer patients; consider dental examination or preventative Rx), e'lyte Δ s (\downarrow **PO**₄, \downarrow or \uparrow K⁺, \uparrow Na⁺, \downarrow Mg²⁺), RF, blood disorders.

Monitor: e'lytes (inc U&E before each dose), Ca^{2+} , PO_4^- . **Warn:** not to drive/operate machinery immediately after Rx*. **Dose:** 15–90 mg ivi according to indication ($\pm Ca^{2+}$ levels¹). **NB: if RF max rate of ivi 20 mg/h (unless for life-threatening** $\uparrow Ca^{2+}$). *Never given regularly for sustained periods.*

120

PANTOPRAZOLE

PPI; as omeprazole, but \downarrow interactions and can \Rightarrow \uparrow TGs. **Dose:** 40 mg od po (\downarrow ing to 20 mg maintenance if symptoms allow). If unable to take po (e.g. perioperatively, \downarrow GCS, on ITU), can give 40 mg iv over \geq 2 min (or as ivi) od. \uparrow doses if ZE syndrome^{SPC/BNF}. **NB:** \downarrow dose if **RF or LF**.

PARACETAMOL

Antipyretic & mild analgesic. Unlike NSAIDs, *has no anti-inflammatory fx.* Use: mild pain (or moderate/severe in combination with other Rx), pyrexia. Caution: alcohol dependence, L (CI if severe liver disease), R. SE: *all rare*: rash, blood disorders, hepatic (rarely renal) failure – esp if over-Rx/OD (for Mx, see p. 250). Interactions: may W+ if prolonged regular use. Dose: 0.5–1 g po/pr; 1 g (or 15 mg/kg if <50 Kg) iv. All doses 4–6 hourly, max qds. (For children, see Calpol.)

PAROXETINE/SEROXAT

SSRI antidepressant; as fluoxetine, but $\downarrow t_{1/2}^*$. **Use:** depression¹, other Ψ disorders (social/generalised anxiety disorder¹, PTSD¹, panic disorder², OCD³).

Cl/Caution/SE/Interactions: as fluoxetine, but \downarrow frequency of agitation/insomnia, although \uparrow frequency of **antimuscarinic fx** (see p. 225), **extrapyramidal fx** (see p. 227) and **withdrawal fx*** (see p. 226). Avoid if <25 yrs old as may \uparrow suicide risk. Also does not \uparrow carbamazepine levels (but its levels are \downarrow by carbamazepine) but \uparrow s galantamine levels.

Dose: initially 20 mg^{1,3} (10 mg²) mane, \uparrow ing if required to max 50 mg¹ or 60 mg^{2,3}. **NB:** \downarrow **dose if RF, LF or elderly**. Stop very slowly as short $t_{1/2} \Rightarrow \uparrow$ risk of withdrawal syndrome.

PARVOLEX see Acetylcysteine; antidote for paracetamol poisoning.

PENICILLAMINE

Chelates copper/lead \Rightarrow ↑elimination (also acts as DMARD): slow onset of action (6–12 wks).

Use: Wilson's disease*, copper/lead poisoning, rarely for rheumatoid arthritis (also autoimmune hepatitis, cystinuria). **Cl:** SLE, **R** (unless mild when only caution).

Caution: penicillin allergy (can also be penicillamine allergic), taking other nephrotoxic drugs, P.

SE: RF (esp immune nephritis \Rightarrow proteinuria*: stop drug if severe), **blood disorders** (\downarrow **Pt**, \downarrow **NØ**, agranulocytosis, aplastic \downarrow **Hb**), **rashes** (inc SJS, pemphigus), **taste** Δ **s**, **GI upset** (esp nausea, but \downarrow s if taken with food). Can ^neurological symptoms in Wilson's. Rarely hepatotoxicity, pancreatitis, autoimmune phenomena: poly-/dermatomyositis, Goodpasture's syndrome, lupus-/myasthenia-like syndromes.

Warn: immediately report sore throat, fever, infection, non-specific illness, unexpected bleeding/bruising, purpura, mouth ulcers or rash. **Monitor:** FBC, U&Es, urine dipstick ± 24 -h collection*.

Interactions: \uparrow risk of agranulocytosis with clozapine. Absorption \downarrow by antacids and FeSO₄. Can \downarrow levels of digoxin.

Dose: 125–2000 mg daily^{SPC/BNF}. **NB:** consider \downarrow dose if **RF** or elderly.

Can $\Rightarrow \downarrow$ pyridoxine which often needs supplementing. Consider stopping if fever, lymphadenopathy, \downarrow Pt/NØ, proteinuria or worsening neuro symptoms. Sensitivity occurs in 10%; can restart with prednisolone – get senior advice.

PENICILLIN G see Benzylpenicillin.

PENICILLIN V see Phenoxymethylpenicillin.

PENTASA see Mesalazine; aminosalicylate for UC, with \downarrow SEs.

PEPPERMINT OIL

Antispasmodic: direct relaxant of GI smooth muscle. Use: GI muscle spasm, distension (esp IBS). SE: perianal irritation, indigestion. Rarely rash or other allergy. Dose: 1–2 capsules tds, before meals and with water. PEPTAC Alginate raft-forming oral suspension for acid reflux. **Dose:** 10–20 ml after meals and at bedtime (NB: 3 mmol Na⁺/5 ml).

PERINDOPRIL/COVERSYL

ACE-i; see Captopril. **Use:** HTN (for advice on stepped HTN Mx see p. 178), HF, Px of IHD.

CI/Caution/SE/Monitor/Interactions: as Captopril, plus can \Rightarrow mood/sleep Δ s.

Dose: 2–8 mg od^{SPC/BNF}, starting at 2–4 mg od. **NB: consider** ↓dose if **RF**, elderly, taking a diuretic, cardiac decompensation or volume depletion.

PETHIDINE

Opioid; less potent than morphine but quicker action \Rightarrow 1 cuphoria + 1 abuse/dependence potential \therefore not for chronic use e.g. in palliative care.

Use: moderate/severe pain, obstetric and peri-op analgesia. **Cl:** acute respiratory depression, risk of ileus, ↑ICP/head injury/coma, phaeo.

Caution: any other condition where morphine CI/cautioned. **SE:** as morphine, but ↓constipation.

Interactions: as morphine but \Re ↑risk of hyperpyrexia/CNS toxicity with **MAOIs** \Re . Ritonavir \Rightarrow ↓levels and ↑s toxic metabolites. No known interaction with gabapentin or baclofen. **Dose:** 25–100 mg up to 4-hrly im/sc (can give 2-hrly post-op or 1–3 hrly in labour with max 400 mg/24 hrs); 25–50 mg up to 4-hrly slow iv. Rarely used po^{SPC/BNF}. **NB:** ↓dose if LF, RF or elderly.

PHENOBARBITAL (= PHENOBARBITONE)

Barbiturate antiepileptic: potentiates GABA (inhibitory neurotransmitter), antagonises fx of glutamate (excitatory neurotransmitter). **Use:** status epilepticus (SEs and interactions limit other uses). **Caution:** respiratory depression, acute porphyria, L/R/P/B/E.

SE: hepatitis, cholestasis, respiratory depression, sedation, \downarrow BP, \downarrow HR, ataxia, skin reactions. Rarely, paradoxical excitement (esp in elderly), blood disorders.

Interactions: ^P450 \therefore many, most importantly \downarrow s levels/fx of aripiprazole, antivirals, carbamazepine, Ca²⁺ antagonists, chloramphenicol, corticosteroids, ciclosporin, eplerenone, mianserin, tacrolimus, telithromycin, posa-/vori-conazole and OCP. Anticonvulsant fx \downarrow by antipsychotics, TCAs and SSRIs. Avoid with St John's wort. \uparrow s fx of sodium oxybate. Caution with other sedative drugs (esp benzodiazepines), W^- .

Dose: total of 10 mg/kg as ivi at 50–100 mg/min (max total 1 g).

PHENOXYMETHYLPENICILLIN (= PENICILLIN V)

As benzylpenicillin (penicillin G) but active orally: used for ENT/skin infections (esp erisipelas), Px of rheumatic fever/ S. pneumoniae infections (esp post-splenectomy). **Dose:** 0.5-1.0 g qds po (≥ 30 min before food).

PHENTOLAMINE

α-Blocker, short-acting. Use: HTN 2° to phaeo (esp during surgery). CI: ↓BP, IHD (inc Hx of MI). Caution: PU/gastritis, asthma, R/P/B/E. SE: ↓BP, ↑HR, dizziness, weakness, flushing, GI upset, nasal congestion. Rarely, coronary/cerebrovascular occlusion, arrhythmias. Interactions: see Doxazosin.

Dose: 2–5 mg iv (repeat if necessary).

PHENYLEPHRINE EYE DROPS

Topical sympathomimetic for pupil dilation (commonly used in combination with cyclopentolate or tropicamide).

Caution: cardiovascular disease, \uparrow HR, \uparrow T₄, children E.

SE: blurred vision, local irritation, [↑]BP, [↑]HR, arrhythmias, coronary artery spasm.

Dose: 1 drop. 2.5% drops most common (10% available but \uparrow risk of \uparrow BP.

PHENYTOIN

Antiepileptic: blocks Na⁺ channels (stabilises neuronal membranes).

124

Use: all forms of epilepsy¹ (except absence seizures) inc status epilepticus² and Px/Rx of seizures following neurosurgery/head injury³. **CI:** *if giving iv* (do not apply if po); sinus \downarrow HR, Stokes–Adams syndrome, SAN block, 2nd-/3rd-degree HB, acute porphyria. **Caution:** DM, porphyria \downarrow BP, L/H/P (\Rightarrow cleft lip/palate, congenital heart disease), **B**.

SE (acute): *dose-dependent:* **drowsiness** (also confusion/dizziness), **cerebellar fx** (see p. 227), **rash** (common cause of intolerance and rarely \Rightarrow SJS/TEN), N&V, diplopia, dyskinesia (esp orofacial). *If iv, risk of* \downarrow **BP, arrhythmias*** (esp \uparrow QTc), **'purple glove syndrome**' (hand damage distal to injection site), CNS/respiratory depression. **SE (chronic):** gum hypertrophy, coarse facies, hirsutism, acne, \downarrow folate (\Rightarrow megaloblastic \downarrow Hb), Dupuytren's, peripheral neuropathy, rickets, osteomalacia. Rarely, blood disorders, hepatotoxicity, suicidal thoughts/behaviour.

Monitor: FBC**, keep serum levels at 10–20 mg/l (narrow therapeutic index). \mathcal{Q} If iv, closely monitor BP and ECG* (esp QTc) \mathcal{Q} . Warn: report immediately any rash, mouth ulcers, sore throat, fever, bruising, bleeding, Inform patient (and carers) of risk of suicidal thoughts/behaviour and to seek medical advice if develops. **Interactions:** metab by and *s* **P450**... many; most importantly \downarrow s fx of OCP, doxycycline, Ca²⁺ antagonists (esp nifedipine), im-/lap-atinib, ciclosporin, keto-/itra-/posa-conazole, indinavir, quinidine, theophyllines, eplerenone, telithromycin, aripiprazole, mianserin, mirtazapine, paroxetine, TCAs and corticosteroids. Fx ↓by rifampicin, rifabutin, theophyllines, mefloquine, pyrimethamine, sucralfate, antipsychotics, TCAs and St John's wort. Levels 1by NSAIDs (esp azapropazone), fluoxetine, mi-/flu-/vori-conazole, diltiazem, disulfiram, trimethoprim, cimetidine, esomeprazole, amiodarone, metronidazole, chloramphenicol, clarithromycin, isoniazid, sulphonamides, sulfinpyrazone, topiramate (levels of which are \downarrow) and ethosuximide. Complex interactions with other antiepileptics^{SPC/BNF}. W- (or rarely W+).

Dose: po¹: 150–500 mg/day in 1–2 divided doses^{SPC/BNF}. **iv^{2,3}**: load with 18 mg/kg ivi at max rate of 25–50 mg/min, then maintenance iv doses of approximately 100 mg tds/qds, adjusting to weight, serum

6 COMMON/USEFUL DRUGS

levels and clinical response. If available give iv as *fosphenytoin* (NB: doses differ). **NB:** ↓ **dose if LF**.

Stop drug if \downarrow WCC** is severe, worsening or symptomatic $\mathscr{D}_{\mathscr{D}}$.

PHOSPHATE ENEMA

Laxative enemas; ⇒ osmotic H₂O retention ⇒ ↑evacuation. Use: severe constipation (unresponsive to other Rx). CI: acute GI disorders. Caution: if debilitated or neurological disorder, E. SE: local irritation. Dose: 1 prn.

PHYLLOGONTIN CONTINUS see Aminophylline (MR). **Dose:** initially 1 tablet (225 mg) bd po, then \uparrow to 2 tablets bd after 1 wk according to serum levels. (Forte tablets of 350 mg used if smoker/other cause of \downarrow t_{1/2}, e.g. interactions with other drugs; see Theophylline.) **NB:** \downarrow **dose if LF**.

PHYTOMENADIONE

Intravenous vit K_1 for warfarin overdose/poisoning; see p. 204. **Caution:** give iv injections slowly. NB: not compative with NaCl P.

PIGOLAX see Bowel preparations.

Dose: 1 sachet at 8 am and 3 pm the day before GI surgery or Ix.

▼PIOGLITAZONE/ACTOS

Thiazolidinedione (glitazone) antidiabetic; ↓s peripheral insulin resistance (and, to lesser extent, hepatic gluconeogenesis).

Use: type 2 DM in combination with a sulphonylurea (if metformin not tolerated) *or* metformin (if risk of \downarrow glucose with sulphonylurea unacceptable) *or* sulphonylurea + metformin (if obese, metabolic syndrome or human insulin unacceptable due to lifestyle/personal issues)^{NICE}.

Cl: insulin use(\uparrow risk of HF), ACS (inc Hx of), **H** (inc Hx of), L/P/B **Caution:** cardiovascular disease, R

SE: oedema (esp if HTN/CCF), \downarrow Hb, \uparrow Wt, GI upset (esp diarrhoea), headache, hypoglycaemia (if also taking sulphonylureas), \uparrow risk of distal fractures, rarely hepatotoxicity.

126

Monitor: LFTs. & Discontinue if jaundice develops & and for signs of HF. **Interactions:** levels \downarrow by rifampicin and \uparrow by gemfibrozil.

Dose: initially 15–30 mg od (max 45 mg od)

PIPERACILLIN

Ureidopenicillin: antipseudomonal.

Use: with tazobactam* (β -lactamase inhibitor) as Tazocim, reserved for severe infections.

CI/Caution/SE/Interactions: see Benzylpenicillin.

Dose: see Tazocin*.

PIRITON see Chlorphenamine; antihistamine for allergies.

PLAVIX see Clopidogrel; anti-Pt agent for Px of IHD (and CVA).

POTASSIUM TABLETS see Kay-cee-L (syrup 1 mmol/ml), Kloref (effervescent 6.7 mmol/tablet), Samdo-K (effervescent 12 mmol/tablet) and Slow-K (MR non-effervescent 8 mmol/tablet, reserved for when syrup/effervescent preparations are inappropriate; avoid if ↓swallow).

PRAMIPEXOLE/MIRAPEXIN

Dopamine agonist (non-ergot derived); use in early Parkinson's $\Rightarrow \downarrow$ motor complications (e.g. dyskinesias) but \downarrow motor performance cf L-dopa.

Use: Parkinson's¹, moderate-severe restless legs syndrome (RLS)². **Cl: B**.

Caution: psychotic disorders, severe cardiovascular disease R/H/P. **SE:** GI upset, sleepiness (inc sudden onset sleep), \downarrow BP (inc postural, esp initially), Ψ disorders (esp psychosis and impulse control disorders e.g. gambling and \uparrow sexuality), amnesia, headache, oedema. **Warn:** sleepiness and \downarrow BP may impair skilled tasks (inc driving). Avoid abrupt withdrawal.

Monitor: ophthalmological testing if visual Δs occur. **Dose:** initially 88 µg tds¹ (or 88 µg nocte for RLS²) \uparrow ing if tolerated/required to max 1.1 mg tds¹ (or 540 µg nocte²). NB: doses given for *BASE* (not *SALT*) & \downarrow dose if RF.

PRAVASTATIN/LIPOSTAT

HMG-CoA reductase inhibitor: 'statin'; ↓s cholesterol/LDL (and TG). **Use/CI/Caution/SE/Monitor:** see Simvastatin.

Interactions: \uparrow risk of myositis ($\pm \uparrow$ levels) with & fibrates &, nicotinic acid, daptomycin, ciclosporin and ery-/clari-thromycin. **Dose:** 10–40 mg nocte. **NB:** \downarrow **dose if RF**.

PREDNISOLONE

Glucocorticoid (and mild mineralocorticoid activity). **Use:** anti-inflammatory (e.g. rheumatoid arthritis, IBD, asthma, eczema), immunosuppression (e.g. transplant rejection Px, acute leukaemias), glucocorticoid replacement (e.g. Addison's disease, hypopituitarism).

Cl: systemic infections (w/o antibiotic cover).

Caution/SE/Interactions: see p. 219.

Warn: carry steroid card (and avoid close contact with people who have chickenpox/shingles if patient has never had chickenpox).

Dose: usually 2.5–15 mg od po for maintenance. In acute/initial stages, 20–60 mg od often needed (depends on cause and often physician preference), e.g. acute asthma (40 mg od), acute COPD (30 mg od), temporal arteritis (40–60 mg daily). Take with food $(\downarrow Na^+, \uparrow K^+ \text{ diet recommended if on long-term Rx})$. For other causes, consult^{SPC/BNF}, pharmacy or local specialist relevant to the disease. Also available as once or twice weekly im injection.

Warn patient not to stop tablets suddenly (*can* \Rightarrow *Addisonian crisis*). Requirements may \uparrow if intercurrent illness/surgery. Consider Ca/vit D supplements/bisphosphonate to \downarrow risk of osteoporosis and PPI to \downarrow risk of GI ulcer \bigotimes .

PREGABALIN/LYRICA

Antiepileptic; GABA analogue. **Use:** epilepsy (partial seizures w or w/o 2° generalisation), neuropathic pain, generalised anxiety disorder. **CI: B.**

Caution: avoid abrupt withdrawal, H (if severe) R/P/E.

SE: neuro- Ψ disturbance; esp somnolence/dizziness (\Rightarrow falls in elderly), confusion, visual Δ (esp blurred vision), mood \uparrow or \downarrow (and *possibly* suicidal ideation/behaviour[†]), \downarrow libido, sexual dysfunction and vertigo. Also GI upset, \uparrow appetite/Wt, oedema and dry mouth. Rarely HF (esp if elderly and/or CVS disease).

Warn: seek medical advice if \uparrow suicidality or mood \downarrow s[†]. Don't stop abruptly as can \Rightarrow withdrawal fx* (insomnia, headache, N&D, 'flu-like symptoms, pain, sweating, dizziness, pain).

Dose: 50–600 mg/day po in 2–3 divided doses^{SPC/BNF}. **NB:** stop over \geq 1 wk* and \downarrow dose if **RF**.

PROCHLORPERAZINE/STEMETIL

Antiemetic: DA antagonist (phenothiazine \therefore also antipsychotic, but now rarely used for this).

Use: N&V (inc labyrinthine disorders).

CI/Caution/SE/Monitor/Warn/Interactions: as

chlorpromazine, but CI are relative and $\Rightarrow \downarrow$ sedation. NB: can \Rightarrow extrapyramidal fx (esp if elderly/debilitated); see p. 227. **Dose:** *po:* acutely 20 mg, then 10 mg 2 h later (5–10 mg bd/tds for Px and labyrinthine disorders); *im:* 12.5 mg, then po doses 6 h later; *pr:* 25 mg then po doses 6 h later (5 mg tds pr for migraine). Available as quick-dissolving 3-mg tablets to be placed under lip

(Buccastem); give 1-2 bd. NB: Jdose if RF.

PROCYCLIDINE

Antimuscarinic: \downarrow s cholinergic to dopaminergic ratio in extrapyramidal syndromes $\Rightarrow \downarrow$ tremor/rigidity. No fx on bradykinesia (or tardive dyskinesia; may even worsen). **Use:** extrapyramidal symptoms (e.g. Parkinsonism), esp if drug-induced¹ (e.g. antipsychotics; see p. 227).

Cl: urinary retention (if untreated), glaucoma* (angle-closure), GI obstruction, MG.

Caution: cardiovascular disease, ↑prostate, tardive dyskinesia, L/R/H/P/B/E.

SE: antimuscarinic fx (see p. 225), Ψ disturbances, euphoria (can be drug of abuse), glaucoma^{*}.

Warn: can \downarrow ability at driving/skilled tasks.

Dose: 2.5 mg tds po prn¹ (1 if necessary to max of 10 mg tds);

5-10 mg im/iv if acute dystonia or oculogyric crisis.

NB: do not stop suddenly: can \Rightarrow rebound muscarinic fx.

PROMETHAZINE

Sedating antihistamine.

Use: insomnia¹ (see p. 223). Also used iv/im for anaphylaxis and po for symptom relief in chronic allergies.

CI: CNS depression/coma, MAOI w/in 14 days.

Caution: urinary retention, \uparrow prostate, glaucoma, epilepsy, IHD, asthma, porphyria, pyloroduodenal obstruction, **R** (\downarrow dose), **L** (avoid if severe)/P/B/E.

SE: antimuscarinic fx (see p. 225), hangover sedation, headache. **Warn:** can \downarrow ability at driving/skilled tasks.

Interactions: \uparrow s fx of anticholinergics, TCAs and sedatives/hypnotics.

Dose: 25 mg nocte¹ (can \uparrow dose to 50 mg).

PROPRANOLOL

 β -Blocker (non-selective): $\beta_1 \Rightarrow \downarrow HR$ and $\downarrow contractility$, $\beta_2 \Rightarrow$ vasodilation (and bronchoconstriction and glucose release from liver). Also blocks fx of catecholamines, \downarrow s renin production, slows SAN/AVN conduction.

Use: HTN¹ (for advice on stepped HTN Mx see p. 178), IHD (angina Rx², MI Px³), portal HTN⁴ (Px of variceal bleed; NB: may worsen liver function), essential tremor⁵, Px of migraine⁶, anxiety⁷, [↑]T (symptom relief⁸, thyroid storm⁹), arrhythmias⁸ (inc severe⁹).

Cl: asthma/Hx of bronchospasm, peripheral arterial disease (if severe), Prinzmetal's angina, severe \downarrow HR or \downarrow BP, SSS, 2nd-/3rd-degree HB, cardiogenic shock, metabolic acidosis, phaeo (unless used specifically with α -blockers), **H** (if uncontrolled).

Caution: COPD, 1st-degree HB, DM*, MG, Hx of hypersensitivity (may \uparrow to *all* allergens), L/R/P/B.

SE: ↓HR, ↓BP, HF, peripheral vasoconstriction (⇒ cold extremities, worsening of claudication/Raynaud's), fatigue,

130

depression, sleep disturbance (inc nightmares), hyperglycaemia (and ↓**sympathetic response to hypoglycaemia***), GI upset. Rarely, conduction/blood disorders.

Interactions: Severapamil and diltiazem \Rightarrow risk of HB and \downarrow HR Severapamil and HF with nifedipine. Risk of \downarrow BP with α -blockers. \uparrow s risk of bupiva-/lido-caine toxicity. \uparrow s risk of AV block, myocardial depression and \downarrow HR with amiodarone, flecainide. Levels of both drugs can \uparrow with chlorpromazine. Risk of \uparrow BP with moxisylyte. Risk of \uparrow BP (and \downarrow HR) with dobutamine, adrenaline and noradrenaline. Risk of withdrawal \uparrow BP with clonidine (stop β -blocker before slowly \downarrow ing clonidine). \uparrow level of both chlorpromazine and propranolol if given together.

Dose: 80–160 mg bd po¹; 40–120 mg bd po²; 40 mg qds for 2–3 days, then 80 mg bd po³ (start 5–21 days post-MI); 40 mg bd po⁴ ([†]dose if necessary); 40 mg bd/tds po^{5,6}; 40 mg od po⁷ ([†]dose to tds if necessary); 10–40 mg tds/qds⁸; 1 mg iv over 1 min⁹ repeating every 2 min if required, to max total 10 mg (or 5 mg in anaesthesia).

NB: \downarrow **po dose in LF and** \downarrow **initial dose in RF.** Withdraw slowly (esp in angina); if not can \Rightarrow rebound \uparrow of symptoms.

PROPYLTHIOURACIL

Thionamide antithyroid (peroxidase inhibitor): \downarrow s $I^- \Rightarrow I_2 \downarrow$ s and $\therefore \downarrow T_{3/4}$ production, as carbimazole does, but also \downarrow s peripheral T_4 to T_3 conversion. Possible immunosuppressant fx. **Use:** $\uparrow T_4$ (2nd-line in the UK; if carbimazole not tolerated). **Caution:** L/R, **P/B** (can cause fetal/neonatal goitre/ $\downarrow T_4$ \therefore use min dose and monitor neonatal development closely; 'block-and-replace' regimen \therefore not suitable as high doses used for this). **SE: blood disorders** (esp **@agranulocytosis @**; stop drug if occurs), **skin reactions** (esp urticaria, rarely cutaneous vasculitis/lupus), fever. Rarely hepatotoxicity, nephritis. **Warn:** patient to report symptoms of infection (esp sore throat). **Monitor:** FBC, clotting.

Dose: 200–400 mg od po until euthyroid, then \downarrow to maintenance dose of 50–150 mg od. **NB:** \downarrow **dose if LF or RF**.

2 COMMON/USEFUL DRUGS

PROSCAR see Finasteride; antiandrogen for BPH (and baldness).

PROTAMINE (SULPHATE)

Protein (basic) that binds heparin (acidic). **Use:** reversal of heparin (or LMWH) following over-Rx/OD or after temporary anticoagulation for extracorporeal circuits (e.g. cardiopulmonary bypass, haemodialysis). **Caution:** \uparrow risk of hypersensitivity reaction if: (1) vasectomy, (2) infertile man, (3) allergy to fish. **SE:** \downarrow BP, \downarrow HR, N&V, flushing, dyspnoea. Rarely pulmonary oedema, hypertension, hypersensitivity reactions. **Dose:** 1 mg per 80–100 units of heparin to be reversed (max 50 mg) iv/ivi at rate ≤ 5 mg/min; exact regimen depends on whether reversing heparin or LMWH and whether given iv or sc^{BNF/SPC}. NB: $t_{1/2}$ of iv heparin is short; \downarrow doses of protamine if giving to reverse iv heparin >15 min after last dose – see SPC. Max total dose 50 mg: \bigotimes high doses can \Rightarrow anticoagulant fx! \bigotimes

PROXYMETHACAINE

Topical anaesthetic (lasts 20 min). Use: eye examination (if painful eye or checking IOP). SE: corneal epithelial shedding. Dose: 1 drop prn (not for prolonged treatment).

PROZAC see Fluoxetine; SSRI antidepressant.

PULMICORT see Budesonide; inh steroid for asthma. 50, 100, 200 or $400 \mu g$ /puff.

PYRAZINAMIDE

Antibiotic: 'cidal' only against intracellular and dividing bacteria (e.g. TB). Good CSF penetration*.
Use: TB Rx (for initial phase, see p. 171), TB meningitis*.
Cl: acute porphyria, L (if severe, otherwise caution).
Caution: DM, gout (avoid in acute attacks), P.

132

SE: hepatotoxicity**, **1**urate, GI upset (inc N&V), dysuria, interstitial nephritis, **arthr**-/my-algia, sideroblastic \downarrow Hb, \downarrow Pt, rash (and photosensitivity).

Monitor: LFTs**.

Warn: patients and carers to stop drug and seek urgent medical attention if signs of LF (explain symptoms).

Dose: up to 2 g daily – exact dose varies according to Wt and whether Rx is 'supervised' or not^{SPC/BNF}.

PYRIDOSTIGMINE

Anticholinesterase: inhibits cholinesterase at neuromuscular junction $\Rightarrow \uparrow ACh \Rightarrow \uparrow neuromuscular$ transmission.

Use: myasthenia gravis.

CI: GI/urinary obstruction.

Caution: asthma, recent MI, ↓HR/BP, arrhythmias, vagotonia, ↑T, PU, epilepsy, Parkinsonism, R/P/B/E.

SE: cholinergic fx (see p. 225) – esp if xs Rx/OD, where \downarrow BP, bronchoconstriction and (confusingly) weakness can also occur (= cholinergic crisis*); **1**secretions (sweat/saliva/tears) and miosis are good clues** of xs ACh.

Interactions: fx \downarrow d by **aminoglycosides** (e.g. gentamicin), **polymixins**, clindamycin, lithium, quinidine, chloroquine, propranolol and procainamide. \uparrow s fx of suxamethonium.

Dose: 30-120 mg po up to qds (can \uparrow to max total 1.2 g/24 h; if possible give <450 mg/24 h to avoid receptor downregulation). **NB:** \downarrow **dose if RF**.

▼QUETIAPINE/SEROQUEL

Atypical (2nd generation) antipsychotic.

Use: schizophrenia¹, mania², depression in bipolar disorder³. Offlicence use for psychosis/behavioural disorders (esp in dementias).

CI: B.

Caution: cardiovascular disease, Hx of epilepsy, drugs that \uparrow QTc, L/R/E.

SE/Interactions/Warn/Monitor: as olanzapine but therapeutic doses are initially sedating and \downarrow BP requiring \therefore start with \downarrow dose*. Also levels \uparrow by ery-/clari-thromycin.

Dose: Needs titration* (see SPC/BNF): initially 25 mg bd \uparrow ing daily to max 750 mg/day¹; initially 50 mg bd \uparrow ing daily to max 800 mg/day²; initially 50 mg od \uparrow ing daily to max 600 mg/day³. If RF, LF or elderly start at 25 mg od \uparrow ing less frequently. Available in MR form (Serequel XL); initially 300 mg od then 600 mg od the next day², then adjust to response (if giving for depression³ or if RF, LF or elderly start at 50 mg od then \uparrow cautiously^{SPC/BNF}).

QUININE

Antimalarial: kills bloodborne schizonts.

Use: malaria Rx¹ (esp falciparum), nocturnal leg cramps².

Cl: optic neuritis, tinnitus, haemoglobinuria, MG.

Caution: cardiac disease (inc conduction dfx, AF, HB), G6PD deficiency, H/P/E.

SE: visual Δs (inc temporary blindness, esp in OD), tinnitus (and vertigo/deafness), **GI upset**, headache, rash/flushing, hypersensitivity, confusion, hypoglycaemia*. Rarely blood

hypersensitivity, confusion, hypoglycaemia⁺. Karely blood disorders, ARF, cardiovascular fx (can \Rightarrow severe \downarrow BP in OD).

Monitor: blood glucose*, ECG (if elderly) and e'lytes (if given iv).

Interactions: \uparrow s levels of flecainide and digoxin. \uparrow s risk of

arrhythmias with pimozide, moxifloxacin and amiodarone. [†]risk of seizures with mefloquine. Avoid artemether/lumefantrine.

Dose: 200–300 mg nocte po as quinine *sulphate*². For malaria Rx, see p. 174 (**NB:** \downarrow iv maintenance dose if **RF**).

RABEPRAZOLE/PARIET

PPI; as omeprazole, but \downarrow interactions^{BNF/SPC}. **Dose:** 20 mg od (\downarrow to 10 mg od for maintenance). Max 120 mg/day.

RAMIPRIL/TRITACE

ACE-i; see Captopril.

Use: HTN^1 (for advice on stepped HTN Mx see p. 178), HF^2 , Px post-MI³. Also Px of cardiovascular disease (if age >55 years and at risk)⁴.

Cl/Caution/SE/Monitor/Interactions: as captopril.

Dose: initially 1.25 mg od (\uparrow ing slowly to max of 10 mg daily)^{1,2}; initially 2.5 mg bd then \uparrow to 5.0 mg bd after 2 days³ (start 3–10 days post-MI) then maintenance 2.5–5 mg bd; initially 2.5 mg od (\uparrow ing to 10 mg)⁴. **NB:** \downarrow **dose if RF**.

RANITIDINE/ZANTAG

H antagonist $\Rightarrow \downarrow$ parietal cell H⁺ secretion.

Use: PU (Px if on long-term high dose NSAIDs¹, chronic Rx², acute Rx³), reflux oesophagitis.

Caution: acute porphyria, U/R/P/B. & May mask symptoms of gastric cancer &.

SE: all rare: GI upset (esp diarrhoea), dizziness, confusion, fatigue, blurred vision, headache, Δ LFTs (rarely hepatitis), rash. Very rarely arrhythmias (esp if given iv), hypersensitivity, blood disorders.

Interactions: \downarrow s fx of tolazoline

Dose: initially 150 mg bd po (or 300 mg nocte)^{1,2}, \uparrow ing to 600 mg/day if necessary but try to \downarrow to 150 mg nocte for maintenance; 50 mg tds/qds iv³ (or im/ivi^{SPC/BNF}). **NB:** \downarrow **dose if RF.**

REOPRO see Abciximab; antiplatelet agent for MI/ACS.

RETEPLASE (= r-PA).

Recombinant plasminogen activator: thrombolytic. **Use/CI/Caution/SE:** see Alteplase and p. 208 but only for Rx of AMI (i.e. not for CVA/other use).

Dose: 10 units as slow iv injection over $\leq 2 \min$, repeating after 30 min. Concurrent unfractionated iv heparin needed for 48 h; see p. 208.

RIFABUTIN

New rifamycin antibiotic; see Rifampicin.

COMMON/USEFUL DRUGS

Use: TB: Rx of pulmonary TB¹ and non-tuberculous mycobacterial disease². Also Px of *Mycobacterium avium*³ (if HIV with \downarrow CD4).

Cl/Caution/SE/Warn/Monitor/Interactions: as rifampicin, plus levels \uparrow by macrolides, triazoles, imidazoles and antivirals (\Rightarrow \uparrow risk of uveitis; \downarrow rifabutin dose) and \downarrow s carbamazepine levels. **Dose:** 150–450 mg od¹; 450–600 mg od²; 300 mg od³. **NB:** \downarrow **dose**

if LF or RF.

RIFAMPICIN

Rifamycin antibiotic: 'cidal' $\Rightarrow \downarrow$ RNA synthesis.

Use: TB Rx, N. *meningitides* (meningococcal)/*H. influenzae* (type b) meningitis Px. Rarely for *Legionella/Brucella/Staphylococcus* infections. **Cl:** jaundice.

Caution: acute porphyria, L/R/P/B.

SE: hepatotoxicity, GI upset (inc AAC), headache, fever, 'flu-like symptoms (esp if intermittent use), orange/red body secretions*, SOB, blood disorders, skin reactions, shock, ARF.

Warn: of symptoms/signs of liver disease; report jaundice/persistent N&V/malaise immediately. Warn about secretions.*

Monitor: LFTs, FBC (and U&Es if dose >600 mg/day).

Interactions: \uparrowP450 \therefore many; most importantly \downarrow s fx of OCP**, lamotrigine, phenytoin, sulphonylureas, rosiglitazone, tolbutamide, chlorpropamide, atovaquone, keto-/flu-/itra-/.posa-/vori-conazole, antivirals, telithromycin, nevirapine, ciclosporin, siro-/tacro-limus, imatinib, corticosteroids, haloperidol, aripiprazole, disopyramide, quinidine, mefloquine, bosentan, propafenone, eplerenone and Ca²⁺ antagonists. **W**-.

Dose: for TB Rx, see p. 171; for other indications see SPC/BNF. (NB: well absorbed po; give iv *only* if \downarrow swallow.) **NB:** \downarrow **dose if LF or RF**.

Other contraception** needed during Rx.

RIFATER Combination preparation of rifampicin, isoniazid and pyrazinamide for 1st 2 months of TB Rx ($\Rightarrow \downarrow$ bacterial load/infectiousness until sensitivities known); see p. 171.

136

RISEDRONATE

Bisphosphonate: \downarrow s osteoclastic bone resorption.

Use: osteoporosis (Px¹/Rx², esp if postmenopausal or steroid-induced), Paget's disease³.

CI: \downarrow Ca²⁺, **R** (if severe, otherwise caution), **P/B**.

Caution: delayed GI transit/emptying (esp oesophageal abnormalities). Correct Ca^{2+} and other bone/mineral metabolism Δ (e.g. vit D and PTH function) before Rx.

SE: GI upset, bone/joint/muscle pain, headache, rash, HTN. Rarely chest pain, oedema, ↓Wt, apnoea, bronchitis, sinusitis, glossitis, nocturia, infections (esp UTIs), amblyopia, iritis, dry eyes/corneal lesions, tinnitus and oesophageal stricture/ inflammation/ulcer*.

Warn: of symptoms of oesophageal irritation and if develop to stop tablets/seek medical attention. Must swallow tablets whole with full glass of water on an empty stomach \geq 30 min before, and stay upright until, breakfast*.

Interactions: Ca^{2+} -containing products (inc milk) and antacids ($\Rightarrow \downarrow absorption$) \therefore separate doses as much as possible from risedronate. Also avoid iron and mineral suplements.

Dose: $5 \mod \text{od}^{1,2}$ (or $1 \times 35 \mod \text{tablet/week}$ as Actonel once a week²); 30 mg daily for 2 months³.

VRISPERIDONE/RISPERDAL

'Atypical' antipsychotic: similar to olanzapine ($\Rightarrow \downarrow$ extrapyramidal fx cf 'typical' antipsychotics, esp tardive dyskinesia).

Use: psychosis/schizophrenia (acute and chronic)^{NICE}, mania & short term Rx (<6 wks) of persistent aggression in Alzheimer's. **CI:** phenylketonuria (only if Quicklet form used). **B**.

Caution/SE: similar to olanzapine but $\Rightarrow \downarrow$ sedation, Thypotension (esp initially: Tdose slowly* and consider retitrating if many doses missed), \downarrow hyperglycaemia and slightly Textrapyramidal fx. **Interactions:** levels may be \downarrow by carbamazepine and Tby ritonavir, fluoxetine and paroxetine. Trisk of CNS toxicity with sibutramine. Tmortality rate in elderly if taking furosemide. Trisk of arrhythmias

with drugs that \uparrow QTc and atomoxetine. \uparrow risk of \downarrow BP with general anaesthetics. \downarrow s fx of anticonvulsants.

Dose: 0.5-8 mg bd po - titrate up slowly*. Also available as liquid or quick dissolving 1, 2, 3, or 4mg tablets ('Quicklets') and as long-acting im 2-wkly injections ('Consta' ▼) for ↑compliance. NB: ↓dose if LF or RF.

RITUXIMAB/MABTHERA

Monoclonal Ab against B lymphocytes (CD20+).

Use: Various B cell non-Hodgkin's lymphoma¹ (many indications for Diffuse Large B cell Lymphoma and Follicular Lymphoma^{NICE}), RA² (in combination with methotrexate, in severe active cases with inadequate response to DMARDs, inc ≥ 1 TNF- α inhibitor^{NICE}), CLL^{NICE}.

Cl: active severe infections, B.

Caution: IHD, if already on other cardiotoxic/cytotoxic drugs, with active or chronic infections (e.g. hepatitis B), **H** (avoid if severe and giving for RA)/**P**.

SE: \bigotimes infusion hypersensitivity/cytokine release syndrome* (mainly during 1st infusion: fever, chills, arrhythmias, ARDS and allergic reactions) \bigotimes , tumour lysis syndrome, pancytopenia, \downarrow BP, \uparrow risk of PML, \uparrow infections.

Warn: withhold antihypertensive drugs 12 h prior to ivi.

Monitor: BP, neurological function (PML), FBC.

Dose: seek expert advice and product literature for dose/rate¹, 1 g ivi initially and repeat once after 2 wks^{2(see SPC/BNF)}.

Solution of the second second

RIVASTIGMINE/EXELON

Acetylcholinesterase inhibitor that acts centrally (crosses BBB): replenishes ACh, which is \downarrow d in certain dementias.

Use: Alzheimer's disease^{NICE}.

CI: L (if severe, otherwise caution), B.

Caution: conduction defects (esp SSS), PU susceptibility, Hx of COPD/asthma/seizures, bladder outflow obstruction, R/P.

SE: cholinergic fx (see p. 225), **GI upset** (esp nausea initially), headache, dizziness, behavioural/ Ψ reactions. Rarely GI haemorrhage, \downarrow HR, AV block, angina, seizures, rash. **Monitor:** weight

Dose: 1.5 mg bd po initially ($\hat{1}$ ing slowly to 3–6 mg bd: specialist review needed for clinical response and tolerance). Available as daily sc patch releasing 4.6 mg or 9.5 mg/24 h. Continue only if MMSE remains $10-20^{\text{NICE}}$.

NB: If > several days doses missed retitration of dose required.

RIZATRIPTAN/MAXALT

5HT_{1B/1D} agonist for acute migraine.

Use/Cl/Caution/SE/Interactions: see Sumatriptan.

Dose: 10 mg po (can repeat after ≥ 2 h if responded then recurs). Max 20 mg/24 h. NB: give 5 mg doses if RF or LF (and avoid if either severe).

ROPINIROLE/REQUIP¹ OR ADARTREL²

Dopamine agonist (non-ergot derived); use in early Parkinson's $\Rightarrow \downarrow$ motor complications (e.g. dyskinesias) but \downarrow motor performance cf L-dopa. Also adjunctive use in treatment resistant Parkinson's. **Use:** Parkinson's¹, moderate-severe restless legs syndrome (RLS)². **Cl:** P/B.

Caution: major psychotic disorders, severe cardiovascular disease L/R.

SE: GI upset, sleepiness (inc sudden onset sleep), \downarrow BP (inc postural, esp initially), Ψ disorders (esp psychosis and impulse control disorders, e.g. gambling and \uparrow sexuality), confusion, leg odema. **Warn:** sleepiness and \downarrow BP may impair skilled tasks (inc driving). Avoid abrupt withdrawal.

Dose: initially 250 µg tds¹ (or 250 µg note for RLS²) \uparrow ing if tolerated/required to max 8 mg tds¹ (or 4 mg note for RLS²). Available in MR preparation (\mathbf{V} R@quip XL) 2–24 mg od¹.

VROSUVASTATIN/CRESTOR

HMG-CoA reductase inhibitor; 'statin' to \$\$\$\$ cholesterol (and TG).

Use/Cl/Caution/SE: as simvastatin, but safe in porphyria, can \Rightarrow proteinuria (and rarely haematuria) and avoid if severe RF. **Interactions:** \uparrow risk of myositis with \clubsuit **fibrates** and **ciclosporin** \clubsuit , daptomycin, protease inhibitors and nicotinic acid. Levels \downarrow by antacids. Mild W+.

Dose: initially 5–10 mg od. If necessary \uparrow to 20 mg after \geq 4 wks (if not of Asian origin or risk factors for myopathy/rhabdomyolysis, can \uparrow to 40 mg after further 4 wks). **NB:** \downarrow **dose if RF, Asian origin or other** \uparrow **risk factor for myopathy**.

(r)tPA (Recombinant) tissue-type plasminogen activator; see Alteplase.

SALBUTAMOL

 β_2 Agonist, short-acting: dilates bronchial smooth muscle (and endometrium). Also inhibits mast-cell mediator release. **Use:** chronic¹ and acute² asthma. Rarely $\uparrow K^+$ (give nebs prn), premature labour (iv).

Caution: cardiovascular disease (esp arrhythmias*, susceptibility to \uparrow QTc, HTN), DM (can \Rightarrow DKA, esp if iv \therefore monitor GBGs), \uparrow T₄, P/B.

SE: neurological: fine tremor, headache, nervousness,

sleep/behavioural Δs (esp in children); CVS: **\uparrowHR**, palpitations/arrhythmias (esp if iv), \uparrow QTc*; *other*: \downarrow K⁺, muscle cramps. Rarely hypersensitivity, **paradoxical bronchospasm**.

Prolonged $Rx \Rightarrow$ small \uparrow risk of glaucoma.

Monitor: K^+ and glucose (esp if \uparrow or iv doses).

Interactions: iv salbutamol \Rightarrow \uparrow risk of $\downarrow \downarrow$ BP with methyldopa. **Dose:** 100–200 µg (aerosol) or 200–400 µg (powder) inh prn up to qds¹; 2.5–5 mg qds 4-hrly neb². If life-threatening (see p. 237), can \uparrow nebs up to every 15 min or give as ivi (initially 5 µg/min, then up to 20 µg/min according to response).

SALMETEROL/SEREVENT

Bronchodilator: long-acting β_2 agonist (LABA).

Use: 1st choice add-on for asthma Rx (on top of short-acting β_2 agonist and inh steroids; see BTS guidelines, p. 181). Not for acute Rx!

Caution/SE/Monitor: as salbutamol.

Dose: 50–100 µg bd inh.

SALOFALK see Mesalazine; 'new' aminosalicylate for UC (\downarrow SEs).

SANDOGAL Calcium supplement; available in '400' (400 mg calcium = 10 mmol Ca²⁺) or '1000' (1 g calcium = 25 mmol Ca²⁺) effervescent tablets.

SANDO-K

Effervescent oral KCl (12 mmol K⁺/tablet). **Use:** \downarrow K⁺. **Cl:** K⁺> 5.0 mmol/l, **R** (if severe, otherwise caution). **Caution:** GI ulcer/stricture, hiatus hernia, taking other drugs that \uparrow K⁺. **SE:** N&V, GI ulceration. **Dose:** according to serum K⁺: average 2–4 tablets/day if diet normal. Take with food. **NB:** \downarrow **dose in RF/elderly** (\uparrow if established \downarrow K⁺).

SENNA/SENOKOT

Stimulant laxative; takes 8–12 h to work.
Use: constipation.
CI: GI obstruction.
Caution: P (try bulk forming or osmotic laxative 1st).
SE: GI cramps. If chronic use atonic non-functioning colon, ↓K⁺.
Dose: 2 tablets nocte (can ↑ to 4 tablets nocte). Available as syrup.

SEPTRIN see Co-trimoxazole (sulfamethoxazole + trimethoprim).

SERC see Betahistine; histamine analogue for vestibular disorders.

SERETIDE Combination asthma inhaler with possible synergistic action: long-acting β_2 agonist (LABA) salmeterol 50 µg (Accuhaler) or 25 µg (Evohaler) + fluticasone (steroid) in varying quantities (50, 100, 125, 250 or 500 µg/puff).

SEROXAT see Paroxetine; SSRI antidepressant.

SERTRALINE/LUSTRAL

SSRI antidepressant; see Fluoxetine.

Use: depression (also PTSD in women and OCD). Relatively good safety record in pregnancy and breast-feeding.

Cl/Caution/SE/Warn/Interactions: as fluoxetine, but \downarrow incidence of agitation/insomnia, doesn't \uparrow carbamazepine/phenytoin levels, but does \uparrow pimozide levels.

Dose: initially 50 mg od, \uparrow ing in 50 mg increments over several weeks to max daily dose 200 mg (if >100 mg/day, must be divided into at least 2 doses). **NB:** \downarrow **dose if LF**.

SEVELAMER/RENAGEL

 PO_4^- binding agent; contains no Al/Ca²⁺ \therefore no risk of \uparrow ing Al/Ca²⁺ (which can occur with other drugs, esp if on dialysis). Also \downarrow s cholesterol.

Use: \uparrow PO₄ (if on dialysis).

CI: GI obstruction.

Caution: GI disorders, P/B.

SE: GI upset, \downarrow (or \uparrow) BP, headache.

Dose: initially 800-1600 mg tds po, then adjust to response^{SPC/BNF}.

SEVREDOL Morphine (sulphate) tablets (10, 20 or 50 mg). **Dose:** see Oramorph.

SIBUTRAMINE/REDUCTIL

Noradrenaline and serotonin re-uptake inhibitor.

Use: adjunct in obesity.

Cl: Psychiatric illness (esp Tourette's or Hx of eating disorder or drug abuse), Hx of IHD, \uparrow BP (uncontrolled), \uparrow HR, arrhythmias, peripheral arterial occlusive disease, \uparrow prostate, \uparrow T₄, phaeo, **H/P/B**.

Caution: sleep apnoea, epilepsy, Hx of depression or ocular HTN, glaucoma (open-angle or susceptibility to closed-angle), FHx of motor or vocal tics, risk of bleeding, L/R.

SE: N&C&D&V, dry mouth, taste Δ , \uparrow BP, \uparrow HR, arrhythmias, headache, seizures, agitation, sexual dysfunction, Ψ /menstrual disturbance, GI haemorrhage, headache, urinary retention, \downarrow Pt, cutaneous bleeding disorders.

Warn: don't stop suddenly (risk of 5HT withdrawal; see p. 226).

Monitor: BP and HR (initially 2 weekly for 1st 3 months, then monthly for 3 months then at least 3 monthly) and for signs of pulmonary HTN; stop if BP >145/90 mmHg *or* systolic or diastolic >10 mmHg above baseline *or* HR >10 bpm above baseline.

Interactions: risk of CNS toxicity with antidepressants and antipsychotics.

Dose: initially 10 mg od mane, \uparrow ing to 15 mg od if <2kg weight loss after 4 wks. See BNF/SPC for continuation criteria.

SILDENAFIL/VIAGRA OR REVATIO (▼)

Phosphodiesterase type-5 inhibitor: \uparrow s local fx of NO (\Rightarrow \uparrow smooth-muscle relaxation \therefore \uparrow blood flow into corpus cavernosum).

Use: erectile dysfunction¹, pulmonary artery hypertension² (and digital ulceration under specialist supervision).

Cl: recent CVA/MI/ACS, \downarrow BP (systolic <90 mmHg), hereditary degenerative retinal disorders, Hx of non-arteritic anterior ischaemic optic neuropathy and conditions where vasodilation/sexual activity inadvisable. **L/H** (if either severe).

Caution: cardiovascular disease, LV outflow obstruction, bleeding disorders (inc active PU), anatomical deformation of penis, predisposition to prolonged erection (e.g. multiple myeloma/ leukaemias/sickle cell disease), **R/P/B**.

SE: headache, flushing, GI upset, dizziness, visual disturbances, nasal congestion, hypersensitivity reactions. Rarely, serious cardiovascular events, priapism and painful red eyes.

Interactions: \bigotimes Nitrates (e.g. GTN/ISMN/ISDN) and nicorandil can $\downarrow \downarrow$ BP \therefore never give together \bigotimes . Antivirals (esp rito-/ataza-/

indi-navir) $\hat{1}$ its levels. $\hat{1}$ hypotensive fx of α -blockers; avoid concomitant use. Levels $\hat{1}$ by keto-/itra-conazole **Dose:** initially 50 mg approx 1 h before sexual activity¹, adjusting to response (1 dose per 24 h, max 100 mg per dose); 20 mg tds². **NB:** \downarrow **dose if RF or LF**.

▼SIMVASTATIN/ZOGOR

HMG-CoA reductase inhibitor ('statin'): $\Rightarrow \downarrow$ cholesterol $(\downarrow s \text{ synthesis}), \downarrow \text{LDL}$ ($\uparrow s \text{ uptake}), \text{ mildly } \downarrow s \text{ TG}.$ **Use:** 1 cholesterol, Px of atherosclerotic disease: IHD (inc 1° prevention), CVA, PVD. **Cl:** acute porphyria, **L** (inc active liver disease or Δ LFTs), **P** (contraception required during, and for 1 month after, Rx), B. **Caution:** \downarrow T₄, alcohol abuse, Hx of liver disease, **R** (if severe). **SE:** hepatitis and myositis* (both rare but important), headache. GI upset, rash. Rarely pancreatitis, hypersensitivity. **Monitor:** LFTs (and CK if symptoms develop*). **Interactions:** \uparrow risk of myositis ($\pm \uparrow$ levels) with \Re **fibrates** \Re , clari-/ery-/teli-thromycin, itra-/keto-/mi-/posa-conazole, ciclosporin, protease inhibitors, nicotinic acid, fusidic acid, colchicine, danazol, amiodarone, verapamil, diltiazem and grapefruit juice. Mild W+. **Dose:** 10–80 mg nocte (usually start at 10–20 mg^{SPC/BNF}) 1 ing at intervals ≥ 4 wks. \downarrow max dose if significant drug interactions^{SPC/BNF}. NB: ↓dose if RF or other ↑risk factor for myositis*. **W** Wyositis^{*} can rarely ⇒ **rhabdomyolysis**: \uparrow risk if \downarrow T₄, RF or taking drugs that *levels/risk* of myositis (see above) .

SINEMET see Co-careldopa; L-dopa for Parkinson's.

SLOW-K

Slow-release (non-effervescent) oral KCl (8 mmol K⁺/tablet). **Use:** \downarrow K⁺ *where liquid/effervescent tablets inappropriate*. **Cl/Caution/SE:** as Sando-K, plus caution if \downarrow swallow. **Dose:** according to serum K⁺: average 3–6 tablets/day. **NB:** \downarrow **dose if RF** (and caution if taking other drugs that \uparrow K⁺).

SODIUM BICARBONATE iv

Alkalinising agent.

Use: metabolic acidosis; e.g. if RF, DKA, cardiac arrest* (esp if due to $\uparrow K^+$ or TCAs; also controversial use if pH < 7.1), certain drug ODs (esp aspirin and TCAs) and rarely for life-threatening $\uparrow K^+$.

SE: paradoxical intracellular acidosis, $\downarrow s O_2$ delivery (O₂ saturation curve shift), $\downarrow K^+$, $\uparrow Na^+$, \uparrow serum osmolality.

Dose: *iv:* available in 1.26%, 4.2% and 8.4% solutions; in cardiac arrest* give 50 mmol (50 ml of 8.4% solution) repeating if necessary. NB: *specialist use only* – strongly consider getting senior help before giving.

 \Re Toxic if extravasation when given iv (\Rightarrow tissue necrosis) \Re .

SODIUM VALPROATE see Valproate; antiepileptic.

SOTALOL

 β -Blocker (non-selective); class II(+III) antiarrhythmic.

Use: Px of SVT (esp of paroxysmal AF), **Rx of VT** (if life-threatening/ symptomatic, esp non-sustained or spontaneous sustained dt IHD or cardiomyopathy).

Cl: as propranolol, plus \uparrow QT syndromes, torsades de pointes, **R** (if severe, otherwise caution).

Caution: as propranolol, plus electrolyte $\Delta s \implies \uparrow risk$ of arrhythmias, esp if $\downarrow \mathbf{K}^+/\downarrow Mg^{2+}$; \therefore beware if severe diarrhoea). **SE:** as propranolol, plus arrhythmias (can $\Rightarrow \uparrow \mathbf{QT} \pm \mathbf{torsades} \ \mathbf{de} \ \mathbf{pointes}^*$, esp in females).

Interactions: as propranolol (NB: \bigotimes Verapamil and diltiazem \Rightarrow risk of \downarrow HR and HB \bigotimes) plus disopyramides, quinidine, procainamide, amiodarone, moxifloxacin, mizolastine, dolasetron, ivabradine, TCAs and antipsychotics \Rightarrow **↑risk** arrhythmias*.

Dose: 40–160 mg bd po ([†]if life-threatening to max 640 mg/day); 20–120 mg iv over 10 min (repeat 6-hrly if necessary). **NB:** Jdose if **RF**.

Give under specialist supervision and with ECG monitoring.

▼SPIRIVA see Tiotropium; new inhaled muscarinic antagonist.

SPIRONOLACTONE

K⁺-sparing diuretic: aldosterone antagonist at distal tubule (also potentiates loop and thiazide diuretics).

Use: ascites (esp 2° to cirrhosis or malignancy), oedema, HF (adjunct to ACE-i and/or another diuretic), nephrotic syndrome, 1° aldosteronism.

CI: $\uparrow K^+$, $\downarrow Na^+$, Addison's, **P/B**.

Caution: porphyria, L/R/E.

SE: $\uparrow K^+$, gynaecomastia, GI upset (inc N&V), impotence, $\downarrow BP$, $\uparrow Na^+$, rash, confusion, headache, hepatotoxicity, blood disorders.

Monitor: U&E.

Interactions: \uparrow s digoxin and lithium levels. \uparrow s risk of RF with NSAIDs (which also antagonise its diuretic fx).

Dose: 100-400 mg/day po (25 mg od if for HF).

 \bigotimes Beware if on other drugs that $\uparrow K^+$, e.g. amiloride, triamterene, ACE-i, angiotensin II antagonists and ciclosporin. Do not give with oral K^+ supplements inc dietary salt substitutes \bigotimes .

STEMETIL see Prochlorperazine; DA antagonist antiemetic.

STREPTOKINASE

Thrombolytic agent: \uparrow s plasminogen conversion to plasmin \Rightarrow \uparrow fibrin breakdown.

Use: AMI, TE of arteries (inc PE, central retinal artery) or veins (DVT, central retinal vein).

Cl/Caution/SE: see p. 210.

Dose: AMI: 1.5 million units ivi over 60 min; **other indications:** 250 000 units ivi over 30 min, then 100 000 units ivi every hour for up to 12–72 h (see SPC).

146

STREPTOMYCIN

Aminoglycoside antibiotic.

Use: TB (if isoniazid resistance established before Rx); see p. 171.

CI/Caution/SE/Interactions: see Gentamicin.

VSTRONTIUM RANELATE/PROTELOS

↑s bone formation and ↓s bone resorption.
Use: postmenopausal osteoporosis^{NICE} (esp if bisphosphonates CI/not tolerated).
CI: phenylketonuria (contains aspartame), P/B.
Caution: ↑risk of VTE, ∆s urinary and plasma Ca²⁺ measurements.
R (avoid if severe).
SE: severe allergic reactions* GI upset.
Warn: to report any skin rash* and immediately stop drug.
Interactions: absorption ↓ by concomitant ingestion of Ca²⁺ (e.g. milk) and ↓s absorption of quinolones and tetracycline.
Dose: 2 g (1 sachet in water) po od^{SPC/BNF}. Avoid food/milk 2 h before and after taking.
Sensh* can be early DRESS syndrome: Drug Rash, Eosinophilia

****** Rash* can be early DRESS syndrome: Drug Rash, Eosinophilia and Systemic Symptoms (e.g. fever); lymphadenopathy and \uparrow WCC also seen early. Can \Rightarrow LF, RF or respiratory failure \pm death *****.

SULFASALAZINE

Aminosalicylate: combination of the immune modulator *5*-aminosalicylic acid (*5*-ASA) and the antibacterial sulfapyridine (a sulphonamide).

Use: rheumatoid arthritis¹. Also UC^2 (inc maintenance of remission) and active Crohn's disease², but not 1st-line, as newer drugs (e.g. mesalazine) have \downarrow sulphonamide SEs; still used if well-controlled with this drug and with no SEs or if joint manifestations.

Cl: sulphonamide or salicylate hypersensitivity, **R** (caution if mild). **Caution:** slow acetylators, Hx of any allergy, porphyria, G6PD deficiency, L/P(give only under specialist care)/B.

SE: GI upset (esp ↓appetite/Wt), hepatotoxicity, blood disorders, hypersensitivity (inc severe skin reactions), seizures, lupus.

Monitor: LFTs, U&Es, FBC.

Dose: 500 mg/day \uparrow ing to max 3 g/day¹; 1–2 g qds po for acute attacks², \downarrow ing to maintenance of 500 mg qds – can also give 0.5–1.0 g pr bd after motion (as supps) \pm po Rx.

SUMATRIPTAN/IMIGRAN

5HT_{1B/1D} agonist.

Use: migraine (acute). Also cluster headache (sc route only). **Cl:** IHD, coronary vasospasm (inc Prinzmetal's), PVD, HTN

(moderate, severe or uncontrolled). Hx of MI, CVA or TIA.

Caution: predisposition to IHD (e.g. cardiac disease), L/H/P/B/E.

SE: sensory Δ s (tingling, heat, pressure/tightness), dizziness, flushing, fatigue, N&V, seizures, visual Δ s and drowsiness.

Interactions: \uparrow risk of CNS toxicity with SSRIs, MAOIs, moclobemide and St John's wort. \uparrow risk of vasospasm with ergotamine and methysergide.

Dose: 50 mg po (can repeat after ≥ 2 h if responded then recurs and can \uparrow doses, **if** *no* **LF**, to 100 mg if required). Max 300 mg/24 h. Available sc or intranasally^{BNF/SPC}.

NB: frequent use may \Rightarrow medication overuse headache.

SYMBICORT Combination asthma inhaler: each puff contains $x \mu g$ budesonide (steroid) + $y \mu g$ formoterol (long-acting β_2 agonist) in the following '*x*/*y*' strengths; '100/6', '200/6' and '400/12'.

SYNACTHEN SYNthetic ACTH (adrenocorticotrophic hormone). **Use:** Dx of Addison's disease; in 'short' test will find \downarrow plasma cortisol 0, 30 and 60 min after 250 µg iv/im dose. **Cl:** allergic disorders (esp asthma). NB: can \Rightarrow anaphylaxis.

▼TACROLIMUS (= FK 506)

Immunosuppressant (calcineurin inhibitor): $\downarrow s$ IL-2-mediated LØ proliferation.

Use: Px of transplant rejection (esp renal). Also used topically in moderate-severe atopic eczema unresponsive to conventional therapy (specialist use).

148

Cl: macrolide hypersensitivity, immunodeficiency, **P** (exclude before starting), **B**.

Caution/SE: as ciclosporin, but $\Rightarrow \uparrow$ neuro-/nephro-toxicity (although $\Rightarrow \downarrow$ hypertrichosis/hirsutism); also **diabetogenic** and rarely \Rightarrow cardiomyopathy (monitor ECG for hypertrophic Δ s). **Interactions:** metab by **P450** \therefore many, but most importantly: \uparrow s levels of \bigotimes ciclosporin \bigotimes . Levels \uparrow by clari-/ery-/teli-thromycin, quinu-/dalfo-pristin, chloramphenicol, antifungals, ataza-/rito-/ nelfi-/saqui-navir, nifedipine, diltiazem and grapefruit juice. Levels \downarrow by rifampicin, phenobarbital, phenytoin and St John's wort. Nephrotoxicity \uparrow by NSAIDs, aminoglycosides and amphotericin. Avoid with other drugs that \uparrow K⁺.

Dose: specialist use^{SPC/BNF}. **NB:** may require \downarrow dose if LF. Interactions important: \uparrow levels \Rightarrow toxicity; \downarrow levels may \Rightarrow rejection. Available in 2 forms with different dosing; Prograf (bd) and \land dvagraf (MR od preparation) \therefore mustn't confuse &.

TADALAFIL/CIALIS

Phosphodiesterase type-5 inhibitor; see Sildenafil. **CI/Use/Caution/SE/Interactions:** as sildenafil plus CI in moderate HF and uncontrolled HTN/arrhythmias. **Dose:** initially 10 mg \geq 30 min before sexual activity, adjusting to response (1 dose per 24 h, max 20 mg per dose, unless RF or LF when max 10 mg).

TAMOXIFEN

Oestrogen receptor antagonist.

Use: oestrogen receptor-positive Ca breast¹ (as adjuvant $Rx: \Rightarrow \uparrow$ survival, delays metastasis), anovulatory infertility².

CI: P** (*exclude pregnancy before starting* R*x*).

Caution: \uparrow risk of TE* (if taking cytotoxics), porphyria, B. **SE:** hot flushes, GI upset, menstrual/endometrial Δs (\clubsuit inc Ca: if Δ vaginal bleeding/discharge or pelvic pain/pressure \Rightarrow urgent Ix \clubsuit). Also fluid retention, exac of bony metastases pain. Many other gynaecological/blood/skin/metabolic Δs (esp lipids, LFTs). **Warn:** of symptoms of endometrial cancer and TE* (and to report calf pain/sudden SOB). If appropriate, advise non-hormonal contraception**.

Interactions: W+.

Dose: 20 mg od po¹; for anovulatory infertility² see SPC/BNF.

TAMSULOSIN/FLOMAXTRA XL*

 α -Blocker \Rightarrow internal urethral sphincter relaxation ($\therefore \Rightarrow \uparrow$ bladder outflow) and systemic vasodilation.

Use: BPH.

Cl/Caution/SE/Interactions: as doxazosin plus **L** (if severe). **Dose:** 400 μg mane (after food). Available in MR preparation*.

TAZOCIN Combination of piperacillin (antipseudomonal penicillin) + tazobactam (β -lactamase inhibitor).

Use: severe infections/sepsis (mostly in ITU setting or if resistant to other antibiotics).

Cl/Caution/SE/Interactions: as benzylpenicillin. **Dose:** 2.25–4.5 g tds/qds iv. **NB:** \downarrow to bd/tds if RF.

TEGRETOL see Carbamazepine; antiepileptic.

TEICOPLANIN

Glycopeptide antibiotic; 'cidal' against aerobes and anaerobes. **Use:** serious Gram-positive infections (mostly reserved for MRSA). **Caution:** vancomycin sensitivity, R/P/B/E.

SE: GI upset, hypersensitivity/skin reactions, blood disorders, nephrotoxicity, ototoxicity (but less than vancomycin), Δ LFTs, local reactions at injection site.

Monitor: U&Es, LFTs, FBC, auditory function (esp if chronic Rx or on other oto-/nephro-toxic drugs, e.g. gentamicin, amphotericin B, ciclosporin, cisplatin and furosemide).

Dose: single loading dose of 400 mg im/iv, then \downarrow to 200 mg od 24 h later (if severe infection continue at 400 mg 12-hrly for 2 more doses before changing to 200 mg od; if life-threatening continue at

400 mg od). NB: ↑dose if weight >85 kg, severe burns or endocarditis and ↓dose if RF; see SPC/BNF.

TELMISARTAN/MICARDIS

Angiotensin II antagonist; see Losartan. **Use:** HTN; for advice on stepped HTN Mx see p. 178. **CI:** biliary obstruction, **L** (if severe, otherwise caution), **P/B. Caution/SE/Interactions:** as Losartan, plus \uparrow s digoxin levels. **Dose:** 20–80 mg od (usually 40 mg od). **NB:** \downarrow **dose if LF or RF.**

TEMAZEPAM

Benzodiazepine, short-acting. Use: insomnia. Cl/Caution/SE/Interactions: see Diazepam. Dose: 10 mg nocte (can ↑dose if tolerant to benzodiazepines, but

beware respiratory depression). *Dependency common:* max 4-wk Rx. **NB:** dose if LF, severe RF or elderly.

TENECTEPLASE (= TNK-tPA)/METALYSE

Recombinant thrombolytic; advantageous as given as single bolus. **Use:** Acute myocardial infarction.

Cl/Caution/SE: see p. 207, plus B.

Dose: iv bolus over 10 sec according to weight: \geq 90 kg, 50 mg; 80–89 kg, 45 mg; 70–79 kg, 40 mg; 60–69 kg, 35 mg; <60 kg, 30 mg. Concurrent unfractionated iv heparin needed for 24–48 h; see p. 207.

TERAZOSIN/HYTRIN

 α -Blocker \Rightarrow internal urethral sphincter relaxation ($\therefore \Rightarrow \uparrow$ bladder outflow) and systemic vasodilation.

Use: BPH^1 (and rarely HTN^2).

Caution: Hx of micturition syncope or postural \downarrow BP, **P/B/E**. **SE/Interactions:** see Doxazosin. '1st-dose collapse' common. **Dose:** initially 1 mg nocte, \uparrow ing as necessary to max 10 mg/day¹ (or 20 mg/day²).

TERBINAFINE/LAMISIL

Antifungal: oral^{1,2} or topical cream³.

Use: ringworm¹ (*Tinea* spp), dermatophyte nail infections², fungal skin infections³. NB: ineffective in yeast infections.

Caution: psoriasis (may worsen), autoimmune disease (risk of lupus-like syndrome), L/R (neither apply if giving topically), P/B.

SE: headache, GI upset, mild rash, joint/muscle pains. Rarely neuro- Ψ disturbances, blood disorders, hepatic dysfunction, serious skin reactions (stop drug if progressive rash).

Dose: 250 mg od po for 2–6 wks¹ or 6 wks–3 months²; 1–2 topical applications/day for 1–2 wks³.

TERBUTALINE/BRIGANYL

Inhaled β_2 agonist similar to salbutamol.

Dose: 250–500 µg od–qds inh (powder or aerosol); 5–10 mg up to qds neb. Can also give po/sc/im/iv^{SPC/BNF}.

TETRACYCLINE

Tetracycline broad-spectrum antibiotic: inhibits ribosomal (30S subunit) protein synthesis.

Use: acne vulgaris¹ (or rosacea), genital/tropical infections (NB: doxycycline often preferred).

Cl: age <12 years (**stains/deforms teeth**), acute porphyria, **R/P/B**.

Caution: may worsen MG or SLE, L.

SE: GI upset (rarely AAC), oesophageal irritation, headache, dysphagia. Rarely hepatotoxicity, blood disorders, photosensitivity, hypersensitivity, visual Δ s (rarely 2° to BIH; stop drug if suspected).

Interactions: \downarrow absorption with milk (do not drink 1 h before or 2 h after drug), antacids and Fe/Al/Ca/Mg/Zn salts. \downarrow s fx of OCP (small risk). \uparrow risk of BIH with retinoids. Mild **W+**.

Dose: 500 mg bd po¹, otherwise 250–500 mg tds/qds po. **NB: max 1 g/24 h in LF**.

NB: take >30 min before food.

THEOPHYLLINE

Methylxanthine bronchodilator. *Theories of action:* (1) \uparrow s intracellular cAMP; (2) adenosine antagonist; (3) \downarrow s diaphragm fatigue. NB: additive fx with β_2 agonists (but with \uparrow risk of SEs, esp $\downarrow K^+$).

Use: severe asthma/COPD: acute (iv as aminophylline; see p. 237) or chronic (po; see p. 181 for BTS asthma guidelines).

Cl: hypersensitivity to any 'xanthine' (e.g.

aminophylline/theophylline), acute porphyria.

Caution: cardiac disease (risk of arrhythmias^{*}), epilepsy, $\uparrow T_4$, PU, HTN, fever, porphyria, acute febrile illness, glaucoma, DM, L/P/B/E. **SE:** (tachy)**arrhythmias**^{*}, seizures (esp if given rapidly iv), **GI upset** (esp **nausea**), CNS stimulation (restlessness, insomnia), headache, $\downarrow K^+$.

Monitor: K^+ , serum levels (4–6 h post dose) as narrow therapeutic window (10–20 mg/l = 55–110 μ mol/l) but toxic fx can occur even in this range.

Interactions: metab by **P450** (\Rightarrow very variable $t_{1/2}$): **levels** \uparrow **d** in HF/LF*/viral infections/elderly, and if taking **fluvoxamine**/cimetidine/ciprofloxacin/norfloxacin/macrolides (ery-/clari-thromycin)/propranolol/'flu vaccines/fluconazole/ketoconazole/OCP/Ca²⁺ channel blockers. **Levels** \downarrow **d** in smokers/chronic alcohol abuse, and if taking phenytoin/carbamazepine/phenobarbital/rifampicin/ritonavir/St John's wort. \uparrow risk of convulsions with quinolones. **Dose:** MR preparations preferred (\downarrow SEs) and doses vary with brand^{SPC/BNF}; range 200 mg-500 mg bd. *Available iv as aminophylline*. **NB:** \downarrow **dose if LF***.

THIAMINE (= vitamin B1).

Use: replacement for nutritional deficiencies (esp in alcoholism). **Dose:** 100 mg bd/tds po in severe deficiency (25 mg od if mild/chronic). For iv preparations, see Pabrinex and p. 190 for Mx of acute alcohol withdrawal.

THYROXINE (= LEVOTHYROXINE).

Synthetic T₄ (NB: thyroxine often now called 'levothyroxine').

Use: \downarrow T₄ Rx (for maintenence); **NB:** acutely, liothyronine (T₃) often needed – see p. 247.

CI: ↑T₄.

Caution: panhypopituitarism/other predisposition to adrenal insufficiency (*corticosteroids needed 1st*), chronic $\downarrow T_4$, cardiovascular disorders (esp HTN/IHD; can worsen)*, DI, DM**, P/B/E.

SE: features of $\uparrow T_4$ (should be minimal unless xs Rx): D&V, tremors, restlessness, headache, flushing, sweating, heat intolerance, angina, arrhythmias, palpitations, $\uparrow HR$, muscle cramps/weakness, $\downarrow Wt$. Also osteoporosis (esp if xs dose given; use min dose necessary).

Interactions: can Δ digoxin and antidiabetic** requirements, \uparrow fx of TCAs and \downarrow levels of propranolol. **W+**.

Monitor: baseline ECG to help distinguish Δs due to ischaemia or $\downarrow T_4$.

Dose: 25–200 µg mane (titrate up slowly, esp if > 50yrs old/ $\downarrow \downarrow T_4$ / HTN/IHD*).

TIMOLOL EYE DROPS/TIMOPTOL

β-Blocker eye drops; \downarrow aqueous humour production. **Use:** glaucoma (2nd line), ocular HTN (1st line); not useful if on

systemic β-blocker.

Cl: asthma, \downarrow HR, HB, **H** (if uncontrolled).

Caution/SE/Interactions: as propranolol* plus can \Rightarrow local irritation.

Dose: 1 drop bd (0.25% or 0.5%). Also available in long-acting od preparations TIMOPTOL LA (0.25 and 0.5%) and NYOGEL (0.1%). Timolol 0.5% also available in combination with other classes of glaucoma medications; carbonic anhydrase inhibitors (dorzolamide Cosopt, brinzolamide Azarga), PG analogues (latanoprost Xalacom, travoprost Ductrav, bimatoprost Ganfort) α -agonists (brimonidine Comblgan).

Systemic absorption possible despite topical application* &.

TINZAPARIN/INNOHEP

Low-molecular-weight heparin (LMWH).

Use: DVT/PE Rx¹ and Px² (inc pre-operative). Not licensed for MI/unstable angina (unlike other LMWHs).

CI/Caution/SE/Monitor/Interactions: as heparin, plus CI if breastfeeding (**B**) and caution in asthma (\Rightarrow \uparrow hypersensitivity reactions).

Dose: (all sc) 175 units/kg od¹; 50 units/kg or 4500 units od² (3500 units od if low risk).

Consider monitoring anti-Xa (3–4 h post dose) \pm dose adjustment if RF (i.e. creatinine >150), severe LF, pregnancy, Wt >100 kg or <45 kg; see p. 205.

TIOTROPIUM/SPIRIVA

Long-acting inh muscarinic antagonist for COPD/asthma; similar to ipratropium, but only for chronic use and caution in RF.

SE: dry mouth, urinary retention, glaucoma.

Dose: 18 µg dry powder inhaler or 5 µg by soft mist inhaler od inh.

TIROFIBAN/AGGRASTAT

Antiplatelet agent: glycoprotein IIb/IIIa receptor inhibitor – stops binding of fibrinogen and inhibits platelet aggregation.

Use: Px of MI in unstable angina/NSTEMI (*if last episode of chest pain w/in 12 h*), esp if high risk and awaiting PCI^{NICE} (see p. 230). **CI:** abnormal bleeding or CVA w/in 30 days, haemorrhagic diathesis, Hx of haemorrhagic CVA, intracranial disease (neoplasm/aneurysm/ AVM), severe HTN, \downarrow Pt, \uparrow INR/PT, **B**.

Caution: \uparrow risk of bleeding (e.g. drugs, recent bleeding/trauma/ procedures; see^{SPC/BNF}), L (avoid if severe), H (if severe), R/P. **SE: bleeding**, nausea, fever, \downarrow Pt (reversible).

Monitor: FBC (baseline, 2–6 h after giving, then at least daily). **Dose:** 400 *nanograms*/kg/min for 30 min, then 100 *nanograms*/kg/min for \geq 48 h (continue for 12–24 h post-PCI), for max of 108 h. Needs concurrent heparin. **NB:** \downarrow **dose if RF**.

Specialist use only: get senior advice or contact on-call cardiology.

TOLBUTAMIDE

Oral antidiabetic (short-acting sulphonylurea).

Use/Cl/Caution/SE/Interactions: as glibenclamide, but shorter action and hepatic metabolism* means \downarrow risk of hypoglycaemia, esp in elderly/RF* (\downarrow reliance on renal excretion). Can also \Rightarrow headache and tinnitus. fx \uparrow by azapropazone.

Dose: 0.5-2.0 g daily in divided doses, with food. **NB:** \downarrow **dose if RF** or **LF**.

TOLTERODINE/DETRUSITOL

Antimuscarinic, antispasmodic.

Use: detrusor instability; urinary incontinence/frequency/urgency. **Cl/Caution/SE:** as oxybutynin (SEs mostly antimuscarinic fx; see p. 225) plus caution if Hx of, or taking drugs that, \uparrow QTc, **P/B**. **Interactions:** \uparrow risk of ventricular arrhythmias with amiodarone, disopyramide, flecainide and sotalol.

Dose: 1–2 mg bd po. **NB:** Jdose if **RF** or **LF**. (MR preparation available as 4 mg od po; not suitable if **RF** or **LF**.)

tPA (= tissue-type plasminogen activator) see Alteplase.

TRAMADOL

Opioid. Also ↓s pain by ↑ing 5HT/noradrenergic transmission. **Use:** moderate/severe pain (esp musculoskeletal).

Cl/Caution: as codeine, but also CI in uncontrolled epilepsy, acute porphyria, **P/B**. Not suitable as substitute in opioid-dependent patients. **SE:** as morphine, but \downarrow respiratory depression, \downarrow constipation, \downarrow addiction. \uparrow confusion (esp in elderly) compared to codeine. **Interactions:** as codeine; also \uparrow risk convulsions with SSRIs/TCAs/antipsychotics, \uparrow risk serotonin syndrome with SSRIs, carbamazepine. Ondansetron \downarrow s its fx. **W+**.

Dose: 50-100 mg up to 4-hrly po/im/iv to max 400 mg/day. Post-op: initially 100 mg im/iv, then 50 mg every 10–20 min to max total dose of 250 mg in 1st hr, then 50–100 mg 4–6 hourly (max 600 mg/day). **NB:** \downarrow dose if **RF, LF or elderly**.

TRANDOLAPRIL/GOPTEN

ACE-i for HTN (for advice on stepped HTN Mx see p. 178), HF and LVF post-MI.

Cl/Caution/SE/Monitor/Interactions: see Captopril.

Dose: initially 0.5 mg od, \uparrow ing at intervals of 2–4 wks if required to max 4 mg od (max 2 mg if RF). \downarrow doses if given with diuretic. If for LVF post-MI, start \geq 3 days after MI.

TRANEXAMIC ACID

Antifibrinolytic: inhibits activation of plasminogen to plasmin. **Use:** bleeding: acute bleeds¹ (esp 2° to anticoagulants, thrombolytic/ anti-Pt agents, epistaxis, haemophilia), menorrhagia², hereditary angioedema³.

CI: TE disease, **R** (if severe, otherwise caution). **Caution:** haematuria (can clot and obstruct ureters), DIC, **P**. **SE:** GI upset, colour vision Δs (stop drug), TE. **Dose:** 15–25 mg/kg bd/tds po (if severe, 0.5–1 g tds iv)¹; 1 g tds po for 4 days (max 4 g/day)²; 1–1.5 g bd/tds po³. **NB:** \downarrow dose if RF.

TRAVOPROST EYE DROPS/TRAVATAN

Topical PG analogue for glaucoma; see Latanoprost. Use/Cl/Caution/SE: see Latanoprost. Dose: 1 drop od.

TRIAMTERENE

K⁺-sparing diuretic (weak); see Amiloride.

Use/Cl/Caution/SE: as amiloride, but \Rightarrow less \downarrow BP \therefore not used for HTN (unless used with other drugs), plus L (avoid if severe). **Warn:** urine may go blue.

Interactions: \uparrow s lithium, phenobarbital and amantadine levels. NSAIDs \uparrow risk of RF and \uparrow K⁺.

Dose: almost exclusively used with stronger K⁺-wasting diuretics in combination preparations (e.g. co-triamterzide).

For use alone, initially give 150-250 mg daily, \downarrow ing to alternate days after 1 wk.

Sequence if on other drugs that $\uparrow K^+$, e.g. amiloride, spironolactone, ACE-i, angiotensin II antagonists and ciclosporin. Do not give with oral K⁺ tablets or dietary salt substitutes \searrow .

TRI-IODOTHYRONINE

See Liothyronine; synthetic T₃ mostly used in myxoedema coma.

TRIMETHOPRIM

Antifolate antibiotic ('static'): inhibits dihydrofolate reductase. **Use:** UTIs (rarely other infections).

CI: blood disorders (esp megaloblastic \downarrow Hb).

Caution: ↓folate (or predisposition to), porphyria, **R/P/B/E**. **SE:** see Co-trimoxazole (Septralm), but much less frequent and severe (esp BM suppression, skin reactions). Also **GI upset**, rash, rarely other hypersensitivity.

Warn: those on long-term Rx to look for signs of blood disorder and to report fever, sore throat, rash, mouth ulcers, bruising or bleeding. **Interactions:** \uparrow s phenytoin levels. \uparrow s risk of arrhythmias with amiodarone, antifolate fx with pyrimethamine and toxicity with ciclosporin, azathioprine, mercaptopurine and methotrexate. **W+**. **Dose:** 200 mg bd po (100 mg nocte for chronic infections or as Px if at risk; NB: risk of \downarrow folate if long-term Rx). **NB:** \downarrow **dose if RF.**

TROPICAMIDE EYE DROPS

Antimuscarinic: mydriatic (lasts approx 4 hrs), weak cycloplegic. **Use:** dilated retinal examination. See also "Dilating eye drops".

Cl: untreated acute angle closure glaucoma.

Caution: ¹IOP* (inc predisposition to), inflamed eye ([†]risk of systemic absorption).

SE: transient blurred vision & ↓accommodation. Rarely precipitation of acute angle closure glaucoma (↑risk if >60 yrs, long sighted, family history).

Warn: unable to drive until can read car number plate at 20 metres (approx 4 hrs).

Dose: 1 drop 1.0% solution 15–20 min before examination. 0.5% in children <1 yr old. NB: Rare cause of acute angle closure glaucoma* (esp if >60 yrs or hypermetropic).

TURBOHALER Inh delivery device for asthma drugs.

(SODIUM) VALPROATE

Antiepileptic and mood stabiliser: potentiates and ↑s levels of inhibitory neuropeptide GABA.

Use: epilepsy¹, mania (and off-licence for other Ψ disorders).

Cl: acute porphyria, personal or family Hx of severe liver dysfunction, **L** (inc active liver disease).

Caution: SLE, \uparrow bleeding risk*, R, P (\Rightarrow neural-tube/craniofacial dfx, Px folate), B.

SE: sedation, cerebellar fx (see p. 227; esp tremor, ataxia), headache, GI upset, \uparrow Wt, SOA, alopecia, skin reactions, \downarrow cognitive/motor function, Ψ disorders, encephalopathy (2° to \uparrow NH). Rarely but seriously hepatotoxicity, blood disorders (esp \downarrow Pt*), pancreatitis (mostly in 1st 6 months of Rx).

Warn: of clinical features of pancreatitis and liver/blood disorders. Inform women of childbearing age of teratogenicity/need for contraception.

Monitor: LFTs, FBC \pm serum levels *pre-dose* (therapeutic range 50–100 mg/l; useful for checking compliance but \downarrow use for efficacy). **Interactions:** fx \downarrow d by antimalarials (esp mefloquine),

antidepressants (inc St John's wort), antipsychotics and some antiepileptics^{SPC/BNF}. Levels \downarrow by cimetidine. \uparrow s fx of aspirin and primidone. \uparrow risk of \downarrow NØ with olanzapine. Mild **W**+.

Dose: initially 300 mg bd, \uparrow ing to max of 2.5 g/day¹. NB: \downarrow dose if RF.

Can give false-positive urine dipstick for ketones.

VALSARTAN/DIOVAN

Angiotensin II antagonist; see Losartan.

Use: HTN^1 (for advice on stepped HTN Mx see p. 178), MI with LV failure/dysfunction².

CI: biliary obstruction, cirrhosis, **L** (if severe)/**P**/**B**.

Caution/SE/Interactions: see Losartan (inc warning r/e drugs that $\uparrow K^+$).

Dose: initially 80 mg od¹ (**NB:** give 40 mg if >75 yrs old, LF, RF or \downarrow intravascular volume) or 20 mg bd², \uparrow ing if necessary to max 320 mg od¹/160 mg bd².

VANCOMYCIN

Glycopeptide antibiotic. Poor po absorption (unless bowel inflammation*), but still effective against *C. difficile*** as acts 'topically' in GI tract.

Use: serious Gram-positive infections¹ (inc endocarditis Px and systemic MRSA), AAC² (give po)**.

Caution: Hx of deafness, IBD* (only if given po), R/P/B/E.

SE: nephrotoxicity, ototoxicity (stop if tinnitus develops),

blood disorders, rash, hypersensitivity (inc anaphylaxis, severe skin reactions), nausea, fever, phlebitis/irritation at injection site.

Monitor: serum levels: keep predose trough levels 10–15 mg/l; start monitoring after 3rd dose (1st dose if RF). Also monitor U&Es, FBC, urinalysis (and auditory function if elderly/RF).

Interactions: \uparrow nephrotoxicity with ciclosporin. \uparrow ototoxicity with loop diuretics. \uparrow s fx of suxamethonium.

Dose: 1–1.5 g bd ivi over 100 min^1 ; 125 mg qds po². NB: \downarrow dose if RF or elderly.

NB: if ivi given too quickly \Rightarrow \uparrow risk of anaphylactoid reactions (e.g. \downarrow BP, respiratory symptoms, skin reactions).

VARDENAFIL/LEVITRA

Phosphodiesterase type-5 inhibitor; see Sildenafil. **Use/CI/Caution/SE/Interactions:** as sildenafil plus CI in hereditary degenerative retinal disorders, caution if susceptible to (or taking drugs that) \uparrow QTc, and levels \uparrow by grapefruit juice. **Dose:** initially 10 mg approx 25–60 min before sexual activity, adjusting to response (1 dose per 24 h, max 20 mg per dose). **NB: halve dose if LF, RF, elderly or taking \alpha-blocker.**

VENLAFAXINE/EFEXOR

Serotonin and Noradrenaline Reuptake Inhibitor (SNRI): antidepressant with ↓sedative/antimuscarinic fx cf TCAs. ↑danger in OD/heart disease than other antidepressants; see p. 192. Use: depression¹, generalised anxiety disorder. Cl: very high risk of serious cardiac ventricular arrhythmia (e.g. significant LV dysfunction, NYHA class III/IV), uncontrolled HTN, P.

160

Caution: Hx of mania, seizures or glaucoma, L/R (avoid if either severe) H/B.

SE: GI upset, **\uparrowBP** (dose-related; monitor BP if dose >200 mg/day), withdrawal fx (see p. 226; common even if dose only a few hours late), rash (consider stopping drug, as can be 1st sign of severe reaction*), insomnia/agitation, dry mouth, sexual dysfunction, \uparrow weight, drowsiness, dizziness, SIADH and \uparrow QTc.

Warn: report rashes* and can ↓driving/skilled task ability. Don't stop suddenly.

Monitor: BP if heart disease \pm ECG.

Interactions: \bigotimes *Never give with*, or <2 *wks after*, *MAOIs* \bigotimes . \uparrow s risk of bleeding with aspirin/NSAIDs and CNS toxicity with selegiline/sibutramine. Avoid artemether/lumefantrine. \uparrow s levels of clozapine. Mild **W**+.

Dose: 37.5–187.5 mg bd po¹; start low and ↑dose if required. Efexor XL MR od preparation available (max 225 mg od). NB: halve dose if moderate LF (PT 14–18 s) or RF (GFR 10–30 ml/min).

VENTOLIN see Salbutamol; β-agonist bronchodilator.

VERAPAMIL

 Ca^{2+} channel blocker (rate-limiting type): fx on heart ($\Rightarrow \downarrow HR$, \downarrow contractility*) > vasculature (dilates peripheral/coronary arteries); i.e. reverse of the dihydropyridine type (e.g. nifedipine). Only Ca^{2+} channel blocker with useful antiarrhythmic properties (class IV).

Use: HTN¹ *(for advice on stepped HTN Mx see p. 178),* angina², arrhythmias (SVTs, esp instead of adenosine if asthma)³.

CI: \downarrow BP, \downarrow HR (<50 bpm), 2nd-/3rd-degree HB, \downarrow LV function, SAN block, SSS, AF or atrial flutter 2° to WPW, acute porphyria. **H*** (inc Hx of).

Caution: AMI, 1st degree HB, L/P/B.

SE: constipation (rarely other GI upset), **HF**, \downarrow **BP** (dosedependent), HB, headache, dizziness, fatigue, ankle oedema, hypersensitivity, skin reactions. **Interactions:** \uparrow risk of AV block and HF with \Re **β-blockers** \Re disopyramide, flecainide and amiodarone. 1s hypotensive fx of antihypertensives (esp α -blockers) and anaesthetics. \uparrow s levels/fx of digoxin, theophyllines, carbamazepine, quinidine, ivabradine and ciclosporin. Levels/fx ↓by rifampicin, barbiturates and primidone. ↑risk of myopathy with simvastatin. Sirolimus ↑s levels of both drugs. Levels may be 1by clari-/ery-thromycin and ritonavir. Risk of VF with $\frac{1}{2}$ iv dantrolene $\frac{1}{2}$.

Warn: fx \uparrow d by grapefruit juice (avoid).

Dose: $80-160 \text{ mg tds po}^1$; $80-120 \text{ mg tds po}^2$; $40-120 \text{ mg tds po}^3$; 5–10 mg iv (over 2 min (3 min in elderly) with ECG monitoring). followed by additional 5 mg iv if necessary after 5-10 min³. MR (od/bd) preparations available^{BNF}. **NB:** \downarrow oral dose in LF.

VIAGRA see Sildenafil; phosphodiesterase inhibitor.

VITAMIN K see Phytomenadione.

VOLTAROL see Diclofenac; moderate-strength NSAID.

WARFARIN

Oral anticoagulant: blocks synthesis of vitamin-K-dependent factors (II, VII, IX, X) and proteins C and S. Use: Rx/Px of TE; see p. 200.

Cl: severe HTN, PU, bacterial endocarditis, P.

Caution: recent surgery, L/R (avoid if creatinine clearance <10 ml/min)/B.

SE: haemorrhage, rash, fever, diarrhoea. Rarely other GI upset, 'purple-toe syndrome', skin necrosis, hepatotoxicity, hypersensitivity. **Warn:** fx are \uparrow d by alcohol and cranberry juice (avoid). Dose: see p. 200.

₩ NB: W+ and W− denote significant interactions throughout this book: take particular care with antibiotics and drugs that affect cytochrome **P450** (see p. 228) &.

XALATAN see Latanoprost; topical PG analogue for glaucoma.

ZALEPLON

'Non-benzodiazepine' hypnotic; see Zopiclone. Use/Cl/Caution/SE/Interactions: see Zopiclone. Dose: 10 mg nocte (5 mg if elderly). NB: halve dose if LF (avoid if severe), severe RF or elderly.

ZANTAC see Ranitidine; H antagonist.

ZESTRIL see Lisinopril; ACE-i.

ZIDOVUDINE (AZT)

Antiviral (nucleoside analogue): reverse-transcriptase inhibitor. **Use:** HIV Rx (and Px, esp of vertical transmission). **CI:** severe $\downarrow NØ$ or $\downarrow Hb$ (caution if other blood disorders), acute porphyria, **B**. **Caution:** $\downarrow B12$, \uparrow risk of lactic acidosis, L/R/P/E. **SE:** blood disorders (esp $\downarrow Hb$ or $\downarrow WCC$), **GI upset, headache**, **fever**, taste Δ s, sleep disorders. Rarely hepatic/pancreatic dysfunction, myopathy, seizures, other neurological/ Ψ disorders. **Interactions:** levels \uparrow by fluconazole. fx \downarrow by ritonavir. \uparrow myelosuppression with ganciclovir. \uparrow risk of $\downarrow Hb$ with ribavirin. \downarrow s fx of stavudine and tipranavir. **Dose:** see SPC/BNF.

ZIRTEK see Cetirizine; non-sedating antihistamine for allergies.

▼ZOLEDRONIC ACID/ZOMETA

Bisphosphonate: \downarrow s osteoclastic bone resorption. **Use:** Px of bone damage¹ in advanced bone malignancy, damage or Rx of \uparrow Ca²⁺ in malignancy², Rx of Paget's disease of bone³, Rx of osteoporosis (postmenopausal or in men)⁴. **CI:** P/B.

Caution: cardiac disease, dehydration*, \downarrow Ca²⁺/PO₄²⁻/Mg²⁺. L(if severe)/R/H.

SE: 'flu-like syndrome, fever, bone pain, fatigue, N&V. Also arthr-/my-algia, $\downarrow Ca^{2+}/PO_4^{2-}/Mg^{2+}$, pruritus/rash, headache, conjunctivitis, RF, hypersensitivity, blood disorders (esp \downarrow Hb) and **osteonecrosis** (esp of jaw; consider dental examination or preventive Rx before starting drug).

Monitor: Ca^{2+} , PO_4^{2-} , Mg^{2+} , U&E. Ensure patient adequately hydrated predose* and advise good dental hygiene.

Dose: 4 mg ivi every 3–4 weeks¹; 4 mg ivi as single dose². Also available as once yearly preparation ($\bigvee Aclasta$) 5 mg ivi over $\geq 15 \min^{3,4}$. NB: \downarrow dose in RF.

ZOLMITRIPTAN/ZOMIG

 $5HT_{1B/1D}$ agonist for acute migraine.

Use/CI/Caution/SE/Interactions: as sumatriptan plus CI in WPW or arrhythmias assoc with accessory cardiac conduction p'way. **Dose:** 2.5 mg po (can repeat after ≥ 2 h if responded then recurs and can \uparrow doses to 5 mg if required). Max 10 mg/24 h (5 mg/24 h if moderate-severe LF). Available intranasally^{BNF/SPC}.

ZOLPIDEM

'Non-benzodiazepine' hypnotic; see Zopiclone.

Use/Cl/Caution/SE/Interactions: as Zopiclone but CI in psychotic illness, **P**.

Dose: 10 mg nocte. NB: halve dose if LF (avoid if severe), severe RF or elderly.

ZOMORPH Morphine sulphate capsules (10, 30, 60, 100 or 200 mg), equivalent in efficacy to Oramorph but SR: 12 hrly doses. See also Palliative Care section p. 184.

ZOPICLONE

Short-acting hypnotic (cyclopyrrolone): potentiates GABA pathways via same receptors as benzodiazepines (although isn't a benzodiazepine!): can also \Rightarrow dependence* and tolerance. **Use:** insomnia (not long-term*).

164

Cl: respiratory failure, sleep apnoea (severe), marked neuromuscular respiratory weakness (inc unstable MG), L (if severe**), B. Caution: Ψ disorders, Hx of drug abuse*, muscle weakness, MG, R/P/E. SE: all rare: GI upset, taste Δ s, behavioural/ Ψ disturbances (inc psychosis, aggression), hypersensitivity. Interactions: Levels \uparrow by ritonavir. Dose: 7.5 mg nocte, \uparrow ing to 15 mg if necessary. NB: halve dose if LF (avoid if severe**), severe RF or elderly.

ZOTON see Lansoprazole; PPI.

ZYBAN see Bupropion; adjunct to smoking cessation.

This page intentionally left blank

Drug selection

Antibiotics	168
Hypertension management	178
Asthma	181
Analgesia	183
Palliative care and subcutaneous	
pumps	184
Antiemetics	187
Alcohol withdrawal	190
Antidepressants	192

ANTIBIOTICS

IMPORTANT POINTS

- The following *are only guides to a rational start to Rx*. Local organisms, sensitivities and prescribing preferences vary widely, and most UK hospitals now have antibiotic protocols: if unsure, consult your microbiology department/pharmacy.
- Empirical ('best guess') Rx is given unless stated otherwise.
- When deciding if 'severe' treatment is necessary, consider each individual's comorbidity and whether you have time to give simple Rx first and then add on or change if patient is not improving.
- Get as many appropriate cultures as possible *before* starting Rx; if unfamiliar with patient, check for recent culture results to aid choice of agent.
- If severe sepsis/shock (\downarrow BP/urine output $\pm \uparrow$ lactate) see p. 241.

PNEUMONIA

1. Community-acquired pneumonia



Severity assessment of community-acquired pneumonia in hospital¹

Adapted with permission of BMJ Publishing Group from BTS guidelines.

Thorax 2001; 56 (suppl IV) and 2004 update.

'CURB 65' score – 1 point each for:

- Confusion; ${\rm MTS}^2 \leqslant 8/10$ or new disorientation in time, place or person
- Urea > 7 mmol/l

- Respiratory rate ≥ 30/min
- **BP**↓: systolic <90 mmHg **or** diastolic ≤60 mmHg
- 65: age ≥65 yrs

<2: Non-severe*; likely to be suitable for home treatment.

2: Severe** with *increased* risk of death; consider admission (or hospital supervised outpatient care) using clinical judgement. >2: Severe** with *high* risk of death; admit and consider HDU/ITU (esp if \geq 4).

¹For assessment in the community use '*CRB 65*', which doesn't need blood test: 0 = likely to be suitable for home treatment; 1-2 = consider hospital referral; 3-4 = urgent hospital admission. ²MTS = (Abbreviated) Mental Test Score; see p. 259 for details.

Treatment:

Non-severe^{*}: amoxicillin 500 mg–1 g tds po ± clarithromycin^{***} 500 mg bd po (if admitted for clinical reasons).

Severe**: co-amoxiclav 1.2 g tds iv + clarithromycin*** 500 mg bd iv

- \pm flucloxacillin 1 g qds iv if *S. aureus* (Hx or epidemic of 'flu).
- \pm rifampicin 600 mg bd po/iv if *Legionella* (do urinary Ag test).
- If no improvement, consider changing co-amoxiclav to tazocim (piperacillin + tazobactam).
- If risk factors, consider Rx for aspiration or TB as below.
- If penicillin hypersensitivity, use clarithromycin*** only.
- ***Clarithromycin is better tolerated than erythromycin (⇒↓GI upset); consult local protocol to check preference.

Causes of community-acquired pneumonia (UK adults)

Adapted with permission of BMJ Publishing Group from Lim WS, et al. Thorax 2001; 56: 296–301.

- 48% Streptococcus pneumoniae: esp in winter or shelters/prison.
- 23% viruses: influenza (A \gg B), RSV, rhinoviruses, adenoviruses.
- 15% Chlamydia psittaci: esp from animals, but only 20% from birds (less commonly Chlamydia pneumoniae, esp if long-term Hx and headache).
- 7% Haemophilus influenzae.



DRUG SELECTION

3%

3% Legionella pneumophila: îd if recent travel (esp Turkey, Spain).
2% Moraxella catarrhalis: îd in elderly.
1.5% Staphylococcus aureus: mostly post-influenza ∴îs in winter.
1.4% Gram-negative infection: Escherichia coli, Pseudomonas, Klebsiella, Proteus, Serratia.
1.1% Anaerobes: e.g. Bacteroides, Fusobacterium.
0.7% Coxiella burnetii: îs in April–June and in sheep farmers.
NB: 25% are mixed aetiology (accounts for total of >100%).
In ≥20% of cases, causative pathogen is not identified.

Mycoplasma pneumoniae: 1 s during 4-yrly epidemics.

The term 'atypical pathogens' is not considered useful by the BTS (refers to *Mycoplasma*, *Chlamydia*, *Coxiella*, *Legionella*) as there is no characteristic clinical presentation for the pneumonias they cause.

2. Hospital-acquired pneumonia

Non-severe: co-amoxiclav 625 mg tds po.

Severe: co-amoxiclav 1.2 g tds iv (or bazoelin (piperacillin + tazobactam) 4.5 g tds iv if *Pseudomonas* suspected (or meropenem 1 g tds if penicillin allergy). DO NOT prescribe meropenem if history of anaphylactic or accelerated allergic reaction – discuss alternatives with microbiologist. + metronidazole 500 mg tds ivi if aspiration suspected. Now controversial.

+ gentamicin if septic shock or failure to improve.

MRSA: teicoplanin/vancomycin if confirmed colonisation/infection.



Causes of hospital-acquired pneumonia

Reproduced with permission from Hammersmith Hospitals NHS Trust Clinical Management Guidelines & Formulary 2001.

- *Simple:* (w/in 7 days of admission): *H. influenzae, S. pneumoniae, S. aureus,* Gram-negative organisms (see top of page).
- Complicated*: Gram-negative organisms (esp P. aeruginosa), Acinetobacter, MRSA.
- Anaerobic**: Bacteroides, Fusobacterium.

- Special situations:
 - 1 Head trauma, coma, DM, RF: consider S. aureus.
 - 2 Mini-epidemics in hospitals: consider Legionella.

*>7 days after admission, recent multiple antibiotics or complex medical Hx (e.g. recent ITU/recurrent admissions or severe comorbidity).

**esp if risk of aspiration, recent abdominal surgery, bronchial obstruction/poor dentition.

3. Aspiration pneumonia

Treatment as for community- or hospital-acquired pneumonia, + metronidazole 500 mg tds ivi or 400 mg tds po.

4. Cavitating pneumonia

Co-amoxiclav 1.2 g tds iv (or flucloxacillin 1 g qds iv). NB: need to exclude TB with sputum/Heaf test \pm pleural Bx, and consider septic emboli as a cause, e.g. from right-sided endocarditis. If MRSA suspected/confirmed use vancomycin iv plus rifampicin po.

'TANKS' Cause cavitation: TB, Aspergillus, Nocardia, Klebsiella, S. aureus (and PSeudomonas).



ΤВ

Should normally be managed by respiratory or infectious disease physicians with expertise in this area.

NB: Notify cases to public health authorities, and isolate potentially infectious inpatients.

Rx normally comes in two phases:

- Initial phase: for 1st 2 months: ↓s bacterial load and covers all strains: RMater* (Rifampicin + Isoniazid + Pyrazinamide) + Ethambutol** = 'RIPE'.
- Continuation phase: for next 4 months (or longer if CNS involvement): RMMmah* (rifampicin + isoniazid) = 'RI'. If resistance to rifampicin/isoniazid known (or suspected), continue pyrazinamide = 'RIP'.
 - Consider pyridoxine 10 mg od po: \downarrow s isoniazid neuropathy^{BNF}.
 - Combined tablets* \Rightarrow \uparrow compliance and ease of prescribing.
 - All doses are by weight; see BNF for details.

172 DRUG SELECTION

- All are hepatotoxic: check LFTs before and during Rx.
- Ethambutol** is nephrotoxic and can ⇒ optic neuritis: check U&Es and visual acuity before and during Rx. Alternative is streptomycin (also nephrotoxic), but both can be omitted if ↓risk of isoniazid resistance.
- Corticosteroids are usually added to this regimen from the start if meningeal or pericardial TB.

ACUTE BRONCHITIS

Rx not usually needed in previously healthy patients <60 yrs old.

- *Exacerbation of COPD:* 1st-line: doxycycline 200 mg od po. 2nd-line: amoxicillin (or co-amoxiclav).
- *Exacerbation of Bronchiectasis:* co-amoxiclav 1.2 g tds iv (po if mild) or @az@@lm (piperacillin + tazobactam) 4.5 g tds iv (if severe, or if colonised with pseudomonas).
- Cystic fibrosis: ciprofloxacin 500 mg bd po (or 400 mg bd ivi) if Pseudomonas suspected. Otherwise try gentamicin + piperacillin until sensitivities known.

UPPER RESPIRATORY TRACT AND ENT INFECTIONS

- Acute epiglottitis: cefotaxime 1 g tds iv + metronidazole 500 mg tds ivi (or the coefficient of the coeffi
- Pharyngitis/tonsillitis (sore/^cStrep' throat): penicillin V (phenoxymethylpenicillin) 500 mg qds po if Hx of otitis media, confirmed group A Strep infection or 3 of the following 4 clues that infection is not viral: purulent tonsils, Hx of fever, lack of cough or cervical lymphadenopathy.
- Sinusitis/otitis media: amoxicillin 500 mg tds po if local pus or if does not resolve in 2–3 days (as would expect if viral aetiology).
- Otitis externa: mostly bacterial; give topical steroid plus antibiotic combination: Sofradex or Otomize. Less commonly fungal (look for black spores); give topical Otosportin or Neo-cortef. If does not resolve or evidence of perichondritis (inflamed pinna), cellulitis, boils or local abscess, refer to ENT for

specialist advice and consideration of systemic Rx (e.g. amoxicillin, co-amoxiclav, flucloxacillin) and local toilet (esp if fungal).

URINARY TRACT INFECTIONS

- *Simple UTI:* trimethoprim 200 mg bd po. Another option is nitrofurantoin 50–100 mg qds po (not suitable if RF).
- Pyelonephritis (suspect if loin pain/systemic features): cefotaxime 1 g tds iv. If no response within 24 h (and still no culture results), try co-amoxiclav 1.2 g tds iv + gentamicin.

Causes of UTIs

- Most caused by E.coli (70–80%).
- Remainder caused by Enterococci, or other Gram-negatives e.g. Proteus (assoc. with stones), Klebsiella, Serratia or Pseudomonas.
- Staph saprophyticus seen in young women.
- Multi-resistant organisms more likely in catheterised or hospitalised patients.

GI INFECTIONS

Gastroenteritis

- Simple infections rarely need Rx; focus on rehydration and contact microbiology department if in doubt.
- AAC (Clostridium difficile): metronidazole 400 mg tds po and *stop other antibiotics if possible*. If no response after 4 days, change to vancomycin 125 mg qds po for 10–14 days.

Helicobacter pylori eradication: 'triple therapy'

Give 7-day course (for treatment failure consult BNF \pm microbiology opinion).

- 1 Antibiotic 1: clarithromycin 500 mg bd po.
- 2 + *Antibiotic 2*: amoxicillin 1 g bd po (or metronidazole 400 mg bd; if used ↓clarithromycin dose to 250 mg bd).
- **3** + *Acid suppressant:* PPI; choose from omeprazole 20 mg bd, esomeprazole 20 mg bd, lansoprazole 30 mg bd, pantoprazole 40 mg bd or rabeprazole 20 mg bd.

DRUG SELECTION

MALARIA

Clues: fevers (\pm 3-day cycles \pm rigors), \downarrow Pt, \downarrow Hb, jaundice, \uparrow spleen/liver, travel (even >1 year previously).

Always consult infectious diseases \pm microbiology team if malaria suspected/confirmed.

If confirmed non-falciparum ('benign'):

Chloroquine (as base; see below) dose 620 mg po, then 310 mg 6–8 h later, then 310 mg od 24 h later for 2 days (all doses of chloroquine as *base*). Follow, unless pregnant, with 14 days primaquine if *P. ovale* (15 mg od) or *P. vivax* (30 mg od) to kill parasites in the liver and prevent relapses (as a 'radical cure'). Primaquine dose: 30 mg od (*P. vivax*) or 15 mg od (*P. ovale*) for 14 days.

If falciparum ('malignant') or species mixed/unknown: *If seriously ill* (e.g. \downarrow GCS), get senior help and give:

- Quinine (as salt; see below) : load with 20 mg/kg ivi (max 1.4 g) over 4 h (NB: omit loading dose if quinine, quinidine or mefloquine given in past 12 h.) Then, 8 h after the start of the loading dose, give 10 mg/kg (max 700 mg) ivi over 4 h every 8 h for up to 7 days (↓doses to 5–7 mg/kg if RF or >48 h if iv Rx needed), changing to oral quinine (600 mg tds of salt) once able to swallow and retain tablets to complete a 7-day course.
- Doxycycline 200 mg od po (clindamycin 450 mg tds po if pregnant) with or following quinine course for 7 days.
- Consider artesunate or artemether if patient has been to quinineresistant areas of SE Asia: get specialist advice.

If stable, normal GCS, and able to swallow and retain tablets:

Quinine: 600 mg tds po for 7 days followed by doxycycline or clindamycin. Proguanil + atovaquone (Malarone), artemether + lumefantrine (Rlamet) are alternatives (Rx for 3 days only) to quinine which only need to be taken for 3 days and don't need any subsequent drugs.

& Quinine doses here are as "salt" (quinine hydrochloride, dihydrochloride or sulphate). Choloroquine doses are as "base"

174

MENINGITIS

Empirical Rx (until results of LP known - esp Gram stain).

Cefotaxime 2 g qds ivi: Rx of choice for *N. meningitides* (aka meningococcus; commonest cause in UK adults). If Hx of severe hypersensitivity (e.g. anaphylaxis) to cephalosporins (or penicillins as 10% also hypersensitive to cephalosporins) consider chloramphenicol 1 g tds/qds iv (can ↑ to 100 mg/kg/day^{SPC/BNF}); if allergy (but not anaphylaxis) use meropenem 2 g tds iv.

Consider:

- Ampicillin 2 g 4-hrly ivi + gentamicin iv if *Listeria* suspected, e.g. immunosuppression or indicative CSF: Gram-positive bacilli.
- Aciclovir 10 mg/kg over 1 h tds ivi if HSV encephalitis suspected, e.g. more prominent confusion, behavioural Δs and seizures.
- TB Rx as for pneumonia, and discuss with Infectious Diseases/Microbiology: if risk factors or suggestive CSF findings (↑LØ, ↑protein, ↓glucose). Negative CSF stains for acid-fast bacilli do NOT exclude the diagnosis; if clinical suspicion high Rx shouldn't be delayed while awaiting microbiological confirmation.

Causes of meningitis in the UK

Common:

- *N. meningitidis*, serotype B: majority (70–80%) of cases.
- *N. meningitidis*, serotype C: \downarrow ing secondary to vaccine.
- *N. meningitidis*, serotype A: \uparrow ing again (had been \downarrow ing).
- *S. pneumoniae*: stable incidence.

Rarer:

- Gram-negative bacilli (esp. in neonates).
- *Listeria monocytogenes*: esp neonates, age >60 yr, ↓immunity.
- *H. influenzae*, type b: ↓ing secondary to vaccine.

Don't forget:

- Viral: HSV/HZV, EBV, HIV, mumps: esp if encephalitic (↓GCS). Less commonly entero/echo/Coxsackie/polio viruses.
- TB, other bacteria, e.g. *Borrelia*: esp if ↓immunity/HIV.
- Fungi: Cryptococcus, Candida: esp if ↓immunity/HIV.
- Group B Streptococcus: predominantly in neonates.
- S. aureus: if neurosurgery, ↓immunity, iv lines, IVDU.

EYE INFECTIONS

- Conjunctivitis (only Rx if prolonged/atypical) or corneal abrasions: chloramphenicol 0.5% 1 drop qds.
 - Do not pad the eye (\downarrow healing).
- Orbital Cellulitis:
 - If preseptal (lids only) ⇒ oral co-amoxiclav, can be managed as outpatient with close specialist observation.
 - If postseptal (retro-orbital) admit for iv Rx (e.g. ceftriaxone + metronidazole).
- *Corneal ulcer*: Needs urgent ophthalmology referral. ofloxacin 0.3% 1 drop hourly for 5 days.
 - Only give once scrape taken for Gram stain/culture.
 - Suspect in contact lens wearer with painful red eye \Rightarrow refer to ophthalmologist urgently.
 - Don't give topical anaesthetic to patients for analgesia as \Rightarrow epithelium to slough &.
- Blepharitis: Lid margin/eyelash scrubs only. If severe or lid hygiene alone insufficient ⇒ Maxitrol ointment (dexamethasone 0.1% & neomycin 0.35%) applied to lashes BD for 1 month in addition to lid hygiene. Artificial tears (hypromellose) can also be used to reduce symptoms.
- Acute chalazion/Stye: can be managed with regular warm compresses to burst cyst (antibiotics not required). If concern that early cellulitis ⇒ oral antibiotics may also be given (see above).

CELLULITIS

• Mild (e.g. Venflon site infection): co-amoxiclav 625 mg tds po or flucloxacillin 500 mg qds po.

- Severe: benzylpenicillin 1.2 g iv 4–6-hrly + flucloxacillin 1 g qds iv.
- + metronidazole 500 mg tds ivi if suspect anaerobes, e.g. abdominal wound.
- + consider vancomycin 1 g bd ivi if confirmed MRSA colonisation/infection.

BONE AND JOINT INFECTIONS

Osteomyelitis: suspect in any postoperative joint or deep DM ulcer.

- Flucloxacillin 1–2 g qds iv + fusidic acid 500 mg–1 g tds po (can give iv in severe cases, but is poorly tolerated and often not required; see main drugs section for doses). *Staph aureus* is usual cause, but in spinal infection consider also Gram-negatives, and discuss with Microbiology.
- If MRSA suspected consult local guidelines ± microbiologist.
- In osteongelitis associated with chronic ulcers, co-amoxiclar 1.2 g tds iv should be given instead of flucloxacillin.
- If penicillin allergy give clindamycin 600 mg qds iv.

Septic arthritis: suspect if sudden-onset pain/inflammation.

• Treatment as osteomyelitis, but consider changing after urgent Gram stain, e.g. to iv 3rd-generation cephalosporin (e.g. cefotaxime, ceftriaxone) if *H. influenzae* suspected (Gram-negative bacilli, esp in children). Suspect *Salmonella* in sickle cell disease or TB/fungi if immunocompromised.

PUO

No routine antibiotics indicated, but suspect and exclude abdominal abscess, TB, Ca (esp abdominal/haematological) and other causes.

Causes of PUO

- Abdominal abscess: liver, subphrenic, pelvic.
- Other infection: UTI, TB, malaria, infective endocarditis, bone infection, virus (EBV, CMV, HIV).
- Autoimmune: rheumatoid arthritis, Still's disease, PMR, sarcoid, PAN, SLE/connective tissue disease.
- Cancer: lymphoma, leukaemia, solid tumours (esp abdominal).
- Drugs: almost any (inc drugs of abuse), often assoc w ↑EØ.



DRUG SELECTION

• Other: PEs, haematomas, alcoholic hepatitis, FMF.

NB: up to 25% of cases remain unexplained.

FEBRILE NEUTROPENIA

If temperature 38°C for \ge 2 h (or \ge 38.5°C for \ge 1 h) and no clues as to the fever's aetiology, give:

- For 1st/2nd episodes: gentamicin 5 mg/kg od iv + Tazocin 4.5 g tds iv (use ceftazidime 2 g tds iv if penicillin allergy).
- For persistent or recurrent fever at any later stage: call haematologist/oncologist ± microbiologist on call for advice.

NB: Always do full septic screen before giving/prescribing antibiotics: blood, urine and any other appropriate cultures (e.g. sputum, stool, central/other lines) \pm CXR.

HYPERTENSION MANAGEMENT

Adapted with permission of the BMJ Publishing Group from Joint British Societies (includes BHS) guidelines. *Heart* 2005; **91** (suppl 5): 1–52.

Severity	Systolic ¹	OR	Diastolic ¹	Drug therapy ²
Normal	<120		<80	No
High-normal	135–139		85–89	Consider ³
Mild (grade 1)	140–159		90–99	Consider ⁴
Moderate (grade 2)	160–179		100-109	Yes
Severe (grade 3)	≥180		≥110	Yes

When to treat: depends on severity and other factors:

1. All measurements are in mmHg. 2. Encourage lifestyle modifications for all \uparrow BP: \downarrow salt, \downarrow Wt, \downarrow alcohol, stop smoking, \uparrow exercise, \uparrow fresh fruit/vegetables, \downarrow intake of total and unsaturated fat. For mild and high-normal cases without CVD or target organ damage, *these measures can be tried before drug therapy. 3. May be indicated if established CVD, chronic kidney disease, or DM with complications at BP levels >130/80 mmHg. 4. Recommended if established CVD or DM, or evidence of target organ damage*, or 10-yr CVD risk \geq 20% (see risk charts at back of BNF or at www.bhsoc.org/resources/prediction chart.htm).

*HF, established IHD, CVA/TIA, chronic kidney disease (CKD, JGFR, [↑]creatinine or proteinuria/ microalbuminuria), hypertensive/diabetic retinopathy or LVH.

178

 \bigotimes See p. 234 for Dx and Mx of accelerated HTN \bigotimes .

Aim for: BP $\leq 140/85$ mmHg. If DM or CKD $\leq 130/80$ mmHg. If CKD and $\geq 1 g/24$ h proteinuria $\leq 120/75$.

Primary causes: look for and exclude (esp if treatable), e.g. RAS, Conn's (1° hyperaldosteronism), $\uparrow Ca^{2+}$, Cushing's, phaeo (esp if variable BP, headaches, sweats, palpitations), oestrogen-containing contraceptive pills and recreational drugs (e.g. alcohol, cocaine, amphetamines).

Important points:

- Make a *written* Rx plan for (other) doctors, nurses and patient. Include target BP and how Rx should change if it is not achieved.
- Age/ethnic origin influence response to drugs (see table below).
- A single agent is rarely successful at achieving target BP. Rather than ↑ing doses, add 2nd and 3rd agents, which often work in an additive or complementary fashion, esp if table below used.
- Exclude/minimise dietary salt and NSAID (inc unrecognized 'over-the-counter') use, as reason for poor treatment response.

Step	Younger (<55 yrs) <i>and</i> non-black		Older (≥55 years) <i>or</i> black ¹
1	A ²		C or D
2		$A^2 + C \text{ or } D$	
3		$A^2 + C + D$	
4		Resistant hypertension ³	

Choice of drug: rational combination therapy^{NICE/BHS 2006}

1. Black = African (not Asian) origin. 2. β -Blockers are an alternative to ACE-i/ARBs but reserved for those with CVD (e.g. IHD or chronic stable LVF) due to $\hat{}$ incidence of new onset diabetes. 3. Add α -blocker, spironolactone or other diuretic \Rightarrow specialist referral and consider missed 1° cause or poor adherence or effects of lifestyle factors or other medicines.

180 DRUG SELECTION

© good for, @ avoid/caution, & beware!


- A = ACE-i, e.g. enalapril initially 5 mg od (2.5 mg if elderly or RF). © CRF (but with caution!), HF, DM, IHD. ⊗PVD (as assoc with RAS*) .
 Pregnancy, bilateral RAS*. (Must monitor U&Es 2 wks after starting, then regularly, esp if vasculopathy or renal impairment). Angiotensin II receptor blockers (ARBs) can also be used but are normally reserved for when ACE-i not tolerated (esp dt dry cough) must monitor as for ACE-i.
- B = β-blocker, e.g. atenolol 50 mg od. ☺ anxiety, IHD (post-MI/ angina), chronic stable LVF. ☺ dyslipidaemia, PVD, DM (unless also IHD), if on diltiazem. asthma/COPD, HB, acute LVF, if on verapamil.
- C = Ca²⁺-channel blocher: dihydropyridines such as amlodipine 5 mg or nifedipine LA (e.g. Adalat LA 20-30 mg od) usually 1st-line. ☺ elderly. ⊗ oedema, polyuria. & aortic stenosis, recent ACS.
- D = diuretic, e.g. bendroflumethiazide 2.5 mg od. © oedema/ HF, elderly, isolated systolic HTN, 2° CVA prevention.
 Ødyslipidaemia. & gout.

NB: only starting doses are given; see main drugs section or SPCs/BNF for doses thereafter.

When to change Rx (after checking compliance first!):

- BP <5 mmHg lower: if HTN mild and uncomplicated, switch across 'AB' or 'CD' category of drug, i.e. from A (or B) *to* C or D (or vice versa). If HTN severe or complicated, add 2nd agent as per table above.
- BP >5 mmHg lower but:
 - drug not tolerated: swap within category, i.e. from A* to B (or vice versa) or from C to D (or vice versa);
 - still suboptimal: either [†]dose or add 2nd agent (often better).
- *Consider swapping from ACE-i to ARB (or vice versa) as
- β-blockers often less preferable, as above.

ASTHMA



*Beclometasone or budesonide (NB: fluticasone equivalent doses are half this).

Figure 1 BTS guidelines for management of asthma in adults. Adapted with permission of BMJ group from *Thorax* 2008; **63** (suppl 4): iv1–iv121.

Patients should start treatment at the step most appropriate to the initial severity of their asthma. Check concordance and technique at every step and reconsider diagnosis if response to treatment is unexpectedly poor. Remember to move down (as well as up) the ladder to find and maintain lowest controlling step.

DRUG SELECTION




Figure 2 Peak expiratory flow (PEF) predictor for normal adults using European standard 'EU' (EN 13826) scale. Adapted with permission of BMJ group from Gregg I, Nunn AJ. *BMJ* 1989; **298:** 1098, corrected to the EN 13826: 2003 scale values by Clement Clarke International Ltd.

182

ANALGESIA

Choice of analgesic:

General rules

- Look for/treat reversible causes and reassess cause at each step.
- Regular $Rx \downarrow s$ relapses but always review to check whether still needed.
- If pain $\downarrow\uparrow$ s, 'step down' and ensure adequate prn analgesia in case s again.
- Pain has many adverse medical fx and is rarely refractory to the correct Rx.
- If pain persists, get senior or specialist help (e.g. anaesthetist or pain team).

Step 3


- All opioids can ⇒ constipation, respiratory depression and ↓GCS (esp if elderly or RF – even low doses). Can also ⇒ coma if LF.
- All NSAIDs can ⇒ PU (related to strength of drug and length of Rx. Consider PPI or changing to COX2 inhibitor^{NICE}) Can also ⇒ ARF if fluid depleted (∴rehydrate 1st or avoid).

Step

- Strong opioid: iv if acute (e.g. morphine) po if chronic (e.g. oramorph) sc in palliative care: see p. 184
 High dose weak opioid e.g.:
- dihvdrocodeine 30 mg ads
- tramadol 50–100 mg qds (also has 5HT fx: ↓SEs for same analgesia)
- Compound prep. of paracetamol with low dose weak opioid (e.g. cocodamol or codydramol) or weak opioid alone (e.g. dihydrocodeine)
- Simple analgesia: paracetamol 1 g qds usually 1st-line as few SEs.
 - NSAIDs 2nd-line; 1st line if predominant... inflammatory component, e.g.: – Ibuprofen 200–400 mg tds po for mild pain.

Step 1

- Diclofenac (Voltarol) 50 mg tds im/po or 75 mg SR bd im/po or 100 mg pr (max 150 mg/day) for moderate pain (esp good postoperatively).
- Consider specialist analgesia according to cause, e.g. buscopan for colic, colchicine for gout, antacids for reflux, GTN for angina. For neuropathic pain try amitriptyline, gabapentin or pregabalin.



Important points for postoperative patients:

- Oral route often ineffective for all operations (due to gastric stasis).
- Epidural anaesthesia (EDA) and patient-controlled analgesia (PCA) normally provide maximal opiates (as well as other drugs)

 \therefore beware of giving more. Consider NSAID and get advice from anaesthetist if this does not work.

• Consider local/regional anaesthesia.

PALLIATIVE CARE AND SUBCUTANEOUS PUMPS

- Underprescribed due to stigma of being a 'final measure': ensure good communication with patient, relatives and nurses as to reasons for use.
- Gives smooth symptom control, esp for pain, but also useful for other symptoms, e.g. nausea, xs secretions, agitation. Good if unable to take po medications, avoids cannulation, only single 24-h prescription needed (no delays in drug administration on busy wards).
- Palliative care, Macmillan and hospital pain teams will help if unsure of the indications or how to set up these pumps.

CONTENTS OF SUBCUTANEOUS PUMP

1 Diamorphine (or morphine sulphate): calculate dose needed for 24-h prescription from the past 24 hours' requirements (if variable, look at longer-term trend). If taking other opioids, use the following *rough* guide:

1 mg diamorphine sc/im	= 1.5 mg morphine sc/im
	= 3 mg morphine po
	= 15 mg tramadol po
	= 35 mg codeine po/im

(For conversion from fentanyl, see its entry in main drugs section.)

NB: these equivalent doses only apply for the specific route(s) of each drug stated, as bioavailability can vary widely with routes. Also, it does not take into account duration of action, although this can be ignored if 24-h requirements for each drug are calculated. At high opioid doses, conversion factors become less reliable – err on the conservative side and gradually titrate up.

- 2 Antiemetic: choose from (generally start at lowest dose):
 - Metoclopramide 30–90 mg/24 h: (esp for promotility fx slow gastric emptying; but CI if GI obstruction with abdominal pain!).
 - Haloperidol 0.5-5 mg/24 h: good general antiemetic.
 - Cyclizine 50 mg tds sc/po/24 h: good if cause unknown or multifactorial.
 - Levomepromazine 6.25–12.5 mg/24 h. Good if cause unknown or multifactorial (¹doses to 25–50 mg/h if sedation needed and patient not ambulant.)
- **3** Optional extras:
 - Drugs to \$\u00e4 respiratory secretions:
 - glycopyrronium 0.6-1.2 mg/24 h.
 - hyoscine hydrobromide 0.6–2.4 mg/24 h: normally sedative but can ⇒ paradoxical agitation. ↑risk of seizures.
 - Sedatives, e.g. midazolam 10–80 mg/24 h if restlessness or agitation is the solitary symptom. Consider levomepromazine if not responsive to midazolam. Care/↓dose if elderly, respiratory depression, benzodiazepine-naive.

Compatibility of drugs in syringe drivers

It is advised that only two or three drugs are used per syringe driver. All antiemetics listed above are compatible with diamorphine and morphine. For addition of 'optional extras', see table below; for all other combinations, check with the hospital pharmacy or drug information office. Out-of-hours authoritative information on compatibility (and other palliative care prescribing issues) can be found at the excellent website www.palliativedrugs.com.

Compatibility* of specific three-drug combinations: diamorphine and antiemetic and one other 'optional extra' drug.

Diamorphine <i>plus</i>	Glycopyrronium	Hyoscine	Midazolam
		hydrobromide	
Metoclopramide	Not recommended	Not recommended	Compatible*
Haloperidol	Not known	Compatible*	Compatible*
Levomepromazine	Compatible*	Compatible*	Compatible*

*Compatibility is restricted to usual dose ranges of the drugs.

EXAMPLE PRESCRIPTION

Prescribe each drug individually in the 'regular prescriptions' section of the drug chart, as shown here:



Figure 4 Example drug chart of diamorphine subcutaneous pump. NB: 60 mg diamorphine/24 h is example dose; individual patient needs will vary (see above).



Graseby syringe drivers: mm (instead of ml) per unit time

This type of syringe driver is the most common in the UK (esp in specialist palliative care settings). Infusions are given in millimetres (mm) rather than millilitres (ml) per unit time. There are 2 types: for each unit on the 'rate' dial, the MS16 (blue) delivers 2 mm/h, but the MS26 (green) delivers 48 mm/day.

Examples of prescriptions of a syringe to be given over 24 h:

- MS16: 'Diamorphine 60 mg over 24 h as subcutaneous infusion via syringe driver. Mix with water for injection to a length of 48 mm in syringe, set at rate of 2 mm/h.'
- MS26: 'Diamorphine 60 mg over 24 h as subcutaneous infusion via syringe driver. Mix with water for injection to a length of 48 mm in syringe, set at rate of 48 mm/24 h.'

GENERAL POINTERS IN CHRONIC PAIN/ PALLIATIVE CARE

- Laxatives: give with opiates as Px rather than later as Rx.
- *Simple analgesia:* do not forget as often effective, e.g. regular paracetamol.

- Breakthrough analgesia: always write up in case regular medications become insufficient. Oral opiates (e.g. Oramorph) often best; 1/6 of regular 24-h opiate equivalent dose is usually sufficient. If ↓GCS or ↓swallow add sc or iv drugs (e.g. morphine).
- Fentanyl patches: smooth pain control w/o multiple injections or tablets (just change patch every 3rd day). Also less constipating.
 Only use if stable opioid requirements; long action means dose overestimation can be fatal.
- Steroids: consider for nausea, as pain adjuvant (esp liver capsule pain), and for short-term Rx of ↓appetite: get specialist help.
- Always consider new causes of pain/distress, esp if patient unable to give Hx: often treatable, iatrogenic or can be disguised/made worse by more analgesia, e.g. opiate-induced constipation, patient positioning, UTI, urinary retention, mental anguish (esp 'unfinished business'), pathological fractures.

Commonly missed problems

- ¹Ca²⁺: esp consider if confusion and constipation (other symptoms: 'bones, stones, groans and psychic moans'); see p. 249 for Mx.
- Spinal cord compression: ¹back pain, sensory/sphincter disturbance, limb weakness – can be treated with immediate high-dose steroids (e.g. dexamethasone phosphate 12–16 mg iv stat then 8 mg po bd) and radiotherapy; refer urgently to oncologist.

ANTIEMETICS

Commonly used 1st-line/narrow-spectrum antiemetics (see also Palliative Care section, p. 184).

General rules

- Look for/treat reversible causes (see below).
- Reassess causes at each step.
- Start sc/im/iv switching to po when able.
- Consider sc pump if chronic uncontrolled (see p. 180).
- Don't stop Rx unless cause removed.




Figure 5 Antiemetic ladder – designed for cancer patients; steps 3 and 4 are rarely needed in other settings.



Causes of nausea

- Drugs: esp opiates, chemotherapy/cytotoxics. Commonly also dopamine agonists, antibiotics (esp erythromycin), antidepressants (esp fluoxetine), theophyllines, colchicine, FeSO₄ and acutely amiodarone/digoxin.
- *GI:* constipation, but also surgical (obstruction, peritonism) and medical (oesophagitis, gastritis, PU) causes.
- Neurological: migraine, [↑]ICP (esp tumour), meningitis, Menière's, labyrinthitis.
- *Metabolism:* $\uparrow Ca^{2+}$ (also $\downarrow Na^+$, $\uparrow K^+$), DM, ARF, Addison's.
- Infection: gastroenteritis but also UTI, respiratory infections.
- Other: pregnancy, MI (esp inferior, often ↓pain if DM/elderly).

Class	Example	Good for	Beware
Phenothiazine (D ₂ antagonist)	Haloperidol 0.5–1.5 mg sc/po	Opiates, general anaesthetic, postoperative, chemo-/radio- therapy (if mild), 1st choice in LF	⇒ ↑prolactin, extrapyramidal fx, ↓s seizure threshold, ↓BP
Phenothiazine (D ₂ antagonist)	Levomepromazine 6.25–25 mg od or bd po/sc/iv	Broad spectrum: useful when cause unclear/multifactorial	\Rightarrow sedation, \downarrow BP \downarrow s seizure threshold
Benzamine (D ₂ antagonist)	Metoclopramide 10(–20) mg tds po/sc/im/iv (Maxolon)	GI causes (↑s GI motility*), migraine, drugs (esp opiates)	⇒ \uparrow prolactin, extrapyramidal fx, & Cl if Gl obstruction & *
Benzamine (D ₂ antagonist)	Domperidone 10–20 mg tds po or 30–60 mg bd pr (<i>not</i> <i>iv or im</i>)	Parkinson's disease**, morning-after pill, chemotherapy	$\Rightarrow \uparrow$ prolactin, but minimal sedation and extrapyramidal fx**
Antihistamines	Cyclizine 50 mg tds po/sc/im/iv	GI obstruction*/postoperative N&V, vestibular/labyrinthine disorders. Antiemetic of choice in LF.	\Rightarrow Antimuscarinic fx (esp sedation). Avoid in IHD (\downarrow s beneficial cardiodynamic fx of opiates)
5HT ₃ antagonists	Ondansetron 4–8 mg bd po/im/iv (16 mg od pr) Granisetron Tropisetron	Severe/resistant cases (esp chemo-/radio-therapy)	Minimal side effects: headache, constipation, dizziness

*Prokinetic fx of metoclopramide antagonised by anticholinergic drugs (see p. 225), esp cyclizine if also used in this setting.

**Extrapyramidal fx possible with all D2 antagonists (see p. 227) but less so with domperidone.

ALCOHOL WITHDRAWAL

A 'detox' programme comprises the following components:

1. PREVENTION OF AGITATION, SEIZURES AND DELIRIUM TREMENS

Give a long-acting benzodiazepine in a tapered regimen as follows:

Day	Chlordiazepoxide	OR	Diazepam
1	30 mg gds		15 mg gds
2	30 mg tds		10 mg qds
3	20 mg tds		10 mg tds
4	20 mg bd		5 mg qds
5	10 mg bd		5 mg tds
6	10 mg od		5 mg bd
7	10 mg prn		5 mg od

Alcohol withdrawal regimen. Courtesy of Professor

These are only suggested initial average regimens

Requirements vary considerably with severity of symptoms and previous experience of or tolerance to benzodiazepines. Regular dose review and prescription of prn doses is essential. Ideal regimens involve an initial 24-h assessment of prn doses, but require adequate training and time of staff to monitor closely and ensure no under- (or over-) treatment occurs. Start with dose of 20–40 mg chlordiazepoxide or 10–20 mg diazepam and add up doses used in 1st 24 h, then reduce by 1/5th (–1/7th) per day for 5(–7) days.

- Chlordiazepoxide usually 1st line, but diazepam preferred if Hx of seizures (esp if occurred in context of alcohol withdrawal).
- If significant liver failure (e.g. ↑AST or ALT), consider shorteracting benzodiazepines such as oxazepam or lorazepam at equivalent doses (see p. 224); avoids xs metabolite build up and sedation (but marginal ↑seizure risk).
- Only start once acute alcohol intoxication has resolved as benzodiazepines are contraindicated in this state.

2. THIAMINE (VIT B1) AND OTHER SUPPLEMENTS

For Px or Rx of suspected Wernicke's encephalopathy (WE): must give before patient receives carbohydrate load po or iv, which can precipitate WE.

& ∴ Take particular care if hypoglycaemic and iv glucose needed! &

- Parenteral (iv or im) thiamine: e.g. Pabrinex (contains other B and C vits); prescribe as '1 pair Pabrinex vials' or 'Pabrinex 1 and 2'. British Association of Psychopharmacology guidelines 2004 recommend:
 - If WE established (or *suspected*; see note box below): 2 pairs tds iv (or im) for 3 days, then 1 pair od for 3–5 days.
 - If high risk of WE (malnourished/chronic severe abuse):1 pair od iv im for 3–5 days.
 - If low risk of WE no parenteral treatment needed.

\bigotimes Pabrinex can \Rightarrow anaphylaxis

... ensure resus facilities at hand. NB: \uparrow risk if given iv too quickly; ensure mixture of both vials either given as injection over ≥ 10 min or as infusion (with 50–100 ml saline) over ≥ 30 min &.

- Oral vitamins and supplements.
 - Thiamine 100 mg bd/tds po; should be given for 1 month if no parenteral treatment required.
 - Multivitamins 1 tablet/day long-term; cheap and potentially important if future diet unlikely to be good.

Wernicke's encephalopathy

Caused by thiamine deficiency and often missed; only 10% have classical triad of confusion, ataxia and eye signs (ophthalmoplegia or nystagmus; seen in only 30% of cases). Suspect diagnosis if any evidence of chronic alcohol misuse and any one of: acute confusion, ataxia, ophthalmoplegia, $\downarrow BP + \downarrow temp$, $\downarrow GCS$ or \downarrow memory. If unsure whether intoxication or WE causing any of these, always assume it is WE and give treatment. Rarely WE is caused by other malnutrition, e.g. malabsorption, eating disorders, protracted vomiting, CRF, AIDS and other drug misuse. NB: $\downarrow Mg^{2+}$ can \Rightarrow Rx refractory WE \therefore check \pm correct Mg^{2+} .

3. MAINTENANCE OF ABSTINENCE

It is essential to:

- Encourage abstinence and refer to local alcohol liaison nurse (if available) ± addiction services.
- Treat depression and try to arrange adequate social support.

Consider the following as aids:

- Acamprosate: modulates alcohol withdrawal fx & limits -ve reinforcement of drinking cessation ⇒ ↓cravings and ↓relapse rate.
- *Disulfiram:* \Rightarrow unpleasant symptoms if alcohol consumed.
- *Naltrexone*: ↓s pleasurable fx of alcohol and ↓s craving and relapse rate. Specialist use only (not yet licensed in UK for this indication).

ANTIDEPRESSANTS

Depression is common, esp in chronic illness/inpatients (50%). It is easy to miss, responds to treatment and has impact on medical outcomes. Be vigilant for its presence \pm screen (e.g. PHQ-9 screening tool). NICE recommends asking if during the last month the patient has been bothered by 'Feeling down, depressed or hopeless?' or 'Having little interest or pleasure in doing things?'. If suspected, establish ICD-10 diagnosis by enquiring for the following 10 symptoms:

- 1 Depressed mood
- **2** Energy loss: \Rightarrow fatiguability and \downarrow activity
- 3 Pleasure, interest and enjoyment loss (=anhedonia)
- 4 Retardation (psychomotor). NB: atypically \Rightarrow agitation
- **5** Eating Δ : \downarrow appetite/wt. NB: atypically can \uparrow
- 6 Sleep disturbance (early morning waking)
- 7 Suicidal/self-harm thoughts
- 8 I'm a failure; loss of confidence/self-esteem
- 9 Only me to blame (guilt/unworthiness)
- 10 No concentration or attention

1st 3 are 'core'* symptoms: ≥ 2 required for diagnosis.

NICE	recommendations

Severity	ICD-10 Symptoms	Action
	(≥2 core*)	
Mild	4	Watchful waiting + consider self
		help/psychological Rx
Moderate	5–6	Consider antidepressant and/or CBT
Severe	\geq 7 (± psychotic symptoms)	Antidepressant \pm CBT

- If moderate/severe depression treat for 6 months beyond recovery and review need for further treatment.
- Treat for ≥2 years if ≥2 depressive episodes with significant functional impairment in the recent past.

Seware prescribing in the depressive phase of bipolar disorder (screen for previous mania/hypomania); risk of inducing mania (esp with venlafaxine and paroxetine)

Give information sheet on antidepressants (e.g. http://www.rcpsych. ac.uk/mentalhealthinformation/mentalhealthproblems/depression/ antidepressants.aspx) highlighting risk of discontinuation syndrome if stopped abruptly (see p. 226).

TREATMENT RESISTANCE/POOR TOLERANCE

- 1 Check compliance/adequate dose.
- 2 \uparrow to max dose unless limited by side effects.
- **3** Change class if adequate trial given for ≥ 6 weeks.
- **4** Consider specialist input: trial of MAOI, combination of antidepressants or augmentation with lithium or atypical antipsychotic.
- Monitor for increased suicidal ideation or development of hypomania/mania

Class	Drug	© Good for/reas	ons to prescribe	⊗Bad for/reasons to avoid			
SSRI	Fluoxetine	Risks for OD ⁵ (safer); Anxiety;	Risk of abrupt stopping (long t _{1/2}); Children ⁸	Sexual SEs (↓libido, impotence etc); agitation	Polypharmacy (↑interactions)		
	Paroxetine	OCD; Few SEs		(or akathisia); risk of	Inconsistent use ¹¹ or <25 years old ¹²		
	(Es) ¹ Citalopram	1		osteoporosis with			
	Sertraline	1	Polypharmacy ⁹ or IHD	long-term use			
SARI	Trazodone	Insomnia		(Postural) hypotension			
NaSSA	Mirtazapine	Insomia ⁶ , sexual dysfunction ⁴ or polypharmacy ⁹		Concern about weight gain			
TCA	Amitriptyline	Insomnia (esp init	ial,	Risks for OD ⁵ (less safe)			
	Imipramine	i.e. getting off to		(Postural) hypotension;	Women ¹⁰		
	Lofepramine	sleep); chronic pai	n	cardiovascular disease ⁷ ;			
	Dosulepin ²	(neuralgia, migrai	ne,	urinary retention			
	Clomipramine ³	back pain etc)	OCD				
DRI	Bupropion	Smoking cessation	1	Risks of OD ⁵ , seizures, anx	iety, polypharmacy (↑interactions)		
SNRI	Venlafaxine	Treatment resistance; anxiety		Cardiac disease ⁷ (contrain	dicated)		
	Duloxetine	Urinary incontinence					
MRA	Agomelatine	Inconsistent use;	sleep	Liver disease (monitor LFT	s)		

SSRI = selective serotonin reuptake inhibitor, SARI = serotonin antagonist and reuptake inhibitor, TCA = tricyclic antidepressant, DRI = dopamine reuptake inhibitor, SNRI = serotonin and noradrenaline reuptake inhibitor; NaSSA = noradrenaline and serotonin specific antidepressant; MRA = melatonin receptor agonists. **1.** Escitalopram is the active enantiomer of citalopram. **2.** Old name dothiepin. **3.** Also has serotonergic effects (hence efficacy in OCD) – only TCA with this effect. **4.** Either concern about sexual dysfunction or experienced this on other antidepressants. **5.** OD = overdose. **6.** Can be oversedating initially and lead to intolerance – titrate up slowly and warn patient but reassure normally passes. **7.** Associated with cardiac complications; monitor BP (\pm ECG) recommended. **8.** Currently this is the best choice in most cases of child/adolescent depression due to less evidence of increasing suicidal ideation. **9.** Has few drug interactions – particularly useful in the elderly. **10.** Women poorly tolerate imipramine. **11.** Trisk of discontinuation syndrome. **12.** Trisk of suicidality.

How to prescribe

Insulin	196
Anticoagulants	200
Thrombolysis	208
Controlled drugs	212

INSULIN

TYPES

Many exist, with differences in the timing of action onset O, peak P and duration D.

For acute use, e.g. DKA and sliding scales, inc perioperative:

• Soluble (aka normal/neutral) can be given **iv** (and **sc** as other types), e.g. Actrapid, Humulin S:

iv: O/P immediate, D 0.5 h. sc: O 0.5-1 h, P 2-4 h, D 6-8 h.

For maintenance use, i.e. normal chronic control (sc only):

- Aspart (NovoRapid), lispro (Humalog) or glulisine (▼Apidra): recombinant human analogues. Rapid onset ⇒ ↑eating flexibility (can give immediately before meals; other types of sc insulin must be given 30 min before), ↓duration ⇒ fewer hypos (esp before meals). O 0.25 h, P 1–3 h, D 2–5 h.
- Isophane: intermediate-acting e.g. Humulin I, Insulatard or Insuman Basal.
- Glargine: long-acting recombinant insulin with delayed and prolonged absorption from sc injection site ⇒ constant, more 'physiological' basal supply; mostly given od but can be split into bd dosing (e.g. Lamtus).
- **Detemir**: long-acting analogue. Binds to albumin and has different action from that of glargine but similar advantages. Give od or bd (e.g. Levemir).

Biphasic insulins contain mixtures of intermediate- or long-acting insulin (e.g. isophane) with short-acting soluble insulin (e.g. aspart or lispro); e.g Humalog Mix 25, Humulin M3, Insuman Comb 15, Mixtard 30, Novomix 30.

SLIDING SCALES

For optimal blood glucose control in diabetics if (i) DKA/HONK, (ii) pre-operative/NBM, (iii) MI*/ACS*, (iv) severe concurrent illness (e.g. sepsis).

RATE TIME TIME SET UP DATE/ VOL-ADDITIVES IF ANY DURA-DR'S BATCH INFUSION FLUID OF TION SIGNATURE START-COM-BY SIG-TIME LIME DRUG AND DOSE No ADMIN PLETED NATURE ACTRAPID As below 08/01 Normal saline 50 ml TN SO units 08/01 Glucose saline 1 litre CBG INSULIN ivi (ml/h) (= BM)0 - 40.5 (+ call Dr if CBG < 2.5)4.1-7 1 71-9 2 9.1-11 3 11.1-13 4 ≥ 13.1 6 Always run glucose saline (4% glucose \pm 0.18% saline) ivi at 125 ml per hour if CBG (BM) \leq 15.

Example of how to write an insulin sliding scale on a drug chart

Figure 6 Drug chart, showing slide scale.

These are average requirements and ∴ only a suggested initial regimen: requirements will vary widely between individuals and within an individual over time (esp with intercurrent illness, e.g. infections). Regular review and adjustment is essential – see below. Use your hospital's protocols where possible.

Important points

- Carefully consider need for starting a sliding scale if patient eating/drinking normally and there is no other compelling indication; a poorly managed sliding scale ⇒ fluctuating glucose and ↑length of admission.
- Check cannula working before adjusting sliding scale (if not working could be why BG not improving/\u00fcing). prn insulin is not recommended due to risk of hypoglycaemia.

HOW TO PRESCRIBE

- Always give 5% glucose or glucose saline (4% glucose and 0.18% saline) ivi at 125 ml/h when CBG <15. If RF or mild HF give 5% glucose ivi at a slower rate. If severe HF give 10% glucose (preferably via central line) at 60–70 ml/h. KCl should be added according to individual needs (see pp. 218–19).
- State clearly to nursing staff the frequency with which CBGs are required: very sick patients (e.g. DKA/HONK) need CBGs every half-hour and ideally regular laboratory glucose readings (more accurate). If not very sick and CBGs stable (e.g. pre-operative), 2–4-hrly usually suffices.
- Stop oral hypoglycaemics and adjust for residual effects they may be having. Remember to reintroduce before stopping sliding scale!

*NB: glucose = dextrose. Low-strength glucose solutions used to be called dextrose solutions; this is now being phased out.

Amount of insulin: initial doses and adjustment

Prescribe 50 units of soluble insulin (Actrapid or Humulin S) in 50 ml normal saline to run via a syringe driver according to one of the regimens (A, B, C, D) below:

- 1 Start with regimen A, unless severe insulin resistance (i.e. normally takes ≥100 units sc insulin/day), in which case start with B.
- 2 If BG >10 (or >7 during acute MI, where target BG even lower) for 3 consecutive hourly tests and is ↑ing (or ↓ing by <25% in the past hour), step up to next sliding scale (i.e. if on A, step up to B; if on B, step up to C, etc).
- **3** If BG <3.5 mmol/l, step down to next scale (i.e. if on B, step down to A; if on C, step down to B, etc).

Coming off a sliding scale

Consider once eating/drinking normally and CBGs normal/stable:

 If post-DKA, change back only if urine free of ketones (ideally, blood ketones should also be checked) and pH back to normal.

199

CBG (=BM)	Insulin ivi (units/h)						
	Regime A	Regime B	Regime C**	Regime D**			
0.0-4.0*	0.5	0.5	0.5	0.5			
4.1-7.0	1	2	3	4			
7.1–9.0	2	4	6	8			
9.1–11.0	3	6	9	12			
11.1–13.0	4	8	12	16			
>13.0	6	12	18	24			

*Stop ivi for 15 min if severe hypoglycaemia (CBG <2.5 or symptoms) and give Rx as on p. 245. Otherwise treat more gently with 5–10% glucose ivi and maintain insulin infusion (esp if DKA). **Rarely needed; used mostly for patients with severe insulin resistance (i.e. on more than 100 units insulin/day before admission).

Reproduced with permission from Professor S Kumar, Dr A Rahim and Dr P Dyer, Endocrinology Department, University of Warwick Medical School.

- If postoperative and no reason to suppose change in needs (i.e. no infection), go straight back to pre-operative regimen.
- Avoid hypos by continuing ivi until 1st sc dose starts to work (usually 10–30 min). Always change from iv to sc before a meal.

The following is only a guide to how to start sc regimens (always consult your hospital's diabetes team if unsure):

- 1 Calculate daily requirements by doubling the number of units used in the past 12 h from the sliding scale. Note what fluids were given during this period.
- 2 Start qds sc regimen. If patient is well and CBGs very stable, this step may be omitted (i.e. go straight to a bd regimen). Give 1/3 of total daily dose at 10 pm (as intermediate, e.g. isophane, or long acting, e.g. glargine or determir, insulin) and give remaining 2/3 (as short-acting soluble insulin) divided equally between pre-breakfast, pre-lunch and pre-evening meal doses.
- 3 Start bd sc regimen: give 60% of daily dose pre-breakfast and the remaining 40% pre-evening meal, both doses as biphasic 30/70 insulin (e.g. Humulin M3 or Mixtard 30). Enquire about previous insulin regimens and control.

PRE-OPERATIVE GUIDELINES: GENERAL POINTS (FOR ALL PATIENTS)

Local protocols should be used if they exist, otherwise a sensible way to progress would be to:

- Ensure patient 1st on operating list and fast from midnight*.
- Stop all long-acting insulins the night before the operation.
- Withhold all DM medications for morning of operation.
- Prescribe 5 or 10% glucose ivi in case of hypoglycaemia.
- Proceed as per table below.

*If pm-only list, give light breakfast and normal morning medications (but no intermediate/long acting insulins), monitor CBG 1–2-hrly. Start sliding scale/GIK at 11am (unless well controlled type II) or if CBGs uncontrolled.

Type of Type II (control good) surgery		Type II (control poor/fasting glucose >10) or Type I		
	Monitor CBGs 2-hrly	Monitor CBGs 1-hrly		
Minor: expect	After operation give normal	Start sliding scale/GIK at 10 pm		
to eat normally	medications ASAP with a meal	the night before op. Give		
the same day	(sliding scale not usually	normal medications and meal		
	required)	ASAP after operation		
Major/GI: not	Start sliding scale/GIK if CBGs	Start sliding scale/GIK at 10pm		
expected to eat	not controlled**. Convert back	the night before operation.		
the same day	to normal medications once	Convert back to normal		
	CBGs stable and eating/drinking	medications once CBGs stable		
	normally	and eating/drinking normally		

**Uncontrolled CBGs = single reading >15 or consistently >10.

ANTICOAGULANTS

WARFARIN

Consult your local anticoagulant service if unsure about indications, doses or interactions. Refer as early before discharge as practicable so outpatient monitoring is arranged in time.

Basics

Oral anticoagulant for long-term Rx/Px of TE: loading (see below) usually takes several days and is initially *pro*thrombotic, so heparin (LMWH), which is effective immediately, is used as short-term cover until therapeutic levels are achieved.

Monitoring

Via INR = ratio of patient's PT (prothrombin time) to a control raised to the power of a variable dependent on exact reagents used in each lab. A target INR is set at the start of Rx, according to indication (see below); variations of ± 0.5 are acceptable.

BCSH guidelines for target INRs. Adapted with permission from *British Journal of Haematology* 1998; **101**: 374–387 including BCSH 2005 update, 2006; **132**: 277–285.

Indication	Target INR (± 0.5)
DVT/PE ¹	2.5
Thrombophilia (if symptomatic) ²	2.5
Paroxysmal nocturnal haemoglobinuria (PNH) ³	2.5
AF ⁴ (or other causes of cardiac emboli ⁵)	2.5
Bioprosthetic heart valves ⁶	2.5
Mechanical heart valves ⁷	3.5

1 Treat for ≥6 weeks if calf vein thrombosis, for ≥3 months if provoked proximal (peroneal or above) DVT/PE, for ≥6 months or lifelong if idiopathic venous TE or permanent risk factors. If recurrent DVT/PE *whilst on therapeutic Rx*, target INR = 3.5. Discuss all other than 1st presentation with anticoagulant service.

2 Arterial thrombosis in antiphospholipid syndrome is exception with target INR 3.5.

3 Paroxysmal nocturnal haemoglobinuria (PNH); only under guidance of consultant haematologist.

4 Maintain INR >2.0 for 3 weeks before and 4 weeks after elective DC cardioversion.

5 Dilated cardiomyopathy, mural thrombus post-MI or rheumatic valve disease.

6 Only for first 3-6 months post valve insertion at discretion of each centre.

7 For new generation aortic valves INR target 3.0.

Although not yet in the BCSH guidelines, a target INR of 2.5 is widely agreed for nephrotic syndrome (generally once albumin < 20 g/l).

HOW TO PRESCRIBE

Starting Rx (for acute thrombosis)

Check INR before 1st dose and every day for 4 days, then assess stability of INR and adjust accordingly. If on LMWH, do not stop until 2 days after therapeutic INR achieved.

For loading regimens, where possible use your hospital's own guidelines, since these often vary. Otherwise, it is sensible to use the BCSH guidelines:

Warfarin loading regimen. Adapted with permission of BMJ group from Fennerty A, et al. BMJ 1984; 288: 1268–1270.

Day 1		Day 2		Day 3		Day 4	
INR	Dose (mg)	INR	Dose (mg)	INR	Dose (mg)	INR	Dose* (mg)
<1.4	10	<1.8	10	<2.0	10	<1.4	>8
		1.8	1	2.0-2.1	5	1.4	8
		>1.8	0.5	2.2-2.3	4.5	1.5	7.5
				2.4–2.5	4	1.6–1.7	7
				2.6-2.7	3.5	1.8	6.5
				2.8–2.9	3	1.9	6
				3.0–3.1	2.5	2.0-2.1	5.5
				3.2–3.3	2	2.2–2.3	5
				3.4	1.5	2.4–2.6	4.5
				3.5	1	2.7-3.0	4
				3.6-4.0	0.5	3.1–3.5	3.5
				>4.0	0	3.6-4.0	3
						4.1-4.5	Miss 1 day
							then 2 mg
						>4.5	Miss 2 days
							then 1 mg

*Predicted maintenance dose.



Situations when doses (especially loading) may need review \downarrow doses if: age >80 yrs, LF, HF, post-op, poor nutrition, \uparrow baseline INR or taking drugs that potentiate warfarin (check for W+ symbols in this book) including almost all antibiotics. \uparrow doses if: taking drugs that inhibit warfarin (check for W- symbols in this book).

Herbal remedies/non-prescription drugs: can have significant interactions – always ask patients directly if taking any, as they may not realise the importance (e.g. glucosamine can \uparrow INR). Check each one with your hospital's drug information office for significance.

Alcohol and diet: can affect dosing, especially if intake varies – the goalposts will move for an individual's therapeutic range. *It is a common misconception that BMI influences response.*

NB: slow loading with 3–5 mg for 5–7 days achieves therapeutic levels with less overshoot and may be preferable for outpatient initiation in atrial fibrillation. (BCSH guidelines 3rd edition 2005 update www.bcshguidelines.com.)

If interrupting warfarin (e.g. before operation/procedure), assess thrombotic risk and use bridging anticoagulation with LMWH as necessary; do not reload post-op as above, but restart at usual dose + 50% for 2 days, then return to usual dose *if no contraindications* (e.g. bleeding/taking W+ drugs).

Make small infrequent dose changes unless INR dangerously high or low. 'Steering a supertanker' is a good analogy; there is often significant delay between dose changes and their fx.

Warfarin and surgery

Warfarin is often stopped 4–5 days ahead of surgery and other invasive procedures (\pm heparin cover until day of procedure). Exact protocol depends on procedure involved and risks of bleeding versus thrombosis: get senior advice from team doing the procedure and haematologists if at all unsure.

Warfarin and pregnancy

Warfarin is contraindicated in early pregnancy (teratogenic during weeks 6–12). Women of childbearing age must be counselled by a specialist prior to planning pregnancy (inc informed to do pregnancy test whenever a period is >2 days late) and any woman who is pregnant and on warfarin must be converted immediately to LMWH under specialist guidance.

Overtreatment/poisoning

Seek expert help from haematology on-call as xs vitamin K can make re-anticoagulation difficult, as fx can last for weeks $\therefore \Rightarrow$ \uparrow risk from condition that warfarin was started for.

Recommendations for Mx of excess warfarin (BCSH guidelines). Adapted with permission from *British Journal of Haematology* 1998; 101: 374–387 BCSH 2005 update.

INR	Action
3.0–6.0 if target 2.5	• \downarrow dose or stop warfarin; restart when INR
(4.0–6.0 if target 3.5)	<5.0
6.0–8.0 and no/minor bleeding	• Stop warfarin; restart when INR <5.0
>8.0 and no/minor bleeding	 Stop warfarin; restart when INR <5.0
	• If other bleeding risks (e.g. age $>$ 70 yrs, Hx of
	bleeding complications or liver disease) give
	phytomenadione (vit K_1) 0.5 mg* iv or 5 mg po
Major bleeding, e.g. ↓ing Hb or	Stop warfarin
cardiodynamic instability	 Phytomenadione (vit K₁) 5 or 10 mg iv,
	repeating 24 h later if necessary
	 Prothrombin complex concentrate
	30–50 units/kg not exceeding 3000 units
	(if unavailable give FFP** 15 ml/kg)

*Since the publication of the BCSH guidelines some clinicians advise larger doses of iv vit K, e.g. 2 mg.

**Although not stated in the BCSH guidelines it should be noted that FFP is not fully effective at warfarin reversal.

DABIGATRAN

Dabigatran etexilate (♥Pradaza), a direct thrombin inhibitor, is a new oral anticoagulant licensed for once-daily administration for extended thromboprophylaxis after elective total knee or hip replacement^{NICE}. It doesn't require monitoring of anticoagulant fx, and has fewer drug–food interactions than warfarin. NB: Caution if LF or RF.

HEPARIN

For immediate and short-term Rx/Px of TE. Two major types: low-molecular-weight heparins (LMWHs) and unfractionated heparin.

LMWHs

Given sc. \uparrow convenience (\downarrow monitoring, can give to outpatients). \downarrow incidence of HIT* and osteoporosis cf unfractionated heparin means now preferred for most indications (esp MI/ACS, DVT/PE Rx and pre-cardioversion of AF). Dalteparin (Fragmin), enoxaparin (Glexane) and tinzaparin (Innohep) are the most commonly used; each hospital tends to use one in particular; ask nurses which one they stock or call pharmacy. Prophylaxis does not need monitoring but do not use for >7–10 days if creatinine >150.

Monitoring of treatment with LMWH

Via peak anti-Xa assay: usually necessary only if renal impairment (i.e. creatinine >150), pregnancy or at extremes of Wt (i.e. <45 kg or >100 kg). Take sample 3–4 h post dose.

HIT* = heparin-induced thrombocytopenia

Much more common with unfractionated heparin but can occur with all heparins. Watch for ↓ing platelet count. Get senior help if concerned. Discuss investigation and Mx with haematologist. If HIT confirmed, stop heparin immediately – danaparoid (@rg@r@n) or lepirudin (Reflud@n) may be substituted.

Unfractionated heparin

Given iv*: quickly reversible (immediately if protamine given; see p. 207), which makes it useful in settings where desired amount of anticoagulation may change rapidly, e.g. perioperatively, if patient at \uparrow risk of bleeding, or if using extracorporeal circuits such as cardiopulmonary bypass and haemodialysis. Also used with recombinant fibrinolytics in AMI.

*Can be given sc (only for Px), but now largely replaced by LMWH.

Monitoring

Via APTT ratio (= Activated Partial Thromboplastin Time of patient plasma divided by that of control plasma). Results can (rarely) be given as patient's exact APTT: the normal range is 35-45 sec. You then need to calculate the ratio: take the middle of the normal range for your lab (e.g. 40 sec) for your calculations. *Target ratio is commonly* 1.5-2.5, but this can vary: check your hospital's protocol and aim for the middle of range. NB: there is no national (let alone international) consensus on methods of measuring APTT, so results are not yet standardised.

Starting iv treatment

- Load with 5000** units as iv bolus: prescribed on the 'onceonly' section of the drug chart (give 10 000** units if severe PE).
- 2 Set up ivi at 15–25 units/kg/h: usually = 1000–2000 units/h. A sensible starting rate is 1500 units/h, which can be achieved by adding 25 000 units of heparin to 48 ml of normal saline to make 50 ml of solution (500 units/ml), which runs at 3 ml/h via a syringe driver. This can be written up as follows:

DATE/ TIME	INFUSION FLUID	VOLUME	ADDITIVES IF ANY DRUG AND DOSE	RATE OF ADMIN	DURA- TION	DR'S SIGNATURE	TIME START- ED	SET UP BY SIG- NATURE	BATCH No.
08/01	Normal saline	50 ml	HEPARIN 25,000	units		TN			
	run at 3 ml per hour as ivi								

Figure 7 Drug chart showing how to write up heparin infusion.

 NB

 Dosing for co-therapy with fibrinolytics (according to ESC guidelines) is slightly different; see p. 210.

Check APTT ratio after 6 h, then 6–10 h until stable, and then daily at a minimum, adjusting to the following regimen:

This regimen is based on APTT *ratio* therapeutic range of 1.5–2.5. *Don't take sample from drip arm* (unless from site distal to ivi).

APTT ratio	Action
<1.2	Give 5000-unit bolus iv and ↑ivi by 200–250 units/h
1.2–1.5	Give 2500-unit bolus iv and ↑ivi by 100–150 units/h
1.5–2.5	No change
2.5-3.0	↓ivi by 100–150 units/h
>3.0	Stop ivi for 1 h then restart ivi, \downarrow ing by 200–250 units/h

Adjustments are safest made by writing a fresh ivi prescription at a different strength, but the same effect can also be achieved by calculating the appropriate rate change to the original prescription.

Variable rate of ivi (for fixed prescription of 25 000 units heparin in 50 ml saline):

Desired heparin ivi rate (units/h)	Rate of ivi (ml/h)	Desired heparin ivi rate (units/h)	Rate of ivi (ml/h)
1000	2.0	1500	3.0
1050	2.1	1550	3.1
1100	2.2	1600	3.2
1150	2.3	1650	3.3
1200	2.4	1700	3.4
1250	2.5	1750	3.5
1300	2.6	1800	3.6
1350	2.7	1850	3.7
1400	2.8	1900	3.8
1450	2.9	1950	3.9

Overtreatment/poisoning (all heparins)

If significant bleeding, stop heparin and observe: iv heparin has short $t_{1/2}$ (30 min–2 h), so fx wear off quickly. If bleeding continues or is life-threatening, consider iv protamine (1 mg per 80–100 units of heparin to be neutralised as ivi over 10 min. \downarrow doses if giving >15 min after heparin stopped). NB: protamine is less effective against LMWH, and repeat administration may be required.

Seek expert help from haematology on-call if in any doubt!

▼FONDAPARINUX

A new parenteral anticoagulant (synthetic pentasaccharide). Licensed for use in Rx of VTE and MI/ACS and Px of VTE in medical patients and patients undergoing orthopaedic or abdominal surgery. Monitoring is not necessary. Useful for Px of VTE for patients with history of HIT* or allergy to heparin. See BNF/SPC for dosing. NB: Caution if RF or LF.

THROMBOLYSIS

Thrombolysis is indicated for ischaemic complications of TE. Fibrinolytic drugs activate plasminogen to form plasmin that degrades fibrin. They are most commonly used for acute MI, ischaemic stroke or PE, but can also be used for other arterial (or venous) TE such as DVT, central retinal venous (or arterial) thrombosis, acute arterial TE or for clearing clotted catheters/cannulas. Most fibrinolytics are only licensed for some of these indications^{BNF}. Common side effects are bleeding (mostly mild and at iv sites; if severe or suspect cerebral bleed occurring, stop ivi and get senior help), N&V, \downarrow BP (improves if transiently \downarrow rate of ivi and raise legs). Serious reperfusion arrhythmias and mild hypersensitivity (inc uveitis) can also occur. Anaphylaxis and GBS occur rarely.

General guidance on thrombolysis for MI and stroke are as follows but always check your local protocol:

ACUTE MI; see pp. 230–33 for other steps in management Indications

(From Resuscitation Council (UK) guidelines 2005):

- Onset of (cardiac) chest pain <12 h + Hx compatible with MI + one of:
 - ST elevation ≥2 mV (= 2 small squares) in ≥2 adjacent chest leads
 - ST elevation >1 mV (=1 small square) in >2 limb leads
 - new LBBB: must assume it is new if cannot prove is old
- Onset of chest pain 12–24 h ago and evidence of an evolving infarct, e.g. ongoing chest pain or worsening ECG changes.

Note:

- Primary PCI is often preferred if available/not contraindicated.
- Posterior infarcts are also widely considered to be an indication for thrombolysis. Diagnosis can be hard (look for ST depression + dominant R wave in V1–3); get cardiology advice if suspicious.
- Treatment needs to be started ASAP as 'time = myocardium' and 'door to needle time' is important.

Sontraindications

From ESC guidelines 2008 (with permission from *European Heart Journal* 2008; **29**: 2909–2945). Local guidelines/checklists often exist and should be used if available: consult cardiology \pm haematology on-call if in any doubt.

Absolute:

- · Haemorrhagic stroke or stroke of unknown origin at any time
- · Ischaemic stroke in preceding 6 months
- CNS trauma or neoplasms
- Major trauma/surgery/head injury in preceding 3 weeks
- GI bleeding within the last month
- Known bleeding disorder
- Aortic dissection
- Non-compressible punctures (e.g. liver biopsy, lumbar puncture).

Relative

- TIA in past 6 months
- Oral anticoagulant therapy
- Pregnancy or within 1-wk post partum
- Refractory resuscitation
- Refractory hypertension (systolic >180 mmHg and/or diastolic >110 mmHg)
- Advanced liver disease
- Infective endocarditis
- Active peptic ulcer.

CHOICE OF AGENT

Always use your hospital's protocol if one exists – contact CCU, A&E or look on your hospital intranet for details.

Choose between streptokinase and a recombinant thrombolytic such as alteplase, reteplase or tenecteplase (each hospital tends to stock one in particular); see individual drug entries in common drugs section for dosing regimens.

NICE guidance recommends that, in hospitals, the choice of agent should take account of:

- 'The likely balance of benefit and harm (e.g. stroke) to which each of the thrombolytic agents would expose the individual patient.' Recombinant forms (compared with streptokinase) are probably more efficacious and have ↓incidence of allergic reactions, CCF and bleeding other than stroke. However they have ↑incidence of haemorrhagic stroke.
- 'Current UK clinical practice, in which it is accepted that patients who have previously received streptokinase should not be treated with it again.' Streptokinase is less effective and more likely to cause allergic reaction after first administration (due to Ab production). Don't give if patient has been given it in the past.
- 'The hospital's arrangements for reducing delays in the administration of thrombolysis.' Some agents are quicker to set up and administer and this can reduce 'door to needle times'.

Heparin co-therapy

Recombinant forms always need concurrent iv heparin for 24–48 h (this does not usually apply for *streptokinase*). Use your hospital's A&E/CCU protocol if one exists. Otherwise use *ESC guidelines:* 60 units/kg (max 4000 units) iv bolus, then ivi at 12 units/kg/h for 24–48 h (max 1000 units/h). Monitor APTT at 3, 6, 12, 24 and 48 h, with target APTT (\neq APTT \uparrow *ratio*!) of 50–70 sec. NB: this is different from 'standard' iv heparin regimens (see p. 204).

ACUTE ISCHAEMIC STROKE see algorithm on inside back cover for other steps in management.

Currently only alteplase is licensed for this indication and only if given ≤ 3 h from symptom onset (although ECASS-III trial shows evidence of benefit ≤ 4.5 h).

- Act quickly: 5% ↓ in efficacy per 5 min delay. Aim for 'door to needle' time of 30 min.
- Determine **exact** time of onset of 1st symptoms. If not clear, the last time patient was known to be normal should be used.
- Ensure glucose normal (e.g. check CBG).

Haemorrhagic stroke (or *risk* of) needs to be excluded; perform brain imaging immediately if any of the following apply^{NICE}:

- Indications for thrombolysis (see below) or early anticoagulation treatment
- On anticoagulant treatment
- Known bleeding tendency
- ↓GCS (<13)
- Unexplained progressive or fluctuating symptoms
- Papilloedema, neck stiffness or fever
- Severe headache at onset of stroke symptoms.

Indications and contraindications vary according to centre and research into risk/benefit is ongoing; always ensure you check your local protocol. Most centres currently use similar criteria to those shown on the next page.

NB: Consent (where possible) according to latest evidence: e.g. 1:8 chance of ↑improvement and 1:30 chance of symptomatic bleed.

When all of the above are satisfied give alteplase: total dose = 0.9 mg/kg (maximum 90 mg). 10% given as iv bolus over 2 min, remaining 90% given over 60 min via iv pump. Dissolve in water for injections to a concentration of 1 mg/ml or 2 mg/ml.

HOW TO PRESCRIBE

Indications	Contraindications		
Clinical signs of acute stroke	Rapidly improving or minor symptoms		
Clear time of onset	• Stroke or serious head injury in last		
 Treatment within 3 h of onset 	3 months		
 Haemorrhage excluded on 	• Past history of intracranial haemorrhage		
brain imaging	 Recent major surgery, GI bleed, etc. 		
 Age 18–80 yrs** 	• BP >185/110 mmHg*		
• Some centres use NIHSS to define	• INR >1.6 or other clotting disorder		
suitable severity (e.g. score of	• Infarction of >1/3 MCA territory seen on CT		
5–25, but can vary)	Fit at onset		

*If \uparrow BP is a contraindication can \downarrow BP with labetolol or GTN; get senior advice.

**Often given to older patients.

Post-thrombolysis management

- Bed rest for 24 h (flat bed recommended initially)
- Treat $\downarrow O_2/\downarrow$ glucose if present
- \downarrow glucose if >8 mmol/l
- Observations: every 15 min for 2 h, every 30 min for 6 h, then hrly
- No antiplatelet therapy for 24 h. Avoid cannulas, NGTs and ivis
- If BP >180/105 mmHg consider labetalol 10 mg iv over 1–2 min, then infusion at 2–8 mg/min
- If intracranial haemorrhage occurs, consider 5–10 units cryoprecipitate (± platelets ± FFP) and seek neurosurgical opinion.

CONTROLLED DRUGS

In the UK special 'Prescription requirements' apply to 'schedule' 1, 2 or 3 drugs only, the most likely of which to be prescribed by junior doctors are morphine, diamorphine, fentanyl, methadone, oxycodone (and less commonly buprenorphine or pethidine). The following must be written 'so as to be indelible, e.g. written by hand, typed or computer generated' (*NB: this is a recent change from*

previously having to be written by hand – only the signature now needs to be handwritten):

- Date
- The patient's full name and address and, where appropriate, age
- Drug name plus its form* (and, where appropriate, strength)
- Dosing regimen
- Total amount of drug to be dispensed *in words and figures* (e.g. for morphine 5 mg qds for one week (5 mg × 4 times a day × 7 days = 140) write: '140 milligrams = one hundred and forty milligrams')
- Prescriber's address must be specified (should already be on prescription form, e.g. hospital address).

*Omitting the form (e.g. tablet/liquid/patch) is a common reason for an invalid prescription. It is often assumed to be obvious from the prescription (e.g. fentanyl as a patch or Oramorph as a liquid), but it still has to be written even if only one form exists.

These requirements *don't* apply to temazepam (despite being schedule 3), schedule 4 drugs (e.g. benzodiazepines) and schedule 5 drugs (such as codeine, dihydrocodeine/DF11® and tramadol). For full details on controlled drug guidance in the UK see www.dh.gov.uk/controlleddrugs.

This page intentionally left blank

Miscellaneous

Intravenous fluids	216
Steroids	219
Sedation/sleeping tablets	221
Benzodiazepines	223
Side effect profiles	224
Cytochrome P450	228

INTRAVENOUS FLUIDS

CRYSTALLOIDS

Isotonic: used mostly for maintenance (replacement) regimens:

- Normal (0.9%) saline: 1 litre contains 150 mmol Na⁺. Use as default maintenance fluid in all situations unless local protocol dictates otherwise. Caution in ↑Na⁺ and liver dysfunction.
- 5% glucose*: 1 litre contains 278 mmol (=50 g) glucose, which is rapidly taken up by cells and included only to make the fluid isotonic (calories are minimal, at 200 kcal). Used as method of giving pure H₂O and as ivi with insulin sliding scales (see p. 197). NB: commonest cause of ↓Na⁺ in hospital is overuse of 5% glucose as fluid replacement.
- Glucose* saline: 1 litre contains mixture of NaCl (30 mmol Na⁺) and glucose (4% = 222 mmol). Useful as contains correct proportions of constituents (excluding KCl, which can be added to each bag) for average daily requirements (see below).
 Suboptimal long term, as does not account for individual patient needs (esp if these are far from average). Also used as ivi in insulin sliding scales (see p. 196).

Non-isotonic: used less commonly; only for use in specialist/emergency situations by those accustomed to their use:

- Hypertonic (5%) saline: 1 litre contains 856 mmol Na⁺; given mostly for severe hyponatraemia. Seek specialist help first See.
- *Hypotonic (0.45%) saline:* for severe ↑Na⁺ (e.g. HONK).
- 10% and 20% glucose*: for mild/moderate hypoglycaemia.
- 50% glucose*: for severe hypoglycaemia (see p. 245) and if insulin being used to lower K⁺ (see p. 248).
- Sodium bicarbonate (1.26% or move rarely 1.4%): useful replacement for 0.9% saline if ↓pH or ↑K⁺ which often coexist. Not isotonic so caution re: salt load and accompanying fluid retention. Seek specialist help from nephrologists/others accustomed to its use .

*NB: glucose = dextrose. Low-strength glucose solutions used to be called dextrose solutions; this is now being phased out.

COLLOIDS (= plasma substitutes/expanders)

- Gelofusine: gelatin-based and used in resuscitation of shock (non-cardiogenic). NB: the electrolyte contents are often overlooked: 1 litre Gelofusine has 154 mmol Na⁺.
- Hartmann's solution: compound sodium lactate, used in surgery/trauma (also 1 litre contains 5 mmol K⁺). Avoid if RF.
- Blood/packed cells: helpful to ↑/maintain plasma oncotic pressure.

STANDARD DAILY REQUIREMENTS

= 3 litres H_2O , 40–70 mmol K⁺, 100–150 mmol N a⁺.

If no oral intake (preoperative, \downarrow GCS, unsafe swallow, post-CVA, etc), this can be provided as follows:

DATE	INFUSION FLUID	VOL- UME	ADDITIVES IF ANY DRUG AND DOSE	RATE OF ADMIN	DURA- TION	DR'S SIGNATURE	TIME START- ED	TIME COM- PLETED	SET UP BY SIG- NATURE	BATCH No.
08/01	5% Glucose	1 litre	20 mmal KCI		86	TN				
08/01	Normal saline	1 litre			8h	TN				
08/01	S% Glucose	1 litre	20 mmal KCI		8 h	TN				

Figure 8 Drug chart showing how to write up intravenous fluids.

This '2 sweet (5% glucose), 1 sour (0.9% saline)' regimen is commonly used in fit pre-operative patients. If in any doubt, normal (0.9%) saline is generally safest unless liver failure (see below) or if Na⁺ outside normal range (\downarrow or \uparrow). Always get senior help if unsure: incorrect fluids can be as dangerous as any other drug.

Individual requirements may differ substantially according to:

- Body habitus, age, residual oral intake, if on multiple iv drugs (which are sometimes given with significant amounts of fluid).
- Insensible losses (normally about 1 litre/day). $\hat{}$ skin losses if fever or burns. $\hat{}$ lung losses in hyperventilation or inhalation burns.

MISCELLANEOUS

- GI losses (normally about 0.2 litre/day). Any vomiting (↑Cl⁻ content) or diarrhoea (↑K⁺ content) must be taken into account as well as less obvious causes, e.g. ileus, fistulae.
- Fluid compartment shifts, esp vasodilation if sepsis/anaphylaxis.

All the above points seem obvious but are easy to forget!

K⁺ CONSIDERATIONS

Do not give >10 mmol/h unless K⁺ dangerously low, when it can be given quicker (see p. 248). Surgical patients often need less K⁺ in 1st 24 h post-op, as K⁺ is released by cell death (\therefore proportional to extent of surgery).

IMPORTANT POINTS

- Take extreme care if major organ failure:
 - Heart failure: heart can quickly become 'overloaded' and ⇒ acute LVF. Even if not currently in HF, beware if predisposed (e.g. Hx of HF or IHD).
 - Renal failure: unless pre-renal cause (e.g. hypovolaemia), do
 not give more fluid than residual renal function can deal
 with. Seek help from renal team if at all concerned; good
 fluid Mx greatly influences outcomes in this group. Only use
 saline unless specialist advice taken.
 - Liver failure: often preferable to use 5% glucose. Serum Na⁺ may be ↓d, but total body Na⁺ is often ↑d. Any saline will work its way into the wrong compartment (e.g. peritoneal fluid ∴ îng ascites) but may be essential to ensure renal perfusion (RF often coexists).
- If in doubt, give 'fluid challenges': small volumes (normally 200–500 ml) of fluid over short periods of time, to see whether clinical response to BP, urine output or left ventricular function is beneficial or detrimental before committing to longer-term fluid strategy.
- In general, encourage oral fluids: homeostasis (if normal) is safer, less expensive and less consuming of doctor/nurse time than iv fluids. Beware if ↓swallow, fluid overload (esp if HF or RF), pre-/ post-operative or if homeostasis disorders (esp SIADH).

- Check the following before prescribing any iv fluids:
 - Clinical markers of hydration: skin turgor/temperature, mucous membranes, JVP, peripheral oedema, pulmonary oedema. Often overlooked and very useful!
 - Recent input and output: if at all concerned, ask nurses for strict fluid balance chart. However, on a busy ward this is difficult to achieve so daily weights often most informative.
 - Recent U&Es, esp K⁺.

It can be difficult to elicit all this information under time pressure. The trick is to know when to take extreme care. Be particularly careful if you do not know the patient when on call, and be wary when asked to 'just write up another bag' without reviewing the patient. Often, you will be asked to prescribe fluids when no longer necessary or even when they may be harmful. To save time for those on call (and to ↑ the chances of your patients getting appropriate fluids), leave clear instructions with the nurses and on the drug chart for as long as can be sensibly predicted (esp over weekends/long holidays).

STEROIDS

CORTICOSTEROIDS

Drug	Equivalent		
	dose	Main uses	
Prednisolone	5 mg	Acute asthma/COPD, rheumatoid arthritis (po)	
Methylprednisolone	4 mg	Acute flares rheumatoid arthritis/MS (iv)	
Dexamethasone	750 μg	↑ICP, CAH, Dx Cushing's (iv/po)	
Hydrocortisone	20 mg	Acute asthma/COPD (iv)	

The most commonly used systemic drugs are:

Glucocorticoid fx predominate; mineralocorticoid fx for these are all mild apart from hydrocortisone (has moderate fx) and dexamethasone (has minimal fx \therefore used when H₂O and Na⁺ retention are particularly undesirable, e.g. \uparrow ICP).

Side effects = Cushing's syndrome!

- Metabolic: Na⁺/fluid retention^{*}, hyperlipoproteinaemia, leukocytosis, negative K⁺/Ca²⁺/nitrogen balance, generalised fluid/electrolyte abnormalities.
- *Endocrine:* hyperglycaemia/↓GTT (can ⇒ DM), adrenal suppression.
 - *Fat**: truncal obesity, moon face, interscapular ('buffalo hump') and suprascapular fat pads.
 - Skin: hirsutism, bruising/purpura, acne, striae, ↓healing, telangiectasia, thinning.
 - Other: impotence, menstrual irregularities/amenorrhoea, ↓growth (children), ↑appetite*.
- GI: pancreatitis, peptic/oesophageal ulcers: give PPI if on ↑doses.
- Cardiac: HTN, CCF, myocardial rupture post-MI, TE.
- Musculoskeletal: proximal myopathy, osteoporosis, fractures (can ⇒ avascular necrosis).
- Neurological: ¹epilepsy, ¹ICP/papilloedema (esp children on withdrawal of corticosteroids).
- Ψ : mood Δs (\uparrow or \downarrow), psychosis (esp at \uparrow doses), dependence.
- Ocular: cataracts, glaucoma, corneal/scleral thinning.
- *Infections:* \$usceptibility, \$speed (\$severity at presentation), TB reactivation, \$\prisk of chickenpox/shingles/measles.



SEs are dose-dependent

If patient is on high doses, make sure this is intentional: it is not rare in fluctuating (e.g. inflammatory) illnesses for patients to be left on high doses by mistake. Seek specialist advice if unsure. If on long term Rx consider giving Calvit D supplements/ bisphosphonate to \downarrow risk of osteoporosis and PPI to \downarrow risk of GI ulcer.



Cautions

Can mostly be worked out from the SEs. Caution should be taken if patient already has a condition that is a potential SE. Systemic corticosteroids are CI in systemic infections (w/o antibiotic cover). NB: avoid live vaccines. If never had chickenpox, avoid exposure.

Interactions

Apply to all systemic Rx. fx can be $\downarrow d$ by rifampicin, carbamazepine, phenytoin and phenobarbital. fx can be $\uparrow d$ by erythromycin, ketoconazole, itraconazole and ciclosporin (whose own fx are $\uparrow d$ by methylprednisolone). $\uparrow risk$ of $\downarrow K^+$ with amphotericin and digoxin.

Withdrawal effects

Acute adrenal insufficiency (= Addisonian crisis; & can be fatal see p. 247): \downarrow BP, fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy nodules, \downarrow Wt. \therefore must withdraw slowly if patient has had >3 wks Rx (or a shorter course w/in 1 year of stopping longterm Rx), other causes of adrenal suppression, received high doses (>40 mg od prednisolone or equivalent), or repeat doses in evening, or repeat course. Also note intercurrent illness, trauma, surgery needs \uparrow doses and can precipitate relative withdrawal.

Steroid Rx card must be carried by all patients on prolonged Rx.

MINERALOCORTICOIDS e.g. fludrocortisone

Used for Addison's disease and acute adrenocortical deficiency (rarely needed for hypopituitarism). Can also be used for orthostatic/postural hypotension. Main SEs are H_2O/Na^+ retention.

SEDATION/SLEEPING TABLETS

ACUTE SEDATION/RAPID TRANQUILLISATION

For the acutely agitated, disturbed or violent patient (and for temporary sedation before unpleasant procedures).

Important points

- Organic causes (i.e. delirium) are commonest cause outside of Ψ wards: look for and treat sepsis, hypoxia, drug withdrawal (esp alcohol/opiates) and metabolic causes (esp hypoglycaemia).
- A well-lit calm room and reassurance can be all that is required.
- Oral medications should be tried first if possible.
- Obtain as much drug Hx as possible, esp of antipsychotics and benzodiazepines as influences selection of appropriate agent/dose.

MISCELLANEOUS

Antipsychotics

- ☺ Taking benzodiazepines, elderly (use with caution, esp if ↑ risk of CVA), delirium (non-alcohol withdrawal), psychosis (e.g. hallucinations/delusions/schizophrenia).
- Antipsychotic-naive, alcohol withdrawal, cardiac disease, movement disorders (esp Parkinson's; de novo extrapyramidal fx are also common – see p. 227).
- Haloperidol 0.5–5 mg po (or im/iv if necessary). 1–2 mg is sensible starting dose for delirium in elderly. 5 mg is safe for acute psychosis in young adults. Maximum 18 mg im or 30 mg po in 24 h.
- If suspect *acute schizophrenia* use atypical antipsychotic as 1st-line^{NICE}, e.g. olanzapine 10 mg po (⇒ ↓SEs) – now also available im.

Benzodiazepines

- © Alcohol withdrawal, anxiety.
- ® Respiratory disease (⇒ respiratory depression; care if COPD/asthma), elderly (⇒ falls and rarely paradoxical agitation/aggression but can use with caution/↓ doses).
- Lorazepam 0.5–1 mg po/im/iv (maximum 4 mg/24 h). Shorteracting than diazepam ∴ better if hepatic impairment.
- Diazepam 2-5 mg po/iv (if iv preferably as Diazemuls) or 10-20 mg pr. Can [†]doses^{SPC/BNF} esp if tolerance/much previous exposure to benzodiazepines.
- Midazolam 1.0–7.5 mg iv: titrate up slowly, according to response. Requires iv access and is used mostly for cooperative patients ahead of unpleasant procedures (less suitable for very agitated patients). Also wears off relatively quickly.

SLEEPING TABLETS

Try to avoid giving:

 For >2-4 wks (dependency common). Try reassurance/^'sleep hygiene' (see www.rcpsych.ac.uk/mentalhealthinfoforall/

problems/sleepproblems/sleepingwell.aspx)/non-pharmacological measures 1st. Treat depression if 1° cause.

• At all if hepatic encephalopathy or ↓respiratory reserve (esp asthma/ COPD; NB: *hypoxia can also* ⇒ *restlessness and agitation*!).

Choose from:

- 1 **Benzodiazepines:** 1 the major inhibitory neurotransmitter GABA via their own (benzodiazepine) receptor.
- *Temazepam* 10 mg nocte (can ↑to 20 mg).

Halve doses if LF (avoid if severe; consider oxazepam, or lorazepam instead), RF or elderly.

- 2 'Z'/Benzodiazepine-like drugs: similarly *s* GABA.
- Zopiclone 7.5 mg nocte
- Zolpidem 10 mg nocte
- Zaleplon 10 mg nocte.

Halve doses if LF (avoid if severe), RF or elderly.

- 3 Sedating antihistamines: are a good alternative: ⇒ ↓respiratory depression/addiction but ↑hangover drowsiness; effectiveness may ↓ after several days of Rx ∴ good for inpatients as short-term Rx.
- Promethazine 25 mg nocte (can ↑dose to 50 mg).

BENZODIAZEPINES

Varying pharmacokinetics are utilised. If shorter-acting, $\Rightarrow \downarrow$ hangover/drowsiness (and \downarrow accumulation in LF) but $\Rightarrow \uparrow$ withdrawal fx when stopped.

ADVERSE EFFECTS

Segmentation and the segmentat

Especially in elderly and if naive to benzodiazepines. Put on close nursing observation and monitor O_2 sats if concerned. If using very high doses, get iv access and have flumazenil at hand.



MISCELLANEOUS

- Dependence/tolerance: common .. prescribe long-term benzodiazepines only if absolutely necessary and withdraw ASAP. In order to withdraw safely, if not already on one, swap to longacting drug (e.g. diazepam) and take 1/8 off the dose every 2 weeks. Try β-blockers to reduce anxiety (avoid antipsychotics).
- Withdrawal symptoms: rebound insomnia, tremor, anxiety, confusion, anorexia, toxic psychosis, convulsions, sweating.

Comparison of commonly used benzodiazepines; adapted from www.benzo.org.uk (an excellent resource for information on benzodiazepines), with permission from Professor C.H. Ashton, Institute of Neuroscience, University of Newcastle, UK.

t _{1/2} (h) ¹	Drug	Equivalent dose (mg) ¹	Main use(s)
2–3	Midazolam	N/A	Temporary sedation for procedures (titrated iv)
4–15	Oxazepam	20	Good in LF (↓accumulation of metabolites)
6–12	Alprazolam ²	0.5	Anxiety
6–12	Loprazolam ²	1–2	Anxiety, insomnia
8–20	Lorazepam	1	Status epilepticus (iv), acute Ψ sedation (im/po)
8–22	Temazepam	20	Insomnia
12-60	Clobazam	20	Epilepsy, anxiety
18–50	Clonazepam	0.5	Movement disorders, epilepsy and Ψ disorders
36–200 ³	Diazepam	10	Status epilepticus (iv/pr), anxiety, alcohol withdrawal
36-200 ³	Chlordiazepoxide	25	Alcohol withdrawal

¹These are approximate and can vary considerably between individuals. ²Rarely used in the UK. ³These values are for the *active metabolite*.

SIDE EFFECT PROFILES

Knowledge of these, together with a drug's mechanism(s), will simplify learning and allow anticipation of drug SEs.

CHOLINOCEPTORS

ACh stimulates nicotinic and muscarinic receptors. Anticholinesterases \Rightarrow ACh and \therefore stimulate both receptor types and have 'cholinergic fx'. Drugs that \downarrow cholinoceptor action do so mostly via muscarinic receptors (antinicotinics used only in anaesthesia) and are \therefore more accurately called 'antimuscarinics' rather than 'anticholinergics'.

Cholinergic fx	Antimuscarinic fx
Generally ↑secretions	Generally ↓secretions
Diarrhoea	Constipation
Urination	Urinary retention
Miosis (constriction)	Mydriasis/ \downarrow accommodation*
Bronchospasm/bradycardia**	Bronchodilation/tachycardia
Excitation of CNS (and muscle)	Drowsiness, Dry eyes, Dry skin
Lacrimation \uparrow	
Saliva/sweat ↑	
Commonly ca	used by:
Anticholinesterases:	Atropine, ipratropium (Atrovent)
MG Rx, e.g. pyridostigmine	Antihistamines (inc cyclizine)
Dementia Rx, e.g. rivastigmine, donepezil	Antidepressants (esp TCAs)
	Antipsychotics (esp 'typicals')
	Hyoscine, la antiarrhythmics

* \uparrow blurred vision and \uparrow IOP. ** Together with vasodilation $\Rightarrow \downarrow$ BP.

ADRENOCEPTORS

α generally excites sympathetic system (except*):

- α1 ⇒ GI smooth-muscle relaxation*, otherwise contracts smooth muscle: vasoconstriction, GI/bladder sphincter constriction (uterus, seminal tract, iris (radial muscle)). Also ↑salivary secretion, ↓glycogenolysis (in liver).
- α₂ ⇒ inhibition of neurotransmitters (esp NA and ACh for feedback control), Pt aggregation, contraction of vascular smooth muscle, inhibition of insulin release. Also prominent adrenoceptor of CNS (inhibits sympathetic outflow).

β generally inhibits sympathetic system (except*):

- $\beta_1 \Rightarrow \uparrow HR^*$, $\uparrow contractility^*$ (and $\uparrow s$ salivary amylase secretion).
- β₂ ⇒ vasodilation, bronchodilation, muscle tremor, glycogenolysis (in hepatic and skeletal muscle). Also ↑s renin secretion, relaxes ciliary muscle and visceral smooth muscles (GI sphincter, bladder detrusor, uterus if not pregnant).
- β₃ ⇒ lipolysis, thermogenesis (of little pharmacological relevance).

SEROTONIN (5HT)

Relative excess: **'serotonin syndrome'**; seen with antidepressants at †doses or if swapped without adequate 'tapering' or 'washout period'. Initially causes restlessness, sweating and tremor, progressing to shivering, myoclonus and confusion, and, if severe enough, convulsions/death.

Relative deficit: 'antidepressant withdrawal/discontinuation syndrome' occurs when antidepressants stopped too quickly; likelihood depends on $t_{1/2}$ of drug. Causes 'flu-like' symptoms (chills/sweating, myalgia, headache and nausea), shock-like sensations, dizziness, anxiety, irritability, insomnia, vivid dreams. Rarely \Rightarrow movement disorders and \downarrow memory/concentration.

DOPAMINE (DA)

Relative excess: causes behaviour Δ , confusion and psychosis (esp if predisposed, e.g. schizophrenia). Seen with L-dopa and DA agonists used in Parkinson's (and some endocrine disorders, e.g. bromocriptine).

Relative deficit: causes extrapyramidal fx (see below), ↑prolactin (sexual dysfunction, female infertility, gynaecomastia), neuroleptic malignant syndrome. Seen with DA antagonists, esp antipsychotics and certain antiemetics such as metoclopramide, prochlorperazine and levomepromazine.

EXTRAPYRAMIDAL EFFECTS

Abnormalities of movement control arising from dysfunction of basal ganglia.

- Parkinsonism: rigidity and bradykinesia ± tremor.
- Dyskinesias (= abnormal involuntary movements); commonly:
 - Dystonia (= abnormal posture): dynamic (e.g. oculogyric crisis) or static (e.g. torticollis).
 - Tardive (delayed onset) dyskinesia: esp orofacial movements.
 - Others: tremor, chorea, athetosis, hemiballismus, myoclonus, tics.
- *Akathisia* (= restlessness): esp after large antipsychotic doses.

All are commonly caused by antipsychotics (esp older 'typical' drugs) and are a rare complication of antiemetics (e.g. metoclopramide, prochlorperazine – esp in young women). Dyskinesias and dystonias are common with antiparkinsonian drugs (esp peaks of L-dopa doses).

Most respond to stopping (or \downarrow dose of) the drug – if not possible, doesn't work or immediate Rx needed add antimuscarinic drug (e.g. procyclidine) but doesn't work for akathisia (try β -blocker) and can worsen tardive dyskinesia: seek neurology \pm psychiatry opinion if in doubt.

CEREBELLAR EFFECTS

Esp antiepileptics (e.g. phenytoin) and alcohol.

- Dysdiadokokinesis, dysmetria (= past-pointing) and rebound
- Ataxia of gait (wide-based, irregular step length) ± trunk
- Nystagmus: towards side of lesion; mostly coarse and horizontal
- Intention tremor (also titubation = nodding-head tremor)
- Speech: scanning dysarthria slow, slurred or jerky
- Hypotonia (less commonly hyporeflexia or pendular reflexes).

CYTOCHROME P450

Important inhibitors	Important inducers
Heart/liver failure	Cigarettes
Omeprazole	P henytoin
Fluoxetine/Fluconazole	C arbamazepine
Disulfiram	B arbiturates (e.g. phenobarbital)
Erythromycin and clarithromycin	R ifampicin
Valproate	Alcohol (chronic abuse*)
Isoniazid	Sulphonylureas/St John's wort
Cimetidine/Ciprofloxacin	
EtOH (acute abuse – note chronic abuse can induce!*)	
S ulphonamides	

Substrates of P450 that often result in significant interactions (these drugs can \uparrow severe problems if rendered ineffective or toxic by interactions \therefore always exclude interactions when prescribing!):

- Inhibitors and inducers can affect warfarin, phenytoin, carbamazepine, ciclosporin and theophyllines. Interactions can

 → toxicity or treatment failure.
- Inducers affect OCP ∴ can ↑ failure as contraceptive!

🌱 🛛 NB

This system is very complex and mediated by many isoenzymes; predicting significant interactions requires understanding which drugs are metabolised by which isoenzymes as well as which, and to what degree, other drugs affect these isoenzymes. Look for P450 symbols in this book as a rough guide; check SPCs if concerned (available online at www.emc.medicines.org.uk) and for a full overview of the P450 system see www.edhayes.com/startp450.html.

Medical emergencies

Acute coronary syndromes (ACS)	230
Acute LVF	233
Accelerated hypertension	234
Atrial fibrillation	235
Acute asthma	237
COPD exacerbation	238
Pulmonary embolism	238
Acute upper GI haemorrhage	239
Sepsis (severe or septic shock)	241
Epilepsy	241
DKA	243
HONK	245
↓Glucose	245
Thyrotoxic crisis	246
Myxoedema coma	247
Addisonian crisis	247
Electrolyte disturbances	248
Overdoses	249

ACUTE CORONARY SYNDROMES (ACS)

Clues: angina, N&V, sweating, LVF (see p. 233), arrhythmias , Hx of IHD. Remember atypical pain and silent infarcts in DM, elderly or if \downarrow GCS.

ACS encompasses the following:

- 1 STEMI: ST elevation myocardial infarction (see p. 207).
- **2 NSTEMI:** Non-ST elevation MI; troponin (T or I) +ve.
- **3** UA(P): Unstable angina (pectoris); troponin (T or I) -ve.

FOR ALL ACS

- O₂: maximal flow through re-breather mask (care if COPD).
- Aspirin: 300 mg po stat (chew/dispersible form) unless CI. If in A&E, check has not been given already by paramedics or GP.
- Clopidogrel: 300 mg po (some give 600 mg, esp if immediate PCI planned). Some centres now use prasugrel see local guidelines for details.
- Opiate: in UK most centres give diamorphine 2.5–5 mg iv + antiemetic (e.g. metoclopramide 10 mg iv), repeat diamorphine iv according to response. Morphine is an alternative, initially 3–5 mg iv, repeating every few minutes until pain free.
- *GTN*: 1–2 sprays or sl tablets (max 1.2 mg). If pain continues or LVF develops, set up ivi, titrating to BP and pain. NB: can $\Rightarrow \downarrow$ BP; don't give if systolic \leq 100 mmHg (esp if combined with \downarrow BP) or inferior infarct (i.e. suspected RV involvement).

DATE/ TIME	INFUSION FLUID	VOL- UME	ADDITIVES IF ANY DRUG AND DOSE	RATE OF ADMIN	DURA- TION	DR'S SIGNATURE	TIME START- ED	SET UP BY SIG- NATURE	BATCH
25/12	N. Saline	50 ml	SO mg GTN	0-10 /	n//hr*	TN			
	*7176	RATE TO) PAIN: Stop if sys	stolic BP	< 100) mmHg			

Figure 9 Drug chart showing how to write up GTN ivi.

Consider:

- - Can be given iv or po: it is often recommended to give iv for STEMI and po for NSTEMI and UAP. In acute settings, metoprolol is often drug of choice as short t_{1/2} (if chronic LVF use bisoprolol) means it wears off quickly if acute LVF develops. Consult local protocol or get senior advice if unsure.
 - *iv*: e.g. metoprolol 1–5 mg iv, giving 1–2 mg aliquots at a time while monitoring BP and HR. Repeat to max 15 mg, stopping when BP ≤100 mmHg or HR ≤60. Then consider starting metoprolol po.
 - po: e.g. metoprolol 25–50 mg bd. If cardiodynamically stable 24 h later, change to long-acting β-blocker, e.g. bisoprolol 5–10 mg od.
 - If already on β -blocker, ensure dose adequate to control HR.
 - If β-blocker CI and \uparrow HR consider Ca²⁺ blocker (e.g. diltiazem SR 60–120mg bd) and get senior ± cardiology advice.
- *Insulin:* for all type I DM and type II DM or non-diabetics with CBG >11 on admission. Give conventional sliding scale or GIK ivi (e.g. DIGAMI) if local protocol exists; contact CCU for advice.
- *iv fluids*: if RV infarct. *Clues*: ↓BP with no pulmonary oedema, inferior or posterior ECG Δs (esp ST elevation ≥1 mm in a VF) and ↑JVP. If suspected, do right-sided ECG and look for ↑ST in V4. Avoid vasodilating drugs (esp nitrates and ACE-i). Care with β-blockers (can ⇒ HB).

IF STEMI

• Reperfusion therapy: primary PCI is the preferred option, if unavailable or CI consider thrombolysis. NB: starting one or the other ASAP is paramount ('time = myocardium'!) ∴ if appropriate, initiate/organise during above steps. See p. 207 for thrombolysis indications, CIs and choice of agent.

2 MEDICAL EMERGENCIES

- Heparin: iv heparin is given with recombinant thrombolytics for 24–48 h (see p. 207) to avoid the rebound hypercoagulable states they can cause, but is not needed with streptokinase. If ongoing chest pain or unresolving ECG Δs, get senior advice on further anticoagulation and arrange rescue PCI.
- Consider (consult local protocol/cardiology on-call if unsure):
 - Glycoprotein IIb/IIIa inhibitor: esp if not thrombolysed (CI or presentation too late) or PCI planned and still unstable. Use with caution (esp <48 h post-thrombolysis).
 - Rescue PCI: esp if thrombolysis given and doesn't ↓pain (e.g. within 90 min) or non-resolving (e.g ≤50% reduction in) ST elevation on ECG.

IF NSTEMI OR UAP

- Heparin: LMWH, e.g. enoxaparin 1 mg/kg bd sc or fondaparinux 2.5 mg od sc esp if PCI planned in 1st 24–36 h after symptom onset.
- Consider (consult local protocol/cardiology on-call if unsure):
 - Glycoprotein IIb/IIIa inhibitor: if high risk* (defined by ACC/ESC as: haemodynamic or rhythm instability, persistent pain, acute or dynamic ECG Δs, TIMI risk score >3 (see below),

TIMI risk score for UA/NSTEMI. (Source: Antman E, et al. JAMA 2000; 284: 835–842).

1 point for presence of each of the following:

- Age ≥65 yrs
- ≥3 of following risk factors for IHD: FHx of IHD, ↑BP, ↑cholesterol, DM, current smoker
- Prior coronary stenosis (≥50% occlusion)
- Aspirin use in past 7 days
- Severe angina (≥2 episodes w/in 24 h)
- ST segment deviations (\uparrow or \downarrow) at presentation
- +ve serum cardiac markers (troponin).

Score >3 indicates \uparrow risk* of developing cardiac events and death.

 \downarrow left ventricular function, \uparrow troponin) and/or ongoing chest pain/ECG Δ s.

SECONDARY PREVENTION

For all ACS unless CI or already started:

- Next day: aspirin 75 mg od, 'statin' (e.g. simvastatin 40 mg od) and clopidogrel 75 mg od (for 1 yr^{NICE}). If prasugrel used (instead of clopidogrel) see local guidelines for dose.
- When stable: β-blocker (if not already started, e.g. bisoprolol 1.25 mg od once any LVF clears; see above for CI) and ACE-i (e.g. ramipril 2.5 mg bd po started 2–10 days after MI, then 5 mg bd after 2 days if tolerated). Consider addition of aldosterone antagonist eplerenone in established LVF (EF <40%) and signs of HF after 3 days (closely monitor U&Es).
- *ASAP*: diet/lifestyle Δ s (\downarrow Wt, diet Δ s, \uparrow exercise, \downarrow smoking, etc).

ACUTE LVF

Clues: SOB, S_3 or S_4 , pulmonary oedema (can \Rightarrow pink frothy sputum if severe), peripheral oedema, \downarrow BP, Hx of IHD, \uparrow JVP (if also RVF, i.e. CCF).

- 60–100% O₂ to maintain SaO₂ >95% (care if COPD) and sit patient upright.
- Furosemide 20–40 mg iv initially (max 100 mg in 1st 6 h); consider repeat doses or ivi (5–40 mg/h) later. If not 'in extremis', consider ↓doses (40 or 60 mg) od and monitor urine output.
- Diamorphine 2.5–5.0 mg iv + metoclopramide 10 mg iv.
- GTN ivi: see ACS section pp. 230–233.

If patient does not respond/worsens, get senior help and consider:

- Non-invasive ventilation (NIV) as continuous positive airways pressure (CPAP). If no machine on ward, find one ASAP!
- Inotropes: if ↓BP, e.g. dobutamine (2–20 μg/kg/min) via central line; if patient is this sick, will also be needed for CVP

measurement and CCU care (± intra-aortic balloon pump). Get cardiology advice if needed.

• *?Underlying cause:* MI, arrhythmias (esp AF), ↑↑BP, ↓↓Hb, ARF, anaphylaxis, sepsis, ARDS, poisons/OD (e.g. aspirin).

ACE-i: once stable and if no CI, e.g. enalapril 2.5 mg od (¹later).

ACCELERATED HYPERTENSION

Dx: diastolic >120 mmHg (or systolic >220 mmHg) plus grade III (haemorrhages/exudates) or IV (papilloedema) hypertensive retinopathy. Do not drop BP too quickly as can e.g. \Rightarrow MI, CVA or ARF &. NB: patients are often salt and water depleted (look for postural drop of >20 mmHg) so may require fluid replacement as well as antihypertensives.

If life-threatening target organ damage (e.g. encephalopathy, intracranial haemorrhage, aortic dissection, unstable angina, acute MI, acute LVF/pulmonary oedema or pre-eclampsia/ eclampsia): get senior help immediately and aim to ↓diastolic to 110–115 mmHg over 4–6 h and then more slowly thereafter (e.g. ↓diastolic to 100 mmHg after 48 h). This should always be done in the ITU/HDU/CCU setting and generally (but not always) involve iv antihypertensives; choose from nitroprusside (most commonly used but can \Rightarrow cyanide poisoning, esp used in if RF), hydralazine (commonly used in pregnancy), labetalol (in pregnancy but can \Rightarrow severe ↓BP) or phentolamine (esp if phaeo known/ suspected). If pulmonary oedema, consider GTN/ISDN.

If no life-threatening target organ damage (i.e. renal failure, mild LVF, etc): aim to \downarrow diastolic BP to 110–115 mmHg over 24–48 h using *oral* medication such as:

- Nifedipine (e.g. Adalat Retard) 10 mg po. Monitor and reassess; consider repeat doses (e.g. after 2 h) and if required/tolerated aim to get patient on to higher doses (e.g. 20 mg tds). Tablets to be swallowed (not chewed) and avoid quick release or sl preparations. Convert to amlodipine once stable.
- If IHD consider adding β-blocker* later (e.g. atenolol 25–50 mg od).

- If nifedipine CI, consider diltiazem (e.g. 60 mg SR bd initially) or β-blocker instead*: metoprolol is good choice (e.g. 12.5–25 mg initially then tds regimen) as short acting and needs no dose adjustment in RF. When BP controlled withdraw β-blocker except in IHD (risk of new-onset DM). In IHD consider converting to atenolol (e.g. 50 mg po) once stable.
- Other drugs to consider are ACE-i** (can ⇒ severe ↓BP; if so give iv saline) and diuretics (if patient fluid overloaded).

*If cause is phaeo: will need α -blocker (phenoxybenzamine) and may need salt supplements. If tachycardia a problem, must not give β -blocker until several days after α -blocker started. Suspect if BP very variable, headaches, sweats or palpitations; get senior help.

**Beware: if cause renal artery stenosis (other clinical vascular disease/multiple CVD risk factors/ \downarrow GFR) if possible avoid renin system blockade (i.e. ACEi/ARB/direct renin inhibitor) as $\frac{1}{82}$ risk of severe \downarrow BP) and U&Es monitored (risk of RF including delayed onset after 3–4 weeks) $\frac{1}{82}$; if used, starting dose must be low (e.g. enalapril 2.5 mg od).

ATRIAL FIBRILLATION

Clues: $^{HR} \pm$ SOB, angina or heart failure. Confirm diagnosis with repeat ECGs; narrow QRS, absent 'P' waves (esp V1), (irregularly) irregular R-R interval.

Treatment (rate and rhythm control) depends on: presence of haemodynamic instability (systolic BP <90 mmHg), acuteness of onset (<48 h) and presence of structural heart disease (e.g. LVH: clinically/ECG/echo) or heart failure (clinically/CXR/echo).

For haemodynamically unstable patients:

 DC cardioversion (see ALS tachycardia algorithm on inside back cover); ideally after initiating anticoagulation* but this shouldn't delay emergency intervention^{NICE}.

For haemodynamically stable patients:

If acute onset (<48 h)

+ no evidence of structural heart disease: flecainide 100 mg bd po or 2 mg/kg iv over 30 min (max 150 mg) with appropriate

antithrombotic cover (e.g. enoxaparin 1.5 mg/kg daily); seek cardiology advice if unsuccessful and consider DC cardioversion. + evidence of structural heart disease (or any doubt): amiodarone 300 mg ivi over 20–60 min followed by 900 mg ivi over next 24 h and then 1.2-1.8 g/day (po or iv) until 10 g total. Then minimum maintenance dose (100-400 mg/day) to control sinus rhythm. If unsuccessful consider DC cardioversion.

If onset >48 h (or unknown)

+ no evidence of heart failure: β-blocker po (e.g. metoprolol 25–50 mg bd). If β -blocker CI (e.g. COPD/ asthma) use Ca²⁺ channel blocker (e.g. diltiazem MR 120 mg bd).

+ evidence of heart failure: digoxin 250-500 µg iv/po loading dose and two repeat half doses at 6-12-h intervals followed by appropriate maintenance dose (62.5-250 µg). Use half the dose if elderly or RF. Monitor levels and e'lytes to avoid toxicity (see p. 54).

- All inpatients initially need anticoagulation (e.g. LMWH); for paroxysmal, persistent and permanent AF^{NICE} use risk stratification for benefit and haemorrhagic risk to guide thromboprophylaxis; high stroke risk^{NICE} use warfarin (post stroke/TIA/TE; age \geq 75 with HTN, diabetes or vascular disease; structural heart disease or LVF; CHADS₂* >3); moderate risk^{NICE} use warfarin or aspirin (age $\geq 65 + \text{no risk factors; age } <75$ and HTN, diabetes or vascular disease); low risk^{NICE} use aspirin.
- If non-acute (planned) cardioversion anticoagulate ≥ 3 wks before (and after) cardioversion^{NICE}.

	*CHADS ₂ score for risk of stroke in (non-rheumatic) AF: JAMA 2001; 285: 2864–2870.				
	Congestive heart failure HxHypertension Hx	= 1 point = 1 point			
1.	Typertension fix	= i point			

- Age ≥ 75 = 1 pointDM Hx = 1 point= 2 points
 - Stroke symptoms or TIA

ACUTE ASTHMA

Clues: SOB, wheeze, PEF <50% of best**, RR >25/min, HR >110/min, cannot complete sentences in 1 breath.

- Attach sats monitor
- 40-60% O2 through high-flow mask, e.g. Hudson mask
- Salbutamol 5 mg neb in O₂: repeat up to every 15 min if life-threatening
- Ipratropium 0.5 mg neb in O₂: repeat up to every 4 h if lifethreatening or fails to respond to salbutamol
- Prednisolone 40 mg po od for at least 5 days. Hydrocortisone 100 mg qds iv can be given if unable to swallow or retain tablets.

Both prednisolone and hydrocortisone can be given if very ill.

```
Life-threatening features
```

- PEF <33% of best**</p>
- O₂ sats <92%
- PaO₂ <8.0 kPa, PaCO₂ >4.6 kPa or pH <7.35
- Silent chest, cyanosis or ↓respiratory effort
- \downarrow HR, \downarrow BP or dysrhythmia
- Exhaustion, confusion or coma

**Or predicted best (see p. 182).

If life-threatening features (\bigotimes NB: patient may not always *appear* distressed \bigotimes), get senior help and consider the following:

- $MgSO_4$ ivi: 8mmol over 20 min (= 2 g = 4 ml of 50% solution).
- Aminophylline iv: attach cardiac monitor and give loading dose* of 5 mg/kg iv over 20 min then ivi at 0.5–0.7 mg/kg/h (0.3 mg/kg/h if elderly). If already on maintenance po aminophylline/ theophylline, omit loading dose* and check levels ASAP to guide dosing set.
- *iv salbutamol:* 5 μg/min initially (then up to 20 μg/min according to response): back-to-back or continuous nebs now often preferred.
- Call anaesthetist for consideration of ITU care or intubation. Initiate this during the above steps if deteriorating.

COPD EXACERBATION

Clues: SOB, wheeze, RR >25/min, HR >110.

- Attach sats monitor and do baseline ABGs.
- 28% O₂ via Venturi mask; should be prescribed on drug chart. ↑dose cautiously if hypoxia continues, but repeat ABGs to ensure CO₂ not ↑ing and (more importantly) pH not ↓ing.
- Ipratropium 0.5 mg neb in O2: repeat up to every 4 h if very ill.
- Salbutamol 5 mg neb in O₂: repeat up to every 15 min if very ill (seldom necessary >hourly).
- Prednisolone 30 mg po then od for ≤2 wks (often 7–10 days). Some give 1st dose as hydrocortisone 200 mg iv – rarely used now unless unable to swallow.
- Antibiotics (see p. 172) if 2 out of 3 of Hx of ↑ing SOB, ↑ing volume or ↑ing purulence of sputum.

If no improvement, consider:

- Aminophylline ivi: see Mx of asthma (p. 237) for details.
- Assisted ventilation: CPAP if just ↓PaO₂ or NIV (BIPAP) if also ↑PaCO₂; consider doxapram if NIV not available.
- Intubation: discuss with ITU/anaesthetist.

PULMONARY EMBOLISM

Clues: unlikely unless RR >20 and PaO₂ <10.7 kPa (or \downarrow O₂ sats).

- 60–100% O₂ if hypoxic. Care if COPD.
- Analgesia: if xs pain or distress, try paracetamol/ibuprofen 1st; consider opiates if severe or no response (an ⇒ respiratory depression).
- Anticoagulation: LMWH, e.g. dalteparin or enoxaparin. Once PE confirmed, load with warfarin (see pp. 200–204). Consider iv heparin if surgery being contemplated, or rapid reversal may be required*.

If massive PE, worsening hypoxia or cardiovascular instability (\downarrow BP, RV strain/failure), seek senior help and consider:

- *Fluids* ± *inotropes:* if systolic BP <90 mmHg
- Thrombolysis (e.g. alteplase): if \downarrow BP \pm collapse
- Embolectomy*: seek urgent cardiothoracic opinion.

ACUTE UPPER GI HAEMORRHAGE

Clues: Haematemesis and/or melaena; consider as differential in sudden collapse/shock.

Assess severity of bleeding

- Pulse $>100 \text{ or } \uparrow \text{ of } >20 \text{ bpm}$
- Systolic BP <100 mmHg (or postural drop >10 mmHg)
- Cold, clammy peripheries
- Urine output <0.5 ml/kg/h (30 ml/h).

Management

- Resuscitate:
 - Give high-flow O2
 - Insert 2 wide bore intravenous cannulae (grey/brown)
 - iv fluid (blood *or* colloid *or* crystalloid) to maintain systolic BP >100
 - Correct clotting with iv fresh frozen plasma if INR >1.5 (NB: Vit K reverses warfarin but doesn't affect clotting problems due to synthetic liver function abnormalities).
- Take blood for:
 - FBC, INR, U&E, LFT
 - Group and save or cross match 2–6 units depending on severity of bleed.
- Monitor (at least hourly):
 - Pulse, BP, urine output (consider catheter)
 - Consider CVP for elderly or suspected variceal bleed.
- Drugs:
 - Stop antihypertensives, diuretics, NSAIDs, anticoagulants
 - In severe non-variceal bleed, give omeprazole 40 mg iv
 - Give 2 mg terlipressin iv 'stat' if variceal bleed suspected (and continue qds – NB: caution in IHD)

0 MEDICAL EMERGENCIES

- All suspected variceal bleeds should receive a short course of prophylactic antibiotics active against Gram negative bacteria.
- Endoscopy: indicated urgently if:
 - Variceal bleed suspected
 - Continued bleeding requiring >4 units blood to maintain systolic BP >100 mmHg
 - Re-bleed after resuscitation
 - Consider if 'Rockall' pre-OGD score ≥ 2 (see *below*).

			Score				
	Variable	0	1	2	3		
Pre-OGD	Age	<60	60–79	>80			
Score	Shock	sBP > 100;	sBP > 100;	sBP < 100			
		HR < 100	HR > 100				
	Comorbidity	nil major		HF, IHD, or	RF, LF,		
				any major	disseminated		
				comorbidity	malignancy		
Post-OGD	Diagnosis	Mallory–Weiss	All other Dx	Malignancy			
Score		tear, no lesion,		of upper			
		no SRH		GI tract			
	Major SRH	None or dark		Blood in upper			
		spot only		GI tract,			
				adherent clot,			
				visible or			
				spurting vessel			

Rockall score (Gut 1996; 38: 316-321)

 $\mathsf{OGD} = \mathsf{Oesophagogastroduodenoscopy}; \mathsf{sBP} = \mathsf{systolic blood pressure}; \mathsf{SRH} = \mathsf{stigmata of recent haemorrhage}.$

Pre-OGD score 0 or 1 assoc with <2.5% mortality; can usually be safely endoscoped on the next available list (but w/in 24 hours).

Pre-OGD score >2 assoc with >5% mortality; may require urgent endoscopy.

SEPSIS (SEVERE OR SEPTIC SHOCK)

Clues: evidence of infection + \downarrow BP (MAP <65 mmHg), serum lactate >4 mmol/l or \downarrow urine output

- Oxygen: 100% via non-rebreathe mask (caution if COPD).
- Fluid: 1 litre of crystalloid (or 300–500 ml of colloid bolus) over 30 min; if still ↓BP measure CVP and consider further iv fluids (20ml/kg) to achieve CVP ≥8 mmHg and urine output >0.5 ml/kg/h (caution if LVF).
- Inotropes: if systolic BP <90 mmHg after fluid resuscitation start noradrenaline (1–10 μg/min) to maintain MAP >65 mmHg. Measure mixed venous O₂ saturation and if <65–70% need further fluid/packed RBCs to achieve haematocrit >30%.
- Antibiotics: as appropriate (see pp. 168–78) ASAP (ideally w/in 1 h) ensuring all cultures taken 1st (unless significantly delays antibiotics).
- Steroids: consider iv hydrocortisone (200–300 mg/day) when ↓BP responds poorly to adequate fluid resuscitation and vasopressors.
- Activated protein C: consider if multiorgan dysfunction, ↑risk of death (e.g. Acute Physiology and Chronic Health Evaluation (APACHE) II score >25) and no CIs.
- Blood products: aim for Hb >10 g/dl to maximise tissue perfusion.
- Blood glucose: aim for <8.3 mmol/l using validated insulin sliding scale.
- Deep vein thrombosis prophylaxis: low-dose LMWH (e.g enoxaparin 40 mg sc od) unless CI.
- Stress ulcer prophylaxis: H₂ antagonist or PPI.

Adapted from Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Medicine* 2008; 34(1).

EPILEPSY

Status epilepticus = seizure lasting >30 min or multiple seizures lasting > 30 min without full recovery between episodes. NB: 5 min

242 MEDICAL EMERGENCIES

has been suggested as more suitable definition than 30 min and >80% of epileptic seizures last <2 min. Mortality: 35% if seizures last > 1 hr; 4% if last < 30 min.



NB

Non-convulsive/absence seizures are missed easily. Keep in mind non-epileptic (='pseudo') seizures, esp if atypical fits.

- Protect airway with tracheal intubation if necessary: call anaesthetist early if concerned.
- Attach O₂ sats, ECG and BP monitors and place in recovery position.
- Give O₂ 5–8 litres via Hudson mask.
- Exclude or treat reversible metabolic causes: esp ↓O₂, ↓glucose (remember to give thiamine if treating ↓glucose in alcoholic or malnourished patient).
- Lorazepam 4 mg iv over 2 min (terminates 60–90% of status epilepticus). If not available use diazepam 10 mg iv over 2 min. If no iv access consider midazolam 5–10 mg im.
- Check BP: maintain or ↑mean arterial BP to provide appropriate cerebral perfusion pressure.

If seizures continue get senior help.

• Repeat lorazepam 4 mg iv over 2 min (or alternative as above).

If no response after 5 min, call for anaesthetist, and give:

Phenytoin initially total dose 18 mg/kg ivi with normal saline (not compatible with glucose) at 25–50 mg/min then adjust (see p. 124. Fosphenytoin iv is an alternative: see p. 73 for dose as different to phenytoin). Monitor BP and HR (both can drop) and ECG (esp QTc, as arrhythmias not uncommon). Phenytoin will abort 60% of status epilepticus not terminated by lorazepam.

If seizures persist, phenobarbital (15 mg/kg ivi) at 100 mg/min should be considered. If already taking phenytoin po (and plasma levels assumed adequate) consider giving phenobarbital before phenytoin ivi; get senior advice if required. If the above measures do not terminate seizures, refractory status epilepticus is present. Requires general anaesthesia with propofol or thiopental in a specialised unit, often with EEG monitoring.

DKA

Clues: ketotic breath, Kussmaul's (deep/rapid) breathing, dehydration, confusion/↓GCS.

'The Joint British Diabetes Societies Inpatient Care Group has recently published UK guidelines for the Mx of DKA in adults (http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID= 345687).These involve using a fixed rate insulin infusion and routine use of 10% glucose as iv fluid. This guidance has yet to be implemented universally but will be increasingly incorporated into local guidelines. NB: follow local trust diabetes team policy where applicable and the below guidance is an example of a guideline for DKA Mx'.

- Diagnostic criteria: BG >11.1 mmol, pH <7.3, HCO₃ <15, +ve ketones (serum or urine).
- Initial measures: O₂ if hypoxic, weigh patient (if possible), 2 wide bore iv cannulae. Consider NGT (if coma) and central line (esp if ↓↓pH or Hx of HF), but urinary catheter often sufficient (insert if no urine after 2–3 h). Do ECG.
- *iv fluids:* initially 0.9% saline according to individual patient needs (guided by urine output ± CVP). The following is a guide:
 - If severe dehydration, i.e. shock, oliguria or ARF (in this context = urea >21 mmol/l or creatinine >350 µmol/l), give 1st litre over 30 min, 2nd litre over 1 h and 3rd litre over 2 h. Consider colloid if ↓BP (e.g. systolic <100 mmHg) or no improvement in hydration.
 - Otherwise give more slowly, e.g. 2 litres over 4 h, then 1 litre over 4 h.
 - Add KCl once K⁺ <5.5 mmol/l, as can ↓ rapidly dt insulin (but do not give KCl in 1st litre unless K⁺ <3.5 mmol/l).

243

Roughly 20–30 mmol needed per litre during rehydration: adjust to individual response with regular checks (easiest and quickest done with ABG machines: most give K⁺ levels, and blood gases also needed regularly for pH monitoring; can use venous samples as long as put in ABG or other heparinised syringe).

- Insulin: as soluble insulin ivi (e.g. Actrapld). A sensible start is 6 units/h, îing stepwise to 12 units/h if no ↓BG w/in 2 h. Higher doses can ⇒ too rapid a fall in BG and K⁺ (aim for ↓BG of 3–6 mmol/h). Until ivi facilities available, give 10 units im (or sc if not shocked) stat (↓dose if BG <20 mmol/l). Once BG <15 change iv fluids to 5% glucose and start insulin sliding scale (see p. 196), adjusting to response but ideally maintaining min rate of 4 units/h with sufficient glucose ivi (if insulin continued, speed of ketone clearance îs; if BG <7 do not stop insulin but îrate of glucose ivi or switch to 10% solution). Continue until ketones cleared (check urine ± blood), pH normal and eating/drinking; then switch to sc regimen (see p. 198 for advice).
- *Heparin:* if comatose or hyperosmolar (<350mosmol/l), give LMWH (or unfractionated heparin 5000 units sc bd/tds). Continue until mobile.

Consider:

- Antibiotics: search for and treat infection. NB: rely on CRP more than WCC (WCC can be artificially ↑d) and temperature can be normal even in severe infections ∴ dipstick urine and send urine, blood and any other relevant cultures (consider CXR). If suspect infection and no clear cause, start blind Rx, follow local protocol ± discuss with microbiologist.
- Pregnancy test: for presentation of gestational diabetes.
- *Bicarbonate:* if severe acidosis (e.g. pH <7); very rarely needed and potentially dangerous. Get senior help if concerned.
- *HDU/ITU:* for one-to-one nursing \pm ventilation if required.

Watch for complications: $e'lyte \Delta s$ (esp $\downarrow Na^+, \downarrow K^+, \downarrow Mg^{2+}, \downarrow PO_4$), TE (esp DVT/PE), *cerebral oedema* (\downarrow GCS, papilloedema, falselocalising cranial nerve palsies), *infections* (esp aspiration pneumonia).

HONK

Clues: as for DKA, but no ketones, normal pH, \uparrow glucose, \uparrow dehydration and \uparrow confusion. Generally \uparrow age of patient and \uparrow length of Hx of decline/insidious onset (NB: may be 1st presentation and no past Hx). Can also be precipitated by steroids and thiazides.

- *Initial measures:* as DKA; see above.
- *iv fluids*: as DKA, but can correct dehydration more slowly (will have occurred more slowly and also ↓s risk of e'lyte abnormalities). A rough guide is 1 litre of 0.9% saline over 1 h, then 2 litres over 4 h × 2, then 1 litre over 4 h. Less KCl will be needed, as less insulin will be used. NB: can remain in circulatory collapse despite clinically adequate fluid replacement; if so, give 500 ml colloid and monitor CVP. Consider 0.45% saline if Na⁺ >155 mmol/l; get senior (ideally specialist) help first.
- Insulin: start at lower dose than DKA (e.g. 2 units/h ivi). Again aim to ↓BG by 3–6 mmol/h and continue ivi for >24 h (adding glucose if necessary to keep BG normal) before switching to sc regimen.
- *Heparin:* iv or LMWH (see pp. 205–7). Always give, as $\uparrow\uparrow$ osmolality $\Rightarrow\uparrow$ risk of TE (and consider TEDS).

Consider:

• *Antibiotics:* search for and treat infection, as above. Watch for complications, esp TE (CVA, IHD) and ARF.

↓GLUCOSE

Treat if <3 mmol/l or symptoms: \uparrow sympathetic drive (\downarrow HR, sweating, aggression/behavioural Δ s), seizures or confusion/ \downarrow GCS.

- Glucose orally: esp sugary drinks, mouth gel (e.g. hypostop/glucogel) or dextrose tablets. Miss this step if severe, but can be useful if delays in iv access.
- *Glucose* 20–50 *ml* of 50% iv stat via large iv cannula. Always flush liberally with saline as 50% glucose is very viscous and will act slowly otherwise. Repeat if necessary. A brisk 5–20% glucose

246 MEDICAL EMERGENCIES

ivi can be used if only mild symptoms or until 50% glucose found, but beware of fluid overload if HF.

• Glucagon 1mg im/iv stat: if very low glucose or no iv access.

NB: think of and correct any causes, esp xs DM Rx, alcohol withdrawal, liver failure, aspirin OD (rarely Addison's disease, $\downarrow T_4$).

THYROTOXIC CRISIS

Clues: ¹HR/AF, fever, abdominal pain, D&V, tremor, agitation, confusion, coma. Look for goitre, Graves' eye disease, Hx of ↓ compliance with antithyroid Rx.

- O₂: if hypoxic.
- 0.9% saline ivi: slowly as per individual needs (care if HF).
- Propranolol 40 mg tds po: aim for HR <100 and titrate up dose if necessary (if β-blocker CI, give diltiazem 60–120 mg qds po). If ↑↑HR, give propranolol iv 1 mg over 1 min, repeating if necessary every 2 min to max total of 10 mg.
- Digoxin and LMWH (if AF): DC shock rarely works until euthyroid .: load with 500 μg iv over 30 min then 250 μg iv over 30 min every 2 h until HR <100 (up to max total of 1.5 mg).
- *Carbimazole:* 15–30 mg qds po (↓later under specialist advice).
- *Lugol's solution (iodine)*: 0.1–0.3 ml tds po (normally for 1 wk). Start 4 h after carbimazole.
- Hydrocortisone: 100 mg qds iv (or dexamethasone 4 mg qds po).

Consider:

- Treat any heart failure (common if fast AF), e.g. furosemide.
- Antibiotics: if evidence/suspicion of infection.
- Cooling measures: paracetamol, sponging.

If vomiting, insert NGT to avoid aspiration and for drug administration.

MYXOEDEMA COMA

Clues: 'facies', goitre, thyroidectomy scar, \downarrow temperature, \downarrow HR, \downarrow reflexes, \downarrow glucose, seizures, coma. NB: Ψ features common.

- O₂: if hypoxic.
- *Glucose iv:* if hypoglycaemic (often coexists); see p. 245.
- 0.9% saline ivi: slowly as per individual needs (care if HF).
- Liothyronine (= T₃ = tri-iodothyronine): 5–20 µg ivi bd for >2 days then ↑dose gradually with endocrinologist's advice before converting to thyroxine po. Liothyronine can precipitate angina; slow down ivi if occurs.
- *Hydrocortisone*: 100 mg iv tds, esp if suspect hypopituitarism (much more likely if no goitre or past Hx of Rx for ↑T₄).

Consider:

- Rewarming measures: e.g. Bair-Hugger, warm iv fluids (and O₂).
- *Antibiotics:* infections are common and may have precipitated decline ∴ have low threshold for aggressive Rx.
- Ventilation/ITU: condition has high mortality.

ADDISONIAN CRISIS

Clues: \downarrow BP, \uparrow HR, \downarrow glucose, \uparrow K⁺/ \downarrow Na⁺, Hx of chronic high-dose steroid Rx with missed doses or intercurrent illness^{*}.

- O₂ if cyanosed.
- Glucose iv: if hypoglycaemic; see p. 245.
- Steroids: usually hydrocortisone 100 mg iv stat then qds (ensure blood sample for cortisol and ACTH taken before first dose if Dx is not certain). Give 1st dose as dexamethasone 8 mg iv if Symmethan test planned (hydrocortisone affects test results). Consider fludrocortisone once stable.
- *Fluids iv:* normal saline \pm central line if $\downarrow \downarrow$ BP.
- *Antibiotics:* look for and treat infection*: dipstick urine, MSU, CXR and blood cultures. If in doubt, start Rx.

NB: Check other pituitary hormones in case of associated other pituitary dysfunction.

ELECTROLYTE DISTURBANCES

↑κ+

 $K^+ > 6 \text{ mmol/l considered dangerous. Is haemolysis of sample possible cause? Ring lab <math>\pm$ repeat sample if suspicious.

If K^+ >6.5 mmol/l or ECG Δs (tall tented T waves, QRS >0.12 sec (>3 small squares), loss of P waves or sinusoidal pattern) the following is needed:

- Attach cardiac monitor (+ECG if possible): risk of arrhythmias.
- 10 ml of 10% Ca²⁺ gluconate iv over 3 min for 'cardioprotection', or 10 ml of 10% CaCl iv at ≤1 ml/min (often found in crash trolleys).
- 10 units insulin (e.g. Actrapid) + 50 ml 50% glucose ivi over 30 min: stimulates cellular membrane H⁺/K⁺ pumps ∴ ↓s plasma K⁺ levels. Beware of too rapid a drop as this may precipitate arrhythmias: aim for drop of 1–2 mmol/l over 30–60 min.
- Consider salbutamol 5-20 mg nebs: utilises K⁺-lowering fx.

For all patients with $\uparrow K^+$:

 Look for and treat causes, esp ARF (consider dialysis) and drugs; e.g. iv KCl, oral K⁺ supplements, ACE-i, ARBs, K⁺-sparing diuretics, NSAIDs. Also ciclosporin but don't adjust without specialist advice.

If $\uparrow K^+$ persists:

- Assess fluid balance and whether passing urine (uric); if not uric total body K⁺ won't ↓ with the above measures and plasma K⁺ will eventually return to former levels.
- Consider kaliuretic agents (diuretics not K⁺-sparing) if uric.

NB: Contrary to dogma Calcium Resonium is not useful.

↓K+

 $<2.5 \text{ mmol/l} \Rightarrow$ risk of arrhythmias: attach cardiac monitor.

248

- 1 litre normal saline (0.9%) + 40 mmol KCl over 4 h. If unstable or arrhythmias develop, seek senior help. KCl can be given quicker but non-specialist wards may not allow >10 mmol/h and patient may not tolerate fast peripheral ivi due to pain (consider central line).
- Oral K⁺ replacement should also be commenced (e.g. Sando-K_p Slow-K 2 tablets tds, or as much as can be tolerated – unpleasant taste!). Beware of overshooting later, esp if cause removed.

NB: po replacement is often sufficient if $K^+ > 2.5$ mmol/l and no clinical features/ECG Δs (small T waves or large U waves).

↑Ca²⁺

>2.65 mmol/l is abnormal. Symptoms usually start once >2.9 mmol/l. *Clues:* bones (pain, esp consider metastases), stones (renal colic \pm ARF), groans (abdominal pains, constipation \pm vomiting; polyuria and thirst common) and psychic moans (inc confusion).

If >3.5 mmol/l or severe symptoms treat urgently as follows:

 0.9% saline ivi: average requirements 4–6 litres over 24 h (↓ if elderly/HF). Monitor fluid balance carefully and correct electrolytes.

If insufficient improvement in Ca²⁺ levels or symptoms get senior help and consider:

- Loop diuretic (e.g. furosemide): consider once rehydrated.
- *Bisphosphonate* (e.g. pamidronate) esp if **^**PTH or malignancy.
- Calcitonin: if no response to bisphosphonate.
- Steroids: if sarcoid, lymphoma, myeloma or vitamin D toxicity.
- Dialysis: if ARF or life-threatening symptoms.

OVERDOSES

Unless you are familiar with the up-to-date Mx of the specific overdose in question, the following sources should always be consulted:

MEDICAL EMERGENCIES

- Toxbase website (www.toxbase.org): authoritative and updated regularly. Should be used in the 1st instance to check clinical features and Mx of the poison(s) in question. You will need to sign in under your departmental account; if your department is not registered, contact your A&E department to obtain a username and password.
- National Poisons Information Service (NPIS): if in UK phone 0844 892 0111 (if in Ireland 01 809 2566) for advice if unsure of Toxbase instructions and for rarer/mixed overdoses.

GENERAL MEASURES

- Activated charcoal: if w/in 1 h of significant ingestion. CI if ↓GCS (unless ET tube *in situ*), or if bowel sounds absent or if corrosive substance/petroleum ingested. Repeated doses and administration later than 1 h considered for certain drugs (e.g. quinine, carbamazepine, theophylline, or sustained release preparations). Charcoal not effective for lithium, iron, organophosphates, ethylene glycol, ethanol, methanol.
- *Gastric lavage:* Rarely used, but may be used if w/in 1 h of lifethreatening ingestion. CI ↓GCS (unless airway protected), or if corrosive ingested or risk of GI haemorrhage/perforation.
- See Toxbase for dosage guide for activated charcoal, and consult Toxbase ± NPIS for severe or unusual poisoning, as routine GI decontamination is no longer recommended.
- Check paracetamol and aspirin levels in all patients who are unable to give an accurate Hx of the exact poisons ingested.

PARACETAMOL

Significant OD = ingestion of 150 mg/kg or 12 g (whichever is smaller) within 24 h. If risk factors (see below), 75 mg/kg should be used instead.



Risk factors in paracetamol OD

- Taking enzyme-inducing drugs, e.g. carbamazepine, phenobarbital, primidone, phenytoin, rifampicin, St John's wort.
- Regularly consumes alcohol in xs of recommended amounts.
- Malnourished and likely to be glutathione-deplete, e.g. anorexia, alcoholism, cystic fibrosis, HIV infection, starvation.

250

Initial management

This depends on time since ingestion.

0-8h post-ingestion:

- Activated charcoal: if w/in 1 h of significant OD.
- *Acetylcysteine:* wait until 4 h post-ingestion before taking urgent sample for paracetamol levels (results are meaningless until this time). If presents at 4–8 h post-ingestion, take sample ASAP. If levels above the treatment line (see below), give the following acetylcysteine regimen:
 - Initially 150 mg/kg in 200 ml 5% glucose ivi over 15 min.
 - Then 50 mg/kg in 500 ml 5% glucose ivi over 4 h.
 - Then 100 mg/kg in 1000 ml 5% glucose ivi over 16 h.

NB: if patient weighs > 110 kg, use 110 kg (rather than their actual weight) for these calculations.

Do not delay acetylcysteine beyond 8 h post-ingestion if waiting for paracetamol level and significant OD (beyond 8 h, efficacy \downarrow s substantially) – ivi can be stopped if levels come back as below treatment line and INR, ALT and creatinine normal.

8–15 h post-ingestion:

• *Acetylcysteine:* give above regimen ASAP if significant OD taken. Do not wait for urgent paracetamol level result. Acetylcysteine can be stopped if level later turns out to be below treatment line **and** timing of the OD is certain **and** patient asymptomatic with normal INR, creatinine and ALT.

15-24 h post-ingestion:

 Acetylcysteine: give above regimen ASAP unless certain that significant OD has not been taken. Do not wait for paracetamol level result. Presenting this late ⇒ severe risk, and treatment lines are unreliable: always finish course of acetylcysteine.

>24 h post-ingestion:




Figure 10 Treatment lines for acetylcysteine treatment of paracetamol overdose. Reproduced courtesy of Alun Hutchings and University of Wales College of Medicine Therapeutics and Toxicology Centre.

• Acetylcysteine is controversial when presenting this late. Check creatinine, LFTs, INR, glucose, and paracetamol concentration, and consult Toxbase or NPIS re individual cases.

NB: use high-risk line if any of the risk factors above apply.

Important points regarding acetylcysteine

- Have lower threshold for initiating Rx if doubts over timing of OD, if ingestion was staggered, if presents 24–36 h postingestion, or if evidence of LF/severe toxicity regardless of time since ingestion. Contact NPIS if unsure.
- Anaphylactoid reactions common esp at initial faster rates. Reduce infusion rate or stop temporarily until reaction settles. Give antihistamine (e.g. chlorphenamine 10–20 mg iv over 1 min) if required. Give salbutamol nebs if significant bronchospasm. Once reaction settles restart acetylcysteine, and consider giving the second bag at half normal rate (ie. 50 mg/kg over 8 h). Past Hx of such reactions is not an absolute CI to future treatment. Pretreatment with chlorphenamine 10 mg iv or administration of 1st ivi at slower rate (e.g. over 1 h rather than 15 min) may reduce risk of reaction but the latter is unlicensed.
- Acetylcysteine ⇒ mildly ↑INR itself; ∴ if after treatment ALT is normal but INR is ≤1.3 no further monitoring or treatment is needed. But if ALT is ↑continue acetylcysteine ivi at rate of 150 mg/kg given over 24 h (unless substantial pause in ivi further loading dose not needed).

Subsequent management

Patients may be *medically* fit for discharge once acetylcysteine ivi is completed, and INR, ALT, creatinine and $HCO_3^-(\pm pH)$ are normal (or recovering in two successive checks if additional acetylcysteine has been administered). *Psychiatric* evaluation should be undertaken for all patients who have taken a deliberate overdose.

In patients with laboratory abnormalities despite acetylcysteine, consult Toxbase \pm NPIS for advice on further acetylcysteine and specialist referral.

ASPIRIN

- Consider activated charcoal ± gastric lavage: if w/in 1 h of OD of >125 mg/kg. Aspirin delays gastric emptying (esp if enteric-coated tablets), ∴ both can be considered >1 h after ingestion and activated charcoal can be repeated every 4hrs if salicylate levels continue to rise despite measures below; consult Toxbase for activated charcoal dose and contraindications.
- Monitor U&Es, glucose, clotting, ABGs (or venous pH and HCO₃⁻) and fluid balance (often need large volumes of iv fluid). Salicylate levels needed if OD of >120 mg/kg; take sample at least 2 h post-ingestion if symptomatic or 4 h post-ingestion if not symptomatic, repeating in both cases 2 h later if severe toxicity suspected in case of delayed absorption (repeating until levels↓). Note that peak concentrations are often delayed after large ingestions.

If significant biochemical abnormalities, get senior help or contact ITU for specialist advice, and then consider the following:

- Sodium bicarbonate: Consider 1.5 litres of 1.26% iv over 2 h (or 225 ml of 8.4%) if metabolic acidosis and salicylate levels >500 mg/l (3.6 mmol/l). This will minimise movement of salicylate into tissues, and enhance renal elimination. Ensure given through patent cannula (risk of tissue necrosis if extravasation). Bicarbonate administration may cause hypokalaemia: monitor K⁺ closely. Monitor arterial blood gases to ensure correction of acid–base disturbance, and re-check serum salicylate concentrations.
- Haemodialysis: if salicylate levels >700 mg/l (5.1 mmol/l) or unresponsive to the above measures. Also consider if ARF, CCF, non-cardiac pulmonary oedema, severe metabolic acidosis, convulsions or any CNS fx that are not resolved by correction of pH, and in patients aged >70 yrs due to increased risk of toxicity.

OPIATES

Clues: pinpoint pupils, \downarrow respiratory rate, \downarrow GCS, drug chart and Hx/signs of opiate abuse (e.g. collapsed vein 'track marks').

- O_2 + maintain airway \pm ventilatory support.
- Naloxone 0.4-2.0 mg iv (or im) stat initially, repeating after 2 min if no response. See p. 111 for subsequent dosing. Note that large doses (>2 mg) may be required in some patients.

BENZODIAZEPINES

- O_2 + maintain airway \pm ventilatory support.
- Consider *flumazenil only if access to ventilatory support is likely to be delayed:* see pp. 70–71 for dosage.

Solution of the second second



This page intentionally left blank

Reference information

Coma	258
Cognitive impairment	259
Useful formulae	260
Common laboratory reference values	261

COMA

Glasgow Coma Scale (GCS): standardised assessment of coma.

Motor response	Verbal response	Eye opening
6 Obeys commands	5 Orientated	4 Spontaneous
5 Localises pain	4 Confused	3 Responds to speech
4 Withdraws to pain	3 Inappropriate	2 Responds to pain
3 Flexes to pain	2 Incomprehensible	1 None
2 Extends to pain	1 None	
1 No response to pain		

- GCS 13–15 = minor injury
- GCS 9–12 = moderate injury
- GCS <9 = severe injury

NB: drops of >2 are often significant.

To remember GCS use **MOVE** for 3 categories and mnemonic '**OLDFEZ OCEAN SOON**', visualising an old fez (Moroccan hat) floating down a river that will soon arrive at the ocean!

- Motor: Obeys, Localises, Draws away, Flexor, Extensor, Zero.
- Verbal: Orientated, Confused, Explicit (or eX rated), Absolute rubbish, None.
- Eye: Spontaneous, Orders only, Ouch only, None.

\mathbf{V}

Causes of ψ GCS = DIM TOPS

- Drugs: alcohol, insulin, sedatives, overdoses (esp opiates/benzodiazepines).
- Infections: sepsis, meningitis, encephalitis.
- *Metabolic:* \uparrow/\downarrow glucose, $\downarrow T_4$, Addison's, renal/liver failure.
- Trauma Hx: unwitnessed fall or extradural 'lucid interval'.
- O_2 deficiency: any cause of $\downarrow O_2$ (NB: $\uparrow CO_2$ is also a cause).
- Perfusion: CVA (inc SAH), MI, PE/Pressure: 1CP.
- Seizures: post-ictal fx and non-convulsive status aren't obvious.

258

COGNITIVE IMPAIRMENT

- (A)MTS: (Abbreviated) Mental Test Score most basic assessment of cognition; popular with physicians due to brevity (esp for use on the elderly). <8/10 is abnormal (i.e. dementia and/or delirium).
- W World War II: what year did it end?¹
- H Hospital (what is name of building you are in?).
- A Address: 42 West St (ask to repeat and remember*).
- T Time: to the nearest hour.
- Y Year.
- E Elizabeth II (who is current monarch?)¹.
- A Age (of patient).
- **R** Recognition of 2 persons: e.g. Dr and other².
- B Birthday (patient's date of birth).
- C Count backwards from 20 to 1.
- ? Can you remember the address?*.

¹If culturally inappropriate change to relevant question or omit. ²If alone with patient omit.

If questions omitted, record why and reduce denominator of score.

2 MMSE: Mini Mental State Examination; popular and best	
validated basic cognitive assessment. Questions to ask are in b	old.
Orientation:	
Time – (1–3) Date? 1 point for each for day, month and year.	5
(4) Season? (5) Day of week?	
Place – (1) Country? (2) County/state (or large city)?	5
(3) Town (or city area)? (4) Building? (5) Floor?	
Registration: Say ¹ ball, flag, tree. Repeat until success or	3
5 attempts.	
Attention/concentration: Spell 'WORLD' backwards ² .	5
Recall: Can you remember those 3 items? (ball, flag, tree).	3
3-stage command: Take paper in R hand, fold in half and put	3
on floor.	
Language: What is this? Point to pen and then wristwatch.	2

Repeat exactly after me: 'No ifs, ands or buts.'1Reading/comprehension: Do what the sentence below instructs³.1Praxis: Write a sentence of your choice. Provide dotted line.1Copy this shape as best you can alongside it⁴.1

- Precede with 'I will mention 3 objects to you. Please repeat them to me once I have finished all 3.' Allow 1 s between objects. At end say 'I will ask you to remember these later' which is tested in Recall in next but one section – should be done after 1 min.
- **2** 'Serial 7s' can also be used which obviously tests calculation too so remember to take into account premorbid numeracy skills.
- 3 Write out in large, clear capital letters 'CLOSE YOUR EYES'.
- 4 Only correct if makes 4-sided shape formed by 2 intersecting pentagons.
- Allow 1 min for tasks, except 30 s for 3-stage command and writing of sentence.
 - Score, 25/30 abnormal (i.e. dementia and/or delirium). 25–27 is borderline. NB: frontal lobe tests not covered; useful to add.

USEFUL FORMULAE

Serum osmolality = $1.86 (K^+ + Na^+) + urea + glucose$ NB: all units are in *mmol/l* and this calculation is an *estimate* (actual osmolality usually differs by $\pm 13 \text{ mosm/kg}$).

Anion gap = $(Na^+ + K^+) - (Cl^- + HCO_3^-)$ Normal range 8–16 mEq/l >16 = loss of HCO₃⁻ w/o concurrent increase in Cl⁻.

Creatinine clearance = [Urine creatinine] × urine flow rate/[Plasma creatinine]

Body mass index = Weight (kg)/height $(m)^2$ 'Normal' (target) = 18.5-25

Weight conversions:

- 1 kg = 1000 g; 1 g = 1000 µg; 1 µg = 1000 nanograms
- 1 stone = 6.35 kg; 1 kg = 2.2 lb.

COMMON LABORATORY REFERENCE VALUES

NB: normal ranges often vary between laboratories. The ranges given here are deliberately narrow to minimise missing abnormal results, but this means that your result may be normal for your laboratory's range, which should always be checked if possible.

Biochemistry	
Na ⁺	135–145 mmol/l
K ⁺	3.5–5.0 mmol/l
Urea	2.5–6.5 mmol/l
Creatinine	70–110 μmol/l
Ca ²⁺	2.15–2.65 mmol/l
PO ₄	0.8–1.4 mmol/l
Albumin	35–50 g/l
Protein	60–80 g/l
Mg ²⁺	0.75–1.0 mmol/l
CI [_]	95–105 mmol/l
Glucose (fasting)	3.5–5.5 mmol/l
LDH	70–250 iu/l
СК	25–195* u/l (↑ in blacks)
Trop I	$<$ 0.4 ng/ml (= μ g/l)
Trop T	<0.1 ng/ml (= µg/l)
D-dimers	<0.5**mg/l
Bilirubin	3–17 μmol/l
ALP	30–130 iu/l
AST	3–31 iu/l
ALT	3–35 iu/l
GGT	7–50* iu/l

Biochemistry

*Sex differences exist: females occupy the lower end of the range.

**D-dimer normal range can vary with different test protocols: check with your lab.

Biochemistry (Continued)			
Amylase	0–180 u/dl		
Cholesterol	3.9–5.2 mmol/l		
Triglycerides	0.5–1.9 mmol/l		
LDL	<2.0 mmol/l		
HDL	0.9–1.9 mmol/l		
Urate	0.2–0.45 mmol/l		
CRP	0–10 mg/l		

13.5–17.5 g/dl	
11.5–15.5 g/dl	
$150-400 imes 10^{9}/l$	
$4-11 \times 10^{9}$ /l	
2.0−7.5 × 10 ⁹ /l (40−75%)	
1.3–3.5 × 10 ⁹ /l (20–45%)	
0.04–0.44 $ imes$ 10 ⁹ /l (1–6%)	
0.37–0.54* l/l	
76–96 fl	
<age (+="" 10="" 2<="" in="" td="" women)="" years=""><td></td></age>	
2.3–6.5%	
	$\begin{array}{c} 11.5-15.5 \text{ g/dl} \\ 150-400 \times 10^{9/l} \\ 4-11 \times 10^{9/l} \\ 2.0-7.5 \times 10^{9/l} (40-75\%) \\ 1.3-3.5 \times 10^{9/l} (20-45\%) \\ 0.04-0.44 \times 10^{9/l} (1-6\%) \\ 0.37-0.54^* /l \\ 76-96 \text{ fl} \\ < \text{age in years } (+10 \text{ in women})/2 \end{array}$

*Sex differences exist: females occupy the lower end of the range.

Clotting

APTT	35–45s
APTT ratio	0.8–1.2
INR	0.8–1.2

ema	

Iron	11–30 µmol/l
Transferrin	2-4 g/l
TIBC	45–72 μmol/l
Serum folate	1.8–11 μg/l
B ₁₂	200–760 pg/ml (5 ng/l)

Arterial blood gases

PaO ₂	>10.6 kPa
PaCO ₂	4.7–6.0 kPa
рН	7.35–7.45
HCO ₃ -	24–30 mmol/l
Lactate	0.5–2.2 mmol/l
Base xs	±2 mmol/l

Thyroid function

Thyroxine (total T ₄)	70–140 nmol/l
Thyroxine (free T ₄)	9–22 pmol/l
TSH	0.5–5 mU/l

1

This page intentionally left blank

INDEX

Abbreviated Mental Test Score AMTS 2.59 acetylcholine 225 acetylcysteine 251-3 ACS (acute coronary syndrome) 230 - 3activated charcoal 250, 251, 254 Activated Partial Thromboplastin Time (APTT) 206, 207 acute adrenal insufficiency 221, 247-8 acute bronchitis 172 acute coronary syndromes (ACS) 230-3 secondary prevention 233 acute LVF 233-4 acute upper GI haemorrhage 239 - 40Addisonian crisis 221, 247-8 Addison's disease 221 adrenal insufficiency, acute 221, 247-8 225-6 adrenoceptors adult Basic Life Support algorithm see front cover flap adverse reactions 224 - 7reporting xxii agitation, alcohol withdrawal 190 akathisia 227 alcohol abstinence maintenance 192 withdrawal 190-2

alpha adrenoceptors 225 analgesia 183-4 breakthrough 187 ladder 183 patient-controlled (PCA) 183 - 4postoperative 183-4 anaphylactic reactions, algorithm see front cover flap anaphylactoid reactions 253 angina pectoris 230 unstable (UAP) 232-3 anion gap 260 antibiotic-associated colitis (AAC) 173 antibiotics 168-73, 175-8 in DKA 244 in HONK 245 in sepsis 241 anticholinesterases 2.2.5 anticoagulants 200 - 8new oral agent 204 new parenteral agent 208 see also heparin; warfarin antidepressant(s) 192 - 4adverse effects 226 classes, indications and avoidance 194 resistance and poor tolerance 193 antidepressant withdrawal/discontinuation syndrome 226 antiemetics 187-9 1st line/narrow-spectrum 187-8, 189

266

ladder 188 palliative care 185 antiepileptics, adverse effects 227 antihistamines, sedating 223 antimuscarinic side-effects 225 antipsychotics 222 227 adverse effects arterial blood gases 263 arthritis, septic 177 171 aspiration pneumonia aspirin, overdose 2.54 asthma 181 - 2237 acute life-threatening 237 atrial fibrillation 235-6stroke risk 236 Basic Life Support (BLS) see front cover flap benzodiazepine-like drugs 223 benzodiazepines 222, 223-4 adverse effects 223 dependence/tolerance 224 overdose 255 in palliative care 185 withdrawal 224 226 beta adrenoceptors β-blockers 231 - 2bicarbonate 244 biochem lab reference values 261 - 2bleeding, acute upper GI 239 - 40blepharitis 176 blood gases, arterial 263 body mass index 260 177 bone and joint infections bowel prep(arations) 23

bradycardia, algorithm see back page breastfeeding, safe prescribing xxi bronchiectasis 172 bronchitis, acute 172 calcium ions, elevated levels 249 cellulitis 176-7 cerebellar side effects 227 chalazion, acute 176 charcoal, activated 250, 251, 2.54 chest pain 208 cholinergic side-effects 225 cholinoceptors 225 chronic obstructive pulmonary disease (COPD) 172 exacerbation 2.38 Clostridium difficile colitis 173clotting, lab reference values 2.62 cognitive impairment 259-60 colitis, antibiotic-associated (AAC) 173 colloids 217 coma 2.58 myxoedema 247 conjunctivitis 176 continuity of care xxii controlled drugs 212-13 COPD, exacerbation 172, 238 corneal abrasions 176 corneal ulcer 176 coronary syndrome, acute (ACS) 230 - 3

corticosteroids 219–21 interactions 221 side effects 220 withdrawal 221 creatinine clearance 260 crystalloids 216–17 Cushing's syndrome 220 cystic fibrosis 172 cystic fibrosis 172 cytochrome P450, inhibitors/inducers 228

dabigatran etexilate 204 delirium 259-60 delirium tremens 190 2.59-60 dementia depression 192-4 'detox', alcohol withdrawal 190 diabetes mellitus insulin see insulin pre-operative guidelines 200 diabetic ketoacidosis (DKA) 243 - 4dilating eye drops 55 dopamine (DA) 226 drug charts diamorphine subcutaneous pump 186 GTN ivi 2.30 insulin sliding scale on 197 intravenous fluids 217 - 18dvskinesia 227 dystonia 227

ear, nose and throat (ENT) infections 172–3 elderly, safe prescribing xxi electrolyte disturbances 248 - 9electrolytes, in iv fluids 216. 217, 218 embolism, pulmonary 238 - 9emergencies 229-55 anaphylactic reactions, algorithm see front cover flap ENT infections 172 - 3epidural anaesthesia 183-4 epiglottitis, acute 172 epilepsy 241-2 extrapyramidal effects 227 eve infections 176

falciparum malaria 174–5 febrile neutropenia 178 fluid challenges 218 fluid management 216–19 flumazenil 255 fondaparinux 208 formulae, useful 260

gastric lavage 250, 254 gastroenteritis 173 gastrointestinal haemorrhage, acute upper 239-40 gastrointestinal infections 173Glasgow Coma Scale (GCS) 2.58 glucocorticoids 219-21 glucose, low blood levels 245 - 6glycoprotein IIb/IIIa inhibitors 2.32 GTN (glyceryl trinitrate) 230 267

268

haematinics, lab reference values 263haematology lab reference values 2.62 haemodialysis 254 218, 236 heart failure acute left ventricular 233-4 Helicobacter pylori eradication 173heparin 205 - 7in DKA 244 infusion rate 207 low-molecular-weight (LMWH) 205, 207 monitoring 205,206 in NSTEMI 232 overtreatment/poisoning 2.07in STEMI 232 thrombocytopenia due to 2.05 thrombolysis co-therapy 210unfractionated 205-7 HONK (hyperosmolar nonketotic state) 245 hydration, clinical markers 219 hypercalcaemia 187, 249 hyperkalaemia 248 hyperosmolar non-ketotic state (HONK) 245 hypertension 178 - 802.34 - 5accelerated drug choice 179-80 indication for treatment 178 - 9hypoglycaemia 245–6 hypokalaemia 248 - 9

infections bone and joint 177 ENT 172-3 eve 176 gastrointestinal 173 sepsis (septic shock) 241 upper respiratory tract 172 - 3urinary tract 173 informed consent xxii inotropes 233-4 insulin 196–200 acute coronary syndrome and 231coming off sliding scale 197 - 8in DKA 244 197 drug charts in HONK 245 initial doses and adjustment 198 pre-operative guidelines 200sliding scales 196–9 types 196 International Normalised Ratio (INR) 201 intravenous fluids 216-19 in acute coronary syndrome 231 'challenges' 218 colloids 217 216 - 17crystalloids in DKA 243 in HONK 24.5 isotonic 216-17 K⁺ considerations 218 non-isotonic 216-17 standard daily requirements 217 - 18

ioint infections 177 kidney failure 218 laboratory reference values 2.61 - 3laxatives, in chronic pain/palliative care 186 left ventricular failure (LVF), 233 - 4acute liver failure 218 low-molecular-weight heparin (LMWH) 205, 207 malaria 174-5 falciparum ('malignant') 174 - 5non-falciparum ('benign') 174 meningitis 175-6 meningococcal meningitis 175 Mental Test Score (MTS) 259 mineralocorticoids 219.221 Mini Mental State Examination (MMSE) 259-60 movement control abnormalities 2.2.7 multivitamins 191 myocardial infarction (MI), acute NSTEMI 232-3 STEMI 231-2 thrombolysis 208-9 myxoedema coma 247 National Poisons Information Service (NPIS) 250

nausea 188 causes palliative care 185 see also antiemetics Neisseria meningitidis meningitis 175 neutropenia, febrile 178 non-invasive ventilation (NIV) 233 NSTEMI 232 - 3opiates, overdoses 255 oral fluids 218 orbital cellulitis 176 organ failure 218 osmolality, serum 260 osteomyelitis 177 otitis externa 172 - 3otitis media 172 249 - 55overdoses aspirin 2.54 benzodiazepines 255 general measures for 250 opiates 255 paracetamol 250-3 warfarin 204 P450 symbols 228 pain control 183-4 chronic pain 186 - 7palliative 184–7 palliative care 184-7 pain control 184-7 paracetamol overdose 250 - 3parkinsonism 227 Patient Group Directions xxii peak expiratory flow (PEF) predictor 182

269

pharyngitis 172 plasma expanders/substitutes 217 pneumonia 168 - 72aspiration 171 cavitating 171 community-acquired 168 - 70hospital-acquired 170-1 poisoning/overtreatment see overdoses postoperative patients, analgesia 183 - 4potassium ions depressed levels 248–9 elevated levels 248 intravenous fluids 218 prasugrel 230, 233 pregnancy safe prescribing xxi warfarin and 203 pre-operative care, diabetes 200 pulmonary embolism 238 - 9pyelonephritis 173 pyrexia of unknown origin (PUO) 177-8

rapid tranquillisation 221–2 reference information 257–63 renal artery stenosis 235 renal failure 218 reperfusion therapy 231 respiratory depression, benzodiazepines and 223 respiratory secretion reduction, palliative 185 respiratory tract infections, 172 - 3upper Rockall score 2.40 safe prescribing tips xx-xxii schizophrenia, acute 222 sedation/sleeping tablets 221 - 3acute/rapid 221-2 choice 223 palliative care 185 seizures alcohol withdrawal 190 epilepsy 241-2 sepsis (septic shock) 241 septic arthritis 177 serotonin (5HT) 226 2.2.6 serotonin syndrome serum osmolality 260 side effect profiles 224-7 sinusitis 172 sleeping tablets see sedation/sleeping tablets sodium bicarbonate 254 spinal cord compression 187 status epilepticus 241-2 STEMI 231-2 steroids 219 - 21see also corticosteroids stroke acute ischaemic 211–12 risk in atrial fibrillation 236 176 styes subcutaneous pumps 184 - 6surgery diabetes and 200 warfarin and 203 syringe drivers 185, 186

tachycardia, algorithm see back page tardive dvskinesia 227 thiamine 191 thrombocytopenia, heparininduced 205 thrombolysis 208-12 acute ischaemic stroke 211 - 12acute MI 208-9 choice of agent 210 contraindications 209, 2.12heparin co-therapy 210 indications 208-9, 212 post-thrombolysis management 212 thrombosis, acute, warfarin 202 - 3thyroid function, reference values 263 thyrotoxic crisis 246 tonsillitis 172 Toxbase website 2.50 tranquillisation, rapid 221 - 2triple therapy, Helicobacter *pylori* eradication 173 tuberculosis (TB) 171-2


unstable angina pectoris (UAP) 232 - 3upper respiratory tract infections 172-3 variceal bleeding 239, 240 ventilation, non-invasive 233 vitamin B1 191 vitamin supplements 191 warfarin 200-4 dosing, cautions 202 - 3monitoring 201–3 overtreatment/poisoning 204 pregnancy and 203 starting (acute thrombosis) 202 - 3surgery and 203 weight conversions 260 Wernicke's encephalopathy 191 withdrawal of alcohol 190-2of antidepressants 226 of benzodiazepines 224 of corticosteroids 221

'Z'/benzodiazepine-like drugs 223 271

This page intentionally left blank


Adult tachycardia (with pulse) algorithm

European Resuscitation Council Guidelines 2010



Adult bradycardia algorithm


European Resuscitation Council UK Guidelines 2010



*Alternatives include: Aminophylline, Dopamine, Glucagon (if β -blocker or Ca⁺⁺ channel blocker overdose) or Glycopyrrolate (can be used instead of atropine)

Adult ALS (Advanced Life Support) cardiac arrest algorithm


European Resuscitation Council Guidelines 2010



Correct reversible causes

Tension pneumothorax

Adult BLS (Basic Life Support) algorithm for in-hospital cardiac arrest




European Resuscitation Council Guidelines 2010

*Assess as follows (assuming adequately trained):

- 1. Check safety to approach patient
- 2. Check for response: gently shake shoulders & ask loudly "Are you all right?" If response get urgent medical assessment (e.g. resuscitation team if appropriate). Meanwhile give O₂, attach monitoring & insert iv cannula, taking blood samples if possible. If no response go on to:
- 3. Turn patient onto back
- 4. Open airway: using a head tilt chin lift (if suspect neck injury use jaw thrust). Look in mouth & remove visible foreign body/debris with forceps or suction as appropriate.
- Check breathing: keeping airway open, put your ear above nose/mouth and look towards chest to look, listen & feel for normal breathing for no more than 10 sec.
- 6. Check for circulation: for no more than 10 sec. Can be done simultaneously to checking breathing by feeling carotid. If no breathing or circulation call resuscitation team. If cardiac arrest commence CPR, starting with 30 chest compressions (at rate 100–120/min and depth of 5–6 cm) followed by 2 breaths (inspiratory time 1 sec per breath), continuing at this ratio. If respiratory arrest only (no breathing but pulse present) ventilate lungs & check circulation every 10 breaths. Once trachea intubated give 10 breaths/min.
- ** Airway, Breathing, Circulation, Disability & Exposure

Anaphylaxis algorithm (Resuscitation Council UK 2008)





1. Life-threatening problems:

Airway: swelling, hoarseness, stridor Breathing: rapid breathing, wheeze, fatigue, cyanosis, SpO₂<92%, confusion Circulation: pale, clammy, low blood pressure, faintness, drowsy/coma

- 2. Adrenaline (give IM unless experienced with IV adrenaline)
 - For adult or child more than 12 years: 500 micrograms IM (0.5 mL of 1:1000 adernaline); repeat after 5 mins if no better
 - Adrenaline IV to be given only by experienced specialists: for adults titrate 50 micrograms
- 3. IV fluid challenge: Adult: 500–1000 mL. Stop IV colloid if this might be the cause of anaphylaxis
- 4. Chlorphenamine (give IM or slow IV): Adult or child more than 12 years: 10 mg
- 5. Hydrocortisone (give IM or slow IV): Adult or child more than 12 years: 200 mg


NICE Stroke Algorithm 2008





** Indications for decompressive craniectomy:

- · Aged up to 60 years
- Clinical deficits suggestive of infarction in the territory of the MCA with a score on the National Institute of Health Stroke Scale (NIHSS) of above 15
- · Decrease in the level of consciousness to a score of 1 or greater on item 1a of the NIHSS
- Signs on CT of an infarct of at least 50% of the MCA territory with or without additional infarction in the territory of the anterior or posterior vertebral
 artery on the same side, or infarct volume greater than 143 cm³ as shown on MRI with DWI



BP: at presentation ≥ 140/90 mmHg = 1 point Clinical features: unilateral weakness = 2 points, speech disturbance without weakness = 1 point Duration of symptoms: > 60 mins = 2 points, 10-59 mins = 1 point Diabetes presence of = 1 point **except where contraindicated, in which case CT should be used

according to the European Carotid Surgery Trial (ESCT) criteria